The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2020/2021

European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC)

Abstract

Antimicrobial resistance (AMR) data on zoonotic and indicator bacteria from humans, animals and food are collected annually by the EU Member States (MSs) and reporting countries, jointly analysed by EFSA and ECDC and presented in a yearly EU Summary Report. This report provides an overview of the main findings of the 2020–2021 harmonised AMR monitoring in *Salmonella* spp., *Campylobacter jejuni* and *C. coli* in humans and food-producing animals (broilers, laying hens, turkeys, fattening pigs and bovines under 1 year of age) and relevant meat thereof. For animals and meat thereof, indicator *E. coli* data on the occurrence of AMR and presumptive Extended spectrum β-lactamases (ESBL)-/AmpC β-lactamases (AmpC)/carbapenemases (CP)-producers, as well as the occurrence of methicillin-resistant *Staphylococcus aureus* are also analysed. In 2021, MSs submitted for the first time AMR data on *E. coli* isolates from meat sampled at border control posts. Where available, monitoring data from humans, food-producing animals and meat thereof were combined and compared at the EU level, with emphasis on multidrug resistance, complete susceptibility and combined resistance patterns to selected and critically important antimicrobials, as well as *Salmonella* and *E. coli* isolates exhibiting ESBL-/AmpC-/carbapenemase phenotypes. Resistance was frequently found to commonly used antimicrobials in *Salmonella* spp. and *Campylobacter* isolates from humans and animals. Combined resistance to critically important antimicrobials was mainly observed at low levels except in some *Salmonella* serotypes and in *C. coli* in some countries. The reporting of a number of CP-producing *E. coli* isolates (harbouring *bla*<sub>OXA-48</sub>, *bla*<sub>OXA-181</sub>, and *bla*<sub>NDM-5</sub> genes) in pigs, bovines and meat thereof by a limited number of MSs (4) in 2021, requests a thorough follow-up. The temporal trend analyses in both key outcome indicators (rate of complete susceptibility and prevalence of ESBL-/AmpC-producers) showed that encouraging progress have been registered in reducing AMR in food-producing animals in several EU MSs over the last years.

© 2023 European Food Safety Authority and European Centre for Disease Prevention and Control. EFSA Journal published by Wiley-VCH GmbH on behalf of European Food Safety Authority.

Keywords: antimicrobial resistance, zoonotic bacteria, indicator bacteria, ESBL, MRSA

Requestor: European Commission

Question number: EFSA-Q-2021-00768

Correspondence: zoonoses@efs.a.europa.eu (EFSA); FWD@ecdc.europa.eu (ECDC)
Declarations of interest: If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact interestmanagement@efsa.europa.eu.

Acknowledgements: EFSA and ECDC wish to thank the members of the Scientific Network for Zoonoses Monitoring Data (EFSA) and the Food- and Waterborne Diseases and Zoonoses Network (ECDC) who provided the data and reviewed the report and the members of the Scientific Network for Zoonoses Monitoring Data, for their endorsement of this scientific output. Also, the contribution of EFSA staff members: Raquel García-Fierro, Pierre-Alexandre Beloell, Giusi Amore, Valentina Rizzi, Beatriz Guerra Roman, Anca-Violeta Stoicescu, Alexandra Papanikolau, Kenneth Mulligan, and the contributions of ECDC staff members: Therese Westrell and Hanna Merck, and the contributions of ECDC and EFSA contractor: AUSVET Europe (Angus Cameron, Skye Badger, Hester Tang, Ana Belen García, Céline Faverjon, Angela Fanelli, Alison Hillman, Anders Dalsgaard, Ute Wolff Sønksen) SOLADIS (Florian Kroell, Frédéric Chavanel, Thomas Brière, Omraam Agbohouto, Catherine Pahon) and EFOR-CVO-SOLADIS Group (Patrick Etiévant). Also, the support from the EURL-AR, specifically, Jette Sejer Kjeldgaard, Birhte S. Rosenqvist Lund, Jacob Dyring Jensen and Rene S. Hendriksen for the confirmatory testing are gratefully acknowledged.


Map disclaimer: The designations employed and the presentation of material on the maps included in this report do not imply the expression of any opinion whatsoever on the part of the European Food Safety Authority and of the European Centre for Disease Prevention and Control concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

ISSN: 1831-4732

© 2023 European Food Safety Authority and European Centre for Disease Prevention and Control. EFSA Journal published by Wiley-VCH GmbH on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

Copyright for non-EFSA content: EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.

EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.

The EFSA Journal is a publication of the European Food Safety Authority, a European agency funded by the European Union.
Summary

In 2020–2021, data on antimicrobial resistance in zoonotic and indicator bacteria submitted by 27 EU Member States (MSs), the United Kingdom (Northern Ireland) and five non-MSs were jointly analysed by the EFSA and the ECDC and their contractor. Resistance in zoonotic *Salmonella* and *Campylobacter* from humans, food-producing animals (fattening pigs, calves under 1 year of age, broilers and fattening turkeys) and derived meat, as well as resistance in indicator *Escherichia coli* and methicillin-resistant *Staphylococcus aureus* (MRSA) from animals and food were addressed. In 2020, it was mandatory to report AMR data from fattening pigs and derived meat, while in 2021, it was mandatory to report AMR data from fattening pigs and calves and derived meat. ‘Microbiological’ resistance in the isolate populations was assessed using epidemiological cut-off (ECOFF) values. For some countries, qualitative data on human isolates were interpreted in a way which corresponds closely to the ECOFF-defined ‘microbiological’ resistance.

New legislation related to the harmonised monitoring and reporting of AMR in food-producing animals and derived meat was introduced in 2021, requiring MSs to sample imported fresh meat at border control posts for *E. coli*. New substances were also added in the harmonised antimicrobial panels, including amikacin for *Salmonella* and *E. coli*, and chloramphenicol and ertapenem for *Campylobacter* spp. Also from 2021, whole genome sequencing (WGS) was authorised as an alternative method to supplementary (panel 2) phenotypic testing of *Salmonella* and *E. coli* isolates with resistance to extended-spectrum cephalosporins and carbapenems.

In *Salmonella* spp. from human cases in 2021, resistance to ampicillin, sulfonamides and tetracyclines was observed at overall high levels, while resistance to third-generation cephalosporins in 2021 was noted at overall very low levels of 1.1% for both cefotaxime and ceftazidime, respectively. A decline in resistance to ampicillin and tetracycline in isolates from humans was observed in 13 and 11 countries, respectively, over the period 2013–2021. This was particularly evident in *S. Typhimurium*, a serovar commonly associated with pigs and calves. For cefotaxime, six MSs reported declining trends compared to three MSs reporting increasing trends. A moderate occurrence of resistance to ciprofloxacin (14.9%) was observed in human cases from 2021; however, an extremely high proportion of resistant isolates was noted in S. Kentucky (78.1%) and increasing trends in ciprofloxacin resistance were observed for *S. Enteritidis* in 10 countries over the period 2013–2021, with this serovar predominantly being associated with poultry.

For *Salmonella* spp. and indicator *E. coli* isolates recovered from food-producing animals and poultry carcases in 2020/2021, resistance to ampicillin, tetracyclines and sulfonamides, ranged from moderate to very high in most MSs. Resistance to third-generation cephalosporins (cefotaxime and ceftazidime) was seldom detected in animals and derived meat, except for low-level resistance observed in *Salmonella* spp. isolates from calves and broiler flocks. These findings mirror those observed in *Salmonella* isolates reported from human cases. Resistance to (fluoro)quinolones (ciprofloxacin and nalidixic acid) was high to very high among *Salmonella* spp. and indicator *E. coli* isolates recovered from broilers, fattening turkeys and poultry carcases/meat in 2020, and low or moderate levels in isolates from pigs and calves in 2021.

Resistence to amikacin, the new substance included in the harmonised panel for 2021, was very low or low in *Salmonella* spp. and *E. coli* isolates from fattening pigs and no resistance was detected in *Salmonella* spp. isolates from bovine animals under 1 year of age. Resistance to colistin was uncommon among *Salmonella* spp. and *E. coli* isolates recovered from food-producing animals and poultry carcases, although moderate resistance was observed in certain *Salmonella* serovars (S. Enteritidis) and in *Salmonella* isolates from bovine animals under 1 year of age.

Combined resistance to ciprofloxacin and cefotaxime, categorised as highest priority critically important antimicrobials, was very low in *Salmonella* isolates from humans and rare or very low in *Salmonella* isolates in almost all animal and derived meat categories, with the exception of broilers and calves where low levels were detected. While for *E. coli* isolates low levels were reported in all animal and derived meat. Some *Salmonella* serovars from poultry sources, such as S. Kentucky and S. Infantis, had comparatively elevated levels of combined resistance to ciprofloxacin and cefotaxime.

In 2021, MSs could submit AMR data on *E. coli* isolates recovered from fresh/frozen meat sampled at border control posts for the first time. Four MSs contributed data from imported fresh pig meat (n = 13), and six MSs contributed data from imported bovine meat (n = 110). For meat of both origins, resistance was either undetected, observed rarely or at low levels for most of the antimicrobial substances in the harmonised panel.
Overall, the data obtained in 2020–2021 from *C. jejuni* and *C. coli* from human and animal origins showed high to extremely high levels of resistance to fluoroquinolones, which are critically important antimicrobials (CIA) for the treatment of *Campylobacter* infections in humans. High to extremely high resistance levels to ciprofloxacin were observed in human *C. jejuni* and *C. coli* isolates in the EU in 2021, ranging from 22.2% to 100%. Very high levels of resistance were observed for ciprofloxacin in isolates from food-producing animals (ranging from 41.7% to 80.4%). Overall, the levels of resistance to ciprofloxacin obtained from food-producing animals were higher for *C. coli* than for *C. jejuni*, although the level of resistance to ciprofloxacin obtained from *C. jejuni* isolates from poultry in 2020 were also high (e.g. 77.9% in fattening turkeys – data from nine MSs). The lowest levels of resistance to ciprofloxacin in both *C. jejuni* and *C. coli* were observed in isolates from fattening pigs in 2021 (41.7% and 51.7%, respectively). Resistance to erythromycin (also CIA) was detected at low levels in *C. jejuni* from humans (1.1%) and animals (ranging from 0.8% to 1.7%). However, higher levels of resistance were observed in *C. coli* isolates from humans (8.5%) and animals (range from 4.4% to 35.7%). The level of overall resistance to tetracycline ranged from high to extremely high (43.3%–90.5%) in food-producing animals, and was high in *C. jejuni* and extremely high in *C. coli* from humans.

Over the period 2013–2021, ciprofloxacin resistance in *C. jejuni* from humans increased in 12 countries, while erythromycin resistance decreased in seven countries. Similar trends were observed in *C. jejuni* from broilers over 2009–2020 where resistance to ciprofloxacin increased in 14 countries, and resistance to erythromycin decreased in five countries. In *C. coli*, a decrease in resistance to erythromycin was observed in isolates from humans, fattening pigs and broilers in few countries while increasing resistance to this substance was only observed in one country in *C. coli* isolated from broilers. Despite these declining trends, several of the erythromycin-resistant isolates displayed high MIC values (MIC > 128 mg/L, 128 mg/L < MIC ≤ 512 mg/L or MIC > 512 mg/L), which could indicate a presence of the transferrable macrolide resistance gene *erm(B)*.

The occurrence of combined resistance to ciprofloxacin and erythromycin in *Campylobacter* spp. is considered of high public health relevance. Overall combined resistance to these antimicrobials was lower in *C. jejuni* isolates than in *C. coli* isolates for humans and food-producing animals. Combined resistance to ciprofloxacin and erythromycin reported from *C. jejuni* isolates was detected in 0.8% of isolates from humans, 0.7% isolates from broilers, 0.8% of isolates from fattening turkeys and from calves and 1.7% of pig isolates. Combined resistance to ciprofloxacin and erythromycin reported from *C. coli* isolates was detected in 7.6% of isolates from humans in 2021, 4.1% of broiler samples and 21.2% of isolates from fattening turkeys in 2020 and 32.7% of samples from calves and 9.3% of pig isolates in 2021. The levels of combined resistance to ciprofloxacin and erythromycin increased from 22.4% in 2019 to 32.7% in 2021 in *C. coli* isolates from calves, which might infer a public health concern. The level of combined resistance to ciprofloxacin and erythromycin observed in *C. coli* isolated from pigs in 2019 was 8% while in 2021 increased to 9.3%.

Multidrug resistance (MDR) levels were generally low for *C. jejuni* isolated from humans and the animal species considered. Compared to *C. jejuni*, it was markedly higher in *C. coli* isolated from humans, calves and fattening pigs (9.9%, 39.3% and 9.7%, respectively) based on data from 2021 and from fattening turkeys (21%) based on data from 2020. These results agree with the higher levels of resistance to selected antimicrobials seen in *C. coli* isolates.

The prevalence of resistance to selected antimicrobials in *C. coli* from fattening pigs in 2021 has been estimated at country level as the proportion of *C. coli* showing microbiological resistance to each antimicrobial as a percentage of all caecal samples cultured for *C. coli*. Between-country variability from low to extremely high levels was observed in the prevalence of ciprofloxacin-resistant (ranging from 6.9% to 78.2%) and tetracycline-resistant (ranging from 0.0% to 86.5%) *C. coli* from fattening pigs. Interestingly, a limited between-country variation and notably lower levels of prevalence of resistance to erythromycin were found in *C. coli* from fattening pigs, which have been estimated to be below 10% for 21 MSs and 3 non-MSs, while ranging from 14.9% to 39.7% in the remaining six reporting MSs. Noteworthy, the MS with the highest prevalence of resistance to erythromycin in *C. coli* from fattening pigs in 2021 had also the highest level of erythromycin resistance in *C. coli* from humans, suggesting that pigs could be a reservoir of erythromycin-resistant *C. coli* for humans. This finding is of particular public health concern since macrolides, such as erythromycin and azithromycin, have become the first-line treatment of human campylobacteriosis.

The monitoring included assessment of the levels of presumptive extended-spectrum β-lactamase (ESBL)-/AmpC/carbapenemase producers among *Salmonella* spp. from human cases, food-producing animals and animal carcasses; as well as among indicator *E. coli* isolates from food-producing animals.
At the reporting MS group level, the proportion of presumptive ESBL or AmpC producers was very low to low among *Salmonella* spp. isolates recovered from animals/carcases (broilers, laying hens, fattening turkeys, fattening pigs and carcasses of broilers and fattening pigs) and very low in isolates from human cases, although higher in some *Salmonella* serovars. Statistically significant decreasing trends are evident in the prevalence of ESBL-producing *E. coli* in broilers, broiler meat and pig meat at the EU level.

Within both the routine and specific monitoring (non-selective and selective media, respectively), varying occurrence/prevalence rates of presumptive ESBL or AmpC-producing *E. coli* were observed in different reporting countries. A larger proportion of isolates were identified as presumptive ESBL-producers compared with AmpC-producers based on phenotypic methods in 2020 and 2021. This was supported by WGS that revealed 976 *E. coli* isolates carrying ESBL genes, 61 isolates carrying AmpC genes and 96 isolates presenting a point mutation in the AmpC promoter.

Furthermore, in 2021, within the specific monitoring of ESBL-/AmpC-/CP-producing *E. coli*, two CP-producing isolates from bovine meat and one isolate from pig were detected by Hungary. Those isolates were confirmed as CP-producers harbouring the *bla*$_{NDM-5}$ gene, responsible for the carbapenemase phenotype, by the EURL-AR during the confirmatory testing exercise. Moreover, within the specific monitoring of carbapenemase-producing microorganisms (using selective media for carbapenemase producers), three isolates from bovine meat and one isolate from pig meat were reported by Hungary. The presence of CP-encoding genes in the Hungarian isolates are pending of confirmation. Additionally, two isolates from fattening pigs detected in Spain, carried the *bla*$_{OXA-48}$ gene. WGS revealed additional 26 *E. coli* isolates from Italy (21 from pigs and five from bovine animals under 1 year of age) and three isolates from Czechia (all from fattening pigs) carrying CP-encoding genes under the specific carbapenemase monitoring. These included *bla*$_{OXA-181}$ (4 isolates from calves and 20 from fattening pigs), *bla*$_{OXA-48}$ (one isolate from a fattening pig), and *bla*$_{NDM-5}$ (1 isolate from a calf) detected in the Italian isolates, and *bla*$_{NDM-5}$ (3 isolates from fattening pigs) reported by Czechia. Carbapenemase-producing *Salmonella* isolates were not detected in animals in 2020/2021, nor in 2021 for human cases.

The voluntary monitoring of MRSA from food and healthy animals in 2020–2021 revealed most MRSA isolates, where typing data were available, was associated with spa-types assigned to livestock associated (LA-)MRSA in both reporting years. However, spa-types associated with community acquired (CA-) and hospital acquired (HA-)MRSA were also reported, as well as mecC-MRSA. The occasional detection of lineages of CA- and HA-MRSA primarily associated with humans is not surprising, since the sporadic interchange of strains between humans and animals may be expected. A notable observation from the 2020 monitoring was the occurrence of a vancomycin-resistant MRSA t011 isolate in meat from sheep. The isolate lacks the typical vancomycin resistance genes and it is likely that the increased MIC of 4 mg/L was due to multiple point mutations as described in the literature. An important observation from the 2021 monitoring includes the detection of rifampicin resistance in isolates from pig and bovine meat. Vancomycin and rifampicin are important compounds in human medicine for the treatment of MRSA.

The key outcome indicators for AMR in food-producing animals – complete susceptibility (KOI$_{CS}$) to the harmonised panel of antimicrobials in *E. coli* and the prevalence of ESBL-/AmpC-producing *E. coli* – have also been analysed over the period 2014–2021. There are marked variations in both key outcome indicators among reporting countries. Statistically significant decreasing trends in the key outcome indicator of ESBL- and/or AmpC-producing *E. coli* (KOI$_{ESC}$) were observed in 17 MSs and one non-MS. A statistically significant increasing trend was identified in two MSs, and in the remaining countries, no statistically significant trend was seen. Statistically significant increasing trends in the key outcome indicators of complete susceptibility (KOI$_{CS}$) were registered in 8 MSs and decreasing trends in three countries. The increasing trends in changes to CS and KOI$_{CS}$ in indicator *E. coli* isolates reveal a progress towards lower levels of resistance in several countries and in the MS-group. The improvement seen in changes to CS was most pronounced in poultry. Both key outcome indicators show that encouraging progress has been registered in reducing AMR in food-producing animals in several EU MSs over the last years.
# Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Summary</td>
<td>3</td>
</tr>
<tr>
<td>1. Introduction</td>
<td>8</td>
</tr>
<tr>
<td>1.1. Monitoring and reporting of antimicrobial resistance in the EU</td>
<td>11</td>
</tr>
<tr>
<td>1.1.1. Humans: monitoring of antimicrobial resistance</td>
<td>11</td>
</tr>
<tr>
<td>1.1.2. Animals and food: monitoring of antimicrobial resistance</td>
<td>12</td>
</tr>
<tr>
<td>1.2. Further harmonised monitoring of antimicrobial resistance</td>
<td>13</td>
</tr>
<tr>
<td>1.3. The 2020–2021 EU Summary Report on AMR</td>
<td>15</td>
</tr>
<tr>
<td>2. Antimicrobial resistance in Salmonella spp.</td>
<td>15</td>
</tr>
<tr>
<td>2.1. Key findings</td>
<td>15</td>
</tr>
<tr>
<td>2.2. Data on AMR in Salmonella spp. addressed</td>
<td>16</td>
</tr>
<tr>
<td>2.3. Humans: occurrence of antimicrobial resistance in Salmonella</td>
<td>17</td>
</tr>
<tr>
<td>2.3.1. Data reported</td>
<td>17</td>
</tr>
<tr>
<td>2.3.2. Occurrence of resistance to commonly used antimicrobials in human and/or veterinary medicine</td>
<td>17</td>
</tr>
<tr>
<td>2.3.3. Occurrence of resistance to highest-priority critically important antimicrobials (hpCIAs) and last resort antimicrobials</td>
<td>19</td>
</tr>
<tr>
<td>2.3.4. ESBL, AmpC and carbapenemase-producing Salmonella</td>
<td>21</td>
</tr>
<tr>
<td>2.3.5. Complete susceptibility (CS) and multidrug resistance (MDR)</td>
<td>22</td>
</tr>
<tr>
<td>2.3.6. Temporal trends</td>
<td>23</td>
</tr>
<tr>
<td>2.3.7. High-level ciprofloxacin resistance</td>
<td>25</td>
</tr>
<tr>
<td>2.4. Food-producing animals and meat thereof: occurrence of antimicrobial resistance in Salmonella spp.</td>
<td>26</td>
</tr>
<tr>
<td>2.4.1. Data reported</td>
<td>26</td>
</tr>
<tr>
<td>2.4.2. Occurrence of resistance to commonly used antimicrobials in veterinary medicine</td>
<td>27</td>
</tr>
<tr>
<td>2.4.3. Occurrence of resistance to highest priority critically important antimicrobials (hpCIAs) and last resort antimicrobials</td>
<td>28</td>
</tr>
<tr>
<td>2.4.4. Tigecycline and colistin resistance in Salmonella serovars</td>
<td>33</td>
</tr>
<tr>
<td>2.4.5. Complete susceptibility (CS) and multidrug resistance (MDR)</td>
<td>36</td>
</tr>
<tr>
<td>2.4.6. High-level resistance to ciprofloxacin (CIP) in Salmonella spp</td>
<td>43</td>
</tr>
<tr>
<td>2.4.7. Phenotypic characterisation of third-generation cephalosporin and carbapenem resistance in Salmonella spp</td>
<td>44</td>
</tr>
<tr>
<td>2.4.8. Carbapenem resistance in Salmonella spp. from food-producing animals and carcasses</td>
<td>45</td>
</tr>
<tr>
<td>2.4.9. Resistance exhibited by dominant Salmonella serovars</td>
<td>46</td>
</tr>
<tr>
<td>2.5. Comparison of resistance data in Salmonella from human and food-producing animals</td>
<td>46</td>
</tr>
<tr>
<td>2.6. Discussion</td>
<td>46</td>
</tr>
<tr>
<td>3. Antimicrobial resistance in Campylobacter spp.</td>
<td>51</td>
</tr>
<tr>
<td>3.1. Key findings</td>
<td>51</td>
</tr>
<tr>
<td>3.2. Data on AMR in Campylobacter spp. addressed</td>
<td>52</td>
</tr>
<tr>
<td>3.3. Humans: occurrence of antimicrobial resistance in Campylobacter</td>
<td>53</td>
</tr>
<tr>
<td>3.3.1. Data reported</td>
<td>53</td>
</tr>
<tr>
<td>3.3.2. Occurrence of resistance</td>
<td>53</td>
</tr>
<tr>
<td>3.3.3. Combined resistance to ciprofloxacin and erythromycin</td>
<td>55</td>
</tr>
<tr>
<td>3.3.4. Complete susceptibility and multidrug resistance</td>
<td>56</td>
</tr>
<tr>
<td>3.3.5. Temporal trends</td>
<td>56</td>
</tr>
<tr>
<td>3.3.6. High-level resistance to erythromycin</td>
<td>58</td>
</tr>
<tr>
<td>3.4. Food-producing animals and meat thereof: occurrence of antimicrobial resistance in Campylobacter coli</td>
<td>59</td>
</tr>
<tr>
<td>3.4.1. Data reported</td>
<td>59</td>
</tr>
<tr>
<td>3.4.2. Occurrence of resistance in meat samples from broilers</td>
<td>60</td>
</tr>
<tr>
<td>3.4.3. Occurrence of resistance in poultry, pigs and calves</td>
<td>61</td>
</tr>
<tr>
<td>3.4.4. Combined resistance to ciprofloxacin and erythromycin</td>
<td>64</td>
</tr>
<tr>
<td>3.4.5. Prevalence of antimicrobial resistance in Campylobacter coli from fattening pigs</td>
<td>69</td>
</tr>
<tr>
<td>3.4.6. Complete susceptibility and multidrug resistance</td>
<td>71</td>
</tr>
<tr>
<td>3.4.7. Temporal trends in resistance</td>
<td>72</td>
</tr>
<tr>
<td>3.4.8. High-level resistance to erythromycin</td>
<td>74</td>
</tr>
<tr>
<td>3.5. Comparison of human and animal data on Campylobacter spp.</td>
<td>78</td>
</tr>
<tr>
<td>3.6. Discussion</td>
<td>81</td>
</tr>
<tr>
<td>4. Antimicrobial resistance in indicator E. coli</td>
<td>84</td>
</tr>
<tr>
<td>4.1. Key findings</td>
<td>84</td>
</tr>
<tr>
<td>4.2. Data on AMR in indicator E. coli addressed</td>
<td>85</td>
</tr>
<tr>
<td>4.3. Antimicrobial resistance in poultry, porcine and bovine populations</td>
<td>86</td>
</tr>
<tr>
<td>4.3.1. Data reported</td>
<td>86</td>
</tr>
</tbody>
</table>
4.3.2. Occurrence of antimicrobial resistance ................................................................. 87
4.3.3. Temporal trends in resistance .............................................................................. 93
4.3.4. Phenotypic characterisation of third-generation cephalosporin and carbapenem resistance 98
4.3.5. Colistin resistance .................................................................................................. 99
4.3.6. Multidrug resistance ............................................................................................ 100
4.3.7. Completely susceptibility .................................................................................... 101
4.3.8. Key Outcome Indicator of Complete Susceptibility (KOCIc) .................................. 106
4.4. Discussion ................................................................................................................. 107
5.1. Key findings ............................................................................................................... 111
5.2. Data on ESBL-, AmpC- and/or CP-producing Salmonella and Escherichia coli addressed ........................................................................................................... 112
5.3. Food-producing animals and derived meat: routine antimicrobial resistance monitoring. Presumptive ESBL/AmpC/CP producers and related WGS data ........................................................................................................... 112
5.4. Food-producing animals and derived meat: specific monitoring of presumptive ESBL/AmpC-producing E. coli and related WGS data .................................................. 113
5.4.1. Prevalence and occurrence of presumptive ESBL/AmpC/CP producers ............... 113
5.4.2. Relative abundance (occurrence) of presumptive ESBL/AmpC producers. ....... 116
5.4.3. Temporal trends in prevalence of presumptive ESBL/AmpC/CP producers .......... 127
5.4.4. Key outcome indicator of prevalence of ESBL and/or AmpC producers .............. 134
5.4.5. Discussion ............................................................................................................. 136
5.5. Monitoring of carbapenemase (CP)-producing E. coli ............................................ 137
5.5.1. Specific E. coli ESBL/AmpC/CP-producers monitoring .................................... 137
5.5.2. Specific CP-producers monitoring ..................................................................... 138
5.5.3. Discussion ............................................................................................................. 139
6.1. Antimicrobial resistance in methicillin-resistant Staphylococcus aureus (MRSA) .... 140
6.2. Key findings ............................................................................................................. 140
6.3. Food and animals: MRSA ......................................................................................... 142
6.3.1. Food: monitoring of MRSA ................................................................................ 142
6.3.2. Animals: monitoring of MRSA ......................................................................... 143
6.3.2.1. Monitoring of MRSA in healthy animals ......................................................... 143
6.3.2.2. Monitoring of MRSA in animals following clinical investigations ............... 145
6.3.3. Animals and food: results of molecular typing of isolates .................................... 146
6.4. Temporal trends of MRSA occurrence ................................................................. 150
6.4.1. Temporal trends of MRSA occurrence in various types of meat ....................... 150
6.4.2. Temporal trends of MRSA occurrence in various animals .................................. 152
6.5. Summary data on the occurrence and susceptibility of MRSA .......................... 155
6.5.1. Susceptibility data of MRSA isolates from meat and food-producing animals (excluding clinical investigations) ......................................................... 155
6.5.2. Meat and food-producing animals: multidrug resistance in MRSA isolates (excluding clinical investigations) ................................................................. 158
6.6. Discussion ................................................................................................................. 159
References ......................................................................................................................... 162
Abbreviations ....................................................................................................................... 173
Definitions .......................................................................................................................... 176
Appendix A – High-level resistance to ciprofloxacin among certain Salmonella serovars recovered from poultry origins as well as a single isolate from a fattening pig .................................................. 177
Appendix B – Cefotaxime, ceftazidime and ciprofloxacin resistance in Salmonella spp. recovered from each of the animal/carcase origins and humans considering all reporting MSs in 2020/2021 ..................................... 179
Appendix C – Occurrence of antimicrobial resistance at the Salmonella serovar level .... 180
Appendix D – Comparison of human Salmonella data by serovar to that in food-producing animals ........................................................................................................ 193
Appendix E – Trends in colistin resistance in indicator E. coli from fattening pigs, calves under 1 year of age and broilers ................................................................................. 200
Appendix F – Materials and methods ............................................................................. 204
Appendix G – Additional information and supporting data ......................................... 228
Appendix H – ESBL-, AmpC- and CP- encoding genes identified during the specific monitoring of ESBL-/AmpC-/CP – producing E. coli isolates using whole genome sequencing (WGS) ......................................................... 230
1. Introduction

Legal basis

Monitoring of AMR in bacteria from food-producing animals and derived meat

- **Regulation (EC) 178/2002** Article 33 establishes that EFSA is responsible for examining data on antimicrobial resistance (AMR) collected from the Member States (MSs) in accordance with Directive 2003/99/EC and for preparing the EU Summary Report from the results.
- **Directive 2003/99/EC** on monitoring zoonoses and zoonotic agents lays down the provisions for monitoring AMR in zoonotic and indicator bacteria in food-producing animals and derived meat. The Directive obliges EU MSs to collect relevant and, where applicable, comparable data on zoonoses, zoonotic agents, AMR and food-borne outbreaks.
- **Commission Implementing Decision (EU) 2020/1729** on the monitoring and reporting antimicrobial resistance in zoonotic and commensal bacteria repeals Commission Implementing Decision (EU) 2013/652. Commission Implementing Decision 2020/1729 (EU) applies from 2021 to 2027 and sets up priorities for the monitoring of AMR from a public health perspective, prescribes a list of combinations of bacterial species, food-producing animal populations and foodstuffs and lays down harmonised rules for the period 2021–2027, for the monitoring and reporting of AMR in food-producing animals and food.

Monitoring of AMR in bacteria from humans

- **Decision 2018/945/EU** on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions stipulates mandatory testing and reporting of a representative subset of isolates using methods and criteria specified in the EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and Campylobacter isolates (ECDC, 2016).
- The data collection on human diseases from MSs is conducted in accordance with **Decision 1082/2013/EU** on serious cross-border threats to health.

Terms of Reference

- In accordance with the Zoonoses **Directive 2003/99/EC**, the EU MSs are required to assess trends and sources of zoonoses, zoonotic agents and AMR, as well as outbreaks in their territory, submitting an annual report each year by the end of May to the European Commission covering the data collected.
- In accordance with Article 9 of **Directive 2003/99/EC**, the EFSA shall examine the submitted national reports of the MSs and publish a summary report on the trends and sources of zoonoses, zoonotic agents and AMR in the EU.
- The ECDC has provided data on zoonotic infections in humans and their analyses for the EU Summary Reports since 2005. Since 2007, data on human cases have been reported through The European Surveillance System (TESSy), maintained by the ECDC.

The antimicrobial agents used in food-producing animals and human medicine in Europe are frequently the same or else belong to the same classes. The route of administration and the administered quantities of antimicrobials differ between humans and food-producing animals.

---

Moreover, there are important variations between and within food-producing animal populations and countries. Nevertheless, frequently exposing the bacterial biota in both humans and animals to antimicrobial agents might result in the development of AMR by favouring the selection of resistant bacterial clones, regardless of whether these are pathogenic, commensal or environmental bacteria. This could, over time, change the population structure of microbial communities with serious consequences for human and animal health.

**Antimicrobial resistance**

AMR is defined as the inability or reduced ability of an antimicrobial agent to inhibit the growth of a bacterium, which, in the case of a pathogenic organism, can lead to therapy failure. A bacterial strain can acquire resistance by mutation, by the uptake of exogenous genes by horizontal transfer from other bacterial strains or by the activation/trIGGERing of a genetic cascade, thereby inducing the expression of resistance mechanisms (EMA and EFSA, 2017). AMR is also an acronym for the health problems arising in humans and animals, when antimicrobial-resistant microorganisms spread within a population or society. The development and spread of resistance can be triggered by different factors such as use of antimicrobials in human and veterinary medicine, poor hygiene conditions and practices in healthcare settings or the food chain that facilitate the transmission of resistant microorganisms. Over time, this makes antimicrobials less effective.

Antimicrobial-resistant bacteria derived from food-producing animals can spread to humans by ingestion of, or from handling, food contaminated with zoonotic bacteria such as *Campylobacter*, *Salmonella* or *Escherichia coli* (*E. coli*), from direct contact with animals, or rarely, by environmental contamination. Infections with antimicrobial-resistant bacteria may result in treatment failures or the need for second-line antimicrobials for therapy. The commensal bacterial flora can also form a reservoir of resistance genes, which may be transferred between bacterial species, including organisms capable of causing disease in humans and animals (EFSA, 2008).

The European Commission adopted an Action Plan to tackle AMR on 29 June 2017. The Action Plan is underpinned by a One Health approach that addresses resistance in bacteria from both humans and animals. EU actions have focused on the areas with the highest added value for MSs, such as promoting the prudent use of antimicrobials via antimicrobial stewardship (AMS), enhancing cross-sectorial work, improving infection prevention and control (IPC), and consolidating surveillance of AMR and antimicrobial consumption (AMC). AMR monitoring in zoonotic and commensal bacteria in food-producing animals and foodstuffs entails specific and continuous data collection, analysis, and reporting. It enables the understanding of the development and diffusion of resistance, the following of temporal trends in the occurrence and distribution of AMR, the identification of emerging or specific resistance patterns, it provides relevant risk assessment data and helps to evaluate targeted interventions.

The European Commission has announced plans to boost the implementation of the 2017 One Health Action Plan against AMR by the end of 2022 (European Commission, 2022). This is supported by the Trio Presidency of the Council of the EU (France, Czech Republic, and Sweden), who released a Declaration on Antimicrobial Resistance calling for strengthened action and cooperation on AMR, including support for the update of the 2017 Action Plan (Trio Presidency of the Council of the European Union, 2022). Moreover, the Organisation for Economic Cooperation and Development (OECD), in collaboration with the ECDC, EFSA and the European Medicines Authority (EMA), released a briefing note on the One Health response to AMC and AMR in the EU and European Economic Area (EEA), setting out policy options for national governments and the EU (OECD, 2022) (see text box below).

**A joint report by ECDC, EFSA, EMA and OECD on antimicrobial resistance and the One Health response in the EU/EEA**

In March 2022, the OECD, in collaboration with the ECDC, EFSA and EMA, released a briefing note on the One Health response to AMC and AMR in the EU and European Economic Area (EEA) (OECD, 2022). The briefing note summarises important findings on AMC and AMR in the EU/EEA over the past decade (2011–2020) and sets out policy options for national governments and the EU.

---

The OECD reports that overall consumption of antibiotics in humans decreased by 23% in the EU/EAA between 2014 and 2020, although there was considerable variability in AMC in the countries evaluated. Much of the reported decrease in AMC (approximately 18%) occurred between 2019 and 2020 during the COVID-19 pandemic. It is unclear whether reduced AMC in human health settings was sustained in 2021 and if there are implications for AMR. Despite reductions in AMC, the relative use of broad-spectrum antibiotics in human health increased over the same period, which is a cause for some concern. For food-producing animals, overall AMC decreased by 43% between 2011 and 2020 in 25 countries with consistent reporting, suggesting that interventions aimed at reducing AMU in these sectors have been successful.

While AMC levels are dropping, AMR in bacteria from humans and animals has increased for many antibiotic–bacterium combinations in the past decade. Of concern in human health is the rise in resistance to critically important antibiotics (CIAs) used to treat common healthcare-associated infections. In food animals, recent trends in AMR are encouraging, with the proportion of indicator *E. coli* isolates testing completely susceptible to all tested antibiotics increasing and there is a continuing trend of low-level occurrence of combined resistance to CIAs in *Salmonella* and *Campylobacter*. However, resistance to commonly used antibiotics in bacteria from food-producing animals remains high (> 20% to 50%) or very high (> 50% to 70%), and there is significant regional variation across the EU/EEA region.

Analyses by the OECD identify urgent priorities for the EU/EAA, including:

- Monitoring and evaluating the implementation of national action plans across the EU/EAA
- Supporting efforts to strengthen surveillance of AMR through enhanced laboratory network capacity, integration of new data sources and technologies (e.g. WGS), and harmonisation of data collection methods across the EU/EEA
- Investing in cost-effective interventions such as antimicrobial stewardship (AMS) programmes and infection, prevention and control (IPC) initiatives.

The report concludes that there is mounting evidence that AMR can spread between animals, humans and the environment. Reducing the use of antibiotics in food-producing animals, replacing them where possible, and rethinking livestock production systems in a One Health approach are critical for the future of animal and public health. AMR remains a serious challenge in the EU/EAA, underlying the need for concerted action.

**EU4health and HaDEA: new EU initiatives to combat AMR**

In 2021, in response to the COVID-19 pandemic and to strengthen crisis preparedness in the EU, the European Commission announced a €5.3 billion investment in the EU4Health program (2021–2027). Established by Regulation (EU) 2021/522, the programme complements the policies of MSs to build more resilient and accessible health systems and undertake activities in line with the One Health approach. Funding is provided to EU countries, health organisations and non-government organisations (NGOs) for a range of health priorities, including for activities aimed at reducing the number of AMR infections in human health. EU4Health has four work programmes, (i) crisis preparedness, which includes activities related to tackling AMR, (ii) health promotion and disease prevention, (iii) health systems and healthcare workforce and (iv) digital health. The 2022 work programme for EU4Health includes actions to develop a monitoring and evaluation framework to strengthen the 2017 EU Action Plan against AMR. Work in this area is under active consideration by MSs and the European Commission.

The European Health and Digital Executive Agency (HaDEA) was established in February 2021 to implement European programmes and initiatives on behalf of the European Commission, by managing projects related to health, food safety, digital technologies and networks, industrial

---

capacities and space. One area of responsibility of HaDEA is to improve EU networking and provide support for public health reference laboratory functions for AMR in *Salmonella* species and *Campylobacter* species in human samples.\(^{10}\) The FWD AMR-RefLabCap project\(^ {11}\) (2021–2024) is a major initiative of HaDEA, which supports capacity building of public health reference laboratories responsible for the microbiological analyses, including antimicrobial susceptibility testing, of food-borne bacteria from human infections. The outcomes are to strengthen preparedness to respond to food-borne outbreaks and improve prevention and management of AMR from zoonotic bacteria. The project will achieve this by supporting the implementation and greater use of whole genome sequencing (WGS) in all laboratories, improving networking of national reference laboratories, and strengthening molecular surveillance of AMR throughout the EU.

This EU Summary Report (EUSR) on AMR includes data related to the occurrence of AMR in isolates from animals, foodstuffs and humans. The EUSR on AMR is a collaboration between EFSA and ECDC with the assistance of EFSA’s contractors. EU MSs, European Free Trade Association (EFTA), the European Commission and the relevant EU Reference Laboratory for antimicrobial resistance (EURL-AR) are consulted while preparing the report. The efforts made by the MSs, and the other reporting countries are gratefully acknowledged.

Data on AMR collected by the EU MSs and compiled in the EUSR on AMR are also used to perform wider analyses, such as the Joint Report on Consumption of Antimicrobial Agents and AMR in animals, food, and humans – Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA), produced by ECDC, EFSA and EMA, under a One Health approach on a regular basis (2015, 2017, 2021) (ECDC, EFSA, and EMA, 2021). The JIACRA report provides evidence-based analysis of the possible association between AMC and AMR in humans and food-producing animals by focusing on combinations of antimicrobials and bacterial species considered important for public health.

### 1.1. Monitoring and reporting of antimicrobial resistance in the EU\(^ {12}\)

#### 1.1.1. Humans: monitoring of antimicrobial resistance

Together with its Food- and Waterborne Diseases and Zoonoses (FWD) network, ECDC has developed an EU protocol for harmonised monitoring of AMR in human *Salmonella* and *Campylobacter* isolates (ECDC, 2016, 2021). This document is intended for the National Public Health Reference Laboratories to guide the susceptibility testing required for EU surveillance and reporting to ECDC. Consultation was also sought from EFSA, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the EURL-AR to facilitate comparison of data between countries and with results from the AMR monitoring performed in isolates from animals and food products. The protocol is effective from 2014 and supports the implementation of the 2017 European Commission Action Plan on AMR. One of the recommendations is that, for the joint report with EFSA, human data should also be interpreted based on EUCAST epidemiological cut-off values (ECOFFs).\(^ {13}\) As this requires quantitative data, ECDC introduced reporting of quantitative antimicrobial susceptibility testing (AST) results in the 2013 data collection. From 2019 data collection, it has also been possible to report resistance predicted from whole genome sequencing. Since Decision 2018/945/EU came into force in July 2018, national public health reference laboratories are obliged to report their AMR test results to ECDC according to the methods and criteria specified in the EU protocol.

The protocol also proposes a testing algorithm for screening and confirmation of ESBL-producing *Salmonella* spp., including detection of AmpC. Some laboratories have implemented this, while others use a modification of the algorithm or test the suspected isolates directly with PCR or WGS.

---

\(^{10}\) [https://etendering.ted.europa.eu/cft/cft-display.html?cftId=5967

\(^{11}\) [https://www.fwdame-reflabcap.eu/]

\(^{12}\) Additional information on Materials and methods can be found in Appendix F. and links to supporting data for this chapter (Annex A–E) are provided in Appendix G.

\(^{13}\) The epidemiological cut-off (ECOFF) values separate the naive, susceptible wild-type bacterial populations from isolates that have developed reduced susceptibility to a given antimicrobial agent (Kahlmeter et al., 2003). The ECOFFs may differ from breakpoints used for clinical purposes, which are set out against a background of clinically relevant data, including therapeutic indication, clinical response data, dosing schedules, pharmacokinetics and pharmacodynamics. The use of harmonised methods and ECOFFs ensures the comparability of data over time at the country level and facilitates the comparison of resistance between MSs.
External quality assessments to support laboratories in implementing the recommended test methods and antimicrobials and obtaining high-quality AST results are provided by ECDC via a contract with Statens Serum Institute in Denmark.

1.1.2. Animals and food: monitoring of antimicrobial resistance

According to Commission Implementing Decision (EU) 2020/1729, which applies from 1 January 2021 until December 2027, monitoring of AMR is mandatory in Salmonella spp., Campylobacter coli (C. coli), Campylobacter jejuni (C. jejuni) and indicator E. coli, in the major domestically produced animal populations and their derived meat. Further characterisation is required for E. coli and Salmonella isolates showing resistance to extended-spectrum cephalosporins and carbapenems. Moreover, specific monitoring of ESBL-, AmpC- and carbapenemase (CP)-producing E. coli is also required. Monitoring is performed on a rotating basis, targeting fattening pigs and bovine animals under 1 year of age and meat derived thereof in odd years and poultry populations (broilers, laying hens, fattening turkeys) and derived meat in even years, as specified by the legislation.

Monitoring AMR in food-producing animals is performed in domestically produced animal populations, corresponding to different production types to collect data that could be combined with data on exposure to antimicrobials. From 2021, monitoring of imported fresh meat at border control posts shall also be undertaken to complement AMR monitoring in food-producing animals. MSs may also voluntarily perform complementary monitoring for MRSA. Representative random sampling of food-producing animals and derived meat is based on a generic proportionate stratified sampling and performed according to the legislation and the technical specifications issued by EFSA.

Microdilution methods for testing should be used and results interpreted using EUCAST ECOFFs to understand ‘microbiological’ resistance. The harmonised panels of antimicrobials used for Salmonella, Campylobacter and indicator E. coli include substances important for human health, such as critically important antimicrobials (CIAs), and can provide clearer insight into the resistance mechanisms involved. The concentration ranges to be used encompass both the ECOFF and the clinical breakpoints (CBPs), as defined by EUCAST, allowing for comparison with data coming from humans. For Salmonella and E. coli, a supplementary panel of antimicrobial substances for testing isolates showing resistance to third-generation cephalosporins or carbapenems in the first panel is also used. From 2021, whole genome sequencing (WGS) is authorised as an alternate method to conventional phenotypic testing for isolates obtained for the specific monitoring of ESBL/AmpC/CP-producing E. coli and for indicator E. coli or Salmonella spp. isolates showing resistance to extended-spectrum cephalosporins and carbapenems from routine monitoring. WGS is authorised on a voluntary basis only; however; technical conditions on the WGS technique have been imposed to ensure data comparability (EFSA, 2020).

External quality assurance is provided by the EURL-AR, which distributes panels of well-characterised organisms to all MSs for susceptibility testing, arranges proficiency tests (PTs) trials for the National Reference Laboratories for Antimicrobial Resistance (NRLs-AR) of the MSs every year, and, together with EFSA and the MSs, performs a reference testing exercise that includes re-testing the antimicrobial susceptibility and WGS analysis of selected isolates (Appendix F, Materials and methods). The EURL-AR also provides a source of reference for MSs when there are issues or problems with the susceptibility test methodology.

Data reporting is performed at the isolate level to enable analyses on the occurrence of resistance and patterns of multidrug resistance (MDR). The reporting of isolate-based data also allows in-depth phenotypic characterisation of certain resistance mechanisms, e.g. third-generation cephalosporin and carbapenem resistance. The voluntary reporting of WGS data from 2021 on ESBL/AmpC/CP-producing E. coli and Salmonella isolates will facilitate an understanding of the potential contribution of food-producing animals and derived food to the burden of AMR in humans (EFSA, 2019).

1.2. Further harmonised monitoring of antimicrobial resistance

To facilitate data comparability, the AMR surveillance methodology should be harmonised across countries as much as possible. The main issues when comparing AMR data originating from different countries are the use of various laboratory methods and different interpretive criteria for resistance. These issues have been addressed by the development of ECDC’s protocol for harmonised monitoring and reporting of resistance in humans and by the legislation on harmonised monitoring in food-producing animals and derived meat. To respond effectively to the constantly evolving threat of AMR, ongoing enhancement and specific adaptations will be regularly required. Under the 2017 Action Plan on AMR, the European Commission is committed to reviewing this legislation to consider new scientific
developments and data collection needs. In 2019, EFSA received a mandate from the European Commission to provide recommendations on harmonised randomisation procedures for AMR monitoring. The new technical specifications were published in November 2020 (EFSA, 2020), with the new legislation on the monitoring and reporting of AMR in animals and food enacted on 17 November 2020 (see text box below).

### New legislation on the monitoring and reporting of AMR in animals and food comes into effect on 1 January 2021

Monitoring of AMR is essential to have comprehensive and reliable information on the development and spread of resistant bacteria and resistant determinants. AMR data provide insights to inform decision-making and facilitate the development of appropriate strategies and actions to manage AMR at the EU level. In its Communication of 29 June 2017 to the Council and the European Parliament – A European One Health Action Plan against AMR, the Commission committed to review EU implementing legislation, namely Commission Implementing Decision (EU) 2013/652, on monitoring AMR in zoonotic and commensal bacteria in food-producing animals and food to take into account new scientific developments and data collection needs. After this, EFSA issued the new technical specifications, for implementing updated guidelines for the harmonised monitoring of AMR in food-producing animals and derived meat and to ensure continuity in assessing occurrence and temporal trends in resistance (EFSA, 2019).

On November 17, 2020, the European Commission laid down the new technical specifications in Commission Implementing Decision (EU) 2020/1729 and repealed Commission Implementing Decision (EU) 2013/652. The new legislation came into effect on 1 January 2021, and updates technical specifications for harmonised AMR monitoring and reporting to include the monitoring of AMR in derived meat sampled at border control posts, the testing of new substances, and authorises WGS as an alternate method to phenotypic testing, for the specific monitoring of ESBL/AmpC/CP-producing *E. coli* and indicator *E. coli* and *Salmonella* isolates with resistance to extended cephalosporins or carbapenems. The new rules apply to monitoring performed in 2021 onwards.

1.3. The 2020–2021 EU Summary Report on AMR

This EUSR presents AMR data on zoonotic and indicator bacteria from humans, animals and food collected in 2020 and 2021, jointly analysed by the EFSA and the ECDC. This report includes an introduction section, followed by five main chapters on AMR in *Salmonella*, *Campylobacter*, indicator *E. coli*, ESBL/AmpC/CP-producing *Salmonella* and *E. coli*, and MRSA, with sections detailing resistance in isolates from humans, food-producing animals and derived meat. A section on key findings is located at the end of each chapter. Appendices containing complementary information are available at the end of the report. The list of annexes is available on the EFSA Knowledge Junction community on Zenodo: https://doi.org/10.5281/zenodo.7544221.

For food-producing animals and derived meat, most data reported by the MSs in 2021 comprised data collected in accordance with Commission Implementing Decision (EU) 2020/1729. For 2020, the data collected by MSs were in accordance with Commission Implementing Decision (EU) 2013/652 (repealed on 17 November 2020). Quantitative antimicrobial susceptibility data for *Campylobacter*, *Salmonella* and indicator *E. coli* isolates from animals and food were interpreted using ECOFFs. The occurrence of resistance, complete susceptibility (CS) and MDR is reported at the country and EU level, along with the results from the phenotypic monitoring of resistance to third-generation cephalosporins and/or carbapenems caused by ESBL/AmpC/CP-producing *Salmonella* and *E. coli*. Results from the monitoring of MRSA in food and animals are also reported for countries that contribute data.

For human data in 2021, MSs reported results from antimicrobial susceptibility testing of *Salmonella* spp. and *Campylobacter* spp. isolates from clinical cases of salmonellosis and campylobacteriosis. Phenotypic test results were reported by MSs to TESSy either as quantitative or categorical/qualitative data at the isolate level according to the EU protocol for harmonised monitoring of AMR in human *Salmonella* and *Campylobacter* (ECDC, 2016, 2021). Quantitative phenotypic data were interpreted using EUCAST ECOFFs, where available, to understand microbiological resistance. Qualitative phenotypic data were interpreted using clinical breakpoints (CBPs). CBPs enable clinicians to choose the appropriate treatment based on information relevant to the individual patient while ECOFFs help epidemiologists identify small changes in bacterial susceptibility, which may indicate emerging resistance and allow for appropriate control measures to be considered. The breakpoints for
'clinical' resistance are often less sensitive than the ECOFF for a specific bacterium–drug combination resulting in higher levels of 'microbiological' resistance than 'clinical' resistance. By combining the categories of 'clinically resistant' (R) and 'susceptible with increased exposure' (I) into one category, however, close correspondence with the ECOFF can be achieved. A couple of countries reported resistance predicted from WGS. Such results are considered to correspond to the ECOFF with a separation between wild-type and non-wild-type isolates. For assessing MDR in *Salmonella* and *Campylobacter*, ECDC and EFSA have agreed on a harmonised panel of nine and four antimicrobial classes, respectively, for better comparison between the two sectors.

Information on the materials and methods used in this EUSR on AMR can be found in Appendix F – ‘Materials and methods’ at the end of this document. Additional information on the human data reported in 2020 can also be found in the European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2019/2020 (EFSA and ECDC, 2022).

**Effect of the UK withdrawal on the analysis of AMR data at the EU**

As a consequence of the UK withdrawal from the EU on 31 January 2020, the entry into force of the Withdrawal Agreement was ratified by the UK and the EU. The AMR data retrieved until 2019 covered all 28 EU Member States (MSs), which during that period included the UK. From 1 February 2020, the UK withdrew and became a 'third-country' in relation to the EU, with final withdrawal effective after a transition period ending on 31 December 2020. The UK's withdrawal from the EU impacts the AMR data reported at the EU level in 2020 and 2021. UK data from 2020 are included in reporting and are shown with non-MSs in the relevant tables and figures in this report. For 2021, data at the EU level are reported in accordance with the membership of the EU (i.e. EU without the UK). In 2021, the only United Kingdom data that were reported to EFSA were from Northern Ireland. In accordance with the Agreement on the withdrawal of the United Kingdom from the European Union, and in particular with the Protocol on Ireland/Northern Ireland, the European Union requirements on data sampling are also applicable to and in the United Kingdom with respect to Northern Ireland. Therefore, pursuant to Article 5(4) and Section 24 of Annex 2 of the Protocol on Ireland/Northern Ireland, which is an integral part of the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, for the purpose of this report, references to MSs should be read as including Northern Ireland, despite it being part of the United Kingdom. Hence, the European Union requirements on data sampling were also applicable to Northern Ireland and data transmitted by the United Kingdom (Northern Ireland) have been assigned to the MSs group.

Monitoring of non-typhoidal Salmonellas

Non-typhoidal Salmonellas (NTS) are the focus of this section, which summarises the occurrence and AMR patterns of isolates recovered from various food-producing animal populations and their derived carcases. Whereas typhoidal salmonellas are human host-adapted organisms that cause typhoid fever and paratyphoid fever; non-typhoidal strains may be host generalists, infecting or colonising a broad range of animals or tend to host specificity to particular animal species (Crump et al., 2015). Typhoidal salmonellas refer to Salmonella enterica subsp. enterica serovars Typhi, Paratyphi A, Paratyphi B (d-tartrate negative) and Paratyphi C, while all other serovars within the subspecies enterica (including the d-tartrate positive Paratyphi B variant Java) refer to NTS.

The WHO states that transmission of bacterial infection from non-human sources to humans, with the ability to cause disease, is more evident in particular bacteria (including non-typhoidal Salmonella, Campylobacter spp. and E. coli) and comments that the potential for such transmission should be recognised (WHO, 2019). In 2021, salmonellosis was the second most common food-borne zoonosis in the European Union, with 60,050 confirmed human cases (an increase compared with 2020 but still about a 20% decrease compared with the pre-pandemic situation in 2019), as well as the most frequent cause of food-borne outbreaks accounting for 19% of all food-borne outbreaks reported in 2021 (EFSA and ECDC, 2022).

2.1. Key findings

- Among the reporting countries the number of Salmonella spp. in isolates from human cases varied considerably: Out of 26 reporting countries (inclusive of EU/EAA countries), six countries reported on very few (<100) human isolates, while three countries reported more than 1,000 isolates.
- Overall resistance to ampicillin, sulfonamides, and tetracyclines was observed at high levels in Salmonella spp. isolates from humans in 2021 and ranged from moderate to very high in isolates from food-producing animals and poultry carcases, except for laying hens where low levels of resistance were reported.
- Over the period, 2013–2021, declining trends in resistance to ampicillin and tetracyclines in isolates from humans was observed in 13 and 11 countries, respectively, accompanied by declines in Salmonella Typhimurium, a serovar commonly associated with pigs and calves.
- Overall resistance to fluoroquinolones (ciprofloxacin) was observed at moderate levels in Salmonella isolates from fattening pigs (10.1%) and bovine animals under 1 year of age (calves) (12.7%) from data reported in 2021, and at high to very high levels among isolates recovered from broilers (57.5%), fattening turkeys (65.0%), broiler carcases (69.3%) and turkey carcases (46.9%) in 2020. In Salmonella isolates from humans reported in 2021, the average resistance to ciprofloxacin was 14.9%, with lowest levels observed in S. Typhimurium (7.6%) and S. Typhimurium, monophasic variant (8.9%) and high to extremely high levels in S. Infantis (33.9%) and S. Kentucky (78.1%).
- Extremely high resistance to ciprofloxacin was also reported in S. Kentucky isolates from broilers (78.0%), laying hens (91.9%), fattening turkeys (96.6%), broiler carcases (100%) and turkey carcases (93.3%). In S. Enteritidis, the most common serovar detected in humans, resistance to ciprofloxacin and nalidixic acid was 22.6% and 24.8%, respectively. Resistance trends calculated for 2013 to 2021 for human data showed increasing trends in resistance to ciprofloxacin in nine MSs and decreasing trends in five MSs, primarily accompanied by an increase in S. Enteritidis.
- Overall resistance to third-generation cephalosporins was noted at very low levels in isolates from humans in 2021 (1.1% to ceftazidime and 1.1% to cefotaxime on average) and was seldom detected in animal and carcase origins in 2020–2021, except for calves (2.6% to cefotaxime and 1.3% to ceftaroline) and broiler flocks (2.1% to cefotaxime and 2.0% to ceftazidime). Overall, combined resistance to fluoroquinolones and cephalosporins was very low in isolates from both humans and animals but higher in certain Salmonella serovars, e.g. S. Kentucky and S. Infantis.
Among isolates from human cases, *S. Enteritidis* had the highest levels of resistance to ciprofloxacin and colistin (22.6% and 17.6%, respectively) compared to all serovars (14.9% and 5.1%, respectively). *S. Kentucky* isolates from human cases were characterised by overall high to extremely resistance levels for ampicillin 62%, ciprofloxacin 77%, tetracycline 57%, sulfamethoxazole 51%, gentamicin 27.9%, and low to moderate levels of resistance to cefotaxime/cefazidime 6% and chloramphenicol 12.6%.

Multidrug resistance (MDR) was overall high (22.5%) among *Salmonella* spp. reported in human cases in the EU, ranging from low levels among *S. Enteritidis* (1.9%) to very high among *S. Kentucky* (54.8%) and extremely high for monophasic *S. Typhimurium* 1,4,[5],12:i- (78.4%). Similarly, MDR was observed at moderate to very high levels in *Salmonella* spp. recovered from carcasses of turkeys and broilers (19.1% and 53.6%, respectively) and at high levels for fattening pigs (39.1%), calves (30.4%), fattening turkeys (41.7%) and fattening broilers (44.0%), except for laying hens which had low-level MDR (6.0%).

Overall, in 2021, complete susceptibility (CS) in *Salmonella* spp. isolates from humans was observed to be 60.0%. For animal data where there is some difference in the harmonised panel of antimicrobials included for CS analysis compared to human data (e.g. inclusion of amikacin for 2021 animal data), CS was high for pigs (40.5%) and very high in calves (55.7%). For 2020 data on poultry flocks and carcass origins, CS ranged from high (24.4%) in meat from broilers to extremely high (75.6%) in laying hens.

At the reporting EU group level, the overall proportion of presumptive ESBL- or AmpC-producers was from very low to low among *Salmonella* isolates recovered from all food-producing animal populations and carcasses of broilers and very low in isolates from human cases, although higher resistance was observed in specific *Salmonella* serovars. No carbapenemase-producing *Salmonella* spp. were isolated from human cases in 2021, nor in animal isolates from 2020 to 2021.

### 2.2. Data on AMR in *Salmonella* spp. addressed

Commission Implementing Decision (EU) 2020/1729 stipulates detailed protocols for harmonising AMR monitoring and reporting in zoonotic and commensal bacteria. In 2020, the monitoring of carcasses of broilers and fattening turkeys at slaughter was mandatory, in accordance with Regulation (EC) No 2073/2005. Additionally, in 2020, the monitoring of AMR in *Salmonella* isolates recovered from faecal samples and/or environmental samples (boot swabs or dust) of broiler, laying hen and fattening turkey flocks was mandatory, in accordance with Regulation (EC) No 2160/2003, collected as part of National Control Programmes (NCPs) for *Salmonella* in poultry. While for 2021, the AMR monitoring in *Salmonella* isolates recovered from caecal contents of fattening pigs and bovine animals under 1 year of age taken at slaughter was mandatory.

This chapter describes 2021 AMR data from bovine animals under 1 year of age (referred to as ‘calves’) and fattening pigs (referred to as ‘pigs’). As well as 2020 AMR data on *Salmonella* isolates collected from flocks of broilers, fattening turkeys, and laying hens. Data for *Salmonella* spp. from human cases are reported for both 2020 and 2021. Section 2.3 however only presents data for 2021 since 2020 data from humans were published in the EU Summary report for 2019/2020 (EFSA and ECDC, 2022). Results from antimicrobial susceptibility testing (AST) in *Salmonella* isolates from human cases includes that of prevalent serovars corresponding to those occurring in animal species.

Data from *Salmonella* spp. isolates include results for all serovars reported from the different carcasses/animal origins, with one isolate per *Salmonella* serovar from the same epidemiological unit per year being tested for AMR (Commission Implementing Decision (EU) 2020/1729). As the potential for acquiring AMR markedly varies between serovars, the relative contribution of different serovars to the total occurrence of resistance results can influence the overall resistance levels reported for *Salmonella* spp. for the different carcasses/animal origins. Therefore, results are also presented for selected serovars if they have a high prevalence (i.e. recovery rate from samples) or are considered important to public health. Resistance profiles were also considered when less than ten isolates were recovered from a given carcass/animal in a country to account for the low prevalence of certain serovars, to prevent exclusion of emerging serovars, and to ensure that the analysis included all relevant data. Note that some figures in this chapter only present individual MS data where ten or more *Salmonella* spp. were reported, although the occurrence of resistance at the MS-group level includes all reported isolates.
Variations in *Salmonella* prevalence from food-producing animal or carcase origins

In 2020 and 2021, countries reported *Salmonella* spp. data from the different origins according to their national situation. Of note, some MSs did not obtain any *Salmonella* isolates from animal or meat origins, therefore data are not presented for those countries. In 2020, the number of countries reporting results for broiler carcases was considerably higher than for turkey carcases because the size of the turkey sector is relatively small in some MSs, with production levels below the threshold at which mandatory monitoring is required. Similarly, in 2021, the number of MSs reporting data from pigs was considerably higher than MSs reporting data from calves. Additionally, the number of isolates reported by countries differed due to varying *Salmonella* prevalence, and these factors may introduce a source of variation in results when considering all reporting countries.

In this chapter, the occurrence of resistance refers to microbiological resistance (i.e. determined by the ECOFF value) unless otherwise stated. The level of resistance is described as either ‘rare’: < 0.1%, ‘very low’: 0.1%–1.0%, ‘low’: > 1%–10.0%, ‘moderate’: > 10.0%–20.0%, ‘high’: > 20.0%–50.0%, ‘very high’: > 50.0%–70.0%, ‘extremely high’: > 70.0%. The significance of a given level of resistance depends on the antimicrobial substance and its relative importance in human and veterinary medicine. The small sample size from some reporting countries should be considered when interpreting results.

2.3. Humans: occurrence of antimicrobial resistance in *Salmonella*

2.3.1. Data reported

For 2021, 24 MSs and two non-MSs reported data on AMR in *Salmonella* isolates from human cases of non-typhoidal salmonellosis. This is four countries more than in 2020. Twenty-one countries provided data as measured values (quantitative data), four as data interpreted with clinical breakpoints and one as predicted phenotypic resistance based on whole genome sequencing. Not all countries reported results for all antimicrobials in the harmonised panel (ECDC, 2016, 2021). The reported data represented 20.6% of the confirmed human cases with non-typhoidal *Salmonella* reported in the EU/EEA in 2021.

2.3.2. Occurrence of resistance to commonly used antimicrobials in human and/or veterinary medicine

In 2021, high proportions of human *Salmonella* isolates were resistant to ampicillin (25.3%), sulfonamides (26.8%), and tetracyclines (26.2%) (see Figure 1; Table 1; Annex A). By serovar, resistance to these compounds ranged from low (3.1%–4.9%) in *S. Enteritidis* to extremely high in *S. Kentucky* (51.6%–62.9%) and monophasic *S. Typhimurium 1,4,[5],12:i:-* (84.5%–88.2%) (Annex A, Tables 2, 4, and 6). The variation in the proportion of resistance was large when considering countries reporting ten or more isolates. Overall, for all *Salmonella* spp., outliers in terms of high proportion of resistance were observed in Luxembourg for sulfonamides (75.0%) and Italy for tetracycline (52.4%) (Annex A, Table 1). For *S. Enteritidis*, outliers with a high proportion of resistance were observed in Greece (28.0%) and Luxembourg (70.7%) for sulfonamides, and in Slovakia for tetracycline (15.0%) (Annex A, Table 2). For *S. Typhimurium*, outliers were observed in Lithuania for ampicillin (90.9%), and Luxembourg for sulfonamides (71.4%) (Annex A, Table 3). For monophasic *S. Typhimurium 1,4,[5],12:i:-, Estonia and Sweden reported a higher proportion of ampicillin resistance (100%) compared to other countries and Austria and Hungary a lower proportion (70.5% and 78.3%, respectively) (Annex A, Table 4). Austria also reported a lower proportion of resistance to sulfonamides in the same serovar. For *S. Infantis*, Italy reported a much higher proportion of resistance to ampicillin than the EU average (65.6% vs. 15.7%) and for tetracycline (81.2%), along with Austria (64.2%) (Annex A, Table 5). Considering *S. Derby*, only France observed high levels of resistance to sulfonamides (43.1%) (Annex A, Table 7). Only three countries reported more than 10 *S. Kentucky* isolates, meaning there was insufficient data to be included in the analysis presented in Figure 1.
Overall, resistance to gentamicin was low (1.8%) and across all reported serovars (Annex A, Tables 1–7) except in S. Kentucky where gentamicin resistance was high (27.9%) at the EU level (Annex A, Table 6). Similarly, levels of trimethoprim resistance were overall low among *Salmonella* spp. (5.8%) (Annex A, Table 1), but moderate in S. Infantis (15.5%) and high in S. Kentucky (24.4%) (Annex A, Tables 5 and 6).

Figure 1: Occurrence of resistance to selected and critically important antimicrobials in *Salmonella* spp. and selected serovars isolated from humans, 2021

Table 1: Occurrence of resistance to selected and critically important antimicrobials in *Salmonella* spp. and selected serovars from humans, 2021

<table>
<thead>
<tr>
<th>EU total</th>
<th>AMP</th>
<th>SMX</th>
<th>TET</th>
<th>CIP</th>
<th>CTX</th>
<th>Combined CIP/CTX</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Salmonella</em> spp. (24 MSs)</td>
<td>11,832</td>
<td>6,872</td>
<td>10,949</td>
<td>11,725</td>
<td>11,572</td>
<td>11,532 0.8</td>
</tr>
<tr>
<td>S. Enteritidis (23 MSs)</td>
<td>3,194</td>
<td>1,724</td>
<td>2,616</td>
<td>3,103</td>
<td>3,005</td>
<td>2,973 0</td>
</tr>
<tr>
<td>S. Typhimurium (22 MSs)</td>
<td>1,382</td>
<td>872</td>
<td>1,330</td>
<td>1,373</td>
<td>1,355</td>
<td>1,353 0.9</td>
</tr>
<tr>
<td>Monophasic S. Typhimurium (17 MSs)</td>
<td>1,958</td>
<td>1,236</td>
<td>1,913</td>
<td>1,958</td>
<td>1,957</td>
<td>1,957 1.2</td>
</tr>
<tr>
<td>S. Infantis (20 MSs)</td>
<td>530</td>
<td>336</td>
<td>499</td>
<td>528</td>
<td>525</td>
<td>525 5.0</td>
</tr>
<tr>
<td>S. Kentucky (12 MSs)</td>
<td>105</td>
<td>62.9</td>
<td>86</td>
<td>105</td>
<td>105</td>
<td>105 5.7</td>
</tr>
<tr>
<td>S. Derby (14 MSs)</td>
<td>261</td>
<td>10.3</td>
<td>259</td>
<td>260</td>
<td>261</td>
<td>260 1.2</td>
</tr>
</tbody>
</table>
2.3.3. Occurrence of resistance to highest-priority critically important antimicrobials (hpCIAs) and last resort antimicrobials

The proportion of *Salmonella* isolates resistant to the highest-priority critically important antimicrobial (hpCIA) ciprofloxacin was overall 14.9% (see Figure 1; Table 1). A high proportion of resistance to ciprofloxacin was observed in *S. Infantis* isolates (33.9%), while an extremely high proportion was observed in *S. Kentucky* isolates (78.1%) (Figure 1; Annex A, Tables 5 and 6). At the country-level, an extremely high proportion of ciprofloxacin in *Salmonella* spp. was observed in Poland (90.7%), with much of the resistance to be found in *S. Enteritidis* isolates (95.5%) (Annex A, Tables 1 and 2). For Poland, 2021 is the first year that quantitative data has been provided to ECDC, allowing for the application of the most up to date ECOFF and CBP to the test values. Austria and Italy also reported extremely high resistance to ciprofloxacin in *S. Infantis* isolates (73.6% and 81.3%, respectively) (Annex A, Table 5). Caution should be taken when interpreting results for some countries as they report data on a small number of isolates.

For cefotaxime and ceftazidime, representing third-generation cephalosporins, another class of hpCIAs for *Salmonella*, resistance levels were generally low among *Salmonella* spp. (1.1%, respectively) (Annex A, Table 1), with low levels of resistance ranging from 0.1% to 6.2% across the serovars of interest (Annex A). Resistance was more pronounced in *S. Infantis* and *S. Kentucky* isolates (range: 5.2%–6.2%) (Annex A, Tables 5 and 6). When only considering countries with more than 10 isolates for a serotype, more reported low resistance to either third-generation cephalosporin, except for Italy, which reported very high resistance in *S. Infantis* isolates (59.4% and 56.3%, respectively) (Annex A, Table 5).

Only nine countries tested resistance to last line antimicrobials azithromycin and tigecycline. Resistance was overall low among *Salmonella* spp. (0.5% and 1.4%, respectively, Annex A, Table 1). Among the individual serovars, the highest proportion of isolates resistant to azithromycin was observed in *S. Infantis* and *S. Derby* (both 2.0%) and *S. Kentucky* (3.9% – see Annex A, Tables 5–7). In 2021, the ECOFF applied for azithromycin was changed from MIC $> 1$ mg/L to MIC $> 0.5$ mg/L to harmonise with EFSA animal and carcase data. This likely explains the higher proportion of isolates resistant to azithromycin compared to 2020 (1.4% compared to 0.2%) Resistance to colistin was detected in 5.1% of *Salmonella* isolates, with resistance being most pronounced in *S. Enteritidis* isolates (17.6%), a serovar belonging to group D *Salmonella* which tend to show a higher natural tolerance to colistin (Agersø et al., 2012; Ricci et al., 2020).

Combined resistance to both ciprofloxacin and cefotaxime was overall very low in *Salmonella* spp. in human cases (0.8%) (Figure 2a; Annex A, Table 8). Notably, for *S. Enteritidis*, combined resistance to ciprofloxacin and cefotaxime was only reported in one isolate out of 2,973 (< 0.1%) (Annex A, Table 8). Similarly, for *S. Typhimurium* and monophasic *S. Typhimurium*, combined resistance was also observed to be very low or low (0.9% and 1.2%, respectively) (Figure 2c). When considering other serovars, combined resistance was observed to be low in *S. Derby* isolates (1.2%) and higher in *S. Infantis* and *S. Kentucky* isolates (overall 5.0% and 5.7%, respectively) although few countries reported more than ten isolates (Figure 2b; Annex A, Tables 11 and 12). For *S. Infantis*, Italy was the major contributor to overall combined microbiological and clinical resistance, with 56.3% of isolates displaying combined resistance (Figure 2b; Annex A, Table 11).
2.3.4. ESBL, AmpC and carbapenemase-producing Salmonella

In 2021, of the 23 MSs and one non-MS reporting data on third-generation cephalosporins, 16 MSs and one non-MS reported very low- or low-level resistance, and six MSs reported no resistance. Two countries reporting cephalosporin-resistant isolates did not provide further details on phenotypic/genotypic characterisation, and these isolates were excluded from analysis in Table 2 and Annex A, Table 15. A small number of isolates from one country that were not further typed were also not included in Table 2 and Annex A, Table 15. In Italy, there is a special focus on ESBL/AmpC monitoring in Salmonella where primary laboratories are requested to send any isolates resistant to cefotaxime and/or ceftazidime to the national public health reference laboratory for confirmation. This may have resulted in an overrepresentation of such isolates in the Salmonella AMR dataset from Italy.

Presumptive ESBL-producing Salmonella were identified in 0.8% of the tested isolates, ranging by MS from 0.1% in Belgium to 3.5% in Italy (Annex A, Table 15). AmpC was less frequent, identified in 0.1% of tested isolates, with the highest occurrence in Italy (1.3%). No isolates were reported presumptive AmpC- and ESBL-producing, or as carbapenemase-producing Salmonella (Annex A, Table 15). ESBL was reported in 12 serovars (and in S. enterica subspecies I) in 2021, with the highest proportions observed in S. Infantis isolates (5.2%, n = 517), S. Kenya (5.3%, n = 19) and S. enterica subspecies I (4.5%, n = 44) (Table 2). AmpC-type β-lactamases were overall reported in 0.1% of tested isolates and in five serovars, with the highest proportion observed in S. Goldcoast (5.1%, n = 39). No isolates were reported as resistant to meropenem in 2021 (Annex A, Table 1). It should however be noted that in six of 24 reporting countries, meropenem results were interpreted using the EUCAST clinical breakpoint (CBP), which is substantially higher (+4 dilutions) than the ECOFF.
2.3.5. Complete susceptibility (CS) and multidrug resistance (MDR)

In this report, complete susceptibility (CS) is defined as susceptibility to each of the nine antimicrobial classes tested in the harmonised panel described by the ECDC (ECDC, 2016, 2021). Multidrug resistance (MDR) is defined as resistance to three or more antimicrobial classes among Salmonella isolates from human cases.

The level of CS was 60.0% in Salmonella spp. with the highest proportion in S. Enteritidis (72.1%), followed by S. Derby (61.5%), S. Typhimurium (58.9%) and S. Infantis (54.5%). The lowest levels of CS were observed in S. Kentucky (19.4%) and monophasic S. Typhimurium (4.5%) (Figure 3; Annex A, Tables 16–22).

MDR was high overall (22.6%, n = 6,867) among Salmonella spp. reported from human cases in the EU (Figure 3; Annex A, Table 16). For the investigated serovars, MDR was most frequently reported among monophasic S. Typhimurium 1,4,[5],12:i:- (78.4%, n = 871), S. Kentucky (54.8%, n = 62), followed by S. Infantis (38.1%, n = 336), S. Typhimurium (23.0%, n = 871), S. Derby (10.1%, n = 148) and lastly S. Enteritidis (1.9%, n = 1,722) (Figure 3; Annex A, Tables 17–22). Ten isolates (four S. Infantis, three S. Typhimurium and one each of S. Brandenburg, S. enterica subsp. I and monophasic S. Typhimurium) were resistant to eight of the nine tested substances, only susceptible to meropenem.

<table>
<thead>
<tr>
<th>Serovar</th>
<th>Tested for CTX and/or CAZ</th>
<th>Res to CTX and/or CAZ</th>
<th>Resistance phenotype</th>
<th>Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>S. Brandenburg</td>
<td>110</td>
<td>2</td>
<td>1.8</td>
<td>blaCMY-2 (1), blaCMY-4 (1)</td>
</tr>
<tr>
<td>S. Derby</td>
<td>260</td>
<td>4</td>
<td>3</td>
<td>blaCTX-M-1 (3)</td>
</tr>
<tr>
<td>S. Enteritidis</td>
<td>2,448</td>
<td>1</td>
<td>1</td>
<td>Unknown</td>
</tr>
<tr>
<td>S. Give</td>
<td>34</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-3 (1)</td>
</tr>
<tr>
<td>S. Goldcoast</td>
<td>39</td>
<td>2</td>
<td>5.1</td>
<td>blaCMY-2 (2)</td>
</tr>
<tr>
<td>S. Paratyphi B var Java</td>
<td>53</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M (1)</td>
</tr>
<tr>
<td>S. Kedougou</td>
<td>32</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-8 (1), blaSHV-12 (1)</td>
</tr>
<tr>
<td>S. Kentucky</td>
<td>105</td>
<td>7</td>
<td>4</td>
<td>blaCTX-M-14 (1), blaCTX-M-14b (1), blaCTX-M (1)</td>
</tr>
<tr>
<td>S. Kenya</td>
<td>19</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-15 (1)</td>
</tr>
<tr>
<td>Monophasic S. Typhimurium 1,4,[5],12:i:-</td>
<td>1,867</td>
<td>30</td>
<td>1.2</td>
<td>6</td>
</tr>
<tr>
<td>S. Newport</td>
<td>234</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-55 (1)</td>
</tr>
<tr>
<td>S. Rissen</td>
<td>49</td>
<td>1</td>
<td>1</td>
<td>blaCMY-2 (1)</td>
</tr>
<tr>
<td>S. Subsp I (enterica)</td>
<td>44</td>
<td>2</td>
<td>2</td>
<td>blaCTX-M-1 (1)</td>
</tr>
<tr>
<td>S. Typhimurium</td>
<td>1,246</td>
<td>14</td>
<td>11</td>
<td>0.9</td>
</tr>
<tr>
<td>S. Worthington</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M (1)</td>
</tr>
</tbody>
</table>

CTX: cefotaxime; CAZ: ceftazidime; ESBL: extended spectrum beta-lactamase. Genotypic data are reported at the family level. Slovakia and Hungary did not report results that could be included in this table.

### Table 2: ESBL, AmpC and carbapenemase phenotypes and genotypes in Salmonella spp. isolates from humans by serovar for all reporting EU/EEA countries, 2021

<table>
<thead>
<tr>
<th>Serovar</th>
<th>Tested for CTX and/or CAZ</th>
<th>Res to CTX and/or CAZ</th>
<th>Resistance phenotype</th>
<th>Genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>S. Brandenburg</td>
<td>110</td>
<td>2</td>
<td>1.8</td>
<td>blaCMY-2 (1), blaCMY-4 (1)</td>
</tr>
<tr>
<td>S. Derby</td>
<td>260</td>
<td>4</td>
<td>3</td>
<td>blaCTX-M-1 (3)</td>
</tr>
<tr>
<td>S. Enteritidis</td>
<td>2,448</td>
<td>1</td>
<td>1</td>
<td>Unknown</td>
</tr>
<tr>
<td>S. Give</td>
<td>34</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-3 (1)</td>
</tr>
<tr>
<td>S. Goldcoast</td>
<td>39</td>
<td>2</td>
<td>5.1</td>
<td>blaCMY-2 (2)</td>
</tr>
<tr>
<td>S. Paratyphi B var Java</td>
<td>53</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M (1)</td>
</tr>
<tr>
<td>S. Kedougou</td>
<td>32</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-8 (1), blaSHV-12 (1)</td>
</tr>
<tr>
<td>S. Kentucky</td>
<td>105</td>
<td>7</td>
<td>4</td>
<td>blaCTX-M-14 (1), blaCTX-M-14b (1), blaCTX-M (1)</td>
</tr>
<tr>
<td>S. Kenya</td>
<td>19</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-15 (1)</td>
</tr>
<tr>
<td>Monophasic S. Typhimurium 1,4,[5],12:i:-</td>
<td>1,867</td>
<td>30</td>
<td>1.2</td>
<td>6</td>
</tr>
<tr>
<td>S. Newport</td>
<td>234</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M-55 (1)</td>
</tr>
<tr>
<td>S. Rissen</td>
<td>49</td>
<td>1</td>
<td>1</td>
<td>blaCMY-2 (1)</td>
</tr>
<tr>
<td>S. Subsp I (enterica)</td>
<td>44</td>
<td>2</td>
<td>2</td>
<td>blaCTX-M-1 (1)</td>
</tr>
<tr>
<td>S. Typhimurium</td>
<td>1,246</td>
<td>14</td>
<td>11</td>
<td>0.9</td>
</tr>
<tr>
<td>S. Worthington</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>blaCTX-M (1)</td>
</tr>
</tbody>
</table>

CTX: cefotaxime; CAZ: ceftazidime; ESBL: extended spectrum beta-lactamase. Genotypic data are reported at the family level. Slovakia and Hungary did not report results that could be included in this table.
2.3.6. Temporal trends

Trends in resistance over the period 2013–2021 were assessed with logistic regression. In 2020, the statistical power of the model used to determine temporal trends was reduced because the number of isolates reported by country was markedly lower in almost all countries compared to previous years as an effect of the pandemic. However, in 2021, most countries reported more data than the year before which has slightly improved the power of the model. Trends varied by country for the different serovars and antimicrobials (Table 3; Annex A, Figures 1–6). As the number of isolates tested in humans is high, small changes in resistance may come out as significant. For Salmonella spp. overall, 13 and 11 countries observed a decrease in resistance to ampicillin and tetracycline, respectively, whereas four and six countries reported an increase. For cefotaxime and ciprofloxacin, six and five countries, respectively, observed a decrease in resistance, while four and nine countries reported an increase (Table 3; Figure 4).

By serovar, increasing trends in resistance were more commonly observed for ciprofloxacin/quinolones in S. Enteritidis (10 countries) and S. Infantis (five countries). Thirteen countries reported decreasing trends in resistance to ampicillin and to tetracycline in S. Typhimurium while for monophasic S. Typhimurium and S. Infantis, increasing trends in ampicillin resistance were observed in six and seven countries (Annex A, Figures 1–6).

Table 3: Number of countries with statistically significant (p < 0.05) increasing or decreasing trends in resistance to selected antimicrobials for Salmonella spp. and selected serovars in humans in 2013–2021

<table>
<thead>
<tr>
<th>Serovar</th>
<th>Ampicillin</th>
<th>Cefotaxime</th>
<th>Ciprofloxacin/quinolones</th>
<th>Tetracycline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salmonella spp. (24 MSs + 3 non-MS)</td>
<td>4 (BE, FI, HU, SI)</td>
<td>13 (BE, DE, DK, EL, ES, FR, HU, IE, IS, LT, PT, SE, UK)</td>
<td>6 (EE, FR, IE, MT, PL, SK)</td>
<td>5 (AT, BE, DE, EE, FI, NL, NO, PL, SK)</td>
</tr>
<tr>
<td>S. Enteritidis (23 MSs + 2 non-MS)</td>
<td>5 (AT, BE, NL, SI, SK)</td>
<td>5 (ES, IE, LT, MT, RO)</td>
<td>–</td>
<td>10 (AT, BE, DE, EE, HU, NO, PL, RO, SI, SK)</td>
</tr>
</tbody>
</table>

Figure 3: Number of multidrug (MDR) resistant isolates, isolates resistant to one and/or two antimicrobial classes and completely susceptible Salmonella isolates from humans in 2021
<table>
<thead>
<tr>
<th>Serovar</th>
<th>Ampicillin</th>
<th>Cefotaxime</th>
<th>Ciprofloxacin/quinolones</th>
<th>Tetracycline</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. Typhimurium</em> (23 MSs + 3 non-MSs)</td>
<td>–</td>
<td></td>
<td>13 (AT, CY, DE, EE, ES, FR, IE, IS, LU, NO, PT, SI, UK)</td>
<td>2 (DE, HU)</td>
</tr>
<tr>
<td>Monophasic <em>S. Typhimurium</em> (15 MSs + 2 non-MSs)</td>
<td>6 (EE, IT, MT, NL, NO, SE)</td>
<td>1 (AT)</td>
<td>1 (IT)</td>
<td>1 (BE)</td>
</tr>
<tr>
<td><em>S. Infantis</em> (12 MSs + 1 non-MS)</td>
<td>7 (AT, BE, FR, HU, LT, NL, SK)</td>
<td>1 (ES)</td>
<td>2 (DE, UK)</td>
<td>1 (BE)</td>
</tr>
<tr>
<td><em>S. Kentucky</em> (7 MSs + 1 non-MS)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (MT)</td>
</tr>
<tr>
<td><em>S. Derby</em> (7 MSs + 1 non-MS)</td>
<td>1 (LT)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

AT: Austria; BE: Belgium; BG: Bulgaria; CY: Cyprus; DE: Germany; DK: Denmark; EE: Estonia; EL: Greece; ES: Spain; FI: Finland; HU: Hungary; FR: France; IS: Iceland; IT: Italy; LI: Luxembourg; LV: Latvia; MT: Malta; NL: Netherlands; NO: Norway; PL: Poland; PT: Portugal; RO: Romania; SE: Sweden; SI: Slovenia; SK: Slovakia; UK: United Kingdom.
2.3.7. High-level ciprofloxacin resistance

In 2021, 1.2% (n = 6,162) of *Salmonella* spp. expressed high-level resistance to ciprofloxacin (MIC $\geq$ 4 mg/L, Table 4). Such isolates were reported from eight of the thirteen countries reporting MIC values for ciprofloxacin. Among the twelve serovars reported with MICs of $\geq$ 4 mg/L, high-level ciprofloxacin resistance was most frequently observed in *S. Kentucky* (81.2% of tested *S. Kentucky*).

**Table 4:** Occurrence of high-level resistance to ciprofloxacin (MIC $\geq$ 4 mg/L) in *Salmonella* serovars from human cases in 2021

<table>
<thead>
<tr>
<th>Serovar</th>
<th>N</th>
<th>High-level resistance to ciprofloxacin (MIC $\geq$ 4 mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td><em>S. Bonn</em></td>
<td>1</td>
<td>NA</td>
</tr>
<tr>
<td><em>S. Enteritidis</em></td>
<td>1,174</td>
<td>0.1</td>
</tr>
<tr>
<td><em>S. Infantis</em></td>
<td>364</td>
<td>0.8</td>
</tr>
<tr>
<td><em>S. Kedougou</em></td>
<td>20</td>
<td>5.0</td>
</tr>
<tr>
<td><em>S. Kentucky</em></td>
<td>69</td>
<td>81.2</td>
</tr>
<tr>
<td><em>S. Newport</em></td>
<td>153</td>
<td>0.7</td>
</tr>
<tr>
<td><em>S. Potsdam</em></td>
<td>5</td>
<td>20.0</td>
</tr>
</tbody>
</table>

Data from the United Kingdom included up to 2019. Trend at EU MS group level is excluding UK data.

**Figure 4:** Trends in resistance to ampicillin, ciprofloxacin/pefloxacin/nalidixic acid, cefotaxime and tetracycline in *Salmonella* spp. from humans in 27 reporting countries and EU MSs group, 2013–2021
Additional data on certain resistance traits of *Salmonella* isolates from humans are provided hereafter and presented in parallel to corresponding data on *Salmonella* spp. from animals and food.

### 2.4. Food-producing animals and meat thereof: occurrence of antimicrobial resistance in *Salmonella*

#### 2.4.1. Data reported

In 2021, 25 MS, the United Kingdom (Northern Ireland) and one non-MS reported AMR data on *Salmonella* isolates recovered from the caecal contents of pigs at slaughter, and 10 MSs reported AMR data on *Salmonella* isolates recovered from the caecal contents of calves at slaughter. In addition, three MSs voluntarily reported AMR data on *Salmonella* isolates recovered from flocks of broilers; six MSs for laying hens and two MSs for fattening turkeys before slaughter. In 2019, under the previous legislation (Commission Implementing Decision (EU) 2013/652), AMR data was mandatory for *Salmonella* isolates recovered from carcases at slaughter, and a similar number of MSs reported AMR data on pigs (26 MSs, one non-MS), and calves (seven MS). While, the sampling of caecal contents for *Salmonella* was voluntary in 2019, and nine MS reported data on pigs, and three MSs reported data on calves.

In 2020, under the previous legislation, AMR data for *Salmonella* isolates recovered from carcases of broilers and fattening turkeys at slaughter, was reported by 18 MSs and two non-MSs for broilers, and 8 MSs for fattening turkeys. Additionally, in 2020, 22 MSs and three non-MSs reported AMR data for *Salmonella* isolates recovered from flocks of broilers; 24 MSs and two non-MSs for laying hens and 16 MSs and one non-MS for fattening turkeys at slaughter.

The reporting of isolate-based data enables the analysis of MDR patterns, the detection of high-level ciprofloxacin resistance and combined resistance to ciprofloxacin and cefotaxime (first-line agents critically important for treating human salmonellosis). As required by Commission Implementing Decision (EU) 2020/1729, the MSs included information on serovars and production type, which allowed for detailed analysis of the occurrence of resistance and MDR by serovar for the different animal/carcase origins (see Appendix C).

### Additional data on resistance traits of *Salmonella*

<table>
<thead>
<tr>
<th>Serovar</th>
<th>N</th>
<th>High-level resistance to ciprofloxacin (MIC $\geq$ 4 mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Rissen</td>
<td>22</td>
<td>1</td>
</tr>
<tr>
<td>S. Saintpaul</td>
<td>27</td>
<td>2</td>
</tr>
<tr>
<td>S. Thompson</td>
<td>30</td>
<td>1</td>
</tr>
<tr>
<td>S. Typhimurium</td>
<td>840</td>
<td>2</td>
</tr>
<tr>
<td>Monophasic S. Typhimurium</td>
<td>1,155</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>209</td>
<td>5</td>
</tr>
<tr>
<td>Other</td>
<td>2,093</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total (13 MSs)</strong></td>
<td><strong>6,162</strong></td>
<td><strong>76</strong></td>
</tr>
</tbody>
</table>

Changes in the harmonised panel of antimicrobial substances for the monitoring of AMR in animals and food for *Salmonella* spp. according to the new legislation

The Commission Implementing Decision (EU) 2020/1729 lays down specific technical requirements, for AMR testing and reporting in representative isolates deriving from randomised sampling in food-producing animals performed at farm and/or at slaughter and derived meat performed at retail and at border control posts. The new rules apply to monitoring performed from 2021 onwards.

In 2021, **amikacin** has been added to the harmonised panel of antimicrobials for the monitoring and reporting of AMR in *Salmonella* and was included in the analyses of the occurrence of resistance, CS and MDR. While amikacin is not used in food-producing animals, it is commonly used in hospitals to treat urinary tract infections, bacteraemia and intra-abdominal infections caused by Gram-negative bacteria. Amikacin was added to the harmonised panel because it is thought to improve the detection of 16S RNA methyltransferases (RMTases) (EFSA, 2019).
RMTases have been increasingly associated with carbapenemases, AmpC or ESBL enzymes and fluoroquinolone resistance in Enterobacteriaceae, particularly outside Europe and recently also detected in human cases within Europe (Arca-Suárez et al., 2022; Fournier et al., 2022).

Additionally, under the new legislation, the ECOFFs and CBPs used to determine the microbiological resistance of Salmonella isolates to some antimicrobial substances have also changed. This is the case for tigecycline: the ECOFF has changed from > 1 to > 0.5 mg/L. Also, the ECOFF for nalidixic acid changed from MIC > 16 mg/L to MIC > 8 mg/L, while the CBP for ciprofloxacin changed from MIC > 1 mg/L to MIC > 0.064 mg/L.

Based on the changes on the current legislation in this report, the occurrence of resistance to tigecycline and nalidixic acid for 2021 data (i.e. pigs and calves) is determined using the new ECOFFs (MIC > 0.5 mg/L and MIC > 8 mg/L, respectively), and for 2020 poultry and meat derived data, tigecycline and nalidixic acid resistance are analysed using the previous ECOFFs (i.e. MIC > 1 mg/L and MIC > 16 mg/L). Also, for ciprofloxacin, clinical resistance will be determined using the previous CBP (MIC > 1 mg/L) for 2020 data, and the new CBP (MIC > 0.064 mg/L) for 2021 data.

Summary data on the occurrence of resistance to commonly used antimicrobials in veterinary medicine (ampicillin, sulfamethoxazole and tetracycline) as well as hpCIAs (ciprofloxacin, cefotaxime and combined resistance to these two antimicrobials) are displayed in Figure 5 for Salmonella isolates from (a) poultry carcasses and (b) food-producing animals and are described in the following text. Annex A presents the occurrence of AMR (%), CS, MDR and combined resistance to ciprofloxacin and cefotaxime, in Salmonella spp. from pigs, calves (corresponding to 2021 data), as well as broilers, laying hens and derived meat (corresponding to 2020 data), at the MS and MS-group level. (Annex A is available on the EFSA Knowledge Junction community on Zenodo at: https://doi.org/10.5281/zenodo.7544221).

2.4.2. Occurrence of resistance to commonly used antimicrobials in veterinary medicine

Since 2014, the antimicrobial substances included in the harmonised panel for the monitoring and reporting of AMR in Salmonella from food animals and derived meat have provided continuity of monitoring data and epidemiological tracing of isolates (particularly serovars) with patterns of resistance of interest to public health. The antimicrobial substances included in the panel have been selected because they are either of public health importance or are commonly used in veterinary medicine. Antimicrobial substances such as ampicillin, sulfamethoxazole and tetracycline have been widely used in veterinary medicine for treating infections in production animals. The WHO categorises ampicillin as a ‘critically important antimicrobial’ (CIA) in human medicine, while sulfamethoxazole and tetracycline are categorised as ‘highly important antimicrobials’ (HIA) in human medicine (WHO, 2019).

Carcasses of poultry

In 2020, considering all MSs reporting Salmonella spp. data from poultry carcasses, the overall resistance to ampicillin, sulfamethoxazole and tetracycline ranged from moderate to very high (Figure 5a; Annex A). Ampicillin resistance was reported at overall moderate levels in both broiler carcasses and turkey carcasses (18.6% and 19.1%, respectively); sulfamethoxazole resistance was noted at a very high level in broiler carcasses and a moderate level in turkey carcasses (53.2% and 14.7%, respectively); while tetracycline resistance was noted at an overall very high level in broiler carcasses and at a high level in turkey carcasses (52.6% and 48.1%, respectively) (Annex A). In addition, among Salmonella isolates recovered from turkey carcasses, resistance levels were substantially lower than those obtained from broiler carcasses for trimethoprim (3.8% and 16.2%, respectively) (Annex A).

Food-producing animals

In 2021, among Salmonella spp., most MSs reported high resistance to tetracyclines and sulfonamides recovered from pigs and calves. Overall tetracycline resistance was reported at high levels for pigs and calves (44.9% and 36.7%, respectively), and overall high sulfamethoxazole resistance...
Resistance was also reported at levels of 45.5% and 39.2%, respectively (Annex A). **Ampicillin** resistance levels were generally observed at similar levels to those of tetracycline and sulfamethoxazole in pigs (43.4%) and slightly lower in calves (22.8%). Overall, resistance levels in *Salmonella* isolates recovered from both species were low to moderate for other antimicrobial substances in the harmonised panel (Annex A). In 2019, similar overall levels of resistance to the antimicrobial substances in the harmonised panel were reported for pigs, considering the difference in the total number of isolates between the two time periods (EFSA and ECDC, 2021).

For data from 2020 on poultry flocks, overall resistance was high for tetracyclines and sulfonamides in broilers and fattening turkeys. For **tetracycline**, overall resistance was 42.2% for broilers and 47.0% for fattening turkeys, while for flocks of laying hens, low tetracycline resistance was reported (7.0%) (Annex A). For **sulfamethoxazole**, high resistance levels were reported for broiler flocks (45.0%) and fattening turkeys (32.3%) in contrast to flocks of laying hens (7.2%) (Annex A). Considering **ampicillin**, overall resistance was observed at somewhat lower levels than those of tetracycline and sulfamethoxazole within all poultry flocks, with the highest resistance levels in isolates from turkeys (47.2%) (Figure 4b; Annex A).

2.4.3. Occurrence of resistance to highest priority critically important antimicrobials (hpCIAs) and last resort antimicrobials

**Use of critically important antimicrobials (CIAs) for the treatment of human infections**

(Quinolone/Fluoro)quinolones and third-generation cephalosporins are categorised as highest-priority critically important antimicrobials (hpCIA) in human medicine (WHO, 2019). These hpCIAs often constitute first-line treatment for invasive salmonellosis in humans, and as such, the monitoring of resistance to these compounds in zoonotic bacteria, including *Salmonella* spp., originating from animals is of particular interest. Fluoroquinolones and third-generation cephalosporins are represented by ciprofloxacin and cefotaxime/ceftazidime, respectively, in the harmonised antimicrobial panel for the monitoring and reporting of AMR in *Salmonella* spp. from food animals and derived meat. Additionally, the CIAs, **tigecycline** and **azithromycin**, also included in the *Salmonella* monitoring from food-producing animals and derived meat, are used as alternative treatments for MDR *Salmonella* spp. **Colistin**, categorised as an hpCIA, is not used in the treatment of salmonellosis, but it is used as a last-resort antimicrobial for treating healthcare-associated infections due to carbapenemase-producing Gram-negative bacteria such as *Klebsiella pneumoniae* and *Acinetobacter baumannii*.

**Carcasses of poultry**

As the WHO categorises (Fluoro)quinolones as hpCIAs in human medicine, their use in food-producing animals is subject to prudent use initiatives. Considering *Salmonella* spp. recovered from broiler carcasses in 2020, resistance to the (fluoro)quinolones (ciprofloxacin and nalidixic acid) were reported at very high to extremely high levels by many of the MSs included in the analysis (with overall resistance at 69.3% and 66.6%, respectively) (Annex A). Resistance levels to ciprofloxacin and nalidixic acid in isolates from turkey carcasses ranged from low or not detected to extremely high among reporting MSs (overall, 46.9% and 32.5%, respectively) (Annex A).

In certain *Salmonella* serovars recovered from carcasses of poultry, isolates resistant to ciprofloxacin but not to nalidixic acid were observed; possibly indicating the occurrence of plasmid-mediated quinolone resistance (PMQR) mechanisms – see text box below. This was particularly the case for specific serovars recovered from broilers carcasses in 2020, where 15 S. Agona isolates from the United Kingdom, six S. Hadar isolates from Hungary and two S. Derby from Poland displayed ciprofloxacin resistance, yet none showed resistance to nalidixic acid.

**Quinolone/Fluoroquinolone resistance in Salmonella**

Quinolone/Fluoroquinolone (i.e. nalidixic acid and ciprofloxacin) resistance in *Salmonella* usually arises due to point mutations within the DNA gyrase (*gyrA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) genes, at locations comprising the quinolone resistance-determining regions (QRDR) of the bacterial chromosome. Additionally, plasmid-mediated quinolone resistance (PMQR) mechanisms have also been recognised, including the action of efflux pumps (*qepA* and *ophxAB* genes), enzymatic modifications (*aac(6')Ib-cr* gene – also conferring resistance to...
Iceland, with both reporting resistance in a single Salmonella isolate from broiler carcases.

No reporting countries detected third-generation cephalosporin resistance among Salmonella isolates from the carcases of turkeys (Annex A). Section 2.3.6 provides further information on the phenotypic characterisation of third-generation cephalosporin resistance among Salmonella isolates from broiler carcases.

Considering all reporting MSs, combined resistance to ciprofloxacin and cefotaxime among isolates from broiler carcases was observed at overall very low levels (0.1%) (Figure 5a; Annex A). Only Italy and Iceland reported combined resistance to ciprofloxacin and cefotaxime in single isolates of S. Infantis. Notably, no isolates exhibited clinical resistance to these compounds when 2020 CBPs were applied. Overall resistance to azithromycin in Salmonella spp. isolates from broiler and turkey carcases were low (2% and 0.6%, respectively) (Annex A). When considering MSs, Italy was an exception, reporting high-level azithromycin resistance in 10 isolates from broiler carcases (21.4%, N = 14) (Annex A).

Overall, tigecycline resistance was reported at low levels from carcases of broilers and turkeys (1.6% and 2.5%, respectively) (Annex A). Where countries reported resistance to tigecycline, generally very low or low levels were observed, except for Cyprus, which reported high-level resistance to tigecycline in 2/8 isolates from broilers (25.0%), and Hungary, which reported moderate-level resistance in 6/46 isolates from turkey carcases (13.0%) (Annex A). Where tigecycline resistance was reported, MDR was often a feature, with all resistant isolates recovered from carcases of broilers and turkeys exhibiting multiresistance (n = 14 and n = 8, respectively) (Annex A).

Overall, colistin resistance was reported at very low or low levels among isolates from carcases of broilers and turkeys (1.6% each) (Annex A). Where countries reported resistance to colistin among isolates from carcases, generally very low or low levels were noted. Of those countries that reported colistin resistance in Salmonella isolates from broiler carcases, Cyprus, France, Germany and Portugal only reported a single resistant isolate, while Poland reported two resistant isolates and Spain reported eight resistant isolates (6.5%, N = 124) (Annex A). For turkey carcases, two countries reported colistin resistance in five isolates: France reported two resistant isolates, and Germany reported three (Annex A). The contribution of different serovars can influence these outputs because of the degree of intrinsic resistance to colistin in Group D Salmonella isolates. In total, five of the 14 colistin-resistant isolates from broiler carcases belonged to Group D Salmonella serovars.

Food-producing animals

As previously indicated, for nalidixic acid, the ECOFF used to define microbiological resistance for 2020 data for poultry populations is MIC > 16 mg/L, while for 2021 data on pigs and calves, the new ECOFF (MIC > 8 mg/L) is used. When considering all MSs reporting 2020 AMR data on poultry flocks, high or very high levels of resistance to ciprofloxacin and nalidixic acid were observed in...
Salmonella isolates from broilers (57.5% and 54.1%, respectively) and turkeys (65.0% and 39.0%, respectively), compared with moderate levels observed in Salmonella isolates from laying hens (19.0% and 18.2%, respectively) (Figure 5b; Annex A). Salmonella isolates exhibiting ciprofloxacin resistance and nalidixic acid susceptibility were most frequently observed in Salmonella isolates from turkeys, possibly indicating the occurrence of PMQR mechanisms. This was particularly the case for 13 S. Hadar isolates from Hungary, 46 S. Anatum isolates from Italy and 43 S. Derby isolates from Spain, where all isolates displayed resistance to ciprofloxacin and susceptibility to nalidixic acid. Notably, S. Agona isolates exhibiting a similar fluoroquinolone phenotype were reported from the UK in low numbers in other poultry sources, including turkeys (n = 1), laying hens (n = 4) and broilers (n = 2) which may suggest clonal spread of this variant in poultry in the UK.

For ciprofloxacin, in 2021, overall resistance was reported at 10.1% for pigs and 12.7% for calves, while resistance to nalidixic acid was 9.8% and 10.1%, respectively (Figure 5b; Annex A). Of the Salmonella isolates from pigs with ciprofloxacin resistance and nalidixic acid susceptibility, (,), two were S. Derby (one each from Belgium and Romania), and one each was S. Typhimurium (Spain), monophasic S. Typhimurium (Poland), S. Bovismorbificans (Romania), S. Uganda (Spain) and S. Rissen (Bulgaria). Just two Salmonella isolates from calves displayed ciprofloxacin resistance and nalidixic acid sensitivity (S. Agama and S. Typhimurium), both from Italy.

In 2021, zero resistance to the third-generation cephalosporins, cefotaxime and ceftazidime in Salmonella isolates from pigs and calves was reported by most countries (Annex A). Overall resistance to cefotaxime and ceftazidime was very low (0.9%, each antimicrobial in pigs). Of the few countries that reported resistance to both third-generation antimicrobials in Salmonella isolates from pigs included six isolates from Romania (5.8%, N = 104), four from Hungary (5.0%, N = 80) and one from Italy (1.1%, N = 91) (Annex A). For Salmonella isolates from calves, only Italy reported a single isolate (S. Ngor) as resistant to both substances (N = 20), while Spain reported a single isolate (S. Derby) as resistant to cefotaxime and susceptible to ceftazidime (N = 20) (Annex A).

For 2020 data on poultry flocks, the overall occurrence of resistance to both third-generation cephalosporins in Salmonella isolates was very low or low, with most countries reporting zero resistance in all isolates tested (Annex A). Of those countries that reported isolates with resistance to cefotaxime and ceftazidime in broilers, resistant isolates were most numerous in Italy reporting 29 isolates (13.6%, N = 214) and Malta reporting seven isolates (13.5%, N = 52), while Hungary reported a single Salmonella isolate resistant to cefotaxime and three isolates resistant to ceftazidime (Annex A). For laying hens, just two countries, Italy (N = 172) and Hungary (N = 30) reported two isolates each, with resistance to cefotaxime and ceftazidime. Similarly, for turkeys, Italy (N = 170) reported two isolates and Poland (N = 22) reported a single isolate with resistance to both third-generation cephalosporins (Annex A). Section 2.3.6 provides further information on the phenotypic characterisation of third-generation cephalosporin resistance among Salmonella isolates from animal origins.

Overall combined resistance to ciprofloxacin and cefotaxime in Salmonella isolates from poultry flocks in 2020 and pigs and calves in 2021 was at very low or low levels (broilers: 2.0%, laying hens: 0.2%, turkeys: 0.5%, pigs 0.6%, calves 2.5%), although some exceptions were noted in some countries (Annex A). For instance, there was a moderate level of combined resistance in isolates from broilers: in 29 isolates from Italy (13.6%, N = 214) and 7 isolates from Malta (13.5%, N = 52). When considering pig data from 2021, two isolates from Hungary (2.5%, N = 80) and five isolates from Romania (4.8%, N = 104) had combined microbiological resistance to ciprofloxacin and cefotaxime. For calves, a single isolate each from Italy (N = 20) and Spain (N = 20) was detected with combined resistance to both substances (Annex A).

Overall resistance to Azithromycin in Salmonella from all food-producing animal groups was very low to low, except for calves, where no resistance was detected (broilers: 2.1%, laying hens: 0.5%, turkeys: 1.5%, pigs: 1.9%) (Annex A). However, exceptions were noted in some countries, for instance, there was a high level of resistance in isolates from pigs: in four isolates each from Portugal (21.1%, N = 19) and Slovenia (22.2%, N = 18).

For amikacin, the new substance included in the harmonised test panel of antimicrobials from 2021, resistance was very low in pigs (0.6%), being reported for one single isolate in Austria (14.3%, N = 7), Germany (3.3%, N = 30), Romania (1%, N = 104) and Spain (0.6%, N = 170) and three isolates from the Netherlands (4.8%, N = 63). No resistance was reported in calves (Annex A).

Regarding tigecycline, the new ECOFF (MIC > 0.5 mg/L) laid down in the current legislation was used for the analysis of 2021 AMR data. Considering all reporting countries, overall resistance to tigecycline was reported at a low level for pigs (7.0%) and at a moderate level for calves (10.1%).
Lowering the tigecycline ECOFF from MIC $> 1$ mg/L to MIC $> 0.5$ mg/L may have been in part responsible for a higher-than-expected level of resistance in *Salmonella* isolates from pigs and calves, as many of these isolates were reported with MICs within one dilution range of the new ECOFF. For example, 74/88 tigecycline resistant isolates from pig were reported to have an MIC of 1 mg/L. Under the previous legislation, these isolates would have been categorised as susceptible to tigecycline. Also, instability of tigecycline in the Mueller-Hinton broth medium used in MIC-testing can result in inconsistencies in MIC values (Bradford et al., 2005).

Poultry populations data from 2020 was analysed using the ECOFF (MIC $> 1$ mg/L) according to the previous legislation. For this data, overall resistance was observed at low levels among isolates from broilers (1.0%) and turkeys (5.5%), and at very low levels in isolates from laying hens (0.2%). When only considering countries reporting data for more than ten isolates, a high-level of resistance was observed in 36 isolates from turkeys from Hungary (21.1%, N = 170) and moderate resistance in isolates from pigs in 18 isolates from Ireland (14.6%, N = 123), in eight isolates from Poland (16.7%, n = 48) and 14 isolates from Romania (13.5%, n = 104) and high-resistance in four isolates from Portugal (21.1%, n = 19) and three isolates from Estonia (27.3%, N = 11) (Annex A). Note, some countries reporting moderate or high levels of tigecycline resistance reported data on a very low number of isolates which needs to be considered when interpreting individual results.

In 2020, overall *colistin* resistance in *Salmonella* isolates was reported at low levels among isolates from broilers, laying hens and turkeys (2.5%, 7.2% and 0.9%, respectively) (Annex A). While in 2021, overall resistance to colistin in *Salmonella* isolates from pigs was low (1.0%) but moderate for calves (11.4%) (Annex A). The small overall sample size of *Salmonella* isolates from calves (N = 79) compared to the other animal groups (i.e. pigs, N = 1,258) should be taken into consideration when interpreting these results. Across all animal groups, most individual countries reported no resistance or very low levels of resistance to colistin. Of those countries reporting > 10 isolates, several reported moderate to high levels of resistance to colistin. These countries include Cyprus (12.5%, N = 16) and Germany (23.5%, N = 17) for broiler flocks, Austria (19.2%, N = 26), Belgium (22.5%, N = 40), Cyprus (34.8%, N = 23) and Germany (26.9%, N = 78) for laying hen flocks (Annex A).

Figure 5a,b summarises the overall resistance to commonly used antimicrobials in veterinary medicine (ampicillin, sulfamethoxazole and tetracycline), as well as hpcIAs (represented by ciprofloxacin, cefotaxime and combined resistance to these two antimicrobials) among *Salmonella* isolates recovered from (a) carcasses of broilers and turkeys, and (b) broilers, laying hens, fattening turkeys, pigs and calves.
AMP: ampicillin; SMX: sulfamethoxazole; TET: tetracycline; CIP: ciprofloxacin; CTX: cefotaxime; CIP/CTX: combined 'microbiological' resistance to ciprofloxacin and cefotaxime; AMK: amikacin; N: total number of *Salmonella* spp. isolates reported by MSs; blue diamond shows resistance at the reporting-MS group level. Horizontal lines represent median; Lower and upper box boundaries, 25th and 75th percentiles, respectively; Blue diamond: resistance at the reporting MS group level

Note: Only MSs reporting data for 10 or more isolates are shown in the graph; however, all isolates are included in the calculation of resistance at the reporting-MS group level.

**Figure 5:** Occurrence of resistance to selected antimicrobials in *Salmonella* spp. recovered from (a) carcases of broilers and fattening turkeys, and (b) broilers, laying hens, fattening turkeys, fattening pigs and bovine animals under 1 year of age (calves), 2020/2021.
2.4.4. Tigecycline and colistin resistance in *Salmonella* serovars

**Tigecycline resistance in *Salmonella* serovars**

### Mechanisms of tigecycline resistance

Tigecycline, categorised as a CIA by the WHO (WHO, 2019), is considered a last resort for the treatment of serious infections in adults caused by MDR bacteria. Tigecycline is structurally related to the tetracycline class of antibiotics and is active against Gram-positive and Gram-negative bacteria, as well as tetracycline-resistant bacteria and some anaerobes (Yaghoubi et al., 2022).

Resistance mechanisms to tigecycline include non-mobile tet(X) and mobile-plasmid-mediated transmissible tet(X) and resistance-nodulation-division (RND) efflux pump mediated tmexCD-toprJ genes (Anyanwu et al., 2022). Of most concern is the transferable plasmid-mediated spread of tigecycline resistance genes such as tet(X3) and tet(X4), which confer high levels of resistance to all tetracyclines, including tigecycline (MICs of ≥ 32 mg/L). Two recent studies looking at the global distribution, evolution pattern and spread of tet(X) genes, identified isolates carrying tet(X) genes from over 20 countries across five continents (Pan et al., 2020; Wang et al., 2021).

The first report of transferable high-level tigecycline (HLT) resistance by tet(X3) and tet(X4) genes in Enterobacteriaceae from food animals, meat and the environment came from China in 2019 (He et al., 2019). Another study from China in the same year identified tet(X4) positive MDR *E. coli* isolates from retail pork samples (Bai et al., 2019). The tet(X4) gene in these isolates was located on various conjugative plasmids of diverse replicon types, indicating that the gene may be captured by a range of mobile genetic elements circulating among bacterial strains. Since then, additional plasmid-mediated tet(X) genes, including tet(X5) and tet(X6), have been identified in over 10 different Gram-negative species, although rarely in *Salmonella* spp. (Wang et al., 2021).

While tigecycline is not used in food-producing animals, it is postulated that the excessive use of tetracycline antibiotics in food-producing animals may contribute to the emergence of plasmid-mediated tet(X) genes, with the potential for spread to human bacterial species (Pan et al., 2020; Anyanwu et al., 2022). The potential for other bacteria within the Enterobacteriaceae family (such as *Salmonella*) to acquire such transferable tigecycline resistance genes is highlighted, and the importance of monitoring tigecycline resistance through the determination of MICs or by molecular investigation such as WGS is further underlined.

The number of tigecycline-resistant *Salmonella* isolates detected from (a) poultry flocks and derived carcases, and (b) pigs and calves and the predominant serovars accounting for this resistance, by MSs are shown in Figure 6. Particular serovars displayed microbiological resistance to tigecycline, suggesting clonal expansion of microbiologically-resistant strains of these serovars.

In 2020, Serovar *Infantis* accounted for the majority (60.9%, n = 14) of the tigecycline resistant isolates recovered from broilers and for all tigecycline resistant isolates of their derived carcases (100%, n = 14), while *S. Bredeney* accounted for most (75.6%, n = 31) of the tigecycline-resistant isolates recovered from turkeys and turkey carcases (62.5%, n = 5). In 2021, *S. Rissen* (27.3%, n = 24), *monophasic S. Typhimurium* (25.0%, n = 22), *S. Typhimurium* (14.8%, n = 13) and *S. Derby* (12.5%, n = 11) accounted for most of the resistant isolates recovered from pigs. For calves, of the eight *Salmonella* isolates resistant to tigecycline, three were serotyped as *S. Typhimurium* and the remaining were *S. Infantis, S. Dublin, S. Anatatum, S. Agama* and *S. Muenchen*, one each.

MDR was often a feature where tigecycline resistance was reported among certain serovars within the carcass/animal origins. For instance, among broilers and their derived carcases, all tigecycline-resistant *S. Infantis* isolates were multi-resistant, with resistance to ciprofloxacin, nalidixic acid, sulfamethoxazole and tetracycline, a common feature of all these isolates. This is a resistance pattern typical of MDR broiler clones of *S. Infantis* (Nögrády et al., 2012). Among turkeys, all tigecycline-resistant *S. Bredeney* isolates (n = 31) were multi-resistant, with ampicillin, nalidixic acid, ciprofloxacin and tetracycline resistance being a feature of these isolates. For pigs, MDR was present in 16 of the 24 tigecycline-resistant *S. Rissen* isolates, with most having ampicillin, nalidixic acid, sulfamethoxazole and tetracycline resistance. For calves, all tigecycline-resistant *S. Typhimurium* isolates (N = 3) were MDR, showing resistance to sulfamethoxazole and tetracycline.

Considering individual countries reporting tigecycline resistance, certain features relating to resistance were also evident. For example, 87.8% of tigecycline-resistant isolates recovered from turkeys were...
reported by Hungary. The reporting countries responsible for most of the tigecycline-resistant isolates in pigs (n = 88) were Ireland (n = 18), Spain (n = 17) Romania (n = 14), Poland (n = 8) and France (n = 6). While in calves, Italy reported four of the eight tigecycline-resistant isolates (Annex A).

Figure 6: Breakdown of the number of tigecycline-resistant Salmonella isolates by serovar from (a) broilers, fattening turkeys, laying hens, broiler carcases, and (b) fattening pigs and calves, bovine animals under 1 year old (calves) using harmonised ECOFFs, 2020/2021.
Colistin resistance in Salmonella spp.

Mechanisms of colistin resistance

Colistin, an antimicrobial belonging to the polymyxin class, is considered a highest-priority CIA (hpCIA) and a last resort for treating serious human infection with some Gram-negative bacteria (WHO, 2019). Although not frequently used in human medicine due to its nephrotoxic effects, colistin has been widely used in veterinary medicine for prophylactic/metaphylactic treatment (Kieffer et al., 2017). Various mechanisms of polymyxin resistance in Gram-negative bacteria have been described (lipopolysaccharide modifications, efflux pumps, capsule formation and over-expression of membrane protein, Olaitan et al., 2014); and transferable mobile colistin resistance (mcr) genes have also been detected in Salmonella isolates (Campos et al., 2016; Carnevali et al., 2016; Skov and Monnet, 2016).

Group D Salmonella serovars

Among Salmonella isolates recovered from poultry in 2020, resistance to colistin (i.e. MIC > 2 mg/L) was generally observed in S. Enteritidis isolates; this serovar accounting for 35.7%, 53.1% and 55.4% of the colistin-resistant isolates recovered from broiler carcases, broilers and laying hens, respectively (Figure 7). Two colistin-resistant S. Enteritidis isolates were also reported from turkeys (33.3%). In 2021, of the 12 Salmonella isolates from pigs with resistance to colistin, 41.7% were serotyped as S. Enteritidis (n = 5), three isolates were S. Panama (25%), two isolates were S. Derby (16.7%) and one isolate S. Dublin and other S. Rissen. All nine colistin-resistant isolates from calves were serotyped as S. Dublin.

Notably, S. Enteritidis, S. Dublin and S. Panama are group D salmonellas (serogroup O9). Salmonella belonging to group D tend to show decreased susceptibility to colistin without having any known acquired or mutational colistin resistance mechanisms (Agersø et al., 2012; Ricci et al., 2020). This is exemplified by the proportion of colistin-resistant isolates belonging to S. Enteritidis and S. Dublin in 2020 and 2021, respectively. Figure 7 presents the number of colistin-resistant isolates detected from the animal/carcase origins by MSs and the predominant serovars accounting for this resistance. Serovars Kapemba, Napoli and Panama, are group D salmonella serovars; the other serovars listed do not belong to group D (serogroup O9).

Other Salmonella serovars

S. Bredeney accounted for 42.8% of the colistin-resistant isolates from broiler carcases (6/14), all reported by Spain. Two of the Salmonella isolates recovered from pigs in 2021 were serotyped as S. Derby and three as S. Panama. Colistin resistance was reported in a diverse range of serovars from poultry, including serovars Brandenburg, Bredeney, Chester, Hadar, Infantis, Minnesota, Mishmarhaemek, Montevideo, Napoli, Paratyphi B., Telaviv, Typhimurium and its monophasic variant. Across all poultry data, several MSs reported some colistin-resistant Salmonella isolates as ‘Other serovars’.

A very small number of isolates reported markedly elevated colistin MICs (i.e. MIC > 16 mg/L), including one S. Enteritidis, isolate from broilers and one S. Montevideo isolate from a broiler carcase in 2020, and 2 isolates from pigs in 2021: one S. Rissen isolate and one S. Derby isolate.
2.4.5. Complete susceptibility (CS) and multidrug resistance (MDR)

For 2021 data from *Salmonella* spp. isolates, the new antimicrobial substance included in the harmonised panel for the monitoring of AMR according to the Commission Implementing Decision (EU) 2020/1729 was included in the assessment of CS and MDR (see Appendix F). CS is defined as complete susceptibility to the antimicrobial substances included in the harmonised panel for the monitoring of AMR selected for the CS and MDR analysis. MDR is defined as resistance to three or more antimicrobial classes among *Salmonella* isolates from the monitored food-producing animals and derived meat thereof (see Appendix F). Data from countries submitting less than ten *Salmonella* isolates from carcases or of animal origin are excluded from some of the analyses described in this section.

In 2021 data from pigs and calves, substances included in CS and MDR analysis include amikacin/gentamicin (assessed together as aminoglycoside antimicrobial class), ampicillin, cefotaxime/ceftazidime (assessed together as third-generation cephalosporin), chloramphenicol, ciprofloxacin/nalidixic acid (assessed together as quinolone antimicrobial class), meropenem, sulfamethoxazole, tetracycline/tigecycline (assessed together as tetracycline antimicrobial class) and trimethoprim.

For 2020 data from poultry and derived meat, among the substances included in the harmonised test panel laid out in Commission Implementing Decision (EU) 2013/652, the ones included in the assessment of CS and MDR were gentamicin (aminoglycoside antimicrobial class), ampicillin, azithromycin (macrolide antimicrobial class), cefotaxime/ceftazidime (assessed together as...
third-generation cephalosporin), chloramphenicol, ciprofloxacin/nalidixic acid (assessed together as quinolone antimicrobial class), meropenem, sulfamethoxazole, tetracycline/tigecycline (assessed together as tetracycline antimicrobial class) and trimethoprim. Due to the presence of resistance to colistin considered as intrinsic in serogroup D of *Salmonella* spp., colistin was not included in the analysis of MDR and CS for *Salmonella* in 2020 and 2021.

**Carcases of poultry**

The levels of CS and MDR among *Salmonella* isolates from poultry carcases are shown in Figure 8. In 2020, overall MDR for all reporting countries was observed at high levels in *Salmonella* spp. recovered from carcases of broilers (51.2%) and moderate levels for turkey carcases (19.1%) (Annex A). Across all countries submitting data on ten or more *Salmonella* isolates recovered from broiler carcases, the median MDR was 44.6%, with the highest levels of MDR reported from Austria (73.8%, N = 61), Belgium (78.6%, N = 28), Romania (81.8%, N = 22) and Spain (83.1%, N = 124) (Annex A). For turkey carcases, the median MDR was 34.3%, with Hungary (43.5%, N = 46), Poland (42.1%, N = 19) and Spain (26.5%, N = 34), reporting high to very high levels of MDR (Annex A).

Overall CS, considering all reporting countries, was observed at moderate levels in carcases of broilers and turkeys (28.3% and 27.5%, respectively) (Annex A). The overall median CS for broiler carcases was 22.0%, with results ranging from 0% (i.e. all isolates were resistant to at least one antimicrobial) to 90% (i.e. 90% of isolates tested were susceptible to all antimicrobial substances considered for the CS/MDR analysis). Belgium and Romania reported no isolates as CS, while countries with the highest proportion of isolates with CS include France (74.5%, N = 106) and Germany (56.5%, N = 23) (Annex A). For turkey carcases, the overall median CS for countries reporting data for more than ten isolates was 12.6% and ranged from 5.3% (Poland) to 40.5% (France) (Annex A). The spatial distribution of CS across all reporting countries is visualised in Figure 9.

Differences in the prevalence of serovars and phage types of *Salmonella* in different countries and animal populations and their associated patterns of resistance likely explain some differences in the MDR and CS levels. The proportion of isolates which were completely susceptible and MDR among particular *Salmonella* serovars within the carcase origins are presented in Appendix C.

The MDR analysis of carcase isolates included the following antimicrobials: ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/nalidixic acid, gentamicin, meropenem, sulfamethoxazole, tetracycline, tigecycline and trimethoprim.

MDR and complete susceptibility levels are also expressed as a percentage; N: total number of *Salmonella* spp. reported by MSs and non-MSs. The ECOFFs used to determine microbiological resistance in 2020 data were from the Commission Implementing Decision (EU) 2013/652.

**Figure 8:** MDR and CS *Salmonella* spp. recovered from the carcases of broilers and fattening turkeys for all reporting countries (including two non-MSs in broiler carcases) in 2020
The CS analysis of carcase isolates included the following antimicrobials: ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/nalidixic acid, gentamicin, meropenem, sulphonmethoxazole, tetracycline/tigecycline and trimethoprim.

**Figure 9:** Spatial distributions of complete susceptibility to the selected antimicrobials tested among *Salmonella* spp. from (a) broiler carcases and (b) fattening turkey carcases, using harmonised ECOFFs laid down in Commission Implementing Decision (EU) 2013/652 for 2020 AMR data.
Food-producing animals

The levels of CS and MDR among *Salmonella* isolates recovered from food-producing animals are shown in Figure 10. In this figure, only MSs with ten or more isolates are included in the analysis. Annex A includes tables with overall and individual country MDR and CS. Overall MDR in all animal populations, considering all reporting counties, was observed at high levels in isolates from pigs (39.1%), calves (30.4%), broilers (41.8%) and turkeys (38.2%), and at a low level in isolates from laying hens (6.3%). Few countries reported zero MDR in any of the food-producing animal groups. Across all MSs submitting data, in 2020, from broilers, the median MDR was 30.6%, with extremely high levels of MDR being reported by all isolates from Cyprus (100%, N = 16), 122 isolates from Austria (71.8%, N = 170) and 118 isolates from Slovenia (72.0%, N = 164). The median MDR for MSs with isolates from turkeys was 38.7%, with Hungary reporting the highest MDR, being detected in 118 isolates (69.4%, N = 170). When considering laying hens, the median MDR (1.1%) was much lower, with eleven countries reporting zero MDR. For 2021 data from pigs, the median MDR for MSs was 35.1%, with 15 isolates in Portugal (79.0%, N = 19), 23 isolates in Croatia (74.2%, N = 31) and 13 isolates in Slovenia (72.2%, N = 18) reporting extremely high MDR levels. For data from calves, the median MDR was 17.7% (Annex A).

Overall CS at the MS level was observed at high to very high levels for broilers (34.0%), turkeys (25.8%), pigs (40.5%) and calves (55.7%), and extremely high levels for laying hens (75.6%) (Annex A). However, the levels of CS varied widely between reporting countries, particularly in broiler, turkey and pig populations. This likely reflects the greater number of countries reporting data on these populations than from turkeys and calves. For 2020 MS data, the overall median percentage of isolates from broilers classified as CS was 35.1% with 131 isolates from France (78.4%, N = 167), and 13 isolates from Portugal (81.2%, N = 16) reporting the highest levels of CS, and Cyprus (0%, N = 16), Poland (15.4%, N = 208) and Hungary reporting the lowest percentage of CS in isolates (Annex A). For turkeys, the median CS was 24.6%, with eight isolates in Austria (80%, N = 10), and 69 isolates from France (73.4%, N = 94) reporting the highest levels of CS, and 14 isolates from Hungary the lowest level (8.2%, N = 170). For laying hens, the median CS was extremely high at 75.4%, with almost every country reporting over 60% CS. While for data from 2021, for pigs, the median CS was 42.7% with seven isolates from Greece (70.0%, N = 100), 39 isolates from Latvia (92.9%, N = 42)
and 28 isolates from Luxembourg (75.7%, N = 37) reporting the highest levels of CS. For calves, the median CS was 50.0%, however only three countries submitted AMR data on more than ten isolates. The spatial distribution of CS across all reporting countries is visualised in Figure 11 (Annex A).

It is of note, that the prevalence of particular serovars in different countries and animal populations, and their associated patterns of resistance, may account for the differences in the levels of MDR and CS among *Salmonella* spp. data. Notably, in laying hens, *S. Enteritidis* predominated (accounting for 25% of *Salmonella* isolates recovered from this poultry origin), with 79.5% of isolates exhibiting complete susceptibility reported from EU MSs and 92% from non-EU MSs (including the Republic of North Macedonia and the United Kingdom), respectively. The proportions of isolates which were completely susceptible and MDR among particular *Salmonella* serovars within the animal origins are presented in Annex A.
The ECOFF used to determine microbiological resistance in 2020 data were from the previous legislation (Commission Implementing Decision (EU) 2013/652) and the ECOFFs used for 2021 data are from the current legislation (Commission Implementing Decision (EU) 2020/1729).

The CS analysis included the following antimicrobials: amikacin/gentamicin (for pigs and calves) or gentamicin only (for poultry populations), ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/nalidixic acid, meropenem, sulfamethoxazole, tetracycline/tigecycline and trimethoprim.

**Figure 11:** Spatial distributions of complete susceptibility to the selected antimicrobials tested among *Salmonella* spp. from (a) broilers, (b) laying hens and (c) fattening turkeys, (d) fattening pigs and (e) bovine animals under 1 year old (calves) using harmonised ECOFFs, 2020/2021.
2.4.6. High-level resistance to ciprofloxacin (CIP) in *Salmonella* spp.

The distribution of ciprofloxacin-resistant isolates displaying levels of microbiological resistance or clinical resistance, or high-level resistance to ciprofloxacin within each of the animal/carcase categories is illustrated in Figure 12. Notably, the distribution of MICs provided is only for ciprofloxacin-resistant isolates; the total number of *Salmonella* isolates monitored is provided in the legend. High-level resistance to ciprofloxacin is considered in isolates with an MIC $\geq$ 4 mg/L. It is of note, that in 2021, according to the new implementing decision 2020/1729 the ciprofloxacin CBP was changed from $> 1$ mg/L to MIC $> 0.06$ mg/L, which aligns with the EUCAST ECOFF (MIC $> 0.06$ mg/L).

Among *Salmonella* isolates displaying ciprofloxacin resistance, 3.5% of isolates from broiler carcases and 8% isolates from turkey carcases exhibited MICs of $\geq$ 4 mg/L. For poultry flocks, the highest proportions of *Salmonella* isolates displaying high-level ciprofloxacin resistance originated from broilers (4.5%) and turkeys (6.6%) (Figure 12). A lower proportion of ciprofloxacin-resistant isolates displayed MICs of $\geq$ 4 mg/L from laying hens (1.5%). Considering the total number of *Salmonella* isolates monitored from the different types of poultry by MSs in 2020, the highest proportions of isolates displaying ciprofloxacin MICs of $\geq$ 4 mg/L were noted in turkeys and turkey carcases; being detected in 3 *Salmonella* isolates (0.3%, N = 1,030), 22 isolates (2.4% N = 905), 51 isolates (2.6% N = 1,953), 12 isolates (3.8%, N = 320) and 29 isolates (4.3%, N = 674) reported from laying hens, broiler carcases, broilers, turkey carcases and turkeys, respectively (Figure 12).

In 2021, 127 *Salmonella* isolates from pigs, (10.1%, N = 1,258) recorded resistance to ciprofloxacin, with just a single isolate (S. Kentucky) from Malta displaying high-level resistance to ciprofloxacin (and nalidixic acid). For calves, 10 *Salmonella* isolates (12.7%; N = 79) were resistant to ciprofloxacin, with none displaying high-level resistance (Figure 12).

![Figure 12: Distribution of MIC levels among ciprofloxacin-resistant *Salmonella* spp. from carcases of broilers, turkeys, as well as broilers, laying hens, fattening turkeys, fattening pigs and calves (<1 year of age), for all reporting EU MSs, 2020/2021.](image-url)
The serovars which displayed high-level resistance to fluoroquinolones is of interest from both epidemiological and public/animal health perspectives. A detailed analysis on the high-level resistance to ciprofloxacin in *S. Kentucky* and other Salmonella serovars is presented in Appendix A.

### 2.4.7. Phenotypic characterisation of third-generation cephalosporin and carbapenem resistance in *Salmonella* spp.

According to Decision 2020/1729/EU and the previous legislation (2013/652/EU), any *Salmonella* isolate from food-producing animals or derived meat showing resistance to cefotaxime or ceftazidime or meropenem (i.e. presumptive ESBL/AmpC/carbapenemase-producing *Salmonella*) should be further tested with a second panel of harmonised antimicrobial substances to confirm the phenotypic resistance to third-generation cephalosporins or carbapenems. Further phenotypic characterisation of those *Salmonella* isolates that exhibited resistance to third-generation cephalosporins or carbapenems within each of the animal categories and for *Salmonella* isolates from humans is reported in Appendix B (Table B1). From 2021, whole genome sequencing (WGS) is authorised as an alternative method to conventional phenotypic testing for *Salmonella* isolates that show resistance to extended-spectrum cephalosporins and carbapenems. MSs may choose to either undertake susceptibility testing of the antimicrobials included in panel 2 for the presumptive ESBL, AmpC or CP-producing *Salmonella* or perform WGS and report this data. Information on WGS of these isolates can be found in chapter 5.

**Salmonella** spp. from food-producing animals and derived carcasses

Considering isolates from the animal sectors, a low percentage (1.0%, N = 6,219) of all *Salmonella* recovered from poultry flocks and derived meat in 2020 and from pigs and calves in 2021 by all MSSs, demonstrated resistance to third-generation cephalosporins and were subjected to further phenotypic characterisation. The proportions of *Salmonella* isolates exhibiting ESBL, AmpC or ESBL + AmpC phenotypes within the different animal species and production types are presented in Table 5. The overall percentage of presumptive ESBL, AmpC or ESBL + AmpC producers was from very low to low (range 0.1%–2.1%) in all animal/carcass matrices. The ESBL phenotype was more frequently detected than the AmpC phenotype among all animal categories. Considering the individual MSSs reporting cephalosporin-resistant isolates from poultry and derived meat, the proportion of presumptive ESBL, AmpC or ESBL + AmpC-producers was observed at very low or low levels, although there were a few exceptions. Italy reported the highest number of isolates from broilers and laying hens, with 29 isolates from broilers and 2 isolates from laying hens exhibiting the ESBL phenotype. Of the ten isolates from pigs identified as either presumptive ESBL or ESBL + AmpC-producers, most were from Romania (n = 6) followed by Hungary (n = 4). Notably, no *Salmonella* isolates recovered from turkey carcasses exhibited resistance to third generation cephalosporins.

### Table 5: Summary of phenotypic characterisation of third-generation cephalosporin resistance in non-typhoidal *Salmonella* spp. from food-producing animals, animal carcases and humans, reported in 2020/2021

<table>
<thead>
<tr>
<th>Matrix</th>
<th>Presumptive ESBL- and/or AmpC-producers&lt;sup&gt;(a)&lt;/sup&gt;</th>
<th>Presumptive ESBL-producers&lt;sup&gt;(b)&lt;/sup&gt;</th>
<th>Presumptive AmpC-producers&lt;sup&gt;(c)&lt;/sup&gt;</th>
<th>Presumptive ESBL + AmpC-producers&lt;sup&gt;(d)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humans – 2020 (N = 5,948, 15 MSSs)</td>
<td>45 (0.8)</td>
<td>35 (0.6)</td>
<td>10 (0.2)</td>
<td>1 (0.02)</td>
</tr>
<tr>
<td>Humans – 2021 (N = 9,787, 14 MSSs)</td>
<td>88 (0.9)</td>
<td>76 (0.8)</td>
<td>12 (0.1)</td>
<td>0</td>
</tr>
<tr>
<td>Broiler carcasses – 2020 (N = 905, 18 MSSs)</td>
<td>3 (0.3)</td>
<td>2 (0.2)</td>
<td>1 (0.1)</td>
<td>0</td>
</tr>
<tr>
<td>Turkey carcasses – 2020 (N = 320, 8 MSSs)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Broilers – 2020 (N = 1,953, 22 MSSs)</td>
<td>41 (2.1)</td>
<td>38 (1.9)</td>
<td>3 (0.2)</td>
<td>0</td>
</tr>
<tr>
<td>Laying hens – 2020 (N = 1,030, 24 MSSs)</td>
<td>4 (0.4)</td>
<td>2 (0.2)</td>
<td>2 (0.2)</td>
<td>0</td>
</tr>
</tbody>
</table>
When assessing the 2021 data by serovar, the ESBL or AmpC phenotype was detected in five serovars in pigs: *S.* Derby, *S.*Infantis, *S.*London, *S.*Kedougou and *S.*Rissen. Among *Salmonella* isolates from pigs, ten displayed an ESBL phenotype (two *S.* Derby, two *S.* Infantis, one *S.* London, one *S.* Kedougou and four *S.* Rissen from Hungary and Romania), and two displayed the ESBL + AmpC phenotype (one *S.* Derby from Hungary and one *S.* Rissen from Romania). In calves, a single *Salmonella* isolate displayed an ESBL + AmpC phenotype (*S.* Derby from Spain).

Considering the 2020 data on poultry, the ESBL or AmpC phenotype was associated with multiple isolates belonging to certain serovars, suggesting the possible clonal expansion of particular strains: namely, *S.* Infantis and *S.* Kentucky. Among both broilers and turkeys, presumptive ESBL-producing *Salmonella* was identified more frequently than presumptive AmpC-producing *Salmonella* and encompassed a greater number of serovars. The ESBL phenotype was identified in three different serovars from broilers (Infantis, Kentucky and Java) and three different serovars from turkeys (Agona, Derby and Infantis), while the AmpC phenotype was identified only different serovars from broilers in *S.* Infantis in broilers. Where presumptive ESBL, AmpC or ESBL + AmpC-producers were identified from broilers (41/1,953 isolates), most were attributed to *S.* Infantis (29 isolates reported by Italy and three by Hungary) and *S.* Kentucky (seven isolates reported by Malta). All 29 *S.* Infantis isolates reported by Italy displayed an ESBL phenotype while all three *S.* Infantis isolates reported by Hungary, presented an AmpC phenotype. Conversely, only the ESBL phenotype was expressed in the seven *S.* Kentucky isolates reported by Malta and two *S.* Java isolates reported by Austria.

Three presumptive ESBL, AmpC or ESBL + AmpC-producers were identified from turkeys (N = 674 isolates). These included a *S.* Infantis isolate and a *S.* Agona isolate from Italy, and a *S.* Derby isolate from Poland. All three isolates displayed an ESBL phenotype only. Among laying hens, *S.* Infantis isolates reported by Italy were also identified as a presumptive ESBL only-producer, and a *S.* Enteritidis and *S.* Bovismorbificans isolate reported by Hungary were identified as presumptive AmpC only-producers. The ESBL phenotype was detected in *S.* Infantis isolates from Italy and Iceland (one isolate in each country) while the AmpC phenotype was also detected in a single *S.* Mbandaka isolate reported from a broiler carcass by France.

### 2.4.8. Carbapenem resistance in *Salmonella* spp. from food-producing animals and carcases

**Carbapenems** are recognised as hpCIAs (WHO, 2019), and includes meropenem, an antimicrobial agent specified in the antimicrobial panel for monitoring and reporting AMR in *Salmonella* spp. (as stipulated by Commission Implementing Decision (EU) 2020/1729). This class of antimicrobials are not therapeutically used in food-producing animals but are reserved for use in humans.

In 2020 and 2021, none of the *Salmonella* isolates recovered from any of the animal or carcass origins exhibited microbiological resistance to meropenem. This is consistent with data from animal or carcass origins in 2018 and 2019.

### Table: Presumptive ESBL- and/or AmpC-producers and/or ESBL + AmpC-producers from food-producing animals and carcases

<table>
<thead>
<tr>
<th>Matrix</th>
<th>Presumptive ESBL- and/or AmpC-producers(^{(a)})</th>
<th>Presumptive ESBL-producers(^{(b)})</th>
<th>Presumptive AmpC-producers(^{(c)})</th>
<th>Presumptive ESBL + AmpC-producers(^{(d)})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fattening turkeys – 2020</td>
<td>n (%R) 3 (0.4)</td>
<td>n (%R) 3 (0.4)</td>
<td>n (%R) 0</td>
<td>n (%R) 0</td>
</tr>
<tr>
<td>(N = 674, 16 MSs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fattening pigs – 2021</td>
<td>n (%R) 10 (0.8)</td>
<td>n (%R) 10 (0.8)</td>
<td>n (%R) 2 (0.2)</td>
<td>n (%R) 2 (0.2)</td>
</tr>
<tr>
<td>(N = 1,258, 26 MSs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bovines &lt; 1 year – 2021</td>
<td>n (%R) 1 (1.3)</td>
<td>n (%R) 1 (1.3)</td>
<td>n (%R) 21 (1.3)</td>
<td></td>
</tr>
<tr>
<td>(N = 79, 10 MSs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{(a)}\): Isolates exhibiting only ESBL- and/or only AmpC- and/or combined ESBL + AmpC phenotype.
\(^{(b)}\): Isolates exhibiting an ESBL- and/or combined ESBL + AmpC-phenotype.
\(^{(c)}\): Isolates exhibiting an AmpC and/or combined ESBL + AmpC-phenotype.
\(^{(d)}\): Isolates exhibiting a combined ESBL + AmpC phenotype.
2.4.9. Resistance exhibited by dominant *Salmonella* serovars

The detailed reporting of results at the serovar level demonstrated the major contribution of a few serovars to the observed overall occurrence of resistance when considering aggregated data for *Salmonella* spp. The patterns of resistance associated with these different serovars have a marked influence on the overall resistance levels in *Salmonella* spp., as the proportion of completely susceptible and MDR isolates may vary significantly among serovars recovered from each of the carcase origins/food-producing animal populations studied. The analysis of antimicrobial resistance at the serovar level is presented in Appendix C.

2.5. Comparison of resistance data in *Salmonella* from human and food-producing animals

A comparison of human *Salmonella* data by serovar to that found in food-producing animals for the years 2020–2021 can be found in Appendix D. Comparable AMR data are presented for serovars *S*. Typhimurium and its monophasic variant, *S*. Derby, *S*. Infantis, *S*. Enteritidis and *S*. Kentucky. The prevalence of particular *Salmonella* serovars within countries and animal populations, and their associated patterns of resistance, may explain some of the observed differences in the occurrence of AMR and MDR. The spread of resistant clones and the presence of resistance genes within these clones can be exacerbated by selective pressure from using antimicrobials in human and animal populations. However, it should be noted that relating the occurrence of AMR in human *Salmonella* isolates to that in isolates from food-producing animals and derived meat should be done with caution because other sources of *Salmonella* occur, and such evaluations should be performed and interpreted considering the complex epidemiology of salmonellosis.

2.6. Discussion

The continuous AMR monitoring in *Salmonella* helps to identify new resistance mechanisms emerging in human and animal populations. The harmonised monitoring of *Salmonella* from food-producing animals and carcasses using phenotypic antimicrobial susceptibility testing, seeks to identify emerging issues such as MDR *S*. Kentucky with high resistance to fluoroquinolones and *S*. Infantis isolates exhibiting combined resistance to extended-spectrum cephalosporins, fluoroquinolones and colistin (EFSA, 2019). In 2020 and 2021, the detection of resistant *Salmonella* isolates varied markedly between animal and carcase origins, by serovars and by reporting countries. These factors may introduce a source of variation to results when considering all reporting countries, and results should be interpreted cautiously. Further, the limited number of *Salmonella* isolates reported by some countries at serovar level, in recent years is not enough to perform a full statistical trend analysis of the level of resistance at the serovar level.

Under the new legislation (Commission Implementing Decision (EU) 2020/1729), MSs may perform WGS on *Salmonella* isolates from food-producing animals displaying resistance to third-generation cephalosporins or carbapenems as an alternative method to broth-microdilution when further testing those isolates with the second panel of antimicrobial substances. Information on WGS data from *Salmonella* isolates can be found in chapter 5. Regarding data from humans, resistance predicted from WGS has been an accepted test method since 2019. WGS is increasingly recognised as a powerful tool for epidemiological surveillance of AMR in the 'One Health' context (WHO, 2020). WGS complements phenotypic methods by providing information on molecular determinants and mechanisms, genetic factors that facilitate transmission, and geographical distributions of resistance genes. Many studies on Enterobacteriaceae, including *Salmonella*, have described high concordance between WGS data and phenotypic data (McDermott et al., 2016; Hendriksen et al., 2019).

In 2021, information on AMR in *Salmonella* isolates from human clinical cases was reported by 24 MSs and two non-MSs. No data was reported by the United Kingdom after 2019 due to its withdrawal from the EU on 30 January 2020. The effect of the COVID-19 pandemic on the quantities of isolates reported by countries was not as pronounced in 2021 as for 2020 but the number of isolates were still one quarter (median) fewer compared with 2019, although more countries were able to report data for 2021 compared with 2020. In 2021, twenty-one countries provided data as measured values (quantitative data), four as data interpreted with clinical breakpoints and one as predicted phenotypic resistance based on whole genome sequencing.

Of note, the comparison of AMR data reported for *Salmonella* isolates from pigs and calves in 2019 and 2021 should be made with caution because the legislation in place has changed and the
requirements were different under the previous legislation (Commission Implementing Decision (EU) 2013/652) compared to the new one (Commission Implementing Decision (EU) /2020/1729). In 2019, it was mandatory to collect samples of carcasses of fattening pigs and bovine animals under 1 year of age, while in 2021 the sampling is taken from the caecal contents of pigs and calves. In 2019, far fewer MSs submitted data on pigs (N = 8) and calves (N = 3) compared to 2021 (N = 26, N = 10, respectively).

**Occurrence of resistance to commonly used antimicrobials in veterinary medicine**

Moderate to very high levels of resistance to ampicillin, sulfamethoxazole and tetracycline were generally reported by MSs among *Salmonella* isolates from all animal and carcase origins except laying hens. The highest resistance levels were observed in pigs (2021) and turkeys (2020). Resistance levels to sulfamethoxazole and tetracycline were generally higher than ampicillin in isolates from animal or carcase origins. This may be related to underlying genetic structures responsible for resistance and the proportion of *Salmonella* spp. carrying genetically-linked resistance genes to these agents. Overall, high levels of resistance to antimicrobials used in veterinary medicine were also noted in *Salmonella* isolates from human cases. Considering individual serovars, monophasic *S. Typhimurium* generally showed the highest resistance to these antimicrobials for all the animal/carcase origins. The same observation was also noted among isolates from human cases, where extremely high levels of resistance to these antimicrobials were reported in monophasic *S. Typhimurium* and *S. Kentucky* in 2020 and 2021 (for *S. Kentucky*, very high in 2021).

**Occurrence of resistance to highest-priority critically important antimicrobials (hpCIAs) and last resort antimicrobials**

Third-generation cephalosporins and fluoroquinolones are categorised as hpCIAs because they are commonly used in treatment of gastrointestinal infections, including *Salmonella* infections, in humans (WHO, 2019). This sets the rationale for monitoring combined resistance to these antimicrobial classes within food-producing animals.

From the monitoring of pigs and calves in 2021, the overall resistance levels to CIAs ranged from zero (no resistance to azithromycin and amikacin was observed in *Salmonella* isolates from calves) to moderate in pigs. Moderate levels of resistance to ciprofloxacin/nalidixic acid were observed in isolates from pigs and calves. From the monitoring of pigs in 2021, *S. Rissen*, *S. Typhimurium* and monophasic *S. Typhimurium*, showed the highest levels of resistance to ciprofloxacin and nalidixic acid. From the monitoring of poultry in 2020, highest levels of resistance were generally noted to ciprofloxacin/nalidixic acid and *S. Infantis* and *S. Kentucky* showed the highest resistance to ciprofloxacin and nalidixic acid across poultry origins. This likely reflects the spread of resistant clones belonging to these serovars. From human data reported in 2021, *S. Infantis* and *S. Kentucky* also showed the highest resistance to these substances. Resistance to ciprofloxacin/nalidixic acid, sulfamethoxazole and tetracycline are typical of a clone of *S. Infantis* which is prevalent in Europe in broilers (Nogrády et al., 2012) and *S. Infantis* is a serovar commonly reported in the monitoring by some countries. Ciprofloxacin resistance was observed at equally high levels among isolates from broilers, turkeys and their derived carcases and was generally very similar to nalidixic acid resistance. However, *Salmonella* isolates exhibiting ciprofloxacin resistance and nalidixic acid susceptibility, indicating the occurrence of plasmid-mediated quinolone resistance (PMQR) mechanisms, were mostly evident in turkeys and their derived carcases.

Resistance to third-generation cephalosporins, cefotaxime and ceftazidime in *Salmonella* isolates recovered from animal populations and derived meat was either not discerned or was generally detected at very low/low levels in most of the reporting MSs. Isolates that demonstrated resistance to third-generation cephalosporins were subjected to supplementary testing with a further panel of antimicrobials to determine if they were presumptive ESBL, AmpC or ESBL + AmpC producers. Very small numbers of isolates were determined to be presumptive ESBL, AmpC or ESBL + AmpC producers, notably, no *Salmonella* isolates recovered from turkey carcases in 2020 exhibited resistance to third-generation cephalosporins. In *Salmonella* spp. isolated from human cases the levels of resistance to cefotaxime and ceftazidime were also low, at 1.1%, ranging from 0.0% to 5.1%. In 2021, no *Salmonella* spp. recovered from human cases, or any carcase/animal origins were microbiologically resistant to meropenem.

Overall combined resistance to cefotaxime and ciprofloxacin in all animal/carcase origins was observed at very low or low levels, and in turkey carcases, no isolates displayed combined resistance. Notably, for poultry populations, 2020 data, where cefotaxime and ciprofloxacin MICs
EUSR on AMR in zoonotic and indicator bacteria from humans, animals and food 2020/2021

were interpreted using CBPs, none of the isolates exhibited ‘clinical’ resistance to these compounds, except for broilers at a very low level (0.4%). Note however that the CBP for ciprofloxacin changed in the new legislation and from 2021 corresponds to the ECOFF MIC > 0.06 mg/L. From human cases in 2021, combined resistance to cefotaxime and ciprofloxacin was very low overall (0.8%) but higher in S. Infantis (5.0%) and S. Kentucky (5.7%), with particularly high proportions among S. Infantis isolates from Italy (a similar observation for Italy was made in 2020). Italy also reported the highest proportion of combined resistance in S. Infantis in broiler flocks (20.7%), laying hens (12.5%) and fattening turkeys (3.7%) in 2020. For S. Kentucky from humans the results were based on altogether 105 isolates with very few isolates reported from the majority of countries, the highest number of isolates being from France, Germany and Malta (35, 23 and 18 isolates, respectively).

In 2021, S. Dublin accounted for all of the colistin-resistant isolates observed in calves, while in pigs, S. Enteritidis was most often associated with colistin resistance. From the monitoring of poultry in 2020, colistin resistance was generally observed in S. Enteritidis isolates, with resistance observed in over half of the S. Enteritidis isolates recovered from broilers and laying hens. S. Enteritidis and S. Dublin are group D salmonellas (serogroup O9). This group shows decreased susceptibility to colistin without having any known acquired or mutational colistin resistance mechanisms and, therefore, shows a degree of intrinsic resistance to colistin (Agersø et al., 2012; Ricci et al., 2020). Various serovars from pigs displayed colistin-resistance, including five isolates attributed to S. Enteritidis, three to S. Panama and two to S. Derby. In Salmonella spp. in isolates from human cases, levels of resistance to colistin ranged from 0.0% to 19.2% in 2021 with the highest proportion among the investigated serovars observed in S. Enteritidis (17.6%). Phentypotypical testing for colistin is complicated, and EUCAST recommends performing testing using microbroth dilution or specific PCR. For that reason, colistin results are only available from a third of the reporting MSs. Because of the possible difference in intrinsic resistance to colistin in Salmonella by serogroup, EUCAST removed the Salmonella-specific ECOFF until more data has been made available. A tentative ECOFF has however been suggested for S. Dublin where a MIC of ≤ 16 mg/L would be considered wild type (EUCAST, 2023). If that would be applied also on S. Enteritidis, which belongs to the same antigen O group as S. Enteritidis – O:9, fewer isolates would turn out non-wild type to colistin, making it easier to identify isolates with acquired resistance. Further molecular characterisation of colistin-resistant isolates obtained from the EU AMR monitoring to determine the underlying genetic mechanisms would assist in identifying the emergence and dissemination of colistin-resistant Salmonella clones as well as identify colistin resistance plasmids occurring in Salmonella associated with livestock.

The ECOFF for tigecycline was changed under the new legislation from > 1 to > 0.5 mg/L, and resistance was reported separately for 2021 data from pig and bovine animals under 1 year of age and 2021 AMR data from poultry and meat derived thereof. The CBP for tigecycline was also changed to > 0.5 mg/L. Where tigecycline resistance was reported among the carcase/animal origins, most isolates displayed MICs that were one dilution above the ECOFF. Considering poultry, S. Infantis accounted for most of the resistant isolates recovered from broilers (70.3%) and all isolates from their derived carcasses, as well as three tigecycline-resistant isolates reported from turkeys. S. Bredeney accounted for most (83.8%) of the tigecycline-resistant isolates recovered from turkeys. A low number of tigecycline-resistant isolates were reported from calves (n = 8) with various serovars, while S. Rissen was the most common serovar reported (27.3%, n = 88) from pigs. Microbiological resistance to tigecycline may suggest clonal expansion of microbiologically-resistant strains belonging to these serovars. MDR was often a feature of tigecycline-resistant isolates from pigs and calves. In Salmonella spp. in isolates from humans, resistance to tigecycline was rare to low (overall 1.4%) among the nine countries reporting results for this last-resort antimicrobial.

Determining the susceptibility to tigecycline is not straightforward as this compound can be inactivated by oxidation and exposure to light, which may lead to falsely-elevated MIC values. In addition, upregulation of normal cell pathways or processes may also contribute to elevated tigecycline MIC values at levels above the ECOFF in Enterobacteriaceae (He et al., 2016). Two transferable plasmid-mediated tigecycline resistance genes, tet(X3) and tet(X4) conferring higher levels of tigecycline resistance (MICs of ≥ 16 mg/L), have been reported in numerous Enterobacteriaceae from animals and meat (chicken and pork) in China (Bai et al., 2019; He et al., 2019). The potential for Salmonella to acquire such transferable tigecycline resistance genes is therefore highlighted, and the importance of monitoring tigecycline resistance through determination of MICs or by molecular investigation such as WGS is further underlined.
For the first time in 2021, amikacin, a member of the aminoglycoside class which is a high priority CIA for human medicine, was included in the harmonised panel for testing food-producing animals and derived meat. The rationale for including amikacin, in addition to gentamicin, for harmonised monitoring is that amikacin improves the detection of 16S rRNA methyltransferase enzymes (RMTases) which confer resistance to aminoglycosides (EFSA, 2019). RMTases have been increasingly associated with carbapenemases, AmpC or ESBL enzymes and fluoroquinolone resistance in Enterobacteriaceae from human cases in Europe (Arca-Suárez et al., 2022; Fournier et al., 2022). A small number of studies from outside of Europe have observed that the prevalence of RMTases in Enterobacteriaceae isolated from food-producing animals is low (Yan et al., 2004; Wang et al., 2017; Belaynehe et al., 2019), and that the presence of these genes confers high-level ampicillin resistance (MIC > 512 mg/L) in isolates (Belaynehe et al., 2019). For pigs, few Salmonella isolates were microbiologically resistant to amikacin (MIC > 4 mg/L) (n = 7), with one of those isolates also clinically resistant (MIC > 16 mg/L), while no isolates from calves were resistant to this antimicrobial. One S. monophagic Typhimurium isolate from Austria, from pigs, with amikacin resistance was MDR, also displaying resistance to ampicillin, nalidixic acid, ciprofloxacin, sulfamethoxazole, trimethoprim and tetracycline.

Multidrug resistance (MDR)

In 2020, MDR varied between reporting countries and animal/carcase origins, with overall MDR ranging from a low level of 6.1% in laying hens to the highest level of 53.6% in broiler carcasses. In 2021, MDR was higher among Salmonella spp. from pigs (39.2%) compared to calves (30.4%). Resistance levels varied among serovars which may exhibit particular MDR patterns, so the relative contribution of individual serovars within the different animal origins and between countries should be considered when comparing the situation between reporting countries. For example, the overall lower level of MDR among isolates from laying hens in comparison to those reported from broilers and turkeys most likely reflects in part the predominance of S. Enteritidis, which accounted for 25.5% of Salmonella isolates from laying hens reported by MSs, and where 79.5% of S. Enteritidis isolates exhibited complete susceptibility. Additionally, only a limited number of antimicrobials are authorised for the treatment of laying hens in many EU countries, and this factor may also be reflected in overall AMR levels in Salmonella isolates from this sector. In Salmonella spp. strains from human cases, MDR was detected in 22.6%, ranging from 5.6% reported from Greece to 40.5% in Italy, respectively. The lowest rates of MDR were found in S. Enteritidis (1.9%) and the highest in S. Kentucky (54.8%) and in monophasic S. Typhimurium (78.4%), respectively.

Prevalence of particular Salmonella serovars and associated MDR patterns

In summary, the prevalence of particular Salmonella serovars within countries and animal populations and their associated patterns of resistance likely explain many of the observed differences in the overall levels of AMR and MDR. The spread of resistant clones and the occurrence of resistance genes within these clones can be exacerbated by selective pressure from using antimicrobials in human and animal populations. A detailed analysis of AMR at the serovar level, including possible underlying genetic structures responsible for resistance, is presented in Appendix C. Within a given MS, any attempt to relate the occurrence of AMR in human Salmonella isolates to that in isolates from food/food-producing animals is complicated (see Appendix D), as much of the food consumed in a MS may have originated from other MSs or non-member countries. Salmonella infections can also be associated with foreign travel, other types of animal contact (such as pets, including reptiles) or the environment. Additionally, human infections may result from human-to-human transmission. To improve the investigation of these relationships, human isolates from cases notified as having been acquired during travel outside of the reporting country were excluded from the analysis.

High-level resistance to ciprofloxacin

In 2021, high-level resistance to ciprofloxacin (MIC ≥ 4 mg/L) was detected in one isolate (S. Kentucky) from a pig sample from Malta, while in calves, there was none. In 2020, high-level resistance to ciprofloxacin was also observed among isolates from poultry (see Appendix A). While many serovars (including Bredeney, Derby and Infantis) exhibited high-level resistance among poultry, S. Kentucky accounted for most of the high-level resistant Salmonella isolates recovered from the poultry origins. The same finding was also noted among isolates from human cases in 2021, where high-level ciprofloxacin resistance was most commonly found in S. Kentucky (in 81.2% of S. Kentucky
isolates) among the 13 countries reporting MIC data. S. Kentucky isolates exhibiting high-level ciprofloxacin resistance are likely to belong to the multilocus sequence type (ST) 198 clone, which has shown epidemic spread in North Africa and the Middle East (Belayneh et al., 2019). Notably, in 2020, the occurrence of this serovar exhibiting high-level resistance in poultry was observed by eight MSs from most parts of Europe, suggesting further clonal expansion (S. Kentucky ST198-X1). Furthermore, a very high proportion of the poultry S. Kentucky isolates displaying ciprofloxacin MICs of $\geq$ 4 mg/L were also multiresistant, primarily showing resistance to ampicillin, gentamicin, nalidixic acid, sulfamethoxazole and tetracycline. The same observation was also noted among S. Kentucky isolates from human cases. The sole S. Kentucky isolate showing high resistance to ciprofloxacin from pigs was resistant to nalidixic acid but no other antimicrobial substances.

**Phenotypic characterisation of third-generation cephalosporin and carbapenemase resistance**

For data from animal/carcase origins, very small numbers of isolates were determined to be presumptive ESBL, AmpC or ESBL + AmpC producers. The highest number observed was in broiler flocks from 2020 (2.1%, N = 1,953). Notably, no Salmonella isolates recovered from turkey carcasses in 2020 exhibited resistance to third-generation cephalosporins. In 2021, for further testing third-generation cephalosporin-resistant isolates from pigs and calves, MSs could choose to undertake WGS as an alternative to broth-microdilution, with some countries such as Italy submitting WGS data. More detailed information on the WGS results can be found in chapter 5. Note, in 2021, there were no human cases or animal Salmonella isolates reported with meropenem resistance, similarly for 2020 poultry data, indicating the absence of carbapenemase-producers in the Salmonella isolates reported by MSs for these years.

Among poultry in 2020, the ESBL or AmpC phenotype was associated with multiple isolates belonging to certain serovars, suggesting the possible clonal expansion of particular strains: namely, *S. Infantis* and *S. Kentucky*. Among broilers and turkeys, presumptive ESBL-producing Salmonella was identified more frequently than presumptive AmpC-producing Salmonella and encompassed a greater number of serovars. Except for one MS, presumptive ESBL, AmpC or ESBL+AmpC producers were identified at very low or low levels. Italy, however, reported the ESBL phenotype in 29 Salmonella isolates (76.3% n = 38) from broilers and two (66.6%, n = 3) *Salmonella* isolates from turkeys; of which *S. Infantis* accounted for all those from broilers (n = 29) and half of those from turkeys (1/2). Additionally, some of these isolates also possessed an AmpC phenotype. The proportion of presumptive ESBL/AmpC-producers attributed to *S. Infantis* within broilers and turkeys in Italy suggests clonal expansion and spread among these animal populations in this country. The findings in poultry are interesting because there are no authorised products for use in the poultry sector in the EU, which include third-generation cephalosporins, and off-label use of third-generation cephalosporins in poultry is not permitted (Franco et al., 2015).

Considering the monitoring performed in 2021, the ESBL or ESBL + AmpC phenotype was detected in ten isolates representing five serovars among pig isolates: namely, *S. Derby*, *S. Infantis*, *S. London*, *S. Rissen* and *S. Kedougou*. These isolates from pigs were reported by just two countries, Romania (n = 6) and Hungary (n = 4). Presumptive ESBL-producing Salmonella (n = 8) was more frequently reported than presumptive ESBL + AmpC producing Salmonella isolates (n = 2). In calves, only a single *S. Derby* isolate from Spain displayed an ESBL + AmpC phenotype.

In humans in 2021, presumptive ESBL-producing *Salmonella* were identified in 0.8% of isolates tested, with the highest occurrence in Italy (3.5%). AmpC was less frequent (0.1%). Of note, there were no *Salmonella* isolates reported to be both AmpC- and ESBL-producing nor carbapenemase producing. Of the 13 serovars and subspecies identified with an ESBL phenotype from humans in 2021, it was most commonly found in *S. Infantis*, monophasic *S. Typhimurium* and *S. Typhimurium* (5.2%, n = 27/517; 1.2%, n = 23/1867; 0.9%, n = 11/1,246, respectively). For human cases, the proportion of *S. Kentucky* with an ESBL phenotype decreased from 20.3% in 2017 to 3.8% in 2021, with three countries (France, the Netherlands and Sweden) reporting presumptive ESBL-producing *S. Kentucky* in 2021. The introduction and spread of *S. Kentucky* with *blaCTX-M-14b* in Europe has recently been described by Coipan et al. (2020). AmpC-type β-lactamases were reported in five different serovars, most commonly in monophasic *S. Typhimurium*, *S. Brandenburg* and *S. Goldcoast* (0.3%, n = 6/1867; 1.8%, n = 2/110; 5.1%, n = 2/39, respectively). Of note, all human *Salmonella* isolates resistant to cefotaxime and/or cefazidime identified in local or regional laboratories in Italy are submitted to the national surveillance system for strict monitoring of ESBL/AmpC. This may have resulted in an overestimation of such findings, although the high proportions of ESBL observed in isolates from Italian broilers and turkeys would seemingly confirm these results.
In conclusion, it is important to note that zoonotic *Salmonella* infections in humans tend to be self-limiting diseases, rarely leading to clinical conditions, where a patient should receive antibiotic treatment. However, considering the relatively high number of people that each year fall ill with salmonellosis, the level of resistance to commonly used antimicrobials or antimicrobials used for critically ill patients such as the CIA needs to be continuously watched as these still may be of importance. In addition, the monitoring of the resistance levels in *Salmonella* from food-producing animals and meat derived thereof allows the assessment and the evaluation of the occurrence of AMR in the EU and help to identify the achievements in the efforts to tackle AMR.

3. **Antimicrobial resistance in *Campylobacter* spp.**

3.1. **Key findings**

- For 2021, 22 MSs and two non-MS (Iceland and Norway) reported data on AMR in *Campylobacter jejuni* from human campylobacteriosis infections and 20 MSs and two non-MS (Iceland and Norway) on AMR in *Campylobacter coli*. This is an increase in the number of countries reporting compared to 2019 and 2020.

- In 2020, data related to the antimicrobial susceptibility of 3,382 *C. jejuni* isolates from broilers and 1,066 *C. jejuni* isolates from fattening turkeys were reported by 27 and 9 MSs, respectively. In relation to *C. jejuni*, antimicrobial susceptibility data from 1,198 isolates from calves (bovines less than 1 year old) and from 60 fattening pig isolates were reported in 2021 by 10 and 12 MSs, respectively.

- Data related to the antimicrobial susceptibility of *C. coli* from 388 isolates from broilers and 567 isolates from fattening turkeys were reported in 2020 by 7 and 3 MSs, respectively. Data related to the antimicrobial susceptibility of *C. coli* from 443 isolates from calves and 3,546 isolates from pigs were reported in 2021 by 10 and 27 MSs, respectively.

- Resistance rates differed greatly between reporting countries, between antimicrobials and between the two *Campylobacter* species.

- Levels of resistance to ciprofloxacin ranged from high to extremely high in *C. jejuni* and *C. coli* isolates from humans in the EU and from very high to extremely high in *C. jejuni* and *C. coli* isolates from poultry, fattening pigs and calves. Resistance levels to ciprofloxacin in human *C. jejuni* isolates ranged from 27.6% to 100% among the EU countries. In two countries, all *C. coli* isolates tested from humans were resistant to ciprofloxacin. In 2021 for *C. coli* isolates, 14 out of 18 countries reporting more than 10 isolates found levels of ciprofloxacin resistance of >70%. In relation to animal data, the highest levels of resistance to ciprofloxacin were observed in *C. coli* isolates from fattening turkeys in 2020 (80.4%) and from calves in 2021 (79.7%), followed by broilers (61.9%) in 2020 and fattening pigs (51.7%) in 2021. Overall, the levels of resistance to ciprofloxacin were higher for *C. coli* than for *C. jejuni* although the level of resistance to ciprofloxacin obtained from *C. jejuni* isolates from poultry in 2020 were also extremely high (77.9% in fattening turkeys and 72.8% in broilers).

- Resistance to erythromycin was either not detected or detected at very low levels in *C. jejuni* from humans, poultry and calves, but was higher in *C. coli* isolates from humans (8.5%), calves (35.7%), fattening turkeys (21.5%), fattening pigs (12.3%) and broilers (4.4%).

- Combined resistance to both ciprofloxacin and erythromycin, which are considered critically important antimicrobials for the treatment of campylobacteriosis, was generally rare to low in *C. jejuni* from humans, poultry, pigs and calves. The combined resistance was low to moderate in *C. coli* from humans and broilers, and moderate in *C. coli* isolated from fattening turkeys and calves. This finding may be a cause for public health concern.

- The observed levels of resistance to gentamicin and ertapenem in *C. coli* isolated from calves in 2021 were 12.4% and 29.1%, respectively, which might be a cause for public health concern as they are recommended antimicrobials for treatment in severe invasive infections of *Campylobacter* in humans. Gentamicin resistance in *C. coli* from humans was observed at low levels except in one MS, while ertapenem is not (yet) included in the priority panel for *Campylobacter* monitoring of human isolates at EU level.

- The prevalence of resistance to selected antimicrobials in *C. coli* from fattening pigs in 2021 has been estimated at country. Between-country variability from low to extremely high levels was observed in the prevalences of ciprofloxacin resistant (ranging from 6.9% to 78.2%) and tetracycline resistant (ranging from 0.0% to 86.5%) *C. coli* from fattening pigs.
Interestingly, a limited between-country variation and notably lower levels of prevalence of resistance to erythromycin were found in C. coli from fattening pigs (below 10% for 21 MSs and 3 non-MSs; ranging from 14.9% to 39.7% in six MSs). Noteworthy, the MS with the highest prevalence of resistance to erythromycin in C. coli from fattening pigs in 2021 had also the highest level of erythromycin occurrence of resistance in C. coli from humans.

- **Overall, complete susceptibility (CS)** (i.e. defined in this report as susceptibility to ciprofloxacin, erythromycin, tetracycline and gentamicin) was higher in C. jejuni than in C. coli isolates. The overall CS observed from C. jejuni isolates was: 30.9% in humans in 2021, 23.0% in broilers in 2020, 16.8% in fattening turkeys in 2020 and 21.6% in calves in 2021 and 48.3% in fattening pigs in 2021. Regarding C. coli, the overall CS observed was moderate for humans (13.2%), broilers (13.7%) and fattening pigs (19.9%), while it was low for isolates from fattening turkeys (4.4%) and calves (6.3%).

- **Over the period 2013–2021, resistance to ciprofloxacin in C. jejuni from humans increased in 12 reporting countries (11 MSs and 1 non-MS) and decreased in three (2 MSs and 1 non-MS).** Resistance to ciprofloxacin in C. coli from humans increased in three MSs and decreased in two countries (1 MS and 1 non-MS) in the same period. Similar trends were observed in C. jejuni from broilers in the period between 2009 and 2020 where resistance to ciprofloxacin increased in 14 reporting countries (12 MSs and 2 non-MSs) and decreased only in one MS. During the period 2009–2021 (2015–2021 for 1 MS), an increasing trend in resistance to ciprofloxacin was also observed in C. coli isolates from fattening pigs in four reporting countries (2 MSs and 2 non-MSs).

- **Based on trend data, erythromycin** resistance decreased in C. jejuni from humans in seven countries (5 MSs and 2 non-MSs; period 2013–2021), from broilers in five MSs (over 2009–2020), from fattening turkeys in three MSs (period 2014–2020) and in C. coli from humans in five MSs (period 2013–2021), from broilers in one MS (period 2009–2020) and from fattening pigs in four countries (3 MSs and 1 non-MS; period 2009–2021).

- **Although the period assessed for the trend and the countries providing data are slightly different for humans and animals, similar increasing and decreasing trends were often observed within a country in both humans and poultry, particularly regarding trends in increasing ciprofloxacin resistance.**

### 3.2. Data on AMR in Campylobacter spp. addressed

**Campylobacter** bacteria are ubiquitous and can be found widespread in the environment and in animals. Campylobacter is frequently found in water, animals, biofilms and other environmental niches that can all be considered potential modes of transmission to humans (Garcia and Percival, 2011; WHO, 2012, 2020; Garcia and Heredia, 2013; Kreling et al., 2020; Lopez-Chavarrias et al., 2021). Birds are considered natural hosts for Campylobacter (Sopwith et al., 2008; Jokinen et al., 2011; Lopez-Chavarrias et al., 2021). Campylobacter is frequently present in the intestines of poultry, cattle, sheep and pigs, and may contaminate the food processing environment and food products thus posing a public health risk to consumers (Dykes and Moorhead, 2001; Garcia et al., 2010a,b). Food-producing animals are a major source of human campylobacteriosis through contamination of food products. However, wild birds, pets and environmental water may also play a role as potential modes of transmission (Moré et al., 2017; Szczepanska et al., 2017; EFSA, 2019). Campylobacter strains resistant to antibiotics may interfere with the treatment of human campylobacteriosis (Moore et al., 2006; Garcia and Heredia, 2013; Lopez-Chavarrias et al., 2021).

The two main Campylobacter species responsible for human infections are C. jejuni, which is a predominant species in poultry, followed by C. coli (Jehanne et al., 2020), frequently found in pigs and in poultry, sometimes at higher rates than C. jejuni (Pergola et al., 2017). C. coli is often more resistant than C. jejuni to several important antimicrobials and may contain and transfer resistance genes to C. jejuni.

Campylobacter AMR data from human infections either derive from monitoring programs set up by national public health reference laboratories/services or is collected from primary or regional laboratories and integrated with the case information in the national surveillance of human Campylobacter infections. This report covers AMR data for C. jejuni and C. coli from human cases from 2021. Data from 2020 are presented in the 2019/2020 report (EFSA and ECDC, 2022).

In the framework of the most recent Commission Implementing Decision (EU) 2020/1729 the monitoring of AMR in Campylobacter spp. from food-producing animals and meat derived thereof is focused on the species C. jejuni and C. coli. In accordance with Commission Implementing Decision (EU) 2020/1729, from 2021 onward, the AMR monitoring is mandatory, at biannual basis, in C. jejuni.
and C. coli from caecal samples from broilers, fattening turkeys, bovine animals under 1 year of age (where the national production of turkey meat and bovine meat is more than 10,000 tonnes per year) and fattening pigs at slaughter.

This chapter includes 2021 data on C. jejuni and C. coli from fattening pigs and calves resulting from mandatory monitoring in accordance with Commission Implementing Decision (EU) 2020/1729, as well as 2020 data from mandatory monitoring of AMR in C. jejuni and voluntary monitoring of C. coli in broilers and fattening turkeys in accordance with Commission Implementing Decision 2013/652/EU. In addition, the voluntary monitoring of AMR in Campylobacter isolates recovered from meat samples (of broilers, turkeys, bovine and pigs) at retail was performed in 2020 and 2021 and related data are also presented in this chapter and in the Annex B.

Detailed information on antimicrobial resistance data reporting including requirements, sample descriptions and codes for mandatory and voluntary reporting are presented in EFSA’s manual for reporting AMR data within the framework of Directive 2003/99/EC and Commission Implementing Decision (EU) 2020/1729 (EFSA, 2021).

Further consideration on the data used and on the methodology applied in the analysis can be found in Appendix F – ‘Material and methods’.

### 3.3. Humans: occurrence of antimicrobial resistance in Campylobacter

#### 3.3.1. Data reported

For 2021 AMR monitoring and reporting, 22 MSs and two non-MS (Iceland and Norway) reported data on AMR isolated from Campylobacter jejuni from human cases of campylobacteriosis. The corresponding number for C. coli was 20 MSs and two non-MS (Iceland and Norway). This is an increase in the number of countries reporting compared to 2019 and 2020. Lower reporting figures in 2020 are likely due to the impact of the COVID-19 pandemic on referral of isolates and laboratory capacity. No data has been reported for 2020 and 2021 from the United Kingdom due to its withdrawal from the EU on 30 January 2020. Hungary reported Campylobacter AMR data for the first time for 2021.

Fifteen countries reported measured values, seven reported results interpreted as susceptible standard dosing regimen, susceptible increased exposure or resistant (SIR) according to the clinical breakpoints (CBPs) applied and two countries (Ireland and Sweden) reported results categorised as predicted wild type or predicted non-wild type based on analysis of bacterial genomes (Appendix F – Table F.2). Not all countries reported results for all antimicrobials in the harmonised panel (ECDC, 2016).

The reported data represented 21.6% and 24.7% of the confirmed human cases with Campylobacter jejuni and Campylobacter coli, respectively, reported in the EU/EEA in 2021.

#### 3.3.2. Occurrence of resistance

In 2021, reported data related to occurrence of resistance indicated that high to extremely high resistance levels to ciprofloxacin were observed in human Campylobacter jejuni isolates in the EU ranging from 27.6% reported by Ireland to 100% reported by Poland. The average level of ciprofloxacin resistance in EU was 64.5% for C. jejuni and 69.6% for C. coli; slightly higher than levels reported in 2020. Overall, Nordic countries reported low to high levels of resistance to ciprofloxacin ranging from 8.3% in Iceland to 49.1% in Denmark. The rest of the reporting countries obtained results that indicated very high to extremely high resistance levels to ciprofloxacin (Figure 13; Annex B, Table 1). In 2021, data related to occurrence of resistance to ciprofloxacin in C. coli isolates indicated that very high to extremely high resistance levels to ciprofloxacin were reported, apart from Ireland that reported high levels (Figure 13; Annex B, Table 2). Overall, resistance levels to ciprofloxacin were higher in C. coli than in C. jejuni. The highest levels of resistance to ciprofloxacin in C. coli isolates were reported by Portugal and Estonia (100%). Of note, in 2021, for those countries reporting more than 10 isolates of C. coli, 14 out of 18 found extremely high levels (> 70%) of ciprofloxacin resistance (Annex B, Table 2).

The level of resistance to erythromycin in human C. jejuni isolates in the EU was overall very low (1.1%) except for Spain where the results indicated a higher level of resistance (14.2%) (Figure 13; Annex B, Table 1). The level of resistance in human C. coli isolates to erythromycin in EU was overall low (8.5%) but highly variable between countries, ranging from 0% in Ireland and Slovenia to 55.3% in Portugal. Most of the countries, however, reported values between 1% and 26% (Figure 13; Annex B, Table 2).
The average levels of resistance in human isolates to tetracycline were high (45.3%) in *C. jejuni* (except in Finland, Ireland and Sweden where it was low) and extremely high (70.3%) in *C. coli* (except in Ireland where it was low). These levels of resistance to tetracycline were similar to those reported in 2020. The percentages of resistance to tetracycline in *C. jejuni* isolates ranged from 11.2% in Finland to 77.3% in Portugal. The percentages of resistance to tetracycline in *C. coli* isolates ranged from 16.7% in Ireland to 100% in Portugal (Figure 13; Annex B, Tables 1 and 2).

Resistance levels to gentamicin were overall low with an EU average of 0.7% and 2.4% in human *C. jejuni* and *C. coli* isolates, respectively. The highest levels were reported by Spain (9.6% and 11.9% in human *C. jejuni* and *C. coli* isolates, respectively) (Figure 13; Annex B, Tables 1 and 2).

Horizontal line represents the median; blue diamond: resistance at reporting MS group level (see Table below). Only countries reporting ≥10 isolates per species are included in the graph.

<table>
<thead>
<tr>
<th>EU total</th>
<th>Ciprofloxacin (CIP)</th>
<th>Erythromycin (ERY)</th>
<th>Tetracycline (TCY)</th>
<th>Gentamicin (GEN)</th>
<th>Combined CIP/ERY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>% Res (n)</td>
<td>N</td>
<td>% Res (n)</td>
<td>N</td>
</tr>
<tr>
<td><em>C. jejuni</em> (22 MSs)</td>
<td>15,557</td>
<td>64.5</td>
<td>15,576</td>
<td>1.1</td>
<td>14,334</td>
</tr>
<tr>
<td><em>C. coli</em> (20 MSs)</td>
<td>2,066</td>
<td>69.6</td>
<td>2,065</td>
<td>8.5</td>
<td>1,972</td>
</tr>
</tbody>
</table>

**Figure 13:** Box-plot of the occurrence of resistance to a selection of antimicrobials in *C. jejuni* and *C. coli* isolates from humans, 2021

Few countries reported resistance data in relation to co-amoxiclav. The results indicate overall low levels (average EU level 6.6% and 9.2% in *C. jejuni* and *C. coli* isolates from humans, respectively) except for Germany that reported levels of 41.9% and 44.0% in *C. jejuni* and *C. coli*, respectively (Annex B, Tables 1 and 2).
3.3.3. Combined resistance to ciprofloxacin and erythromycin

Combined resistance to both ciprofloxacin and erythromycin, which are considered critically important for treatment of campylobacteriosis, was generally very low at EU level (0.8%) in *C. jejuni* and low (7.6%) in *C. coli* for 2021 (Figure 13). The levels of combined resistance to both ciprofloxacin and erythromycin in human *C. jejuni* isolates ranged from 0% to 11.1%; the highest level being reported by Spain. The levels of combined resistance to both ciprofloxacin and erythromycin in human *C. coli* isolates ranged from 0% to 55.3%; the highest level being reported by Portugal (Figure 14; Annex B, Tables 3 and 4).

**Figure 14:** Spatial distribution of combined resistance to ciprofloxacin and erythromycin in (a) *C. jejuni* and (b) *C. coli* isolates from humans, 2021
Multidrug resistance (MDR) in isolates tested for four antimicrobial classes (fluoroquinolones, macrolides, tetracyclines and aminoglycosides) was overall very low in *C. jejuni* (1%) and low in *C. coli* (9.9%) (Figure 15; Annex B, Tables 5 and 6). To note, the MDR analysis is based on data from fewer reporting countries as not all countries test gentamicin susceptibility. Complete susceptibility (CS) to the four antimicrobial classes was 30.9% in *C. jejuni* and 13.2% in *C. coli* (Figure 15; Annex B, Tables 5 and 6).

The most common resistance pattern in *C. jejuni* isolates was complete susceptibility to the four antimicrobial classes in the harmonised panel (30.9%) while in *C. coli* it was resistance to both ciprofloxacin and tetracycline (33.9%). The second most common pattern in *C. jejuni* as resistance to both ciprofloxacin and tetracycline, observed in 27.7% of *C. jejuni* isolates while in *C. coli* it was tetracycline resistance alone (13.4%).

Temporal trends were analysed for countries reporting data for at least 3 years over the period 2013–2021. Trends in antimicrobial resistance to *C. jejuni* and *C. coli* varied by country for selected antimicrobials (Table 6; Figures 16 and 17). As the number of *Campylobacter* isolates tested in humans is high, small changes in resistance may come out as significant. Statistically significant (p < 0.05) increasing trends of fluoroquinolone resistance were observed in *C. jejuni* isolates from eleven MSs and one non-MS (United Kingdom) and in *C. coli* isolates from three MSs. Statistically significant (p < 0.05) decreasing trends of fluoroquinolone resistance were observed in *C. jejuni* isolates from two MSs (Finland and Portugal) and one non-MS (Norway) and in *C. coli* isolates from one MS (France) and one non-MS (UK) (Table 6; Figures 16 and 17). Tetracycline resistance increased significantly in six MSs and one non-MS (UK) in *C. jejuni* isolates while four MSs and one non-MS (Norway) observed a significant decrease in the same period. Erythromycin resistance in *C. jejuni* isolates from humans significantly increased in one country (Spain) while significantly decreased in five MSs and two non-MSs (Norway and UK). Erythromycin resistance in *C. coli* isolates significantly decreased in five MSs (Table 6) and significantly increased in one non-MS (UK). Results in relation to significantly increasing or decreasing trends at EU group level indicated that in *C. jejuni* a significant increase was noticed in the levels of resistance to ciprofloxacin and tetracycline during the period 2013–2021 while a significant decrease was observed in relation to resistance to erythromycin. Similarly for *C. coli*, a significant increase in resistance to tetracycline was observed at the EU level (but not to ciprofloxacin) and a significant decrease observed in resistance to erythromycin (Table 6; Figures 16 and 17).

Figure 15: Number of multidrug isolates, isolates resistant to 1 and/or 2 antimicrobials and completely susceptible *Campylobacter* isolates from humans in 2021

3.3.5. Temporal trends
Table 6: Number of countries with significantly increasing or decreasing trends in resistance to selected antimicrobials for Campylobacter jejuni and C. coli in humans, 2013–2021

<table>
<thead>
<tr>
<th>Species</th>
<th>Ciprofloxacin</th>
<th>Erythromycin</th>
<th>Tetracycline</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. jejuni (19 MS + 3 non-MS)</td>
<td>12 (AT, BG, DK, EE, FR, LT, MT, NL, PL, SI, SK, UK)</td>
<td>3 (FI, NO, PT)</td>
<td>7 (DK, FI, IT, MT, NO, SI, UK)</td>
</tr>
<tr>
<td>C. coli (14 MSs + 1 non-MS)</td>
<td>3 (NL, SI, SK)</td>
<td>2 (FR, UK)</td>
<td>5 (EE, ES, FR, MT, SK)</td>
</tr>
</tbody>
</table>

Data from the United Kingdom included up to 2019. Trend at EU MS group level is excluding UK data.

Figure 16: Trends in ciprofloxacin, erythromycin and tetracycline resistance in Campylobacter jejuni from humans in 22 reporting countries and EU MSs group, 2013–2021.
3.3.6. High-level resistance to erythromycin

High-level resistance to erythromycin (MIC > 128 mg/L) was assessed as a potential indication for transferrable erythromycin resistance due to the presence of the *erm*(B) gene. The results indicated that 1.4% of the *C. jejuni* isolates (N = 3,102, 8 MSs + 1 non-MS) showed MIC > 128 mg/L while for *C. coli* the percentage was higher, 4.8% (N = 480, 7 MSs + 1 non-MS) (Figure 18). These results were similar to 2019 but higher than in 2020 (EFSA and ECDC, 2022). Similarly, in 0.5% (N = 2,447, 9 MSs) of *C. jejuni* and 17.5% (N = 200, 6 MSs + 1 non/MS) of *C. coli* tested with disk diffusion no inhibition zone could be observed (6 mm zone equals the disk size), which corresponds to a MIC of ≥ 128 mg/L for *C. jejuni* and 64 - ≥ 128 mg/L for *C. coli*.

Data from the United Kingdom included up to 2019. Trend at EU MS group level is excluding UK data.

**Figure 17**: Trends in ciprofloxacin, erythromycin and tetracycline resistance in *Campylobacter coli* from humans in 15 reporting countries and EU MSs group, 2013–2021

---

<table>
<thead>
<tr>
<th>Year</th>
<th>UK</th>
<th>Austria</th>
<th>Estonia</th>
<th>Finland</th>
<th>France</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Italy</th>
<th>Lithuania</th>
<th>Luxembourg</th>
<th>Malta</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Netherlands</th>
<th>Poland</th>
<th>Portugal</th>
<th>Slovakia</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Slovenia</th>
<th>Spain</th>
<th>Total MSs</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

CIP  ERY  TET

3.4. Food-producing animals and meat thereof: occurrence and prevalence of antimicrobial resistance in *Campylobacter*

3.4.1. Data reported

In the present report, the 2020 resistance data on *Campylobacter* from poultry are considered for comparison with the AMR data on *Campylobacter* isolates from pigs and calves reported in 2021.

In the year 2020, mandatory data on *C. jejuni* isolates recovered from caecal samples of broilers were reported by all 27 MSs and three non-MSs (Norway, Switzerland and the United Kingdom) (N = 3,382 and N = 441, respectively). Data on *C. jejuni* isolates recovered from caecal samples of fattening turkeys were reported by nine MSs (Austria, France, Germany, Hungary, Italy, Poland, Portugal, Romania and Spain) and two non-MSs (Norway and the United Kingdom) in 2020 (N = 1,066 and N = 174, respectively). In addition, seven MSs (Czechia, France, Ireland, Latvia, Luxembourg, the Netherlands and Slovenia) and one non-MS (Switzerland) voluntarily reported data on *C. coli* isolates recovered from caecal samples of broilers (N = 388 and N = 68, respectively). Furthermore, three MSs (France, Germany and Spain) reported data on *C. coli* isolates recovered from caecal samples of fattening turkeys (N = 567). The complete overview of the data reported in 2020, including information on meat categories, is presented in Annex B (Table 7).

In 2021, 12 MSs (Bulgaria, Cyprus, Denmark, Germany, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands and Portugal) and one non-MS (Norway) reported mandatory data on *C. jejuni* isolates recovered from fattening pigs (N = 60 and N = 17, respectively). Ten MSs (Belgium, Croatia, Denmark, France, Germany, Italy, the Netherlands, Portugal, Romania and Spain) and two non-MSs (Norway and Switzerland) reported data on *C. jejuni* isolates recovered from calves under 1 year of age (N = 1,198 and N = 270, respectively). Twenty-six MSs (all MSs, save Czechia) and the United Kingdom (Northern Ireland), as well as three non-MSs (Iceland, Norway and Switzerland) reported mandatory data on *C. coli* isolates recovered from fattening pigs (N = 3,546 and N = 624, respectively). Ten MSs (Belgium, Croatia, Denmark, France, Germany, Italy, the Netherlands, Portugal, Romania and Spain) reported data on *C. coli* isolates recovered from calves under 1 year of age (N = 443) in 2021 (Annex B, Tables 8 and 9).

The complete overview of the data (mandatory and voluntary) from food-producing animal and meat derived thereof, reported in 2020 and 2021, is presented in Annex B (Tables 7–11).

Resistance data concerning food-producing animals and meat derived thereof, reported in 2020 and 2021, are presented in the following sections. Additional tables on *Campylobacter* in food and food-producing animals have been included in Annex B that is available as supporting documentation in Zenodo.

The new EU rules for the AMR monitoring in *Campylobacter* in place from 2021 (Commission Implementing Decision (EU) 2020/1729; see also EFSA, 2021) implemented changes to the harmonised panel of antimicrobials, consisting in the removal of streptomycin and nalidixic acid and in the inclusion of two new substances: ertapenem and chloramphenicol. Therefore, the mandatory antimicrobials to be reported for *C. jejuni* and *C. coli* from 2021 are: chloramphenicol, ciprofloxacin, ertapenem, erythromycin, gentamicin and tetracycline. Furthermore, in accordance with Commission
Implementing Decision (EU) 2020/1729, the range of concentration (mg/L) has been reduced for gentamicin, and increased for erythromycin and ciprofloxacin. As this report presents both 2020 and 2021 data, the legislative requirements laid down in Decision 2013/652/EC have been applied for 2020 data, while 2021 data are reported in accordance with new AMR monitoring rules laid down in Commission Implementing Decision (EU) 2020/1729.

3.4.2. Occurrence of resistance in meat samples from broilers

Data reported during 2020 and 2021 indicate that the highest levels of resistance in C. jejuni and C. coli isolates recovered from broiler meat were noted for ciprofloxacin and nalidixic acid (overall percentages: 65.7%–84.9% in 2020, and 52%–100% in 2021), and for tetracycline (overall percentages: 35.3%–67.7% in 2020, and 42.9%–100% in 2021) considering the 1,001 isolates (809 C. jejuni and 192 C. coli) and 319 isolates (215 C. jejuni and 104 C. coli) reported from nine MSs in 2020 and from five MSs in 2021, respectively (Table 7). It can be noted that in both 2020 and 2021, the levels of resistance to the above-mentioned antimicrobials were reported to be higher in carcases and fresh meat than in meat preparations. Resistance to gentamicin in C. jejuni isolates recovered from poultry meat was not observed in 2020 and 2021 and only low levels of resistance were reported in C. coli from broiler carcases and broiler fresh meat in 2020 (Table 7). Resistance to erythromycin in C. jejuni isolates from broiler meat was detected at low levels while a higher resistance to this antimicrobial was reported in C. coli isolates in both reporting years. Resistance to streptomycin was observed at low levels (data from 2020). Based on data reported for the first time in 2021, moderate to high levels of resistance to ertapenem were observed in particular for C. coli isolates (Table 7). This finding should be interpreted with caution due to the very low number of MSs reporting data on broiler meat in 2021 (from one to three MSs reporting data on the different broiler meat categories). No resistance to chloramphenicol was observed in Campylobacter isolates from broiler meat, as reported for the first time in 2021 (Table 7).

Table 7: Occurrence of resistance (%) to selected antimicrobials in C. jejuni and C. coli from carcases, fresh meat, unspecified meat and meat preparations from broilers, using harmonised ECOFFs, in 2020 and 2021 (only MSs)

| Campylobacter species | Categories | Year | Number of isolates | Reporting Countries (N) | GEN | STR | CHL | ETP | NAL | CIP | ERY | TET | CIP/ERY |
|-----------------------|------------|------|--------------------|-------------------------|-----|-----|-----|-----|-----|-----|-----|------|------|--------|
| C. jejuni             | Carcases   | 2020 | 361                | HR, DE, NL, RO (4)      | 0   | 23.8| 81.4| 82.8| 0.6 | 57.6| 0.3 |
|                       |            | 2021 | 67                 | NL, RO (2)              | 0   | 0   | 11.9| 62.3| 0   | 58.2| 0   |
|                       | Fresh      | 2020 | 343                | AT, BE, DE, LU, NL (5)  | 0   | 22.2| 73.5| 74.9| 0   | 58.6| 0   |
|                       |            | 2021 | 115                | BE, LU, NL (3)          | 0   | 0   | 7.8 | 60.9| 0   | 46.1| 0   |
|                       | Fresh      | 2020 | 35                 | LU, NL (2)              | 0   | 22.9| 65.7| 68.6| 0   | 57.1| 0   |
|                       |            | 2021 | 25                 | LU, NL (2)              | 0   | 0   | 4.0 | 52.0| 0   | 44.0| 0   |
|                       | Meat       | 2020 | 70                 | IT (1)                  | 0   | 1.4 | 55.7| 75.7| 0   | 58.6| 0   |
|                       | preparations | 2021 | 8                  | PT (1)                  | 0   | 0   | 25.0| 87.5| 12.5| 100 | 12.5 |
|                       | Meat       | 2020 | 76                 | DE, LU, NL, RO (4)      | 2.6 | 7.9 | 71.1| 71.1| 10.5| 57.9| 10.5 |
|                       | unspecified| 2021 | 52                 | NL, RO (2)              | 0   | 0   | 25.0| 96.2| 3.9 | 59.6| 3.9 |
|                       | Fresh      | 2020 | 99                 | AT, BE, DE, LU, NL (5)  | 1.0 | 16.2| 84.9| 84.9| 0   | 67.7| 10.1 |
|                       |            | 2021 | 28                 | BE, LU, NL (3)          | 0   | 0   | 46.4| 75.0| 10.7| 60.7| 10.7 |
|                       | Meat       | 2020 | 17                 | NL (1)                  | 0   | 17.7| 70.6| 70.6| 0   | 35.3| 0   |
|                       | preparations | 2021 | 14                 | NL (1)                  | 0   | 0   | 14.3| 85.7| 7.1 | 42.9| 7.1 |
|                       | Meat       | 2020 | 10                 | PT (1)                  | 0   | 0   | 40.0| 100 | 40.0| 100 | 40.0 |
| C. coli               | Carcases   | 2020 | 76                 | DE, LU, NL, RO (4)      | 2.6 | 7.9 | 71.1| 71.1| 10.5| 57.9| 10.5 |
|                       |            | 2021 | 52                 | NL, RO (2)              | 0   | 0   | 25.0| 96.2| 3.9 | 59.6| 3.9 |
|                       | Fresh      | 2020 | 99                 | AT, BE, DE, LU, NL (5)  | 1.0 | 16.2| 84.9| 84.9| 0   | 67.7| 10.1 |
|                       |            | 2021 | 28                 | BE, LU, NL (3)          | 0   | 0   | 46.4| 75.0| 10.7| 60.7| 10.7 |
|                       | Meat       | 2020 | 17                 | NL (1)                  | 0   | 17.7| 70.6| 70.6| 0   | 35.3| 0   |
|                       | preparations | 2021 | 14                 | NL (1)                  | 0   | 0   | 14.3| 85.7| 7.1 | 42.9| 7.1 |
|                       | Meat       | 2020 | 10                 | PT (1)                  | 0   | 0   | 40.0| 100 | 40.0| 100 | 40.0 |

GEN: gentamicin; STR: streptomycin; NAL: nalidixic acid; CHL: chloramphenicol; ETP: ertapenem; CIP: ciprofloxacin; ERY: erythromycin; TET: tetracycline; CIP/ERY: combined 'microbiological' resistance to ciprofloxacin and erythromycin; CS: complete susceptibility to the four antimicrobial classes (ciprofloxacin/nalidixic acid; erythromycin; tetracycline and gentamicin/streptomycin); N: Total number of reporting Member States (MSs).

Additional note: STR was not tested in 2021; however; CHL and ETP were first tested in 2021.
3.4.3. Occurrence of resistance in poultry, pigs and calves

Comparison of resistance data between bacterial and animal species should be done with caution due to the dispersion of resistance rates between countries and because numbers of isolates and reporting countries vary, especially for voluntary monitoring and reporting. Data reported in 2021 for *C. jejuni* and *C. coli* isolates from legislative and non-legislative categories are presented in Annex B, Tables 8–11.

In this Report, data on the occurrence of resistance in *Campylobacter* species in caecal samples from poultry (2020), pigs (2021) and calves under 1 year of age (2021) are presented in Table 8 and Figure 19. The detailed country-level information on the occurrence of resistance is presented in Annex B (Tables 12–19).

Based on the reported animal data, the level of resistance to tetracycline ranged from high to very high (43.3%–90.5%) in both *C. jejuni* and *C. coli* isolates from all the animal categories considered. The highest levels of resistance to tetracycline were observed in *C. coli* isolated from calves under 1 year of age (90.5%) in 2021 (data from 10 MSs) and from fattening turkeys (89.2%) in 2020 (data from three MSs). Overall, the levels of resistance to tetracycline were higher than those observed for the other selected antimicrobials in *C. coli* and *C. jejuni* isolates from calves and fattening pigs in 2021, and for *C. coli* isolated from poultry in 2020.

High levels of resistance were also observed to ciprofloxacin (range from 41.7% to 80.4%) and to nalidixic acid (range from 61.1% to 80.2%; data for 2020 only) in both *C. jejuni* and *C. coli* isolates. The highest levels of resistance to nalidixic acid and to ciprofloxacin were observed in *C. coli* isolated from fattening turkeys in 2020 (80.2% and 80.4%, respectively; data from three MSs). Likewise, a very high level of resistance to ciprofloxacin (79.7%) was obtained from *C. coli* isolated from calves in 2021. Overall, the levels of resistance to ciprofloxacin were higher for *C. coli* than for *C. jejuni* although the level of resistance to ciprofloxacin obtained from *C. jejuni* isolates from poultry in 2020 were also high (e.g. 77.9% in fattening turkeys, data from 9 MSs). The lowest levels of resistance to ciprofloxacin were in both *C. jejuni* and *C. coli* obtained from pig samples in 2021 (41.7% and 51.7%, respectively).

In relation to the levels of resistance to streptomycin, moderate overall levels (range from 11.4% to 16.5%) were reported for *C. jejuni* and *C. coli* isolates from poultry in 2020. Due to recent changes in the legislation, no data in relation to this antimicrobial were reported for pigs and calves in 2021. However, high levels of resistance to streptomycin were reported in *C. coli* isolates from fattening pigs and calves in 2019 (overall, 70.0% and 65.7%, respectively).

Resistance to gentamicin in *C. jejuni* and *C. coli* isolates from poultry was either absent or extremely low in 2020 (0.0%–0.2%). In 2021, the overall levels of resistance to this antimicrobial for *C. jejuni* were 0.5% from calves and 1.7% from pig samples. Higher levels of resistance to gentamicin were observed in *C. coli* isolates from fattening pigs (2.6%) and especially from calves (12.4%) in 2021 (data from 10 MSs).

Resisance to erythromycin was detected at very low levels in *C. jejuni* isolates for the different animal categories (range from 0.8% to 1.7%). Notable higher levels of resistance were reported in *C. coli* isolates (range from 4.4% to 35.7%). The highest level of resistance to erythromycin was observed in *C. coli* isolates recovered from calves (35.7%), followed by fattening turkeys (21.5%), fattening pigs (12.3%) and broilers (4.4%).

Resistance to chloramphenicol in isolates from pigs and calves (2021) was either absent or extremely low in *C. jejuni* isolates from fattening pigs (0.0%) and calves (0.1%), and *C. coli* isolates from pigs (0.5%). A higher level resistance (but still low) to chloramphenicol was observed in *C. coli* isolated from calves (3.4%).

Resistance to ertapenem in isolates from pigs and calves (2021) was either absent or very low in *C. jejuni* isolates from fattening pigs (0.0%) and calves (1%), and *C. coli* from pigs (0.5%). It is noteworthy that a higher level of resistance to ertapenem was reported in *C. coli* isolated from calves (29.1%) in 2021 (see specific textbox on ‘Further considerations on the occurrence of resistance to ertapenem in *C. coli* from calves’).
Table 8: Occurrence of resistance (%) to selected antimicrobials in *C. coli* and *C. jejuni* in caecal samples from poultry, pigs and calves using harmonised ECOFFs, 27 EU MSs and United Kingdom (Norther Ireland), 2020 and 2021

<table>
<thead>
<tr>
<th><em>Campylobacter</em> species</th>
<th>Categories</th>
<th>Year</th>
<th>Number isolates</th>
<th>Reporting countries (N)</th>
<th>GEN</th>
<th>STR</th>
<th>CHL</th>
<th>ETP</th>
<th>NAL</th>
<th>CIP</th>
<th>ERY</th>
<th>TET</th>
<th>CIP/ERY</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>C. jejuni</em></td>
<td>Broilers</td>
<td>2020</td>
<td>3,382</td>
<td>AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IT, LT, LU, LV, MT, NL, PL, PT, RO, SE, SI, SK (27)</td>
<td>0.1</td>
<td>15.6</td>
<td>69.2</td>
<td>72.8</td>
<td>0.8</td>
<td>52.7</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Calves</td>
<td>2021</td>
<td>1,198</td>
<td>BE, DE, DK, ES, FR, IT, NL, PT, RO (10)</td>
<td>0.5</td>
<td>0.1</td>
<td>1.0</td>
<td>54.7</td>
<td>1.0</td>
<td>68.8</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fattening turkeys</td>
<td>2020</td>
<td>1,066</td>
<td>AT, DE, ES, FR, HU, IT, PL, PT, RO (9)</td>
<td>0.1</td>
<td>11.4</td>
<td>71.0</td>
<td>77.9</td>
<td>0.8</td>
<td>58.5</td>
<td>0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fattening pigs</td>
<td>2021</td>
<td>60</td>
<td>BG, CY, DK, DE, IE, IT, LV, LT, LU, MT, NL, PT (12)</td>
<td>1.7</td>
<td>0.0</td>
<td>0.0</td>
<td>41.7</td>
<td>1.7</td>
<td>43.3</td>
<td>1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>C. coli</em></td>
<td>Broilers</td>
<td>2020</td>
<td>388</td>
<td>CZ, FR, IE, LV, LU, NL, SI (7)</td>
<td>0.0</td>
<td>16.5</td>
<td>61.1</td>
<td>61.9</td>
<td>4.4</td>
<td>67.3</td>
<td>4.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Calves</td>
<td>2021</td>
<td>443</td>
<td>BE, DE, DK, ES, FR, IT, NL, PT, RO (10)</td>
<td>12.4</td>
<td>3.4</td>
<td>29.1</td>
<td>79.7</td>
<td>35.7</td>
<td>90.5</td>
<td>32.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fattening turkeys</td>
<td>2020</td>
<td>567</td>
<td>DE, ES, FR (3)</td>
<td>0.2</td>
<td>11.5</td>
<td>80.2</td>
<td>80.4</td>
<td>21.5</td>
<td>89.2</td>
<td>21.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fattening pigs</td>
<td>2021</td>
<td>3,546</td>
<td>AT, BE, BG, CY, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SE, SI, SK, XI (26+XI)</td>
<td>2.6</td>
<td>0.5</td>
<td>1.3</td>
<td>51.7</td>
<td>12.3</td>
<td>69.3</td>
<td>9.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gen: gentamicin; STR: streptomycin; NAL: nalidixic acid; CHL: chloramphenicol; ETP: ertapenem; CIP: ciprofloxacin; ERY: erythromycin; TET: tetracycline; CIP/ERY: combined 'microbiological' resistance to ciprofloxacin and erythromycin; CS: complete susceptibility to the four antimicrobial classes (ciprofloxacin/nalidixic acid, erythromycin, tetracycline and gentamicin/streptomycin); N: Total number of reporting Member States (MSs); XI: Northern Ireland; Additional note: STR was not tested in 2021, however, CHL and ETP were first tested in 2021.
Figure 19: Occurrence of resistance to antimicrobials in *C. jejuni* and *C. coli* and from food-producing animals, 2020/2021
Further considerations on the detected levels of ertapenem resistance in *C. coli* from calves

No validated threshold for resistance to ertapenem has been recommended by EUCAST yet and no indication on the epidemiological cut-off to be used for ertapenem in *C. coli* and *C. jejuni* was provided in Commission Implementing Decision (EU) 2020/1729.

An epidemiological cut-off of 0.5 mg/L was used by EFSA as the threshold for resistance to ertapenem in both *C. coli* and *C. jejuni* isolates, in accordance with the critical concentrations indicated by the Société Française de Microbiologie in CA-SFM 2018 (https://www.sfm-microbiologie.org/wp-content/uploads/2019/02/CASFM-V1_0-FEV_2018.pdf) and CA-SFM 2019 (https://www.sfm-microbiologie.org/wp-content/uploads/2019/05/CASFM2019_V2.0_MAL.pdf). The choice of the epidemiological cut-off has a direct impact on the threshold for considering an isolate as susceptible or resistant to a selected antimicrobial (as shown in the table below) and consequently on the interpretation of the results of the susceptibility testing.

Due to the lack of data, the epidemiological cut-off used by EFSA in this analysis is still under discussion. Additional data will be available in the coming years because of the implementation of the harmonised AMR monitoring in accordance with Commission Implementing Decision (EU) 2020/1729 and these will allow a detailed evaluation and validation of the appropriate threshold for resistance to ETP in both *C. coli* and *C. jejuni*.

### MIC distribution in ertapenem resistant and susceptible *C. coli* isolates from calves (ECOFF = 0.5 mg/L) reported in 2021 by 10 MSs.

<table>
<thead>
<tr>
<th>MIC</th>
<th>Number of isolates</th>
<th>%</th>
<th>ETP resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 0.125</td>
<td>133</td>
<td>30.0</td>
<td>Susceptible</td>
</tr>
<tr>
<td>0.25</td>
<td>78</td>
<td>17.6</td>
<td>Susceptible</td>
</tr>
<tr>
<td>0.5</td>
<td>103</td>
<td>23.2</td>
<td>Susceptible</td>
</tr>
<tr>
<td>1</td>
<td>103</td>
<td>23.2</td>
<td>Resistant</td>
</tr>
<tr>
<td>2</td>
<td>23</td>
<td>5.2</td>
<td>Resistant</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>0.7</td>
<td>Resistant</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>443</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

At present, only few comparable data on the resistance to ertapenem in *C. coli* isolates from calves are available in the EU and further investigations are needed to interpret the unexpected level of ertapenem resistance (29.1%) reported in *C. coli* isolates from calves in 2021.

### 3.4.4. Combined resistance to ciprofloxacin and erythromycin

Macrolides such as erythromycin and fluoroquinolones such as ciprofloxacin are recognised as critically important antimicrobials (CIAs) for the treatment of *Campylobacter* infections in humans. Therefore, the occurrence of combined resistance to ciprofloxacin and erythromycin in *Campylobacter* spp. from food-producing animals is of great importance to public health, since it might hamper the treatment of human campylobacteriosis (Friedrich, 2019; WHO, 2019).

Overall combined resistance to these antimicrobials was lower in *C. jejuni* isolates than in *C. coli* isolates for all animal species tested (Table 8; Figure 19). Very low levels of combined resistance to ciprofloxacin and erythromycin were reported in *C. jejuni* isolates from broilers (0.7%) and fattening turkeys (0.8%) in 2020 (Table 8; Figure 19; see also Annex B, Tables 22 and 24), and from calves (0.8%) and fattening pigs (1.7%) in 2021 (Table 8; Figure 19; see also Annex B, Tables 28 and 29).

The highest levels of combined resistance were reported in *C. coli* isolates from calves (32.7%) in 2021 and from fattening turkeys (21.2%) in 2020, followed by fattening pigs (9.3%) in 2021 and broilers (4.1%) in 2020 (Table 8; Figure 19; see also Annex B, Tables 23, 25–27). The levels of combined resistance to ciprofloxacin and erythromycin observed in *C. coli* isolates from calves notably increased from 22.4% in 2019 to 32.7% in 2021. An increase was also observed in *C. coli* isolates from fattening pigs where the levels of combined resistance to ciprofloxacin and erythromycin increased from 8% in 2019 to 9.3% in 2021.
Combined resistance to ciprofloxacin and erythromycin in *C. jejuni* isolated from broilers was detected in seven MSs (Cyprus, Czechia, Italy, Lithuania, Portugal, Romania and Slovakia) out of 27 reporting data in 2020, ranging from 1.2% to 6.4%, with the highest level of combined resistance reported by Portugal (Figure 20a; Annex B, Table 22). Co-resistance to ciprofloxacin and erythromycin detected in *C. coli* isolates from broilers was reported from four (Czechia, France, Latvia and the Netherlands) out of seven MSs reporting 2020 data. The levels of combined resistance ranged from 1.7% reported by the Netherlands to 33.3% reported by Latvia (Figure 21a; Annex B, Table 23). However, this last finding should be interpreted cautiously as only three *C. coli* isolates from broilers were reported by Latvia.

Combined resistance to ciprofloxacin and erythromycin in *C. jejuni* from fattening turkeys was detected only in Italy (1.2%) and Portugal (16.2%), out of nine reporting MSs in 2020 (Figure 20b; Annex B, Table 24). Data on combined resistance to ciprofloxacin and erythromycin in *C. coli* isolates from fattening turkeys in 2020 were reported by three MSs (France, Germany and Spain) with levels of co-resistance ranging from 2.9% in France, up to 28.2% and 31.9% in Germany and Spain, respectively (see Annex B, Table 25).

Data on combined resistance to ciprofloxacin and erythromycin in *C. jejuni* isolated from fattening pigs were reported by 12 MSs (Bulgaria, Cyprus, Denmark, Germany, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands and Portugal) and Norway in 2021 (Annex B, Table 29). However, only one country (Lithuania) reported co-resistance in 16.7% of pig isolates (N = 6) in 2021. These findings should be interpreted cautiously as only very few isolates were reported by each country (ranging from one to six isolates per country, except for Malta who reported 27 isolates). In 2021, combined resistance to ciprofloxacin and erythromycin in *C. coli* isolated from fattening pigs was detected in 26 MSs (all except Czechia), the United Kingdom (Northern Ireland) and three non-EU countries (Iceland, Norway and Switzerland) (Figure 21b; Annex B, Table 26). All MSs reported combined resistance to these antimicrobials, except Finland, Malta, Slovakia and Sweden. The combined resistance levels ranged from 1.2% reported by Slovenia to 50% reported by Portugal in *C. coli* isolated in 2021. No combined resistance in *C. coli* isolated from fattening pigs was reported by the three non-MSs who submitted data.

Data on combined resistance to both ciprofloxacin and erythromycin in *C. jejuni* isolated from calves under 1 year of age were reported by 10 MSs (Belgium, Croatia, Denmark, France, Germany, Italy, the Netherlands, Portugal, Romania and Spain) and two non-EU countries (Norway and Switzerland) in 2021 (Figure 20c; Annex B, Table 28). Three out of the reporting countries found combined resistance to these antimicrobials with the following levels: 0.8% reported by France, 2.6% reported by Romania and 4.8% reported by Belgium. Data on combined resistance to ciprofloxacin and erythromycin in *C. coli* isolated from calves were reported by 10 MSs (Belgium, Croatia, Denmark, France, Germany, Italy, the Netherlands, Portugal, Romania and Spain) in 2021 (Figure 21c; Annex B, Table 27). Seven MSs reported combined resistance to both antimicrobials in *C. coli* isolates. The combined resistance levels in *C. coli* isolated from calves in 2021 ranged from 2.6% reported by Croatia to 77.8% reported by Belgium. No co-resistant *C. coli* isolates from calves were reported by Denmark, Portugal and Romania.

The combined resistance to ciprofloxacin and erythromycin obtained from calves and pigs tested in 2021 is higher than those reported from these animal species in 2019. This observation is particularly relevant in *C. coli* isolated from calves and pigs in 2021 and could be partly explained by the higher number of reporting countries and isolates in 2021 (due to sampling frequency and changes in legislative requirement based on Commission Implementing Decision (EU) 2020/1729). The levels of resistance to erythromycin in *C. coli* isolates from calves increased from 21.5% in 2019 to 35.7% in 2021 and the levels of combined resistance to ciprofloxacin and erythromycin increased from 22.4% in 2019 to 32.7% in 2021 in *C. coli* isolates from calves, which might infer a public health concern.

The spatial distribution of combined resistance to both ciprofloxacin and erythromycin in *C. jejuni* and *C. coli* isolates from different animal categories is presented in Figures 20 and 21. Detailed data on combined resistance to ciprofloxacin and erythromycin in *C. jejuni* and *C. coli* isolates from food-producing animals are presented in Annex B (Tables 22–29).
Figure 20: Spatial distribution of combined resistance to ciprofloxacin and erythromycin in Campylobacter jejuni isolates from (a) broilers (27 EU MSs and three non-MSs, 2020); (b) fattening turkeys (nine EU MSs and two non-MS, 2020); and (c) calves less than 1 year of age (10 EU MSs and two non-MSs, 2021).
Figure 21: Spatial distribution of combined resistance to ciprofloxacin and erythromycin in *Campylobacter coli* isolates from (a) broilers (seven EU MSs and one non-MS, 2020); (b) fattening pigs (26 EU MSs plus United Kingdom (Northern Ireland) and three non-MSs, 2021) and (c) calves less than 1 year of age (10 EU MSs, 2021)
3.4.5. Prevalence of antimicrobial resistance in Campylobacter coli from fattening pigs

The prevalence of resistance to selected antimicrobials in C. coli from fattening pigs has been estimated at country level as the proportion of C. coli showing microbiological resistance to each selected antimicrobial as a percentage of all caecal samples cultured for C. coli. This prevalence of resistance is the product of the prevalence of C. coli in caecal samples from fattening pigs (Annex B, Table 20) and the occurrence of resistance in the C. coli isolates tested for susceptibility (Annex B, Table 12). Monitoring the prevalence of resistant C. coli in fattening pigs enables to address together both evolving temporal trends in the prevalence of C. coli in fattening pigs and in the occurrence of resistance in C. coli from fattening pigs, through a unique indicator. This indicator is primarily intended to follow up trends over time at the country level. The country-level estimates of the prevalence resistance to selected antimicrobials in C. coli from caecal samples of fattening pigs are presented in Table 21 of Annex B.

The isolation method for Campylobacter has been now harmonised across the EU in accordance to the protocol of the EURL for Campylobacter (https://www.sva.se/en/about-us/eurl-campylobacter/). Therefore, the prevalence of C. coli in fattening pigs can be considered comparable between reporting countries. Similarly, the harmonised implementation of the antimicrobial susceptibility testing in C. jejuni and C. coli isolates allows comparability of the estimates of prevalence of resistance in C. coli from fattening pigs across the EU.

Although the sampling design for the monitoring of antimicrobial resistance in C. coli from fattening pigs is harmonised according to the Commission Implementing Decision 2020/1729, still differences in the intensity of sampling effort exist across the EU MSs, as shown in the numbers of tested samples included in Tables 20 and 21 of Annex B. To account for between-country variation in the intensity of sampling effort, 95% confidence intervals have been calculated together with the estimated point prevalence of resistance as presented in Table 21 of Annex B, as well as in Figure 22a–c. It is to be noted that, according to Commission Implementing Decision (EU) 2020/1729, MSs having an annual national production less than 100,000 tonnes of pig meat are allowed, by derogation, to collect less samples (i.e. 150 instead of 300). Still, small countries may have difficulties to reach the minimum number of samples foreseen by derogation in the decision, due to the limited swine production.

The country-level prevalence of resistance to ciprofloxacin, erythromycin and tetracycline in C. coli isolates from fattening pigs is presented in Figure 22, together with the 95% confidence intervals that provide an indication of the uncertainty around the point prevalence estimates. Between-country variability from low to extremely high levels was observed in the prevalence of ciprofloxacin resistant (ranging from 6.9% to 78.2%; Figure 22a) and tetracycline resistant (ranging from 0.0% to 86.5%; Figure 22c) C. coli from fattening pigs. Interestingly, a limited between-country variation and notably lower levels of prevalence of resistance to erythromycin were found in C. coli from fattening pigs, which have been estimated to be below 10% for 24 reporting countries (21 MSs and 3 non-MSs), while ranging from 14.9% to 39.7% in the remaining six reporting MSs (Figure 22b). Noteworthy, the MS (Portugal) with the highest prevalence of resistance to erythromycin in C. coli from fattening pigs (39.7%) in 2021 had also the highest levels of erythromycin resistance (55.3%) and combined resistance to ciprofloxacin and erythromycin (55.3%) in C. coli from humans. It is also interesting to note that almost all the erythromycin-resistant isolates (19 out of the 20 erythromycin-resistant isolates) reported by Portugal, had very high MIC (≥ 256 mg/L).
(a) Prevalence of ciprofloxacin resistant C. coli in slaughter pigs, 2021

(b) Prevalence of erythromycin resistant C. coli in slaughter pigs, 2021
3.4.6. Complete susceptibility and multidrug resistance

The observed overall complete susceptibility to the four antimicrobial classes (represented by susceptibility to ciprofloxacin/nalidixic acid, erythromycin, tetracycline and gentamicin) ranged from 4.4% in C. coli isolates from fattening turkeys to 48.3% in C. jejuni isolates from fattening pigs. Overall, the observed complete susceptibility was higher in C. jejuni than in C. coli isolates. The highest levels of complete susceptibility were observed from C. jejuni isolates from fattening pigs (48.3%), followed by broilers (23%), calves (21.6%) and fattening turkeys (16.8%). With regard to C. coli, the overall complete susceptibility observed was low for isolates from fattening turkeys (4.4%) in 2020 and calves (6.3%) in 2021, while it was higher for broilers (13.7%) in 2020 and pigs (19.9%) in 2021.

It is interesting to note that the overall complete susceptibility observed in C. coli from calves was higher (6.3%) in 2021 than the complete susceptibility reported in 2019 (1.5%).

Variability in the levels of complete susceptibility was detected between countries (Annex B, Tables 22–29). For example, overall complete susceptibility in C. jejuni isolated from broilers ranged from less than 5% in Greece, Latvia, Poland and Portugal to more than 75% in Finland, Sweden and Norway. Malta reported 100% of complete susceptibility in C. jejuni isolated from broilers, although from only two isolates. When interpreting the results, it is therefore important to account for the between country differences in the number of isolated reported (sample size).

The CS to the selected antimicrobial classes and the levels of MDR (defined as resistance to at least three antimicrobials among the four included in the harmonised panel tested: gentamicin, ciprofloxacin, erythromycin, tetracycline) among Campylobacter isolates recovered from these food-producing animals by EU MSs are displayed in Figure 23.

Overall, the levels of MDR observed were lower in C. jejuni than in C. coli isolates. MDR was observed at low levels in C. jejuni isolates from broilers and fattening turkeys (0.8%) in 2020, and from calves (1.2%) and pigs (3.3%) in 2021. The highest levels of MDR were reported in C. coli isolates from calves (39.3%), followed by fattening turkeys (21.0%) and fattening pigs (9.7%). A lower level of MDR was observed in C. coli isolates from broilers (3.9%) compared with the other

Figure 22: Prevalence of resistances to ciprofloxacin (a), erythromycin (b), tetracycline (c) and related 95% confidence intervals in C. coli from fattening pigs, per reporting country, 2021
monitored animal categories. Moreover, it is relevant to note that the MDR levels observed in pigs and calves (under 1 year of age) in 2021 were higher than the corresponding levels reported in 2019, particularly for isolates recovered from calves.

Detailed data on complete susceptibility and MDR in *C. jejuni* and *C. coli* isolates from different animal categories are presented in Annex B (Tables 22–29).

### 3.4.7. Temporal trends in resistance

#### Temporal trends in resistance in *C. coli* from pigs

Temporal trends showing resistance to selected antimicrobials in *C. coli* isolates from fattening pigs, for the period 2009–2021, are shown in Figure 24 and Table 9 (see also in Annex B, Table 30). Trends of resistance to selected antimicrobials in *C. coli* from fattening pigs were evaluated considering data from six MSs and two non-MSs who reported at least three data points in the recent years and a minimum of 10 isolates per year. Countries reporting data with more than 1-year gap over the period 2016–2020 were excluded from the trend analysis. Overall, seven MSs (Croatia, Denmark, Finland, France, Hungary, Luxembourg and Slovenia) were excluded from the trend analysis, because of the gap in reporting history (two or more missing data points over 2016–2021). A significant increasing trend of resistance to *ciprofloxacin* was observed in four countries (Germany, the Netherlands, Norway and Switzerland). No significantly increasing trend of resistance to *erythromycin* was observed in the reporting countries, while a significantly decreasing trend of resistance to erythromycin was found in Czechia, the Netherlands, Spain and Switzerland. A significantly increasing trend of resistance to *tetracycline* was observed in Estonia and Switzerland, while the results indicated significantly decreasing resistance in the Netherlands and Spain.

![Image](https://example.com/image.png)

**Figure 23:** Number of isolates completely susceptible, resistant to one or two antimicrobial classes and MDR in *C. jejuni* and/or *C. coli* from broilers, fattening turkeys, fattening pigs and calves (< 1 age) in reporting EU MSs, 2020/2021

**Complete susceptibility and multidrug resistance in *C. jejuni* and *C. coli*, food-producing animals, 2020/2021**

- **C. jejuni - Broilers - 2020 (N=3362, 27 MSs)**: 23.0% susceptible, 76.2% resistant, 0.8% MDR
- **C. jejuni - Turkeys - 2020 (N=1066, 9 MSs)**: 16.8% susceptible, 82.4% resistant, 0.8% MDR
- **C. jejuni - Calves - 2021 (N=1198, 10 MSs)**: 21.8% susceptible, 77.2% resistant, 1.2% MDR
- **C. jejuni - Pigs - 2021 (N=388, 7 MSs)**: 48.3% susceptible, 48.4% resistant, 3.3% MDR
- **C. coli - Broilers - 2020 (N=586, 7 MSs)**: 13.7% susceptible, 82.4% resistant, 3.9% MDR
- **C. coli - Turkeys - 2020 (N=567, 3 MSs)**: 4.4% susceptible, 74.6% resistant, 21.0% MDR
- **C. coli - Calves - 2021 (N=443, 10 MSs)**: 6.3% susceptible, 54.4% resistant, 39.3% MDR
- **C. coli - Pigs - 2021 (N=3546, 26 MSs + XI)**: 19.8% susceptible, 70.4% resistant, 9.7% MDR

**N:** Total number of isolates reported by the EU MSs. Complete susceptibility is defined as susceptibility to ciprofloxacin/nalidixic acid, erythromycin, gentamicin and tetracycline. MDR (multidrug resistance) is defined as resistance to at least three antimicrobial classes (including: GEN: gentamicin; CIP: ciprofloxacin; ERY: erythromycin; TET: tetracycline).
The results from the analysis of temporal trends in resistance of *C. jejuni* isolated from broilers over the period 2009–2020 were obtained using data from 24 reporting MSs and 4 non-MSs (Table 9; see also Annex B, Figure 1a and Table 30). Evaluation of temporal trends in resistance was performed for countries reporting data for at least 3 years (three data points). Countries reporting data with more than 1-year gap over the period 2016–2020 were excluded from the trend analysis. Moreover, countries that reported only AMR data for years before 2015 were excluded from the analysis because the evaluation of the trend would not be representative of the current AMR situation. It is relevant to notice that between-year oscillations in the occurrence resistance (%) may not be captured in the evaluation of the trend for the entire period (2009–2020) and that very recent decreasing or increasing trends may therefore be masked by the overall trend.

**Figure 24:** Trends in ciprofloxacin (CIP), erythromycin (ERY) and tetracycline (TET) resistance in *C. coli* from fattening pigs, 2015–2021/2009–2021*

**Temporal trends in resistance in *C. jejuni* and *C. coli* from broilers**

The results from the analysis of temporal trends in resistance of *C. jejuni* isolated from broilers over the period 2009–2020 were obtained using data from 24 reporting MSs and 4 non-MSs (Table 9; see also Annex B, Figure 1a and Table 30). Evaluation of temporal trends in resistance was performed for countries reporting data for at least 3 years (three data points). Countries reporting data with more than 1-year gap over the period 2016–2020 were excluded from the trend analysis. Moreover, countries that reported only AMR data for years before 2015 were excluded from the analysis because the evaluation of the trend would not be representative of the current AMR situation. It is relevant to notice that between-year oscillations in the occurrence resistance (%) may not be captured in the evaluation of the trend for the entire period (2009–2020) and that very recent decreasing or increasing trends may therefore be masked by the overall trend.
The analysis of temporal trends in resistance to ciprofloxacin in *C. jejuni* indicated that, over the period 2009–2020, a significant increase was reported in 12 MSs (Austria, Croatia, Cyprus, Czechia, Denmark, Finland, France, Germany, the Netherlands, Romania, Slovakia and Sweden) and two non-MSs (Switzerland and the United Kingdom). On the other hand, a significant decrease in resistance to ciprofloxacin in *C. jejuni* was detected in Spain. A significant decrease in resistance to erythromycin was detected in five MSs (Bulgaria, the Netherlands, Romania, Slovakia and Spain), while a significant decrease in resistance to tetracycline was seen in seven MSs (Bulgaria, Cyprus, Finland, Greece, Italy, Latvia and Spain). Interestingly, a significant increase in resistance was detected for tetracycline in 10 MSs (Austria, Croatia, Czechia, Denmark, Germany, Hungary, Ireland, Lithuania, Slovakia and Sweden) and two non-MSs (Switzerland and the United Kingdom).

The results from the analysis of temporal trends in resistance of *C. coli* isolated from broilers over the period 2009–2020 were obtained using data from four reporting MSs (Czechia, Germany, the Netherlands, Slovenia) and one non-MS (Switzerland) (Table 9; see also Annex B, Figure 1b and Table 30). Temporal trends showed significant increases of resistance in *C. coli* isolated from broilers for ciprofloxacin (Germany, the Netherlands), erythromycin (Czechia) and tetracycline (Czechia, Netherlands, Switzerland). On the other hand, significant decreases were observed for erythromycin only in one MS (the Netherlands).

When interpreting the results, it is important to note that trend analyses may be driven by particularly high or low levels of resistance reported in one or few data points leading to unexpected findings (e.g. detection of significant increasing or decreasing trends where the observed data do not seem to show any clear trend over the entire period). This is the case, for example, of the detected significant increasing trend of resistance to ciprofloxacin in *C. jejuni* from broilers detected for Finland and of the increasing trend of resistance to tetracycline detected for Sweden (Annex B, Figure 1). For details on the methodology applied for trend analysis, see Appendix F – Materials and methods.

**Temporal trends in resistance in *C. jejuni* from turkeys**

Temporal trends of resistance to selected antimicrobials in *C. jejuni* isolates from fattening turkeys during the period of 2014–2020 are displayed in Figure 2 in Annex B (see also Table 30) and in Table 9. Evaluation of temporal trends in resistance could be performed for countries reporting data for at least 3 years (three data points). It is relevant to note that between-year oscillations in the occurrence resistance may not be captured in the evaluation of the trend for the entire period (2014–2020) and that very recent decreasing or increasing trends may therefore be masked by the overall trend. Moreover, the results of these trends are based on very few data points, and therefore, more data and further analyses will be needed in the future for a more robust evaluation.

The results from the analysis of temporal trends in resistance of *C. jejuni* isolated from fattening turkeys over the period 2014–2020 were obtained using data from eight reporting MSs (Austria, France, Germany, Hungary, Italy, Poland, Portugal and Spain) and one non-MS (the United Kingdom) (Table 9, see Annex B, Figure 2 and Table 30). Temporal trends showed significant increases of resistance in *C. jejuni* isolated from fattening turkeys for ciprofloxacin in two MSs (Germany and Poland) and tetracycline in one MS (Hungary). No significant increase to erythromycin was detected. On the other hand, significant decreases were observed for ciprofloxacin in two MSs (Hungary and Italy), for erythromycin in three MSs (Germany, Poland and Spain) and for tetracycline in three MSs (France, Germany, Spain) and one non-MS (the United Kingdom).

**Temporal trends in resistance in Campylobacter isolates from calves**

Due to the scarcity of comparable historical data on *C. jejuni* and *C. coli* from calves (under 1 year of age), the temporal trends of resistance to selected antimicrobials was not analysed for this animal population. Comparable data will be available in the coming years thanks to the implementation of the monitoring requirements laid down in Commission Implementing Decision (EU) 2020/1729.

### 3.4.8. High-level resistance to erythromycin

High-level resistance to macrolides, streptogramin B and/or lincosamides in *Campylobacter* may be associated with the *erm*(B) gene encoding an rRNA methylase, as firstly described in a *C. coli* isolated from a swine in China (Qin et al., 2014). The *erm*(B) gene can be transferred by natural transformation between strains of *Campylobacter* (Wang et al., 2014). *Erm*(B) is detected more frequently in *C. coli* than in *C. jejuni*, but it may also be found on *C. jejuni* from poultry resistant to all clinically important antimicrobial agents (Liu et al., 2019). In Europe, *erm*(B) has been reported in...
Most high-level erythromycin-resistant Campylobacter jejuni isolates (MIC > 128 mg/L) from broilers were obtained from samples in Romania (seven isolates) and Cyprus (four isolates). Four of the six erythromycin high-level resistant Campylobacter jejuni isolates from fattening turkeys were detected in Portugal, and nine of the 18 high-level erythromycin-resistant Campylobacter coli isolates from broilers were reported by Germany, followed by France and Switzerland (four isolates each), and the Netherlands (one isolate) in 2020. In 2021, a very high level of erythromycin resistance (MIC > 512 mg/L) was obtained in several Campylobacter coli isolates from calves reported by Belgium (54 isolates) and the Netherlands (42 isolates), followed by Italy and Germany (9 isolates each) and France (6 isolates). Several countries reported high-level resistant isolates among the erythromycin-resistant Campylobacter coli from fattening pigs obtained in 2021. The largest number of very high-level resistant isolates (MIC > 512 mg/L) was reported by Germany (21 isolates), Spain (20 isolates) and Italy (18 isolates), followed by Romania (13 isolates), Ireland and Portugal (9 isolates each). Several additional countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Denmark, France, Greece, Hungary, Luxembourg, the Netherlands and Poland) reported less than 9 very high-level resistant Campylobacter coli isolates from fattening pigs.
(a) MIC distribution to erythromycin in *C. jejuni* from broilers and fattening turkeys, 2020

ECOFF: >4 mg/L

<table>
<thead>
<tr>
<th>MIC (mg/L)</th>
<th>Broilers</th>
<th>Fattening turkeys</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>128</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;128</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

% microorganisms

(b) MIC distribution to erythromycin in *C. coli* from broilers and fattening turkeys, 2020

ECOFF: >8 mg/L

<table>
<thead>
<tr>
<th>MIC (mg/L)</th>
<th>Broilers</th>
<th>Fattening turkeys</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>128</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;128</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

% microorganisms
Figure 25: Distribution of MIC values related to erythromycin resistance in (a) *C. jejuni* from broilers and fattening turkeys, (b) *C. coli* from broilers and fattening turkeys, (c) *C. jejuni* from calves and (d) *C. coli* from fattening pigs and calves, in reporting EU MSs and non-EU MSs, 2020 and 2021.
3.5. Comparison of human and animal data on *Campylobacter* spp.

In 2020–2021, quantitative human data were interpreted using EUCAST ECOFF values, where available, in the same way as for the animal and food data. Figure 27 illustrates the CBPs and ECOFFs used to interpret the MIC data reported for *Campylobacter* spp. from humans, animals and/or food. In the absence of CBPs from EUCAST (i.e. gentamicin), CBPs from the French Society for Microbiology (SFM) were applied (CASFM/EUCAST, 2020). For qualitative data interpreted with clinical breakpoints (S = susceptible, I = susceptible with increased exposure and R = resistant), I+R results were combined into one category. It can be observed that there is agreement across interpretive categories, with the exception of the EUCAST CBP for tetracycline in *C. jejuni* which is one dilution above the EUCAST ECOFF. For gentamicin, EUCAST lowered the ECOFF, in 2020, by one dilution compared to the ECOFF value listed in the Commission Implementing Decision (EU) 2020/1729 but then changed it back in 2022. For the comparison of 2021 data, the gentamicin criteria applied are thus the same for data from humans and animals.

**Figure 26**: Number of isolates (and percentage) exhibiting different levels of erythromycin resistance in broilers, fattening turkeys, fattening pigs and calves in reporting EU MSs and non-EU MSs, 2020–2021

**N**: Total number of *C. jejuni* or *C. coli* isolates exhibiting erythromycin resistance. ERY: erythromycin. ERY resistance in *C. jejuni* isolates: 4 mg/L < MIC ≤ 128 mg/L. ERY resistance in *C. coli* isolates: 8 mg/L < MIC ≤ 128 mg/L. For 2021 data, it is possible to discriminate between ERY-resistant *C. coli* and *C. jejuni* isolates with MIC ranging from 128 mg/L to (equal) 512 mg/L and those with MIC above 512 mg/L.
The comparison of occurrence of resistance to selected antimicrobials and combined resistance to erythromycin and ciprofloxacin in *C. jejuni* and *C. coli* isolates between humans and food-producing animals is presented in Figures 28 and 29, respectively.

Human data submitted from MSs revealed that resistance to ciprofloxacin among *C. jejuni* isolates reported in 2020–2021 was detected in 61.2% (2020, 16 MSs) and in 64.5% (2021, 22 MSs) of human isolates. Similar levels of resistance to ciprofloxacin among *C. coli* isolates from humans were reported: 65.8% (2020, 15 MSs) and 69.6% (2021, 20 MSs). The levels of resistance to ciprofloxacin in food-producing animals were estimated to be high to extremely high, ranging from 41.7% to 80.4%. The highest levels of resistance to ciprofloxacin were observed in *C. coli* isolated from fattening turkeys in 2020 (80.4%). Likewise, an extremely high level of resistance to ciprofloxacin (79.7%) was obtained from *C. coli* isolated from calves in 2021 and from broilers (61.9%) in 2020. Overall, the levels of resistance to ciprofloxacin were higher for *C. coli* than for *C. jejuni*, although the level of resistance to ciprofloxacin obtained from *C. jejuni* isolates from poultry in 2020 were also extremely high: 77.9% in fattening turkeys (data from 9 MSs) and 72.8% in broilers (data from 27 MSs). The lowest levels of resistance to ciprofloxacin were obtained from pig samples. The levels of resistance to ciprofloxacin among *C. jejuni* from human isolates and poultry isolates can be considered similar.

Overall resistance to erythromycin was reported at very low levels for *C. jejuni* (range from 0.8% to 1.7%) isolated from food-producing animals. Similarly, overall resistance to erythromycin in human *C. jejuni* isolates was reported at 0.7% (2020) and 1.1% (2021). However, higher levels of resistance were observed in *C. coli* isolates from humans in 2021 (8.5%) and food-producing animals (range from 4.4% to 35.7%). Overall, erythromycin resistance among animals was observed at the highest levels in *C. coli* isolates recovered from calves (35.7%, data from 2021), followed by fattening turkeys (21.5%, data from 2020), fattening pigs (12.3%, data from 2021) and broilers (overall, 4.4%, data from 2020).

Overall resistance to gentamicin was detected very low to low levels for *C. jejuni* (range from 0.1% to 1.7%) isolated from food-producing animals. Similarly, overall resistance to gentamicin in human *C. jejuni* isolates was reported at 0.3% (2020) and 0.7% (2021). Higher levels of resistance to gentamicin were reported in *C. coli* isolates from humans and in fattening pigs and calves.

The overall levels of resistance to tetracycline were high to very high in *C. jejuni* isolates from both humans (43.7% in 2020 and 45.3% in 2021) and food-producing animals (ranging from 43.3% in isolates from fattening pigs to 68.8% in isolates from calves in 2021). Very high to extremely high levels of resistance to tetracycline were detected in *C. coli* isolates from humans (74.0% in 2020 and 70.3% in 2021) and food-producing animals (ranging from 67.3% in isolates from broilers in 2020 to 90.5% in isolates from calves in 2021).

Combined resistance to ciprofloxacin and erythromycin was reported at 0.8% in *C. jejuni* and in 7.6% of *C. coli* isolates from humans (in 2021). Similarly, combined resistance to these
antimicrobials in food-producing animals was overall lower in *C. jejuni* isolates than in *C. coli* isolates for all animal species tested (Table 8). Combined resistance to ciprofloxacin and erythromycin was reported in 0.7% of *C. jejuni* isolates from broilers and 0.8% of isolates from fattening turkeys in 2020 (Annex B, Tables 22 and 24) and in 0.8% of isolates from calves and 1.7% of pig isolates in 2021. Combined resistance to ciprofloxacin and erythromycin was reported in 4.1% of *C. coli* isolates from broilers and 21.2% of isolates from fattening turkeys in 2020 (Annex B, Tables 23 and 25) and in 32.7% of isolates from calves and 9.3% of pig isolates in 2021.

Information from MSs in relation to complete susceptibility to the four antimicrobials (ciprofloxacin/nalidixic acid, erythromycin, tetracycline and gentamicin) was reported at levels of 31.3% (2020) and 30.9% (2021) in *C. jejuni* isolates from humans and in *C. coli* isolates at levels of 12.5% (2020) and 13.2% (2021). Similarly, in food-producing animals, the observed overall complete susceptibility was higher in *C. jejuni* than in *C. coli* isolates. The overall complete susceptibility observed from *C. jejuni* isolates was 23% in broilers in 2020, 16.8% in fattening turkeys in 2020 and 21.6% and 48.3% in calves and pigs, respectively, in 2021. Regarding *C. coli*, the overall complete susceptibility observed was low for isolates from fattening turkeys (4.4%) in 2020 and calves (6.3%) in 2021 while it was higher for broilers (13.7%) in 2020 and pigs (19.9%) in 2021.
It is also relevant to consider that all countries used EUCAST ECOFFs (MIC > 1 mg/L) to determine resistance to tetracycline in C. jejuni isolates from animals, whereas 7 of 22 MS reported SIR results using clinical breakpoints (MIC > 2 mg/L) regarding resistance to tetracycline in C. jejuni isolates from humans, and the gentamicin ECOFF was different between humans and animals in 2020 (1 mg/L for human isolates, and 2 mg/L for animal isolates) (Figure 27).

Table 9 presents countries with significantly increasing or decreasing trends in resistance to selected antimicrobials (ciprofloxacin, erythromycin and tetracycline) from human isolates (2013–2021) and isolates from food-producing animals (2015–2021 or 2009–2020/2021). Factors such as time periods considered, data collected and antibiotic usage may explain the variability observed between countries.

### Table 9:

<table>
<thead>
<tr>
<th>Origin</th>
<th>Campylobacter species</th>
<th>Ciprofloxacin</th>
<th>Erythromycin</th>
<th>Tetracycline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Increase</td>
<td>Decrease</td>
<td>Increase</td>
</tr>
<tr>
<td><strong>Humans</strong></td>
<td>C. jejuni (19 MS + 3 non-MS)</td>
<td>12 (AT, BG, DK, EE, FR, LT, MT, NL, PL, SI, SK, UK)</td>
<td>3 (NO, PT)</td>
<td>1 (ES)</td>
</tr>
<tr>
<td></td>
<td>C. coli (14 MSs + 1 non-MS)</td>
<td>3 (NL, SI, SK)</td>
<td>2 (FR, UK)</td>
<td>1 (UK)</td>
</tr>
<tr>
<td><strong>Broilers</strong></td>
<td>C. jejuni (24 MSs + 4 non-MSs)</td>
<td>14 (AT, DE, HR, CY, CZ, DK, FI, FR, NL, RO, SE, SK, CH, UK)</td>
<td>1 (ES)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>C. coli (4 MSs + 1 non-MS)</td>
<td>2 (DE, NL)</td>
<td>–</td>
<td>1 (CZ)</td>
</tr>
<tr>
<td><strong>Turkeys</strong></td>
<td>C. jejuni (8 MSs + 1 non-MSs)</td>
<td>2 (DE, PL)</td>
<td>2 (HU, IT)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>C. coli (6 MSs + 2 non-MSs)</td>
<td>4 (DE, NL, CH, NO)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

MSs: Member States; AT: Austria; BE: Belgium; BG: Bulgaria; CY: Cyprus; CZ: Czechia; DE: Germany; DK: Denmark; EE: Estonia; EL: Greece; ES: Spain; FI: Finland; HU: Hungary; FR: France; IS: Iceland; IT: Italy; LU: Luxembourg; LV: Latvia; MT: Malta; NL: Netherlands; NO: Norway; PL: Poland; PT: Portugal; RO: Romania; SE: Sweden; SI: Slovenia; SK: Slovakia; UK: United Kingdom.

### 3.6. Discussion

Campylobacter bacteria are ubiquitous and can be found widespread in the environment and animals including food-producing animals which pose a risk to human health. Indeed, Campylobacter is an important food-borne zoonotic agent. Moreover, Campylobacter strains resistant to antibiotics may interfere with the treatment of human campylobacteriosis (Moore et al., 2006; Garcia and Heredia, 2013) and represent an important public health concern. The main species responsible for human infections is C. jejuni, which is usually predominant in poultry, followed by C. coli (Jehanne et al., 2020). Because of this, the monitoring of AMR in Campylobacter spp. from food-producing animals and food derived thereof focuses on these two species, as laid down in the Commission Implementing Decision (EU) 2020/1729.

In accordance with this Decision, from 2021 onwards, the AMR monitoring is mandatory, at biannual basis, in both C. jejuni and C. coli from caecal samples from broilers, fattening turkeys, bovine animals under 1 year of age (where the national production of turkey meat and bovine meat is more than 10,000 tonnes per year) and fattening pigs at slaughter.

In the framework of Commission Implementing Decision (EU) 2020/1729, the monitoring of AMR in C. jejuni and C. coli in food-producing animals provides comparable data on the occurrence and enables to assess the trends of AMR in these Campylobacter species in animal productions. However, it must be highlighted that the number of MSs that report data on AMR in C. jejuni and C. coli from...
food-producing animals and the number of isolates vary considerably, also due to differences in the national production of meat thereof.

*Campylobacter* monitoring programmes, surveillance programmes and epidemiological studies aim to improve the knowledge in relation to the prevalence of *C. jejuni* and *C. coli* in animal production and food of animal origin. Increasing the knowledge on the occurrence of resistance in these bacterial species will contribute to a better understanding of the epidemiology of human infections.

In 2020, information on AMR in *Campylobacter* isolates from human clinical cases was reported in fewer countries than in 2019. Some countries were unable to report any results due to the impact of the COVID-19 pandemic on AMR surveillance and monitoring activities, and laboratory operations. Additionally, the pandemic affected the ability of countries to collect isolates and send them to national reference centres, thus reducing the number of isolates available for antimicrobial susceptibility testing compared to previous years. In 2021, more countries were again able to report *Campylobacter* AMR data from humans, with even some countries reporting quantitative data for the first time. This can be attributed, in part, to the return to regular activities post-pandemic. The increased focus on and support for national surveillance of antimicrobial susceptibility for *Salmonella* and *Campylobacter* in humans via the HaDEA-funded FWD AMR ReflabCap project has most likely also contributed (https://www.fwdamr-reflabcap.eu/about-fwd-amr-reflabcap).

Resistance in bacteria isolated from humans has been associated with resistance in bacteria from food-producing animals, and also with antimicrobial consumption in both humans and animals. In the third joint inter-agency JJICRA report of the three EU agencies ECDC, EFSAs and EMA, providing data from the respective networks on antimicrobial consumption and resistance in isolates from humans and animals, a statistically significant association was observed between resistance to fluoroquinolones, macrolides and tetracycline in *Campylobacter* spp. isolates from animals and isolates from humans in the EU (ECDC, EFSAs, and EMA, 2021). This finding is biologically plausible as *Campylobacter* in meat products is a major source of food-borne infections in humans.

Overall, the data obtained in 2020–2021 from *C. jejuni* and *C. coli* from human and animal origins showed high to extremely high levels of resistance to fluoroquinolones (in this report represented by ciprofloxacin), which are critically important antimicrobials (CIA) for the treatment of *Campylobacter* infections in humans. Moreover, increasing trends of resistance of *C. jejuni* to ciprofloxacin were detected from human isolates in 12 reporting countries and from isolates from broilers in 14 reporting countries (Table 9). The high level of ciprofloxacin resistance in *Campylobacter* is worrisome. Seen from a human perspective, high resistance levels point to a continued high use of fluoroquinolones in food-producing animals and particularly in poultry production, where large numbers of animals could be affected by flock antimicrobial treatment. This might not only affect resistance levels in *Campylobacter* but also select for other resistant microorganisms as well (e.g. *Salmonella*), which are then passed from animals or the meat derived thereof to humans. In general, antibiotic treatment of human infections with *Campylobacter* is discouraged, since these infections tend to be self-limiting diseases. In addition, the use of ciprofloxacin in the treatment of *Campylobacter* infections is not advised due to the risk of treatment failure unless prior testing can confirm susceptibility. As the use of ciprofloxacin is no longer advised for the treatment of human campylobacteriosis, even low levels of resistance to other critically important antimicrobials are a cause for concern in public health.

Resistance to quinolones and fluoroquinolones has been found to be mainly due to the C257T mutation on the gyrA gene (Elhady et al., 2020). Modifications in the expression of the efflux pump CmeABC may result in lower MIC values of various antimicrobials including ciprofloxacin. Highly resistant isolates bearing a transferrable ‘super’ efflux pump variant of CmeABC (RE-CmeABC) were described in China (Yao et al., 2016), and their MIC values of ciprofloxacin, along with florfenicol, chloramphenicol, erythromycin and tetracycline, were found to be increased.

Considering that fluoroquinolones are no longer an option for treatment of severe *Campylobacter* infections in Europe, macrolides are now the main class of antibiotics used as first-line treatment of human campylobacteriosis. Resistance to erythromycin, belonging to macrolides, was either not detected or detected at very low levels in *C. jejuni* from humans, poultry and calves, but was higher in *C. coli* isolates from humans (overall, 8.5%), calves (overall, 35.7%), fattening turkeys (overall, 21.5%), fattening pigs (overall, 12.3%) and broilers (overall, 4.4%). High variability can be observed between countries with some countries reporting high to extremely high levels of resistance to erythromycin in isolates from humans and food-producing animals, e.g. 55.3% and 66.7% erythromycin resistance in *C. coli* isolates from humans and fattening pigs reported by Portugal and 77.8% resistance in *C. coli* isolates from calves reported from Belgium (no AMR data from humans reported). Interestingly, erythromycin resistance significantly decreased in *C. jejuni* from humans in
seven countries (over the period 2013–2021), from broilers in five MSs (over 2009–2020) and from fattening turkeys in three MSs (period 2014–2020). Regarding \textit{C. coli}, decreasing trends of resistance to erythromycin were observed in five MSs for humans, one MS for broilers and four reporting countries for pigs. Not enough comparable data on \textit{C. coli} from calves was available for trend analysis. An increasing trend of resistance of \textit{C. jejuni} to erythromycin has only been detected in humans in one MS (Spain), with no detection in animals. For \textit{C. coli}, increasing trends were only registered in one non-MS for humans and one MS for broilers (Czechia). However, it is to be noted that a high proportion of erythromycin-resistant isolates displayed very high MIC values (MIC > 128 mg/L for 2020 data; MIC > 512 mg/L for 2021 data), particularly in \textit{C. coli} isolated from fattening turkeys (93.4% of resistant isolates with MIC > 128 mg/L), calves (66.7% of resistant isolates with MIC > 512 mg/L; 25% of resistant isolates with MIC between 128 and 512 mg/L) and fattening pigs (31.7% of resistant isolates with MIC > 512 mg/L; 49.1% of resistant isolates with MIC between 128 and 512 mg/L).

Common mechanisms of resistance to macrolides are mutations in one or several copies of the ribosomal RNA genes, such as A2074G, A2074C and A2075G (Luangtongkum et al., 2009). In addition, the transferable \textit{erm}(B) gene, encoding an rRNA methylase, usually present on multidrug resistance islands (MDRI) or plasmids in \textit{Campylobacter}, may confer a high level of resistance to macrolides, lincosamides and/or streptogramin B antibiotics (Wang et al., 2014). Initially described in Asia, this emerging resistance mechanism has also been detected in patients and in animal isolates in Europe (Florez-Cuadrado et al., 2017; Elhadidy et al., 2019; Jehanne et al., 2021). An increase of the tested concentrations of erythromycin (up to 512 mg/L instead of 128 mg/L) has been implemented since 2021 according to Decision (EU) 2020/1729, allowing for 2021 a better screening of isolates which may carry \textit{erm}(B), as it enables differentiation of isolates with an MIC < 128 mg/L, which are likely to only have mutations or alterations in target genes (L4, L22 CmeABC, CmeR genes and the binding site of CmeR) from those with a higher MIC (≥ 512 mg/L) that have an erythromycin resistance phenotype more likely associated with possession of transferable \textit{erm}(B), even though mutational resistance cannot be ruled out (Wang et al., 2014). Point mutations in 23S rRNA might also confer similar levels of high resistance against erythromycin as \textit{erm}B-mediated resistance in \textit{Campylobacter} (Wei and Kang, 2018; Béjaoui et al., 2022).

It should be noted that the level of resistance to tetracycline ranged from high to extremely high in humans and food-producing animals based on data reported in 2020 and 2021. Levels were particularly high in \textit{C. jejuni} and \textit{C. coli} isolated from cattle (under 1 year of age) in 2021 and from \textit{C. coli} isolated from fattening turkeys in 2020. Furthermore, increasing trends of resistance of \textit{C. jejuni} to tetracycline were detected from human isolates in seven reporting countries and from broilers in 11 reporting countries (Table 9).

The prevalence of resistance to selected antimicrobials in \textit{C. coli} from fattening pigs in 2021 has been estimated at country level as the proportion of \textit{C. coli} showing microbiological resistance as a percentage of all caecal samples cultured for \textit{C. coli}. Monitoring the prevalence of resistant \textit{C. coli} in fattening pigs enables to address together both evolving temporal trends in the prevalence of \textit{C. coli} in fattening pigs and in the occurrence of resistance in \textit{C. coli} from fattening pigs, through a unique indicator. This indicator is primarily intended to follow up trends over time at the country level. However, it should be noticed that various factors, such as rearing conditions, feed, climate, etc., may also affect the \textit{C. coli} true prevalence of resistance. Between-country variability from low to extremely high levels was observed in the prevalence of ciprofloxacin resistant (ranging from 6.9% to 78.2%) and tetracycline-resistant (ranging from 0.0% to 86.5%) \textit{C. coli} from fattening pigs. Interestingly, a limited between-country variation and notably lower levels of prevalence of resistance to erythromycin were found in \textit{C. coli} from fattening pigs, which have been estimated to be below 10% for 24 reporting countries (21 MSs and 3 non-MSs), while ranging from 14.9% to 39.7% in the remaining six reporting MSs. Noteworthy, the MS (Portugal) with the highest prevalence of resistance to erythromycin in \textit{C. coli} from fattening pigs (39.7%) in 2021 had also the highest levels of erythromycin resistance (55.3%) and combined resistance to ciprofloxacin and erythromycin (55.3%) in \textit{C. coli} from humans, suggesting that pigs could be a reservoir of erythromycin resistance for humans. This finding is of particular public health concern since, as commented above, macrolides, such as erythromycin and azithromycin, have become the first-line treatment of human campylobacteriosis.

Another important aspect to highlight in this report is linked to the multidrug resistance (MDR) levels in isolates from humans and food-producing animals. MDR in human isolates tested for four antimicrobial classes (fluoroquinolones, macrolides, tetracyclines and aminoglycosides) was overall very low in \textit{C. jejuni} (1%) and low in \textit{C. coli} (9.9%). MDR levels were generally low for \textit{C. jejuni} isolated from the animal species considered; however, it was high in \textit{C. coli} isolates from calves (39.3%) and fattening turkeys (21%).
The implementation of the Decision (EU) 2020/1729, the harmonisation of *Campylobacter* isolation methods and the monitoring in 2021–2027 of the resistance levels of *C. jejuni* and *C. coli* in food-producing animals will improve our knowledge of the prevalence and occurrence of antimicrobial resistance of *C. jejuni* and *C. coli* isolated from animals in the reporting countries. Moreover, the modifications of the panel of antimicrobials and concentrations tested (EFSA, 2021) will enable a better detection of the emerging and threatening resistance mechanisms already mentioned (RE-CmeABC, erm(B)) and other ones such as the *cfr(C)* gene, borne on a conjugative plasmid and conferring resistance to phenicols, lincosamides, pleuromutilins and oxazolidinones (Tang et al., 2017). These mechanisms (efflux pumps) and/or their genetic support (plasmids, MDRI) confer resistance to one or several families of antimicrobials of major importance for human treatment strategies (macrolides, fluoroquinolones or aminoglycosides) and could favour co-selection of resistant clones or plasmids.

According to Commission Implementing Decision (EU) 2020/1729, two new substances, chloramphenicol and ertapenem, were added to the panel of antimicrobials and related findings were reported for the first time in 2021. Resistance to chloramphenicol in isolates from pigs and calves (2021) was either absent or extremely low in *C. jejuni* isolates from fattening pigs and calves (0%–0.1%) and *C. coli* isolates from pigs (0.5%). A higher (but still low) level resistance to chloramphenicol was observed in *C. coli* isolated from calves (3.4%). Similarly, ertapenem resistance in isolates from pigs and calves (2021) was either absent or very low in *C. jejuni* isolates from fattening pigs and calves (0.0%–1%) and *C. coli* from pigs (0.5%). It is noteworthy that an unexpected higher level of resistance to ertapenem was reported in *C. coli* isolated from calves (29.1%) in 2021. This finding is of public health concern as carbapenems, together with aminoglycosides, are the antimicrobial classes recommended for treatment of invasive *Campylobacter* infections in humans (EFSA, 2019; Dai et al., 2020). At present, only few comparable data on the resistance to ertapenem in *C. coli* from calves are available, and therefore, further investigations are needed to interpret this finding. Moreover, it should be noted that the epidemiological cut-off for ertapenem used by EFSA in this analysis is still under discussion as there is not yet a validated threshold for resistance to ertapenem recommended by EUCAST. Also, no indication on the epidemiological cut-off to be used for ertapenem in *C. coli* and *C. jejuni* was provided in Commission Implementing Decision (EU) 2020/1729. Additional data will be available in the coming years because of the implementation of the harmonised AMR monitoring in accordance with Commission Implementing Decision (EU) 2020/1729 and these will allow a detailed evaluation and validation of the appropriate threshold for resistance to ertapenem in both *C. coli* and *C. jejuni*.

Furthermore, WGS of isolates, particularly those with multidrug resistance, high-level resistance to erythromycin or ciprofloxacin, or resistance to gentamicin or ertapenem is strongly encouraged to provide further evidence of involved antimicrobial resistance genes, their genetic origin (chromosome, plasmid, transposon, integrative and conjugative element, genomic islands) and their potential of horizontal transmission (Mourkas et al., 2019). WGS of isolates can also contribute to the detection of prevalent resistant lineages or subtypes (Webb et al., 2018; Mouftah et al., 2021) in the various sources and for comparison of animal and human isolates.

4. **Antimicrobial resistance in indicator *E. coli***

The monitoring of AMR in commensal indicator *E. coli* collected from the intestinal flora of healthy food-producing animals and food provides information on the reservoirs of resistant bacteria that could potentially be transferred between animal populations and humans. It also provides indirect information on the reservoirs of resistance genes that could be transferred to bacteria that are pathogenic to humans and/or animals. Such monitoring has relevance to both public health and animal health. The occurrence of AMR in indicator *E. coli* likely depends on several factors, including the selective pressure exerted by the use of antimicrobials in food-producing animal populations; clonal spread of resistant organisms; dissemination of genetic elements, such as resistance plasmids; and the effects of co-selection in bacteria exhibiting multidrug resistance (MDR).

4.1. **Key findings**

- Resistance to ampicillin, sulfamethoxazole, trimethoprim or tetracycline was common and reported by most MSs at high or very high levels in all animal categories in 2020/2021. Resistance to quinolones was common in poultry, and very high or extremely high levels were
reported by several MSs. Resistance to other antimicrobials was less common, and notably, meropenem resistance was not detected in any animal populations or meat categories in 2020/2021.

- Large differences in the levels of resistance were observed between countries, and generally, lower levels were reported in northern Europe, although countries in southern and central Europe also reported low levels of resistance in isolates from bovines under 1 year of age (calves).
- Complete susceptibility (CS) was more common in isolates from fattening pigs and calves than in those from broilers and fattening turkeys. Conversely, multidrug resistance (MDR) was more common in isolates from broilers and turkeys than in those from pigs and calves.
- Marked differences in the levels of CS and MDR were observed between countries. The antimicrobials most often represented in the patterns of MDR isolates were tetracycline, ampicillin, sulfamethoxazole, trimethoprim and, additionally, quinolones in poultry.
- The weighted summary key outcome indicator of complete susceptibility (KOICS), accounting for differences in the relative size of food animal populations in a country, varied widely between countries ranging from <20% to >80%. Lower KOICS were generally observed in countries in Eastern and Southern Europe and the highest in countries in the Northern part.
- Resistance to highest priority critically important antimicrobials (hpCIA) was uncommon for colistin, azithromycin and third-generation cephalosporins (cefotaxime or ceftazidime), and median levels ranged between rare and low in all animal categories. Ciprofloxacin resistance was more common, and median levels were very high in broilers, high in turkeys, low in calves and moderate in pigs. Combined resistance to third-generation cephalosporins and fluoroquinolones was generally uncommon in all animal categories.
- Statistically significant decreasing temporal trends in resistance to ampicillin, ciprofloxacin, cefotaxime, tetracycline and colistin, as well as increasing trends in CS and KOICS reveal progress towards lower levels of resistance in several countries and in the EU group as a whole. An improvement in the situation was most pronounced in poultry.
- In 2021, MSs started to implement the new monitoring of AMR in indicator E. coli recovered from imported fresh meat sampled at border control posts. A number of MSs submitted E. coli isolates from imported pig meat and imported bovine meat. Similarly, 2021 was the first year MSs could choose to perform WGS as an alternative to supplementary testing of presumptive ESBL, AmpC or CP-producing E. coli from routine monitoring.

4.2. Data on AMR in indicator E. coli addressed

Commission Implementing Decision (EU) 2020/1729 provides detailed requirements for the harmonised monitoring and reporting of AMR in zoonotic and commensal bacteria. In 2021, monitoring AMR in indicator E. coli isolates recovered from caecal contents of domestically produced fattening pigs was mandatory, likewise, for MSs with consistent production of calves over a certain tonnage per annum, monitoring of indicator E. coli was mandatory. For the first time in 2021, the monitoring of fresh meat from pigs and calves imported from third-countries and sampled at border control posts (BCPs) was undertaken. In 2020, data were reported on indicator E. coli isolates from broiler and turkey flocks in accordance with Commission Implementing Decision (EU) 2013/652 (repealed on 17 November 2020). E. coli isolates from all animal origins exhibiting phenotypes suggestive of presumptive ESBL, AmpC or CP-producing E. coli are reported in this chapter and chapter 5.

In 2021, amikacin was added to the harmonised panel for the monitoring of AMR in indicator E. coli and was included in analyses of the occurrence of resistance, complete susceptibility (CS) and multidrug resistance (MDR). While amikacin is not used in food-producing animals, it is commonly used in people to treat urinary tract infections, bacteraemia and intra-abdominal infections caused by gram-negative bacteria. The addition of amikacin to the harmonised panel is thought to improve the
Enterobacteriaceae from human cases in Europe (Arca-Suárez et al., 2022; Fournier et al., 2022).

The harmonised susceptibility testing of *E. coli* isolates derived from fresh meat imported from third countries improves our understanding of the dissemination of AMR through food and provides information that may help reduce the impact of AMR. In 2021, imported meat required for sampling was from pigs and calves. A limited number of countries reported data on isolates from meat samples collected at border control posts (BCPs), as only a small proportion of meat was imported into their country. In this chapter, reference to 'fresh meat' means fresh meat as defined in Annex I to Regulation (EC) No 853/2004. Reference to ‘fresh imported meat’ refers to fresh meat that has been imported from a third country. BCPs are inspection posts designated and approved with EU legislation to carry out checks on animals and animal products arriving from third countries at a European Union border.

From 2021, whole genome sequencing (WGS) is authorised as an alternate method to conventional phenotypic testing for *E. coli* isolates obtained from routine monitoring that shows resistance to extended-spectrum cephalosporins and carbapenems. MSs may choose to either undertake panel 2 testing of presumptive ESBL, AmpC or CP-producing *E. coli* or perform WGS and report these data. WGS is authorised on a voluntary basis only, but technical conditions on the WGS technique have been imposed to ensure data comparability. The voluntary reporting of WGS data from 2021 on ESBL/AmpC/CP-producing *E. coli* isolates will facilitate an understanding of the potential contribution of food-producing animals and derived food to the burden of AMR in humans (EFSA, 2019). Information on WGS of these isolates can be found in chapter 5.

### 4.3. Antimicrobial resistance in poultry, porcine and bovine populations

#### 4.3.1. Data reported

In 2021, 27 MSs and four non-MSs reported data on indicator *E. coli* from pigs and 11 MSs and two non-MSs submitted data on isolates from calves. For *E. coli* isolates recovered from fresh meat samples taken at BCPs, four MSs provided data from pig meat and six MSs on meat from bovine animals. Of those MSs, most submitted AMR data on fewer than 10 isolates. In 2020, 27 MSs and five non-MSs reported data on isolates from broilers and 11 MSs and two non-MSs on isolates from turkeys.

Summary data on the occurrence of resistance to commonly used antimicrobials in veterinary medicine (ampicillin, sulfamethoxazole and tetracyclines) as well as highest priority critically important antimicrobials (hpCIAs) (i.e. ciprofloxacin, cefotaxime and combined resistance to these two antimicrobials) are described in this chapter. Additionally, results from the analysis of MDR patterns and combined resistance to ciprofloxacin and cefotaxime are reported here. Annex C presents detailed information on the occurrence of AMR, MDR and combined resistance in *E. coli* from pigs, calves (corresponding to 2021 data), as well as broilers and turkeys (corresponding to 2020 data), at the MS and MS-group level.

Under the new legislation (Commission Implementing Decision (EU) 2020/1729), changes were made to the ECOFFs and clinical breakpoints for several antimicrobial substances included in the harmonised panel for testing of *E. coli* isolates. The substances include tigecycline, where the ECOFF changed from MIC > 1 to > 0.5 mg/L and the clinical breakpoint changed from MIC > 2 to > 0.5 mg/L. Also, the ECOFF for nalidixic acid changed from > 16 to > 8 mg/L. For ciprofloxacin, the clinical breakpoint changed from > 1 to > 0.5 mg/L. Therefore, for 2021 data from pigs, calves and meat from BCPs, the occurrence of resistance to tigecycline, nalidixic acid and ciprofloxacin is determined using the new ECOFFs and clinical breakpoints, and for 2020 data from

---

17 'Fresh meat' means meat that has not undergone any preserving process other than chilling, freezing or quick freezing, including meat that is vacuum-wrapped or wrapped in a controlled atmosphere. Regulation (EC) No 853/2004 of the European Parliament and of the Council laying down specific hygiene rules for on the hygiene of foodstuffs. OJ L 139/55, 30.4.2004.

18 In the following sections, the occurrence of resistance refers to microbiological resistance (i.e. determined by the ECOFF value) unless otherwise stated. The level of resistance is described as either 'rare': < 0.1%, 'very low': 0.1%–1.0%, 'low': > 1%–10.0%, 'moderate': > 10.0%–20.0%, 'high': > 20.0%–50.0%, 'very high': > 50.0%–70.0%, 'extremely high': > 70.0%. The significance of a given level of resistance depends on the antimicrobial substance and its relative relevance in human and veterinary medicine. The small sample size from some reporting countries should be considered when interpreting results.

19 Ciprofloxacin and cefotaxime are first-line agents that are critically important for treating human infections caused by Enterobacteriaceae.

20 Annex C is available on the EFSA Knowledge Junction community on Zenodo at: https://doi.org/10.5281/zenodo.6257446.
4.3.2. Occurrence of antimicrobial resistance

Since 2014, the antimicrobial substances included in the harmonised panel for the monitoring of AMR in *E. coli* from food-producing animals have provided continuity of monitoring data and epidemiological tracing of isolates with resistance patterns of interest to public health. The antimicrobials included in the panel have been selected because they are either of public health importance, of epidemiological relevance or are commonly used in veterinary medicine. Antimicrobials such as ampicillin, sulfamethoxazole and tetracycline have been widely used for many years in veterinary medicine to treat infections in production animals. The WHO categorises ampicillin as a ‘critically important antimicrobial’ (CIA), while sulfamethoxazole and tetracycline are categorised as ‘highly important antimicrobials’ (WHO, 2019). A new substance, amikacin, was added to the harmonised panel in 2021.

**Food-producing animals**

Resistance to ampicillin, sulfamethoxazole, trimethoprim and tetracycline was the most common resistance trait observed. Considering reporting MSs, median levels of resistance to these antimicrobials were high or very high in all animal populations except for calves, for which the median level of resistance to ampicillin was moderate (16.5%), and trimethoprim resistance was low (8.2%) (Figure 30; Annex C, Table 2). Large differences in resistance levels to ampicillin, sulfamethoxazole, trimethoprim and tetracycline between countries were however observed in all animal populations. For example, Cyprus (n = 22), Greece (n = 73), Portugal (n = 55) and Spain (n = 170) reported extremely high levels of resistance to tetracyclines in pigs (77.3%, 71.2%, 72.7% and 78.8%, respectively), while Finland (n = 170) and Sweden (n = 173) reported moderate resistance at 14.1% and 16.8%, respectively (Annex C, Table 2). In calves, Italy (n = 170) reported very high levels of resistance to ampicillin (60.6%), sulfamethoxazole (65.3%) and trimethoprim (56.5%) and extremely high resistance to tetracycline (74.7%). Belgium (n = 173) and France (n = 182) also reported very high levels of resistance to all four substances, while Denmark (n = 109) and Portugal (n = 53) reported low to moderate levels of resistance to these substances, and Sweden (n = 20) reported zero resistance to sulfamethoxazole and trimethoprim and just 5.0% resistance to ampicillin and tetracyclines, respectively (Annex C, Table 2).

In poultry, resistance to ciprofloxacin and nalidixic acid was common, with very high median levels in broilers and high median levels in turkeys (Figure 30; Annex C, Tables 3 and 4). In contrast, in pigs and calves, median resistance levels to both these antimicrobials were low (Figure 30; Annex C, Tables 1 and 2). For both ciprofloxacin and nalidixic acid resistance, there were large differences between reporting countries. Most countries reported nalidixic acid resistance at lower levels than ciprofloxacin resistance. This was most notable for pigs and calves, and at the MS-group level, nalidixic acid resistance was approximately half that for ciprofloxacin for both these animal populations. For chloramphenicol, the overall median resistance level for all reporting MSs was low to moderate for all animal populations (range 5.0–15.9%). However, some countries reported high to very high resistance, and one country (Romania) reported extremely high resistance in turkeys (74.2%, n = 31) (Annex C, Table 4). The overall median level of resistance to gentamicin was very low or low in all four animal populations (range 0.9–2.9%). Resistance to cefotaxime, ceftazidime, colistin and azithromycin were rare, very low or low in all four animal populations (Annex C). Meropenem resistance was not detected in any isolate of indicator *E. coli*. Overall resistance to tigecycline in *E. coli* isolates from pigs in the MSs was 0.4% (n = 4,013) with Hungary accounting for half of the resistant isolates (4.7%, n = 170), and in isolates from calves (n = 1,599), Belgium accounted for the majority of resistant isolates (5.2%, n = 173). Resistance to tigecycline was reported in a single isolate from a turkey in Portugal and from none in broilers. For amikacin, the new substance required for testing in 2021, overall median resistance in pigs was low (0.2%), with nine resistant isolates spread across seven countries. While for calves, amikacin resistance (0.3%) was detected in four *E. coli* isolates from Belgium (n = 2) and the Netherlands (n = 2).
Imported fresh meat

Four MSs contributed data on imported fresh pig meat sampled at BCPs, representing a total of 13 *E. coli* isolates. For ampicillin, sulfamethoxazole, trimethoprim and tetracycline, overall median resistance levels ranged from zero (trimethoprim) to high (tetracycline) for pig meat and bovine meat (Annex C, Tables 5 and 6). For *E. coli* isolates recovered from imported meat from bovine animals, six MSs contributed data, representing 110 isolates (Annex C, Table 6), most of them being submitted by the Netherlands (n = 79, 71.8%). The overall median resistance levels to ampicillin, sulfamethoxazole and trimethoprim was zero, and for tetracycline, the overall median resistance was low (2.4%). Among *E. coli* isolates tested in the Netherlands, resistance to ampicillin was not detected, while low to moderate resistance was detected for sulfamethoxazole (7.6%), trimethoprim (3.8%) and tetracycline (11.4%). Resistance to amikacin was not reported in either pig or bovine meat (Annex C, Tables 5 and 6).

![Resistance to highest priority critically important antimicrobials (hpCIA)](image)

**Figure 30**: Distribution of occurrence of resistance to selected antimicrobials in indicator *E. coli* isolates recovered from fattening pigs (pigs) and bovines under 1 year of age (calves) in 2019 and from broilers and fattening turkeys (turkeys) in 2020. MSs and non-MSs

### Resistance to highest priority critically important antimicrobials (hpCIA)

Among the antimicrobials tested in the mandatory monitoring of indicator *E. coli*, ciprofloxacin (fluoroquinolones), cefotaxime and ceftazidime (third-generation cephalosporins), colistin (polymyxins) and azithromycin (macrolides) are categorised by the WHO as hpCIA (WHO, 2019).

### Food-producing animals

Considering all reporting MSs, overall median colistin resistance was rare in pigs (0%), calves (0%) and broilers (0%) and very low in turkeys (1.8%) (Annex C). For broilers, just one country, Cyprus, reported moderate resistance to colistin in *E. coli* isolates (10.1%, n = 99), while for turkeys, Portugal reported high-level resistance (23.9%, n = 142). For azithromycin, overall median levels of resistance in *E. coli* isolates for all reporting MSs were very low in calves (0.8%), broilers (0.5%) and low in pigs (1.3%) and turkeys (1.1%). *E. coli* resistance to both colistin and azithromycin was not observed in most countries, with only a small number of countries reporting resistance to both antimicrobials at either low or moderate levels (Annex C).
In contrast, very high levels of resistance to fluoroquinolones/quinolones were recorded in isolates from broilers (median: ciprofloxacin 52.7%; nalidixic acid 49.4%), and high levels in isolates from turkeys (median: ciprofloxacin 33.5%; nalidixic acid 22.9%) (Figure 30; Annex C, Tables 3 and 4). Including all reporting countries, overall median resistance to ciprofloxacin and nalidixic acid were reported at low levels in isolates from pigs (median 5.9% and 3.9%, respectively) and calves (median 4.7% and 3.1%, respectively). Large variations in resistance levels were observed at the individual reporting country level for each of the animal populations. For example, Spain reported very high resistance to ciprofloxacin (50.6%) and high resistance to nalidixic acid (27.1%) in 170 E. coli isolates recovered from pigs. While in broilers and turkeys, nearly all countries reported either high, very high or extremely high resistance to ciprofloxacin and nalidixic acid (Figure 31; Annex C). In all animal populations monitored, overall median resistance to third-generation cephalosporins (ceftazidime or cefotaxime) was very low or low (range 0.2–1.1%) (Figure 30; Figure 31; Annex C).

**Imported fresh meat**

For colistin and azithromycin, resistance was not detected in E. coli isolates from pig meat (Annex C, Table 5). While in bovine meat, one isolate reported resistance to azithromycin, and no isolates were resistant to colistin (Annex C, Table 6). For ciprofloxacin, one E. coli isolate from pig meat was reported to be resistant (Sweden, n = 2) and two isolates from bovine meat (Italy, n = 21; the Netherlands, n = 79). For nalidixic acid, resistance was not detected in any isolates from pig meat; however, two isolates from bovine meat were resistant (Italy, n = 21; the Netherlands, n = 79) (Annex C). When considering cefotaxime and ceftazidime, resistance was not detected in E. coli isolates from pig meat, and just one isolate was resistant to both substances in isolates from bovine meat (Annex C, Table 6).

**Combined resistance to ciprofloxacin and cefotaxime**

**Food-producing animals**

In most reporting countries, combined resistance to ciprofloxacin and cefotaxime was either not observed or discerned at low or very low levels in all four animal populations monitored (Figure 31; Annex C). Overall, the median of microbiological combined resistance to ciprofloxacin and cefotaxime was rare (pigs, calves) or very low (broilers and turkeys). Clinical combined resistance (i.e. defining resistance by the clinical breakpoint) was not generally observed in any of the animal origins, and where it was, fewer than 10 isolates were reported with combined resistance across all reporting countries by animal origin, except in broilers, where 24 isolates were observed as clinically resistant to both substances (Annex C). Overall, 98 E. coli isolates with microbiological combined resistance of which 41 also had clinical combined resistance were detected in the food-producing animal populations monitored (Table 10). Isolates exhibiting combined resistance were more common in poultry than in pigs and calves.

**Imported fresh meat**

Microbiological combined resistance to ciprofloxacin and cefotaxime was not detected in any E. coli isolates recovered from imported pig meat, and only one isolate from imported bovine meat (reported by the Netherlands) exhibited combined resistance (Table 10).

**Table 10:** Combined resistance to ciprofloxacin and cefotaxime in indicator E. coli from fattening pigs (pigs), bovines under 1 year of age (calves), broilers and fattening turkeys (turkeys) applying ECOFFs and clinical breakpoints, as issued by EUCAST for MSs and non-MSs, 2020/2021
### Food-producing animal population

<table>
<thead>
<tr>
<th>Food-producing animal population</th>
<th>'Microbiological' combined resistance to CIP &amp; CTX (using ECOFFs)</th>
<th>'Clinical' combined resistance to CIP &amp; CTX (using clinical breakpoints)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of isolates</td>
<td>% Resistance</td>
</tr>
<tr>
<td>Broilers, 2020 (N = 4,716, 27 MSs, 5 non-MSs)</td>
<td>49</td>
<td>1.0</td>
</tr>
<tr>
<td>Turkeys, 2020 (N = 1,875, 11 MSs, 2 non-MSs)</td>
<td>19</td>
<td>1.0</td>
</tr>
<tr>
<td>Imported pig meat, 2021 (N = 13, 4 MSs)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Imported bovine meat, 2021 (N = 110, 6 MSs)</td>
<td>1</td>
<td>0.9</td>
</tr>
</tbody>
</table>

N: total number of *E. coli* isolates reported by MSs and non-MSs; CIP: ciprofloxacin; CTX: cefotaxime; ECOFF: epidemiological cut-off value.
Figure 31: Spatial distribution of combined microbiological resistance to cefotaxime and ciprofloxacin in indicator *Escherichia coli*. (a) fattening pigs, 2021; (b) bovines under 1 year of age, 2021; (c) broilers, 2020; and (d) fattening turkeys, 2020, EU MSs and non-MSs.
4.3.3. Temporal trends in resistance

Temporal trends in resistance to ampicillin, ciprofloxacin, cefotaxime and tetracyclines in indicator *E. coli* from pigs, calves, broilers and turkeys were evaluated for countries having provided data for three or more years over the period 2009–2021 and for the MS-group (including the United Kingdom). Ampicillin and tetracycline were considered in the temporal trend analysis, as they are the most used antimicrobials in food-producing animals in Europe (EMA, 2021) and decreasing trends in resistance are believed to primarily reflect changes in usage. Resistance trends in the hPCIAs, ciprofloxacin and cefotaxime, have also been assessed, as the presence of such resistance in *E. coli* from food-producing animals may impact human health. The statistical significance (*p* < 0.05) of trends was tested by logistic regression (see Appendix F – for details on methodological approach).

Sufficient data for assessing temporal trends were available from 31 countries for pigs, 30 for broilers and 11 countries each for calves and turkeys. Thus, 83 different animal/substance combinations were available and analysed for trends in resistance to ampicillin, ciprofloxacin, cefotaxime and tetracycline. For poultry data in 2020, 168 analyses were performed, and in total, 89 combinations had statistically significant (*p* < 0.05) decreasing trends, while 24 combinations had statistically significant increasing trends (Table 11). For pig and calf data in 2021, of the 162 analyses performed, 53 combinations had statistically significant (*p* < 0.05) decreasing trends, while 23 combinations had statistically significant increasing trends (Table 11). There were more decreasing than increasing trends and most noticeable was that a decrease in tetracycline resistance was observed in approximately half of the data sets for pig and calf data (24/43) and poultry data (23/42) (Table 11). It is of note that in several countries, levels of resistance were stable over time at low levels, and major changes cannot be expected.

Table 11: Summary of trends in resistance to ampicillin, ciprofloxacin, cefotaxime and tetracyclines in indicator *E. coli* from fattening pigs (pigs) and bovines < 1 year of age (calves) for the period 2009–2021, and broilers, and fattening turkeys (turkeys) for the period 2009–2020, EU MSs and non-MSs

<table>
<thead>
<tr>
<th>Animal population</th>
<th>Ampicillin</th>
<th>Ciprofloxacin</th>
<th>Cefotaxime</th>
<th>Tetracycline</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pigs, 2021 (27 MSs, 4 non-MSs)</td>
<td>↓↑ ↔</td>
<td>↓↑ ↔</td>
<td>↓↑ ↔</td>
<td>↓↑ ↔</td>
<td>↓↑ ↔</td>
</tr>
<tr>
<td>Calves, 2021 (9 MSs, 2 non-MSs)</td>
<td>4 1 6 6 2 3 1 8 7 2 2</td>
<td>19 6 19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total, 2021</td>
<td>11 8 23 12 7 23 6 4 33 24 5 13</td>
<td>53 23 92</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Broilers, 2020 (26 MSs, 4 non-MSs)</td>
<td>15 6 9 18 10 2 20 2 8 15 2 13</td>
<td>68 20 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkeys, 2020 (10 MSs, 1 non-MSs)</td>
<td>7 1 4 4 1 7 2 1 9 8 0 4</td>
<td>21 3 24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total, 2020</td>
<td>22 7 13 22 11 9 22 3 17 23 2 17</td>
<td>89 24 55</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

↓: statistically significant decreasing trends; ↑: statistically significant increasing trends; ↔: stable trend.

**Fattening pigs**

Of the 31 countries reporting AMR data on indicator *E. coli* isolates from pigs between 2009 and 2021, a total of 34 decreasing and 17 increasing trends were registered (Table 11; Figure 32). In 13 countries, only decreasing trends were observed, notably Germany, the Netherlands and the Republic of North Macedonia, for all four antimicrobials and Cyprus, for three antimicrobials (ampicillin, ciprofloxacin, tetracycline). In contrast, two countries (Poland and Slovakia) reported only increasing trends in ampicillin and tetracycline, and for Poland, ciprofloxacin was observed to be also increasing. Most notable was that tetracycline resistance has decreased in 17 countries and increased in just three. Overall, four countries (Croatia, Estonia, Malta and Sweden) were observed to have no statistically significant change in trends. At the MS group level (including the UK), only decreasing trends were observed, especially in ampicillin and tetracycline.
Bovine animals under 1 year of age (calves)

In the 11 countries reporting data on indicator *E. coli* from calves between 2009 and 2021, a total of 19 decreasing and six increasing trends were observed (Table 11; Figure 33). In eight countries, only decreasing trends were recorded for one or more of the following substances: ampicillin, ciprofloxacin, cefotaxime or tetracycline. Germany and the Netherlands registered statistically significant decreasing trends in all four substances, while France and Switzerland recorded decreasing trends in three substances (ampicillin, ciprofloxacin and tetracycline). In contrast, two countries reported only increasing trends in resistance, with Belgium having increasing trends in all four substances, and Denmark having increasing trends in ciprofloxacin and tetracycline. Croatia was the only country observed to have no statistically significant change in trends. At the MS-group level (including the UK), tetracycline was observed to have a decreasing trend in resistance.

Broilers

In the 30 countries reporting data on isolates from broilers, 68 decreasing and 20 increasing trends were registered (Table 11; Figure 34). In 16 countries, only decreasing trends were observed. Notably, in Ireland, Italy, Latvia, the Netherlands and Spain, resistance has decreased for all four antimicrobials and in Croatia, Estonia, France, Lithuania and Portugal for three antimicrobials. In contrast, in three countries, only increasing trends were observed. In the MS group, including also the United Kingdom, resistance to all four antimicrobials has decreased with statistical significance.

Fattening turkeys (turkeys)

In the 12 countries reporting data on isolates from turkeys, there were 21 decreasing and three increasing trends were observed (Table 11; Figure 35). Eight countries reported only decreasing trends; in Spain, for all four antimicrobials and in France, Italy and Portugal, for three antimicrobials. At the MS-group level, including also the United Kingdom, resistance to ampicillin and tetracycline has decreased with statistical significance.
(↘) /(↗): indicates statistically significant trends over the study period.

**Figure 32:** Trends in resistance to ampicillin (AMP), cefotaxime (CTX), ciprofloxacin (CIP) and tetracyclines (TET) in indicator *E. coli* from fattening pigs (pigs), EU MSs and non-MSs, 2009–2021
Figure 33: Trends in resistance to ampicillin (AMP), cefotaxime (CTX), ciprofloxacin (CIP) and tetracyclines (TET) in indicator *E. coli* from bovines under 1 year of age (calves), EU MSs and non-MSs 2009–2021

(↘↗): indicates statistically significant trends over the study period.
\( \text{\(\downarrow\)/\(\uparrow\)} \) indicates statistically significant trends over the study period.

**Figure 34:** Trends in resistance to ampicillin (AMP), cefotaxime (CTX), ciprofloxacin (CIP) and tetracyclines (TET) in indicator *E. coli* from broilers, EU MSs and non-MSs, 2009–2020
4.3.4. Phenotypic characterisation of third-generation cephalosporin and carbapenem resistance

A low number of indicator *E. coli* isolates from caecal samples from pigs and calves in 2021 and from broilers and turkeys in 2020 were phenotypically resistant to third-generation cephalosporins (cefotaxime and/or ceftazidime) upon initial testing on panel 1 (Table 12). Further phenotypic characterisation of these isolates for presumptive production of ESBL- and/or AmpC-enzymes on panel 2 showed that the total number of isolates exhibiting a phenotype of ESBL- and/or AmpC-producers was low in all four animal populations (Table 12). In countries reporting presumptive ESBL- and/or AmpC-producing isolates, the occurrence was generally very low or low, ranging from 0.6% to 8.7% in isolates from pigs, from 0.7% to 3.5% in isolates from calves, from 0.6% to 7.1% in isolates from broilers and from 0.6% to 6.3% in isolates from turkeys. Presumptive ESBL-producers were more common than AmpC-producers in all animal populations and isolates with a combined phenotype (ESBL + AmpC) were uncommon (Table 12).

\[\text{(\checkmark)(\checkmark)}\]: indicates statistically significant trends over the study period.

**Figure 35:** Trends in resistance to ampicillin (AMP), cefotaxime (CTX), ciprofloxacin (CIP) and tetracycline (TET) in indicator *E. coli* from fattening turkeys (turkeys), EU MSs and non-MSs, 2014–2020

4.3.4. Phenotypic characterisation of third-generation cephalosporin and carbapenem resistance

A low number of indicator *E. coli* isolates from caecal samples from pigs and calves in 2021 and from broilers and turkeys in 2020 were phenotypically resistant to third-generation cephalosporins (cefotaxime and/or ceftazidime) upon initial testing on panel 1 (Table 12). Further phenotypic characterisation of these isolates for presumptive production of ESBL- and/or AmpC-enzymes on panel 2 showed that the total number of isolates exhibiting a phenotype of ESBL- and/or AmpC-producers was low in all four animal populations (Table 12). In countries reporting presumptive ESBL- and/or AmpC-producing isolates, the occurrence was generally very low or low, ranging from 0.6% to 8.7% in isolates from pigs, from 0.7% to 3.5% in isolates from calves, from 0.6% to 7.1% in isolates from broilers and from 0.6% to 6.3% in isolates from turkeys. Presumptive ESBL-producers were more common than AmpC-producers in all animal populations and isolates with a combined phenotype (ESBL + AmpC) were uncommon (Table 12).
No indicator *E. coli* recovered from caecal samples by MSs and non-MSs from the four animal populations in 2020/2021 showed microbiological resistance to carbapenems (meropenem) upon initial testing on panel 1 (Table 13).

No *E. coli* isolates from imported pig meat (n = 13) displayed phenotypic resistance to third-generation cephalosporins, while a single isolate from imported bovine meat (n = 110) was resistant to both cefotaxime and ceftazidime (Table 12). This isolate underwent supplementary testing (panel two) and exhibited a phenotype of ESBL producer (Table 13).

Table 12: Occurrence of resistance to third-generation cephalosporins in indicator *E. coli* isolates from fattening pigs (pigs), bovines under 1 year of age (calves), pig meat from border control posts (BCP), bovine meat from BCPs, broilers and fattening turkeys (turkeys). EU MSs and non-MSs, 2020/2021

<table>
<thead>
<tr>
<th>Animal category</th>
<th>No. of MSs/non-MSs</th>
<th>Cefotaxime</th>
<th>Cefotazidime</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n (% R)</td>
<td>n (% R)</td>
</tr>
<tr>
<td>Pigs, 2021 (N = 4,586)</td>
<td>28/3</td>
<td>46 (1.0)</td>
<td>43 (0.9)</td>
</tr>
<tr>
<td>Calves, 2021 (N = 2,067)</td>
<td>11/2</td>
<td>31 (1.5)</td>
<td>26 (1.3)</td>
</tr>
<tr>
<td>Imported pig meat, 2021</td>
<td>4/0</td>
<td>13 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Imported bovine meat, 2021</td>
<td>6/0</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>Broilers, 2020 (N = 4,716)</td>
<td>27/5</td>
<td>47 (1.2)</td>
<td>54 (1.1)</td>
</tr>
<tr>
<td>Turkeys, 2020 (N = 1,875)</td>
<td>11/2</td>
<td>32 (1.3)</td>
<td>31 (1.3)</td>
</tr>
</tbody>
</table>

N: Total number of isolates tested by MSs and non-MSs; n: Total number of isolates resistant; BCP: border control post.

Table 13: Phenotypes of presumptive ESBL-, AmpC- or CP- producing indicator *E. coli* subjected to supplementary testing (panel 2), EU MSs and non-MSs, 2020/2021

<table>
<thead>
<tr>
<th>Animal category</th>
<th>ESBL and/or AmpC</th>
<th>ESBL(a)</th>
<th>AmpC(b)</th>
<th>ESBL + AmpC(c)</th>
<th>CP(d)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (% R)</td>
<td>n (% R)</td>
<td>n (% R)</td>
<td>n (% R)</td>
<td>n (% R)</td>
</tr>
<tr>
<td>Pigs, 2021 (N = 4,568)</td>
<td>42 (0.9)</td>
<td>31 (0.7)</td>
<td>11 (0.2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Calves, 2021 (N = 2,067)</td>
<td>14 (0.7)</td>
<td>8 (0.4)</td>
<td>6 (0.3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Imported pig meat, 2021</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Imported bovine meat, 2021</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Broilers, 2020 (N = 4,716)</td>
<td>54 (1.1)</td>
<td>45 (1.0)</td>
<td>16 (0.3)</td>
<td>7 (0.1)</td>
<td>0</td>
</tr>
<tr>
<td>Turkeys, 2020 (N = 1,875)</td>
<td>30 (1.6)</td>
<td>25 (1.3)</td>
<td>8 (0.4)</td>
<td>3 (0.2)</td>
<td>0</td>
</tr>
</tbody>
</table>

ESBL: extended-spectrum β-lactamase; CP: carbapenemase; N: Total number of isolates reported by MSs and non-MSs; n: number of isolates with this phenotype; % R: percentage of isolates from the total tested; ESBL: extended-spectrum β-lactamase; BCP: border control post.

(a): All isolates showing clavulanate synergy with cefotaxime, ceftazidime or with both compounds, suggesting the presence of an ESBL (independently of the presence of other mechanisms).

(b): Isolates with microbiological resistance to cefoxitin, suggesting the presence of an AmpC enzyme (independently of the presence of other mechanisms).

(c): Isolates showing synergy with cefotaxime or ceftazidime and with microbiological resistance to cefoxitin, suggesting the presence of ESBL and AmpC enzymes in the same isolate. These isolates are also included in the ESBL and AmpC columns.

(d): Isolates with microbiological meropenem resistance.

4.3.5. Colistin resistance

Colistin (polymyxin E) is an antimicrobial of the polymyxin group that has been used extensively in farm animals all over the world, including in Europe. In human medicine, the use of colistin has historically been limited, but an increased usage has been recorded to account for the need for last resort antimicrobials to treat infections caused by multidrug-resistant Gram-negative bacteria. Consequently, polymyxins are now among the five antimicrobials listed by the WHO as critically important and of highest priority for human medicine. The discovery of transferable genetic elements (e.g. mcr- genes) conferring resistance to colistin further underlines the importance of monitoring such resistance in food-producing animals. The mandatory monitoring, in accordance
During the period 2020–2021, the phenotypic resistance to colistin in indicator *E. coli* for all animal origins was very low (1.1%, 143/13,239). While most countries did not detect colistin resistance in *E. coli* isolates from any animal origin, varying levels of resistance were reported in some countries. For example, few countries reported resistance to colistin in isolates from pigs (6/31) or calves (2/13), while more countries reported resistance in broilers (8/32) and turkeys (7/13). At the MS-group level, median levels of colistin resistance were rare in isolates from pigs (0%), calves (0%) and broilers (0%), and low in isolates from turkeys (1.8%) (Annex C). At the country level, low to moderate to high levels of resistance were observed in some countries, up to 3.0% in pigs, 10.1% in broilers and 23.9% in turkeys (Annex C). Colistin resistance was not detected in *E. coli* isolates from imported meat origins.

In pigs, statistically significant decreasing trends\(^{21}\) were observed in three countries (Germany, Spain and the Republic of North Macedonia), and no country had increasing trends (Appendix E). Similarly, in calves, decreasing trends were observed in one MS (Italy), and no country had increasing trends. Trends for colistin resistance in broilers decreased in three countries (Italy, Portugal, Romania) and increasing trends were observed in Bulgaria and Cyprus (Appendix E). In turkeys, no statistically significant trends were observed (Appendix E). At the MS-group level, decreasing trends in isolates from calves and broilers and no changes in trends in isolates from pigs and turkeys (Appendix E).

### 4.3.6. Multidrug resistance

#### Multidrug resistant isolates

**Food-producing animals**

MDR is defined as microbiological resistance to three or more antimicrobial classes of the harmonised panel tested. In 2021, the median MDR observed in indicator *E. coli* isolates from pigs and all reporting MSs was 31.2% and 18.8% in isolates from calves, while, in 2020, the median MDR was assessed at 38.3% of *E. coli* isolates from broilers and in 49.5% of isolates from turkeys in the MSs. Large variations in MDR between reporting countries were observed, and ranged between 8.2 and 78.8% in pigs, 0–62.9% in calves, 2.4–85.2% in broilers and 4.6–90.3% in turkeys (Annex C).

**Imported fresh meat**

MDR was observed in two of the 13 *E. coli* isolates from imported pig meat, while for imported bovine meat, MDR was observed in four of 110 isolates, all reported by the Netherlands.

**MDR patterns**

**Food-producing animals**

A wide variety of resistance patterns were observed in MDR isolates. The antimicrobials most often represented in the patterns of isolates from pigs and calves were *ampicillin*, *sulfamethoxazole*, *trimethoprim* and *tetracycline*. For MDR *E. coli* isolates from pigs, the combination of ampicillin, sulfamethoxazole, trimethoprim and tetracycline was found in 41.6% (564/1355) of all MDR patterns reported for all reporting countries, and one or more of these substances featured in every MDR pattern reported. For MDR *E. coli* isolates from calves, the combination of ampicillin, sulfamethoxazole, trimethoprim and tetracycline was found in 86.9% (483/539) of all MDR patterns reported for all reporting countries, and one or more of these substances featured in every MDR pattern reported. These antimicrobials, alone or in combination with other substances, were also common in resistance patterns of MDR isolates from broilers (41.5%) and turkeys (42.2%).

MDR patterns of isolates from poultry included *(fluoro)quinolones* (i.e. ciprofloxacin and nalidixic acid) at 75.9% for broilers and 73.8% for turkeys. In contrast, ciprofloxacin and/or nalidixic acid were not as common in MDR patterns for MDR *E. coli* isolates from pigs (17.0%, 231/1355) and calves (27.8%, 150/539). Resistance to *third-generation cephalosporins* (i.e. cefotaxime and/or ceftazidime) among MDR *E. coli* isolates was uncommon at 1.3% in pigs, 2.0% in calves, 3.0% in

\(^{21}\) Trends in colistin resistance were analysed by logistic regression for countries reporting data for three years or more in the period 2014–2021 (see Appendix E – for details).

---

with Commission Implementing Decision (EU) 2020/1729, is based on phenotypic susceptibility and molecular testing is required for inference regarding the underlying mechanisms of resistance and the possible presence of mcr- genes.
Colistin was uncommon in the patterns of MDR *E. coli* isolates, with just three MDR isolates from pigs (0.2%) and two MDR isolates from calves (0.4%) featuring resistance to colistin across all reporting countries in 2021. While in 2020, colistin was more common in poultry data, with 2.7% of MDR isolates from broilers, and 9.5% of MDR isolates from turkeys reporting the presence of colistin in resistance patterns. In 2021, the occurrence of tigecycline resistance in MDR patterns was observed in just five isolates from pigs (0.4%) and in 11 isolates from calves (2.0%). While only one MDR isolate each for pigs and calves was observed to include amikacin, the new substance included in harmonised testing in 2021, in their resistance patterns.

**Imported fresh meat**

The resistance patterns of the two MDR *E. coli* isolates from imported pig meat featured sulfamethoxazole and tetracycline, along with other substances. One of the two isolates also featured resistance to ciprofloxacin (reported by Sweden). The resistance patterns for the four MDR *E. coli* isolates from imported bovine meat also featured one or more of the substances: ampicillin, sulfamethoxazole, trimethoprim or tetracycline. One of the isolates was resistant to six antimicrobial classes, including third-generation cephalosporins and fluoroquinolones. No resistance to tigecycline or amikacin was recorded for either imported meat origin.

**4.3.7. Completely susceptibility**

**Completely susceptible isolates**

**Food-producing animals**

The occurrence of resistance can also be addressed by considering the proportion of indicator *E. coli* isolates exhibiting susceptibility to all the 15 antimicrobials tested in the harmonised panel, using ECOFFs for interpretation. Considering all reporting MSs, the median CS in *E. coli* isolates was 38.3% from pigs, 54.1% from calves, 19.4% from broilers and 18.2% from turkeys (Annex C). For all animal populations, CS varied widely between reporting countries and ranged between 6.5% and 85.8% in pigs, 36.4–95.0% in calves, 1.0–82.9% in broilers and 3.2–79.6% in turkeys (Annex C). Typically, the highest levels of CS in all four animal populations were observed in isolates from the Nordic countries, with levels generally decreasing in a north-to-south gradient and, to a lesser extent, in a west-to-east gradient.

**Imported fresh meat**

Considering the four countries that reported data, CS for imported pig meat was 45.0% (n = 13). For imported bovine meat, the median CS was observed to be 95.2%.

**Trends in complete susceptibility**

Trends in complete susceptibility in indicator *E. coli* from pigs, calves, broilers and turkeys were assessed²² for countries providing data for 3 or more years over the period 2014–2021 and also at the EU MS-group level. In pigs, statistically significant difference in CS at the MS-group level was not observed between 2015 and 2021 (Figures 36 and 37). In three countries (France, Germany and the Netherlands), the rate of completely susceptible isolates increased significantly, whereas it decreased in three countries Austria, Iceland and Slovakia. In calves, the level of complete susceptibility has also remained stable at the EU level, but an increase was observed in five countries (Belgium, France, Portugal, Spain and Switzerland) (Figures 36 and 37).

In broilers, complete susceptibility increased between 2014 and 2020 at the MS-group level (including the UK) as well as in 11 countries (Croatia, Estonia, France, Ireland, Italy, Latvia, the Netherlands, Portugal, Romania, Spain, the United Kingdom) and decreased in two countries (Belgium and Hungary) (Figures 36 and 38). In turkeys, the level of complete susceptibility has increased significantly at the MS-group level (including the UK) as well as in seven individual countries (France, Hungary, Italy, Portugal, Spain, Sweden and the United Kingdom) (Figures 36 and 38).

²² The statistical significance (p < 0.05) of trends was tested by logistic regression (see Appendix F – for details on methodology).
Figure 36: Spatial distribution of complete susceptibility to the antimicrobials tested in indicator E. coli. (a) fattening pigs (pigs) 2021; (b) bovines under 1 year of age (calves) 2021; (c) broilers 2020; (d) fattening turkeys (turkeys) 2020
(↓)/(↑): indicates statistically significant trends over the period 2015-2021.

**Figure 37:** Trends in the occurrence of complete susceptibility to the panel of antimicrobials tested in indicator *E. coli* from (a) fattening pigs (pigs) and (b) bovines under 1 year of age (calves) in the years, EU MSs and non-MSs, 2015–2021.
(↑) indicates statistically significant trends over the period 2014-2020.

**Figure 38:** Trends in the occurrence of complete susceptibility to the panel of antimicrobials tested in indicator *E. coli* from (a) broilers and (b) fattening turkeys (turkeys), EU MSs and non-MSs, 2014–2020.
4.3.8. Key Outcome Indicator of Complete Susceptibility (KOICS)

The occurrence of completely susceptible indicator *E. coli* isolates from the most important food-producing animals (broilers, fattening turkeys, fattening pigs, bovines under 1 year of age) in a country is used as a key outcome indicator (KOICS) for the overall AMR situation in food-producing animals. To account for differences in the relative size of food-producing animal populations in a country, the KOICS was calculated as the weighted mean of the proportions of completely susceptible indicator *E. coli* isolates in each of the four animal populations monitored. For the calculation of the KOICS, the occurrence of CS in each animal population was weighted in relation to the relative size of the populations within a country using the ‘population correction unit’ (PCU).

KOICS was calculated using data reported in two consecutive years. KOICS values were calculated from CS data on broilers and fattening turkeys reported in even-numbered years and data on fattening pigs (pigs) and bovines under 1 year of age (calves) reported in the immediately preceding/following odd-numbered years. CS data on broilers and pigs were included in the calculation for each country, while CS data on calves and turkeys were included in the calculation only in those countries reporting such data.

Marked variations in KOICS were observed among the 28 countries reporting consistently over the study period (Figure 39). In 2020–2021, levels of KOICS were <20% in 10 countries, 20–40% in 12 countries, 40–60% in four countries, 60–80% in one country (Sweden) and >80% in three countries (Finland, Iceland, Norway). The lowest KOICS were generally observed in countries in Eastern and Southern Europe and the highest in countries in Northern Europe. KOICS has been stable at a high level over the period in some countries and in others at a low level. Statistically significant increasing trends in KOICS were registered in 17 countries and decreasing trends in three countries.

---

23 PCU is a technical unit of measurement used as an indicator of animal population size and was developed by the EMA primarily to estimate sales of antimicrobials corrected by the animal population in individual countries. The data sources and methodology for the calculation of PCU are comprehensively described in EMA's report 'Sales of veterinary antimicrobial agents in 31 European countries in 2019-2020 (EMA, 2021).
4.4. Discussion

Studying AMR in commensal indicator *E. coli* from the caecal contents of healthy food-producing animals domestically produced provides information on the reservoirs of resistant bacteria that could potentially be transferred between animals and humans. Such monitoring is therefore relevant for both animal and public health. AMR exhibited by indicator *E. coli* is likely to depend on several factors, such as:

\[(↓)/(↑)\]: indicates statistically significant decreasing/increasing trends over the 2014–2021 period. Rates of change are given for statistically significant trends.

**Figure 39:** Changes in weighted key outcome indicator of complete susceptibility (KOICS) in 27 MSs and 4 non-MSs

4.4. Discussion

Studying AMR in commensal indicator *E. coli* from the caecal contents of healthy food-producing animals domestically produced provides information on the reservoirs of resistant bacteria that could potentially be transferred between animals and humans. Such monitoring is therefore relevant for both animal and public health. AMR exhibited by indicator *E. coli* is likely to depend on several factors, such as
as selective pressure from using antimicrobials in food-producing animals, co-selection of bacteria with multiple resistance, clonal spread of resistant bacteria and dissemination of genetic elements, such as plasmids, between bacteria.

**Representative monitoring**

The data on AMR in indicator *E. coli* used in the present report were collected over the years 2014–2021 in accordance with Commission Implementing Decision (EU) 2013/652 (up until December 2020) and the replacement legislation, Commission Implementing Decision (EU) 2020/1729 which came into force on 1 January 2021. The new legislation enlarged the scope of the monitoring, with the inclusion of imported fresh meat from third countries, the addition of a new substance (amikacin) to the harmonised testing panel and the option for MSs to perform WGS as an alternative to the phenotypic testing in presumptive ESBL-, AmpC- or CP-producing *E. coli*. The AMR data are harmonised with respect to representative sampling design, laboratory methodologies, reporting and interpretation of resistance. In addition, as AMR data on indicator *E. coli* from pigs (2021) and broilers (2020) were reported by nearly all MSs and those from calves (11 MSs in 2021) and turkeys (11 MSs in 2020) were submitted by those MSs which are the main producers of meat derived thereof in the EU, AMR data can be considered representative.

**General observations**

At the MS-group level, resistance to ampicillin, sulfamethoxazole, trimethoprim, and tetracycline was generally common in indicator *E. coli* and reported by most MSs at high or very high levels for all animal populations. Median levels of ampicillin resistance were very high in broilers and turkeys and high in pigs and calves. For sulfamethoxazole and trimethoprim, median levels were high in all four animal populations with the exception of calves, where the median level of trimethoprim resistance was moderate. In poultry, resistance to ciprofloxacin and nalidixic acid was also common, and several MSs reported very high or extremely high levels in both broilers and turkeys. In contrast, in pigs and calves, ciprofloxacin resistance was typically observed at moderate levels in most countries, with a few notable exceptions where resistance was high. In *E. coli* isolates from imported meat, very few isolates were observed to be resistant to any of the above-mentioned substances. The frequent occurrence of resistance of isolates from animal origins to these substances likely reflects the widespread past and present use of these antimicrobials in food-producing animals in a number of MSs. The observed differences between animal species likely reflect a diversity in the quantity of antimicrobials used in the different animal populations, but possibly also the mode of administration. In poultry, flock treatment is almost exclusively practised, whereas pigs and calves in some countries are typically treated individually.

Notable spatial differences were observed in the occurrence of resistance to most antimicrobials as well as in the occurrence of MDR, complete susceptibility and for the KOI<sub>CS</sub>. Regarding pigs and broilers, the situation was generally more favourable in Northern Europe compared with Southern and Eastern Europe. Data on turkeys in the main producing MSs indicate a similar spatial distribution as that for pigs and broilers. In calves, the picture was more complex, and although the most favourable situation was registered in the Nordic countries (Norway, Denmark, Sweden), countries in Southern (Portugal, Romania) and Central Europe (Switzerland) also reported favourable situations in comparison to neighbouring countries in these regions.

**Resistance to highest-priority critically important antimicrobials (hpCIA)**

Of the antimicrobials tested in the mandatory monitoring of indicator *E. coli* from caecal contents and imported fresh meat, ciprofloxacin (fluoroquinolones), cefotaxime and ceftazidime (third-generation cephalosporins), colistin (polymyxin E) and azithromycin (macrolides) are categorised by the WHO as hpCIA (WHO, 2019). Bacteria resistant to these antimicrobials in food-producing animals and derived meat is therefore of particular interest due to the risk of spread to humans along the food chain.

At the EU level, there were no major differences in occurrence of resistance to gentamicin, cefotaxime, ceftazidime, meropenem, tigecycline, azithromycin and colistin between the four animal populations monitored. Median levels were rare, very low, or low in all four categories, although individual countries reported considerably higher levels for some antimicrobials in some animal populations. Median levels of phenotypic resistance to third-generation cephalosporins (cefotaxime and ceftazidime) at the EU group level were overall low in calves, broilers, and turkeys and very low in pigs. The highest level of resistance reported to third-generation cephalosporins in each animal category was 5.5% in pigs, 4.1% in calves, 7.1% in broilers, and 7.4% in turkeys. In imported fresh meat, resistance to third-generation cephalosporins was not reported in pork and only 1 isolate in beef. These findings relate to *E. coli* which are isolated using non-selective culture methods. Within the
mandatory monitoring, samples of caecal contents and fresh meat are also cultured on selective media
to specifically detect the presence of *E. coli* resistant to third-generation cephalosporins. The results of
these analyses are presented in Chapter Error! Reference source not found.

Ciprofloxacin and nalidixic acid resistance in isolates from pigs and calves were recorded at low
median levels at the EU level. In contrast, median levels of ciprofloxacin and nalidixic acid resistance
were very high in broilers and high in turkeys. At the EU level, there were decreasing trends in
resistance to ciprofloxacin in *E. coli* isolates from broilers and turkeys. Notably, a substantial proportion
of isolates from all animal populations were resistant to ciprofloxacin but not to nalidixic acid, a
resistance pattern which generally indicates the presence of transmissible genes mediating quinolone
resistance. For isolates from imported fresh meat, one isolate from pig meat was observed to be
resistant to ciprofloxacin, and two isolates from bovine meat.

Combined microbiological resistance to both ciprofloxacin and third-generation cephalosporins was
observed in only 96 of the 13,244 *E. coli* isolates from animal origins tested in 2020 and 2021, with 40
of these isolates demonstrating clinical resistance to both substances. The levels of microbiological co-
resistance were slightly higher in broilers (1.0%) and turkeys (1.0%) than in pigs (0.4%) and calves
(0.6%). A single isolate from bovine meat was observed to have both microbiological and clinical
resistance to ciprofloxacin and third-generation cephalosporins.

Median levels of azithromycin resistance in all reporting countries were very low in calves and turkeys
and low in pigs and broilers. Most countries reported no azithromycin resistance or single isolates only,
but a few countries reported moderate levels, up to 9.1% for pigs, 9.4% for calves and 11.3% for
broilers, and high level for turkeys, 22.6%. A single isolate from imported bovine meat was resistant to
azithromycin. Azithromycin is an azalide antimicrobial, a subgroup of the macrolides, not used in
animals. Possibly, selection pressure exerted using other related macrolides, e.g., gamithromycin, in
food-producing animals may have favoured the emergence of azithromycin resistance.

Altogether only 142 of the 13,244 isolates tested in 2020 and 2021 showed phenotypic resistance
to colistin. Median levels of colistin resistance in the EU group were rare for pigs and broilers, very low
in calves and low in turkeys, although much higher levels were reported in individual countries. There
was no colistin resistance reported in *E. coli* isolates from imported meat origins.

Of the 13,244 indicator *E. coli* isolates from pigs, calves, broilers, and turkeys phenotypically tested
in 2020 and 2021, resistance to carbapenems (meropenem) was not detected. Similarly, meropenem
resistance was not detected in the limited number of *E. coli* isolates derived from imported pig and
bovine meats. Carbapenem resistance appears infrequent in commensal *E. coli* from these food-
producing animals in Europe. Still, further information on specific monitoring of carbapenem resistance
is found in Chapter 5.

**Complete susceptibility and multidrug resistance in all reporting countries**

Considering all reporting countries, median levels of *E. coli* isolates susceptible to all antimicrobial
classes tested were lower in broilers (24.4%) and turkeys (27.7%) than in pigs (41.8%) and calves
(62.8%). Conversely, MDR isolates were more common in broilers (median 37.7%) and turkeys
(median 47.6%) than in pigs (median 28.8%) and calves (median 18.8%). In all four animal
populations, there were marked differences in levels of CS, as well as in MDR between countries.
Generally, completely susceptible isolates from pigs, broilers, and turkeys were more common in
Northern than in Southern and Eastern Europe, whereas the converse situation was observed for MDR.
For calves, there was no obvious spatial pattern, and a favourable situation was reported in the Nordic
countries (Norway, Denmark, Sweden) as well as in countries in southern Europe (Portugal, Romania).
Tetracycline, ampicillin, sulfamethoxazole, and trimethoprim were the antimicrobials most often
represented in the patterns of MDR-isolates, often in combination with other substances. Many of the
MDR isolates from pigs and calves were resistant to all these antimicrobials, and they were also
common in MDR-isolates from broilers and turkeys. Additionally, quinolone resistance was common in
MDR-isolates from broilers (75.9%) and turkeys (73.8%) but less common in isolates from pigs (17%)
and calves (27.8%). The frequent occurrence of these substances as a core component of MDR
patterns in *E. coli* from poultry likely reflects an extensive usage in several countries over many years
and that the genes conferring resistance to these substances often are linked on mobile genetic
elements, resulting in co-selection.

**Key outcome indicator of complete susceptibility**

An abundant and ubiquitous commensal bacterial species, *E. coli*, has been selected as a reporting
organism because it is considered more relevant in representing the overall AMR situation, including
transmissible AMR genes, than less abundant zoonotic bacterial species. The assumption underlying the choice of KOICS as indicator, is that *E. coli* that is rarely, if ever, exposed to antimicrobials will tend to be fully susceptible (Martinez, 2014). As KOICS accounts for differences in the relative size of food animal populations in a country, it is relevant in the overall assessment of risks related to AMR in food-producing animals. Marked variations in KOICS were registered from < 20% in ten MSs to > 80% in three countries (Norway, Finland, Iceland). To fully appreciate the situation within a country, the evaluation of KOICS should be complemented with data on resistance and CS available at the level of each animal population monitored so that any positive or negative trends occurring in one animal population of small relative size may not go unnoticed. The KOICS can be used to assess the development of AMR in relation to the total use of antimicrobials in food-producing animals (Queenan et al., 2016; ECDC, EFSA, and EMA, 2017). Therefore, it is to be expected that a reduction in the use of antimicrobials in food-producing animals would result in a noticeable improvement in this indicator.

**Temporal trends in resistance**

Overall, in several countries, there appear to be statistically significant trends toward reduction of resistance in indicator *E. coli*, notably in broilers and turkeys. Considering data from pigs and calves in 2021 and countries evaluated, there were 53 decreasing and 23 increasing trends in resistance to ampicillin, ciprofloxacin, cefotaxime, and tetracycline in the period 2009–2021. For poultry data in 2020, there were 89 decreasing and 24 increasing trends in resistance to the same four substances in the period 2009–2021. An improved situation was most pronounced in poultry, and in the EU group, there were significant decreases in resistance to ampicillin, ciprofloxacin, cefotaxime, tetracycline and colistin in both broilers and turkeys. For several antimicrobials, there are statistically significant associations between the use of antimicrobials in food-producing animals and the occurrence of resistance in indicator *E. coli* from these animals (ECDC, EFSA, and EMA, 2021). The positive trends in several countries are, therefore, possibly due to the overall decline in sales of antimicrobials for use in animals since 2011, as documented in the ESVAC report (EMA, 2021).

For trends related to colistin resistance, there were four decreasing and no increasing trends between 2014 and 2021 for pigs and calves. While there were three decreasing and two increasing trends for broilers and no trends for turkeys for 2014–2020. As documented in the recent JIACRA III report (ECDC, EFSA, and EMA, 2021), there is a statistically significant association between consumption of polymyxins (colistin) in food-producing animals and occurrence of colistin resistance in intestinal *E. coli* from these animals. The high occurrence of resistance in some animal populations in individual countries indicates large differences in the usage of colistin in Europe, which also was documented in the ESVAC report (EMA, 2021). However, at the EU group level, there were statistically significant decreasing trends in colistin resistance in isolates from broilers and calves. The decrease in resistance for broilers and calves is in accord with the 69.8% decrease in sales of polymyxins for food-producing animals in the EU in the period 2011–2018, as reported in the ESVAC report (EMA, 2021). This shows that measures taken in individual countries to reduce the use of colistin, and thereby occurrence of resistance, are effective.

For levels of CS and considering all animal populations and countries evaluated, there were altogether 27 increasing and five decreasing trends in the period 2014–2021. As for resistance to individual antimicrobials, the improved situation was most pronounced in poultry and in the EU-group there were increasing trends in CS for broilers, turkeys and pigs but no change for calves. There were significant increases in KOICS in 17 of the 28 reporting countries and trends towards decreasing values in four countries.

Statistically significant decreasing trends in resistance to ampicillin, ciprofloxacin, cefotaxime, tetracycline and colistin, as well as statistically significant trends towards higher levels of complete susceptibility and KOICS reveal progress towards reduced resistance in several countries and in the EU MS-group as a whole. It should, however, be noted that in some countries, levels of resistance to individual antimicrobials are consistently stable at low levels, as well as CS and KOICS are at high levels, and major changes cannot be expected.
5. Extended-spectrum \(\beta\)-lactamase (ESBL)-, AmpC- and/or carbapenemase (CP)-producing Salmonella and Escherichia coli

All ESBL-, AmpC- or CP-producers prevalence and occurrence tables from the 2020 and 2021 monitoring, as well as the tables on occurrence of resistance (panel 1 and panel 2) mentioned in this chapter can be found in Annex D and the Salmonella spp., E. coli or ESBL Microsoft Excel® documents available on Zenodo at: https://doi.org/10.5281/zenodo.7544221. Materials and methods are included in the Appendix F.

5.1. Key findings

- The occurrence of presumptive ESBL, AmpC or ESBL + AmpC-producing Salmonella spp. was generally low in 2020.
- Starting in 2021, MSs could use whole genome sequencing (WGS) as an alternative method to broth microdilution when carrying out the specific monitoring of ESBL-/AmpC-/CP-producing E. coli and for the second panel of harmonised antimicrobials when further testing E. coli and Salmonella isolates showing resistance to cefotaxime or ceftazidime or meropenem. Four MSs opted to use this method: Italy, Germany, Finland and Czechia. Finland and Italy reported both phenotypic and genotypic results selecting the WGS results to be used in the analysis. Italy reported WGS data for the routine monitoring of Salmonella spp., E. coli and the specific monitoring of E. coli. Germany reported data for the routine and specific monitoring of ESBL-/AmpC-/CP-producing E. coli, and Finland and Czechia also reported data for this specific monitoring.
- In 2021, three E. coli isolates with the carbapenemase phenotype were detected in the specific monitoring of ESBL-/AmpC-/CP-producing E. coli. Two isolates from bovine meat and one isolate from pig were detected by Hungary. Those isolates were confirmed as CP-producers harbouring the \(\text{bla}_{\text{NDM-5}}\) gene, responsible for the carbapenemase phenotype, by the EURL-AR during the confirmatory testing exercise.
- Furthermore, within the specific monitoring of CP-producing microorganisms using selective media for CP-producers, three isolates from bovine meat and one isolate from pig meat were reported by Hungary (presence of CP-encoding genes pending of confirmation). Additionally, two isolates from fattening pigs were detected in Spain carrying the \(\text{bla}_{\text{OXA-48}}\) gene.
- WGS revealed additional 26 E. coli isolates from Italy (21 from pigs and five from bovine animals under 1 year of age) and three isolates from Czechia (all from fattening pigs) carrying CP-encoding genes under the carbapenemase monitoring. These included \(\text{bla}_{\text{OXA-181}}\) (4 isolates from calves and 20 from fattening pigs), \(\text{bla}_{\text{OXA-48}}\) (one isolate from a fattening pig) and \(\text{bla}_{\text{NDM-5}}\) (one isolate from a bovine animal) detected in the Italian isolates, and \(\text{bla}_{\text{NDM-5}}\) (three isolates from fattening pigs) reported by Czechia.
- WGS also revealed the presence of three different AmpC-genes in E. coli isolates from the four MSs. These included: \(\text{bla}_{\text{CMY-113}}\) detected in one isolate from a fattening pig in Italy. \(\text{bla}_{\text{DHA-1}}\) detected in one, three and three isolates in a bovine animal, fattening pigs and pig meat, respectively, from Italy. \(\text{bla}_{\text{CMY-2}}\) identified in pigs (24 isolates from Italy, 9 from Czechia two from Germany and 1 from Finland), in calves (seven isolates from Italy and one isolate from Germany), in bovine meat (seven isolates from Italy and three from Czechia) and pig meat (three isolates from Czechia and four from Italy).
- A variety of ESBL-encoding genes were identified in the four MSs reporting WGS. The most frequently reported gene in the majority of animal populations and meat categories was \(\text{bla}_{\text{CTX-M-1}}\), identified in 250 isolates from fattening pigs, 202 isolates from bovine animals under 1 year of age, 21 isolates from bovine meat and 33 isolates from pig meat. Followed by \(\text{bla}_{\text{CTX-M-15}}\) identified in 193 isolates from calves, 81 from fattening pigs, 8 from bovine meat and 6 from pig meat.
- The prevalence of ESBL/AmpC-producing E. coli in food-producing animals is still high compared to previous years for some countries. Statistically significant decreasing trends are, however, observed in many countries for several animal categories, as well as at the level of the reporting MS-group (plus the United Kingdom) for broilers and turkeys.
- Statistically significant decreasing trends in the key outcome indicator of ESBL- and/or AmpC-producing E. coli (KOIESC) were observed in 17 MSs and two reporting countries. In nine MSs
and two reporting countries, a statistically significant increasing trend is registered, and in the remaining countries, no statistically significant trend is seen.

5.2. Data on ESBL-, AmpC- and/or CP-producing Salmonella and Escherichia coli addressed

The occurrence of ESBL-, AmpC- or CP-producing bacteria in the intestinal flora of animals is undesirable, as it might lead to the dissemination of resistant bacteria from animals and food to humans. Bacteria from animals with such resistance should also be considered as a reservoir of resistance genes which may be transferable to other bacteria including food-borne zoonoses, such as Salmonella spp., further adding to the potential public health consequences. No statistically significant associations between resistance to third-generation cephalosporins among indicator E. coli from animals and invasive E. coli from humans were observed in the latest JIACRA report (ECDC, EFSA, EMA, 2021). Nevertheless, the epidemiology of ESBL-, AmpC- and CP-producing E. coli is complex. Through continued improvement of monitoring system to study their prevalence in healthy animals and food derived thereof a fuller epidemiological picture can emerge.

Routine monitoring of ESBL-/AmpC-/CP-producing indicator E. coli and Salmonella spp. and the specific monitoring of ESBL-/AmpC-/CP-producing E. coli in caecal samples of animals and their meat products is mandatory. Monitoring in fattening pigs and bovine animals under 1 year of age, as well as pig meat and bovine meat gathered at retail was mandatory in 2021, whereas monitoring in caecal samples of broilers, fattening turkeys and fresh broiler meat sampled at retail was mandatory in 2020. From 2021, MSs were also able to submit fresh meat samples from pigs and bovine animals that were recovered at border control posts. In 2021, the specific monitoring was carried out by 11 MSs and two non-MSs for bovine animals under 1 year, by 26 MSs, the United Kingdom (Northern Ireland) and three non-MSs for fattening pigs, 23 MSs and one non-MSs for meat from pigs, and by 26 MSs and one non-MSs for meat from bovine animals under 1 year. In 2020, the monitoring was performed by 27 MSs and four non-MSs for broilers and broiler meat, and 11 MSs and 2 non-MSs for fattening turkeys.

Until 2020, isolates were categorised as presumptive ESBL-, AmpC- or CP-producers based predominantly on the phenotype exhibited by the isolates. Phenotypic categorisation is performed in accordance with the criteria described in the Materials and Methods, Appendix F. Most, but not all, isolates resistant to extended spectrum cephalosporins (ESC) were therefore classified into these categories. However, not all classified isolates, in particular those exhibiting an AmpC phenotype, necessarily carry any transferable genes. From 2021, whole genome sequencing (WGS) was authorised as an alternative method to the phenotypic testing for E. coli and Salmonella isolates that show resistance to extended spectrum cephalosporins and carbapenems in the first panel of antimicrobials or for the specific monitoring of ESBL-/AmpC-/CP-producing E. coli. Countries who identify ESBL-, AmpC- or CP-producers based on genotypic results using WGS no longer need to report the phenotypic results. In 2021, Czechia, Germany, Italy and Finland reported WGS results and selected those results for the analysis for the specific monitoring of E. coli. Genotypic results for samples isolated from bovine meat (Czechia, Germany and Italy), bovines (Germany and Italy), meat from pigs (Czechia, Germany and Italy) and pigs (Czechia, Germany, Finland and Italy). The reporting of WGS data will facilitate an understanding of the potential contribution of food-producing animals and food derived thereof to the burden of AMR in humans (EFSA, 2019).

5.3. Food-producing animals and derived meat: routine antimicrobial resistance monitoring. Presumptive ESBL/AmpC/CP producers and related WGS data

In 2020 and 2021, third-generation cephalosporin resistance was identified in Salmonella spp. from broilers, fattening turkeys and laying hens, pigs and bovine animals under 1 year of age, and from carcases (meat) of broilers, as well as in indicator E. coli isolates from broiler meat, broilers, turkey meat, fattening turkeys, pig meat, fattening pigs and bovine meat and animals under 1 year of age, within the framework of the routine monitoring. Some samples collected from fattening pigs, bovines...

24 All Salmonella and indicator E. coli isolates tested with the harmonised panel of antimicrobial substances (Panel 1) and exhibiting microbiological resistance to cefotaxime, ceftazidime or meropenem were subsequently subjected to further testing using a supplementary panel of substances (Panel 2) to obtain more detailed phenotypic characterisation (see Appendix F, materials and methods).
under 1 year of age and their derived meat products in 2021 were subjected to whole genome sequencing according to the updated legislation.

ESC resistance and ESBL/AmpC/CP phenotypes and genotypes in *Salmonella* spp.

The proportion of ESC-resistant *Salmonella* spp. isolates (tested with panel 2) collected within the routine monitoring was generally very low or low in 2020 and 2021 (ranging between 0.2% and 2.1% of the investigated isolates, depending on the animal population, see Annex C2 and C3). The occurrence of ESC-resistant *Salmonella* isolates in a specific animal population can be greatly affected by the situation in certain countries regarding the prevalence of different *Salmonella* serovars. As an example, considering all reported isolates, about two-thirds of the ESC-R *Salmonella* isolates from broilers derived from one single MS in 2020 (see chapter 2, *Salmonella* for further details). At the reporting MS-group level, the occurrence of presumptive ESBL- and/or AmpC-producing *Salmonella* spp. was 2.1% in broilers, 0.4% in turkeys, 0.4% in laying hens, 0.8% in fattening pigs and 1.3% in bovine animals under 1 year of age. Detailed data per country and matrix can be found in Annex D2 and D3.

Italy was the only country to report WGS results in *Salmonella* spp. isolates in 2021. One monophasic *S.* Typhimurium from fattening pigs harbouring the *bla*SHV-12 gene and one *S.* Ngor isolate from bovine animals under 1 year of age presenting the *bla*CTX-M-3 were reported.

ESC resistance and ESBL/AmpC/CP phenotypes and genotypes in indicator *E. coli*

The proportion of ESC-resistant indicator *E. coli* isolates (tested with panel 2) collected within the routine monitoring was generally low in 2020 and 2021 (ranging between 0.5% and 1.5% of the investigated isolates, depending on the animal population). Among the reporting MSs, the occurrence of ESC resistance varied from 0% to 5.9% in fattening pigs, from 0% to 4.1% in bovines under 1 year of age, from 0% to 7.1% in broilers and from 0% to 6.4% in fattening turkeys (see chapter 4, *E. coli*, for further details). When only considering the isolates of indicator *E. coli* with ESBL/AmpC-production, similar variations in occurrences are observed. At the MS-group level, the occurrence of presumptive ESBL, AmpC or ESBL + AmpC-producers in indicator *E. coli* was 1.1% in broilers, 1.6% in turkeys, 0.9% in fattening pigs and 0.7% in bovine animals under 1 year of age. For all matrices, the ESBL phenotype was more frequent than the AmpC phenotype. Detailed data per matrix and country can be found in Annex D2 and D3.

Only, two MSs, Italy and Germany, reported ESBL genes identified in the routine monitoring of indicator *E. coli* from fattening pigs and bovine animals under 1 year of age. Germany reported *bla*CTX-M-1 (n = 3), *bla*CTX-M-32 (n = 1) and *bla*SHV-12 (n = 1), in isolates from calves, while Italy reported *bla*SHV-12 in an isolate from a pig and *bla*CTX-M in seven isolates from bovine animals under 1 year of age.

5.4. Food-producing animals and derived meat: specific monitoring of presumptive ESBL/AmpC-producing *E. coli* and related WGS data

5.4.1. Prevalence and occurrence of presumptive ESBL/AmpC/CP producers

The specific monitoring25 of ESBL/AmpC/CP-producers employs culture of samples on selective media (containing cefotaxime at 1 mg/L, as recommended by EUCAST), which can detect very low numbers of resistant isolates present within a sample. The prevalence of presumptive ESBL or AmpC-producing and genotypic results for *E. coli* for all matrices tested in 2020 and 2021 is shown in Figure 41. Detailed prevalence and occurrence data per country and matrix can be found in Annex D2 and D3.

Regarding food-producing animals, marked variations in the prevalence of presumptive *E. coli* ESBL and/or AmpC-producers26 were observed between the MSs for the period 2020–2021, when considering MIC results, as it ranged from 8.3% (Sweden) to 77.1% (Spain) in fattening pigs, from 5.8% (Denmark) to 59.1% (Belgium) in bovine animals under 1 year of age, from 0.3% (Finland) to 96.6% (Slovakia) in broilers and from 0% (Sweden) to 70.4% (Spain) in fattening turkeys (Annex D2 and D3). Important differences among the reporting countries were also evident when assessing the prevalence of ESBL or AmpC producers separately (Annex D2 and D3). The prevalence of ESBL and/or

---

25 The method is described in Appendix F and protocols are available at: https://www.eurl-ar.eu/protocols.aspx.

26 *E. coli* isolates exhibiting an ESBL-, AmpC- or ESBL+AmpC-producing phenotype.
AmpC producers based on genotypic data also varied in the MSs that selected WGS instead of phenotypic results for the analysis in 2021. These results ranged from 64.2% (Germany) to 90.3% (Italy) in calves, and between 6.5% (Finland) and 80.7% (Italy) in fattening pigs.

Regarding meat, the prevalence of presumptive *E. coli* ESBL and/or AmpC-producers in meat varied markedly between the MSs, ranging from 0.3% (Finland) to 96.7% (Malta) in broiler meat, from 0% (Cyprus, Finland and Sweden) to 90.5% (Malta) for pig meat and from 0% (Finland) to 30.7% (Hungary) for bovine meat at retail (Annex D2 and D3). The differences among reporting countries were also evident when the prevalence of ESBL or AmpC producers was considered separately (Annex D2 and D3). The prevalence of ESBL and/or AmpC producers based on genotypic data did not vary greatly in the MSs that performed WGS instead of phenotypic testing in 2021. These results ranged from 2.2% (Germany) to 7.4% (Czechia) in bovine meat, and 4.9% (Germany) to 8.2% (Czechia) in pig meat (Annex D3).

### WGS-based ESBL, AmpC and/or CP results

Four MSs provided WGS data on ESBL and AmpC genes identified in the specific monitoring of ESBL/AmpC/CP-producing *E. coli* isolates. WGS results were reported for isolates from fattening pigs (243 isolates in Italy, 164 by Germany, 152 by Czechia and 20 by Finland), bovines under 1 year of age (280 isolates by Italy and 193 by Germany), bovine meat (13 isolates by Italy, 10 by Germany and 22 by Czechia) and pig meat (23 isolates by Italy, 23 by Germany and 24 by Czechia) in 2021. The majority of the genes identified encoded for ESBLs, followed by AmpC genes. This is in line with the phenotypic findings, where the number of presumptive ESBL-producing isolates largely outnumbered the AmpC-producing *E. coli* isolates in all animal and food groups. Generally, ESBL genes were more commonly identified in samples from animals compared to samples from meat. A summary of CP-producers that were identified in 2020 and 2021 is available in Section 5.5.

ESBL genes were reported by four MSs (Czechia, Germany, Finland and Italy) (Table H.1, Appendix H; Figure 40). The most frequently reported gene in the majority of animal populations and meat categories was *bla*<sub>CTX-M-1</sub>. This gene was reported in 92 pig isolates from Italy (37.9%, N = 243), 94 pig isolates from Germany (57.3%, N = 164), and 64 pig isolates from Czechia (42.1%, N = 152). This gene was also identified in 99 calf isolates from Italy (35.4%, N = 280) and 103 calf isolates from Germany (35.2%, N = 193). The second most commonly identified gene was *bla*<sub>CTX-M-15</sub>, which was detected in 133 bovine isolates from Italy (47.5%, N = 280) and 60 bovine isolates from Germany (31.1%, N = 193) as well as in 36 pig isolates from Italy (14.8%, N = 243), 25 pig isolates from Germany (15.2%, N = 164), 18 pig isolates from Czechia (31.6, N = 152) and 2 pig isolates from Finland (10%, N = 20).

AmpC genes and point mutations in the AmpC promoter region were also reported by the four MSs (Czechia, Germany, Finland and Italy) (Table H2, Appendix H; Figure 40). The most common AmpC gene identified across all MSs was *bla*<sub>CMY-2</sub>. This gene was mainly detected in pigs, specifically, in 24 isolates from Italy, nine isolates from Czechia, two isolates from Germany and one isolate from Finland. However, the point mutations in the AmpC promoter were the mechanism most frequently detected in all MSs reporting WGS, except for Italy where this mechanism was not reported. In particular, the C-42T mutation that is responsible for the AmpC phenotype was frequently detected in Czechia (in 46 isolates from pigs, three isolates from pig meat and two isolates from bovine meat), in Germany (22 isolates from pigs, three isolates from pig meat and one isolate from calves), in Hungary (16 isolates from pigs) and in Finland (10 counties had the C-42T mutation and one had the T-32A mutation).
ESBL: extended-spectrum β-lactamase; AmpC: AmpC β-lactamase; N: Total number of isolates harbouring an ESBL or AmpC gene.

The breakdown of AmpC genes does not include point mutations in the AmpC promoter, only the genes listed in the legend.

These figures incorporate data from countries that supplied WGS results to be used for analysis instead of MIC values. This excludes countries that provided MIC results as well as WGS results voluntarily.

**Figure 40:** *E. coli* isolates harbouring (a) ESBL-encoding genes and (b) AmpC-encoding genes in fattening pigs, bovine animals < 1 year of age, meat from pigs and meat from bovines in 2021
5.4.2. Relative abundance (occurrence) of presumptive ESBL/AmpC producers

As only one isolate per sample is further investigated, the relative abundance of *E. coli* with an ESBL or AmpC phenotype when both are present in the sample influences the probability of detecting either phenotype. In the animal populations/food matrices monitored, at the reporting MS-group level and in most of the countries, the detection of presumptive ESBL-producing *E. coli* exceeded that of presumptive AmpC-producing *E. coli* (Figures 41–46; Annex D). Nevertheless, the occurrence of the different phenotypes varied considerably among the reporting MSs for certain matrices. After excluding the MSs with less than 10 presumptive isolates tested, the occurrence of the ESBL phenotype ranged from 12% (Sweden) to 100% (Bulgaria and Malta) in fattening pigs; from 29.4% (Sweden) to 89.6% (Belgium) in broilers; 16.7% (Denmark) to 97.6% (Croatia) in bovines under 1 year of age; and from 27.6% (Sweden) to 93.3% (Malta) in meat from broilers (Annex D2 and D3). For the other matrices, the difference in occurrence of the ESBL phenotype was less pronounced and ranged between 66.7% (Hungary) and 91.7% (Spain) in fattening turkeys; between 61.9% (Slovenia) and 92.6% (Austria) in meat from pigs and between 53.3% (Denmark) and 100% (Belgium and Romania) in meat from bovine animals. Bovine animals under 1 year of age and fattening turkeys are, however, only investigated by some MSs, as it is not mandatory for those with small production. Furthermore, the overall occurrence of presumptive ESBL/AmpC producers in samples of meat from pigs and meat from bovines, as well as in pigs and bovines, is low.

---

27 *E. coli* isolates exhibiting an ESBL+AmpC-producing phenotype.
N: number of samples tested; Diamond with white outline is the data (one data point per country); Diamond with black outline is Total EU. Outliers (> 1.5 IQR from 75th percentile) are spotted using a different symbol for each matrix (for example square for Pig meat 2021)

**Figure 41:** Prevalence of presumptive ESBL-producing (a) and AmpC-producing (b) *E. coli* from the specific monitoring of ESBL/AmpC-producing *E. coli*, 2020/2021
**Figure 42:** Spatial distribution of the prevalence of presumptive ESBL and/or AmpC-producing *E. coli* from (a) meat from broilers in 2020, (b) meat from pigs in 2021 and (c) meat from bovines in 2021, EU MSs and non-MSs, 2020/2021
Figure 43: Spatial distribution of the prevalence of presumptive ESBL and/or AmpC-producing E. coli from (a) broilers in 2020, (b) fattening turkeys in 2020, (c) fattening pigs in 2021 and (d) bovines under 1 year of age in 2021, EU MSs and non-MSs, 2020/2021.
The upper bounds of the 95% confidence interval of the prevalence of ESBL- and/or AmpC-producing *E. coli* are also indicated.

**Figure 44**: Prevalence of presumptive ESBL-producing versus AmpC-producing *E. coli* from (a) meat from broilers, (b) broilers and (c) fattening turkeys, EU MSs and non-EU MSs, 2020
(a) Prevalence of presumptive ESBL- and AmpC-producing *E. coli* in pigs meat, specific monitoring, 2021.
Prevalence was assessed using genotypic data reported by Czechia, Finland, Germany and Italy. The upper bounds of the 95% confidence interval of the prevalence of ESBL- and/or AmpC-producing *E. coli* are also indicated. Please note the different scales used for the x-axis in the subfigures to improve the visibility of the variations among countries.

**Figure 45:** Prevalence of presumptive ESBL-producing versus AmpC-producing *E. coli* from (a) meat from pigs and (b) fattening pigs, EU MSs and non-EU MSs, 2021
Prevalence was assessed using genotypic data reported by Czechia, Finland, Germany and Italy. The upper bounds of the 95% confidence interval of the prevalence of ESBL- and/or AmpC-producing E. coli are also indicated. Please note the different scales used for the x-axis in the subfigures to improve the visibility of the variations among countries.

**Figure 46:** Prevalence of presumptive ESBL-producing versus AmpC-producing *E. coli* from (a) bovine meat and (b) bovines under 1 year of age, EU MSs and non-EU MSs, 2021
5.4.3. Temporal trends in prevalence of presumptive ESBL/AmpC/CP producers

The temporal trend in the prevalence of presumptive ESBL-producing *E. coli* in each separate animal population and meat category since the start of the harmonised mandatory monitoring is presented at both reporting country and MS-group levels in Figures 47 and 48.

The prevalence of presumptive ESBL-producing *E. coli* at the MS-group level in broilers and meat from broilers has gradually decreased to reach 38.0% in broilers and 30.6% in meat from broilers in 2020. Likewise, the prevalence in fattening turkeys has decreased from over 40% in 2016 to 30.7% in 2020. These decreasing trends are statistically significant and generally paralleled with statistically significant decreases observed in most reporting countries.

The prevalence of presumptive ESBL-producing *E. coli* at the MS-group level assessed in meat from pigs (7.9%) and meat from bovine animals (6.2%) in 2021 is comparable with that assessed in the same meat categories in the previous years. Statistically significant increases have been seen in 2021 for pig meat (Denmark, Estonia, Latvia, Slovakia and Slovenia) and bovine meat (Estonia, Hungary, Latvia and Slovakia).

Likewise, the prevalence of presumptive ESBL-producing *E. coli* assessed in fattening pigs and bovine animals under 1 year of age in 2021 is comparable with that assessed in the previous years. Statistically significant decreasing trends are demonstrated for fattening pigs in seven reporting countries. For bovine animals under 1 year of age, statistically significant decreasing trends were identified in four reporting countries, namely France, Portugal, Spain and Switzerland.

A decreasing trend in prevalence is observed in many of the reporting countries, and certain MSs report a considerable improvement over the study period. This, however, is not uniform and some MSs have reported consistently high or very high prevalence over the study period. Detailed data on the prevalence assessed by country, animal population and meat category for 2020 and 2021 monitoring are presented in Figures 47 and 48, as well as in Annex D. For the 2015–2018 period, complementary data can be found in previous published reports.
Prevalence of presumptive ESBL- and/or AmpC-producing E. coli in broiler meat, specific monitoring, 2016 and 2020

- Austria (\(\leq 70\%\))
- Belgium (\(\leq 49\%\))
- Bulgaria (\(\leq 33\%\))
- Croatia (\(\leq 51\%\))
- Cyprus (\(\leq 61\%\))
- Czechia (\(\leq 47\%\))
- Denmark (\(\leq 84\%\))
- Estonia (\(\leq 61\%\))
- Finland (\(\leq 99\%\))
- France (\(\leq 83\%\))
- Germany (\(\leq 41\%\))
- Greece
- Hungary (\(\leq 40\%\))
- Ireland (\(\leq 74\%\))
- Italy (\(\leq 44\%\))
- Latvia (\(\leq 49\%\))
- Lithuania
- Luxembourg
- Netherlands (\(\leq 79\%\))
- Poland (\(\leq 66\%\))
- Portugal
- Romania (\(\leq 41\%\))
- Slovakia (\(\leq 28\%\))
- Slovenia (\(\leq 41\%\))
- Spain (\(\leq 33\%\))
- Sweden (\(\leq 79\%\))
- Total (MSs+UK) (\(\leq 51\%\))
- Iceland
- Norway (\(\leq 92\%\))
- Switzerland (\(\leq 38\%\))
- United Kingdom (\(\leq 76\%\))
Prevalence of presumptive ESBL producing *E. coli* in meat from pigs, specific monitoring 2015-2021

*Prevalence (%)*

- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- EU

- Norway
- Switzerland

Genotypic data was added to phenotypic data for Germany, Italy and Czechia.
Prevalence was assessed using genotypic data reported by Czechia, Germany and Italy in 2021. The upper bounds of the 95% confidence interval of the prevalence of ESBL- and/or AmpC-producing E. coli are also indicated. Prevalence was assessed using genotypic data reported by Czechia, Germany and Italy in 2021.

**Figure 47:** Trends on the prevalence of presumptive ESBL and/or AmpC-producing E. coli in (a) meat from broilers, (b) meat from pigs and (c) bovine meat over the period 2015-2021, EU MSs and non-MSs
Prevalence of presumptive ESBL- and/or AmpC-producing *E. coli* in broilers, specific monitoring, 2016-2020
Prevalence of presumptive ESBL- and/or AmpC-producing E. coli in fattening turkeys, specific monitoring, 2016-2020

- Austria (~44%)
- Belgium
- France (~80%)
- Germany (~20%)
- Hungary (~40%)
- Italy (~48%)
- Poland (~45%)
- Portugal
- Romania
- Spain (~19%)
- Sweden
- Total (10 MSs+UK) (~29%)

Austria:
- 2016: ~44%
- 2017: ~32%
- 2018: ~40%
- 2019: ~42%
- 2020: ~44%

Belgium:
- 2016: ~48%
- 2017: ~45%
- 2018: ~48%
- 2019: ~50%
- 2020: ~48%

France:
- 2016: ~80%
- 2017: ~78%
- 2018: ~80%
- 2019: ~82%
- 2020: ~80%

Germany:
- 2016: ~20%
- 2017: ~18%
- 2018: ~22%
- 2019: ~20%
- 2020: ~22%

Hungary:
- 2016: ~40%
- 2017: ~38%
- 2018: ~42%
- 2019: ~40%
- 2020: ~40%

Italy:
- 2016: ~48%
- 2017: ~45%
- 2018: ~50%
- 2019: ~48%
- 2020: ~48%

Poland:
- 2016: ~45%
- 2017: ~43%
- 2018: ~48%
- 2019: ~45%
- 2020: ~45%

Portugal:
- 2016: ~20%
- 2017: ~18%
- 2018: ~22%
- 2019: ~20%
- 2020: ~22%

Romania:
- 2016: ~30%
- 2017: ~28%
- 2018: ~32%
- 2019: ~30%
- 2020: ~30%

Spain:
- 2016: ~19%
- 2017: ~17%
- 2018: ~20%
- 2019: ~19%
- 2020: ~19%

Sweden:
- 2016: ~10%
- 2017: ~8%
- 2018: ~12%
- 2019: ~10%
- 2020: ~10%

Total (10 MSs+UK):
- 2016: ~29%
- 2017: ~26%
- 2018: ~28%
- 2019: ~28%
- 2020: ~28%
Prevalence of presumptive ESBL- and/or AmpC-producing E. coli in pigs, specific monitoring, 2015-2021

- Austria: ±26%
- Belgium: ±32%
- Bulgaria: ±47%
- Croatia: ±96%
- Cyprus
- Czechia: ±63%
- Denmark
- Estonia
- Finland: ±124%
- France: ±72%
- Germany
- Greece
- Hungary
- Ireland
- Latvia
- Lithuania
- Luxembourg: ±28%
- Netherlands: ±50%
- Poland
- Portugal: ±28%
- Romania: ±25%
- Slovakia: ±32%
- Slovenia: ±98%
- Spain: ±11%
- Sweden
- Total (26 MSs)
- Iceland
- Norway
- Switzerland: ±74%
5.4.4. Key outcome indicator of prevalence of ESBL and/or AmpC producers

The proportion of samples from broilers, fattening turkeys, fattening pigs and bovines under 1 year, weighted by PCU, that are identified as positive for presumptive ESBL and/or AmpC-producing E. coli in the framework of the specific monitoring for ESBL-/AmpC-/CP-producing E. coli according to Commission Implementing Decision 2020/1729/EU has been retained as a summary indicator.

One of the most medically relevant forms of AMR is mediated by plasmid-encoded ESBL genes (EFSA BIOHAZ, 2011; Maslikowska et al., 2016). In contrast, the AmpC β-lactamases in E. coli can be due to both upregulation and thus overexpression of chromosomally encoded existing ampC genes or to enzyme production by plasmid-encoded transferable genes. There are many different enzymes that can destroy the β-lactam ring (Pimenta et al., 2014), with a corresponding variety of genes and plasmids (Chong et al., 2011). The observation that ESBL-carrying isolates from humans are often more related to chicken isolates than are susceptible isolates indicates that a proportion of ESBL and/or AmpC-encoding isolates from agricultural settings may be of importance in human health-care situations (Törneke et al., 2015). Plasmids carrying ESBL encoding genes can be transferred rapidly between E. coli strains (Händel et al., 2015) and selection can be driven by the use of many β-lactam antimicrobials (Cavaco et al., 2008).

To account for differences in the relative size of food animal populations in a country, a weighted key outcome indicator of the prevalence of ESBL- and/or AmpC-producing E. coli in calves < 1 yr. specific monitoring, 2015-2021 was calculated. The indicator is the weighted mean of the prevalence of ESBL- and/or AmpC-producing E. coli in each of the four animal populations monitored. For the calculation of the mean, the value for each population was weighted in relation to the relative size of the populations within a country using the ‘population correction unit’ (PCU). PCU is a technical unit of measurement used as an indicator of animal population size and was developed by the EMA, primarily to estimate sales of antimicrobials corrected by the animal population in individual countries. The data sources and methodology for the calculation of PCU are comprehensively described in EMA's report "Sales..."
of veterinary antimicrobial agents in 31 European countries in 2019 and 2020’ (EMA, 2021). For each country, KOI\textsubscript{ESC} was calculated using data reported for two consecutive years. Thus, values for 2014–2015 were calculated from data for broilers and fattening turkeys reported in 2014 and on data for fattening pigs and bovines under 1 year of age reported in 2015. Likewise, values for 2015–2016 were calculated from data reported for fattening pigs and bovines under 1 year of age in 2015 and on data for broilers and fattening turkeys reported in 2016, and so on.

A positive development manifested by a decreasing trend in the KOI\textsubscript{ESC} is seen in 18 countries (17 MSs and 1 non-MS). Still, in some of these countries, decreases are observed starting from very high or extremely high levels. For seven MSs, the trends in KOI\textsubscript{ESC} are not statistically significant in any direction, over the period of study. Still, two MSs show a statistically significant increasing trend in their KOI\textsubscript{ESC} which is at a very high level in 2021 (Figure 49).
5.4.5. Discussion

As the classification of the isolates as being presumptive ESBL-, AmpC- or ESBL + AmpC-producers is based on the phenotype observed, not all classified isolates (in particular those exhibiting an AmpC phenotype), necessarily carry any transferable genes. Molecular investigations would be needed to show whether the isolates carry any transferable genes encoding resistance to ESC. From 2021, WGS

(↑)/(↓): indicates statistically significant decreasing/increasing trends over the 2014–2021 period. Rates of change are shown for the statistically significant decreasing/increasing trends observed.

**Figure 49:** Changes in outcome indicator of ESBL- and/or AmpC producing *E. coli* (OI_{ESC}), 27 EU MSs and 4 non-MSs, 2014–2021

5.4.5. Discussion

As the classification of the isolates as being presumptive ESBL-, AmpC- or ESBL + AmpC-producers is based on the phenotype observed, not all classified isolates (in particular those exhibiting an AmpC phenotype), necessarily carry any transferable genes. Molecular investigations would be needed to show whether the isolates carry any transferable genes encoding resistance to ESC. From 2021, WGS
has been authorised as an alternative method to phenotypic testing, only four MSs reported and selected the molecular results for ESBL-, AmpC- and CP-producers to be used in the analysis. Italy, Germany, Czechia and Finland performed WGS on *E. coli* and *Salmonella* isolates from fattening pigs, bovines under 1 year old, as well as from bovine and pig meat. Italy and Finland performed both phenotypic and genotypic testing on *E. coli* isolates, although they indicated to use the genotypic results in the analysis of ESBL-, AmpC- or ESBL + AmpC- producers. The combination of results reported by Finland, however, suggests that the prevalence of ESBL- and AmpC-producing *E. coli* isolates is low in fattening pigs, while no ESBL and/or AmpC producers have been detected in pig and bovine meat samples.

In all monitored animal populations and meat categories, the ESBL-producing phenotype was more common than the AmpC-producing phenotype at the reporting MS-group level and in most of the reporting countries. This was also the case in the molecular data where the vast majority of genes identified were ESBLs, followed by AmpC genes. The prevalence of the different phenotypes did, however, vary considerably among the MSs and in some countries, the AmpC phenotype was dominant, such as broiler populations in Hungary and Lithuania or turkeys from Norway. As only one isolate per sample is to be further investigated, the relative abundance of bacteria with an ESBL and/or AmpC phenotype present in the sample will influence the probability of detecting either phenotype.

Based on the WGS findings, *bla*<sub>CTX-M-1</sub> and *bla*<sub>CTX-M-15</sub> were the most commonly reported ESBL-encoding genes and *bla*<sub>CMY-2</sub> was the most identified AmpC-encoding gene. The CTX-Ms are the largest groups of ESBLs, with *bla*<sub>CTX-M-15</sub> becoming one of the predominant genotypes. *bla*<sub>CTX-M-1</sub> has persisted in Europe suggesting the possible spread of epidemic plasmids (Bevan et al., 2017). *bla*<sub>CMY-2</sub> is one of the most prevalent AmpC genes and has been isolated in numerous species across the globe. Among others, a recent study in China detected *bla*<sub>CMY-2</sub> mediated resistance of food animal-derived *E. coli* to third-generation cephalosporins (Zheng et al., 2022).

Overall, the specific monitoring highlighted that presumptive ESBL-7, AmpC- or ESBL + AmpC-producing *E. coli* were frequently observed in the caecal samples tested, which are representative of all investigated animal populations monitored. However, a statistically significant decrease in the prevalence of ESBL and/or AmpC-producing *E. coli* has been observed in both broilers and turkeys over the period 2016–2020. Notably, since 2012, the off-label use of extended spectrum cephalosporins in poultry has been discontinued (EMA/CVMP, 2018). This has likely contributed to the decreased occurrence of resistance in these species.

Similar to the caecal samples of healthy broilers collected at slaughter, a statistically significantly decreased prevalence of presumptive ESBL-, AmpC- or ESBL + AmpC-producing *E. coli* in broiler meat has been observed. The prevalence assessed in meat was statistically lower, but still comparable to, that observed in broilers.

Conversely, the prevalence of ESBL-producing *E. coli* in meat of pigs and bovine animals was much lower than that assessed in fattening pigs and bovine animals under 1 year of age at slaughter. The range of the prevalence of these phenotypes in pig and bovine meat among the MSs also tended to be narrower than that observed in these animals at slaughter. The findings suggest that many of these animals are carrying ESBL-producing *E. coli* in their intestinal content, but that the bacteria do not contaminate the carcasses during the slaughter process; alternatively, that the bacteria contaminate the carcasses but are somehow removed later in the process. This may be impacted by the differences in the slaughter process applied to broilers compared with those applied to pigs and bovine animals.

### 5.5. Monitoring of carbapenemase (CP)-producing *E. coli*

#### 5.5.1. Specific *E. coli* ESBL/AmpC/CP-producers monitoring

The specific monitoring of ESBL/AmpC-producing *E. coli* on selective media (including cefotaxime) enables the detection of isolates with some mechanisms of carbapenem resistance.

In 2021, Hungary detected the CP-phenotype in an isolate from pig meat and two isolates from bovine meat collected at retail, although molecular data was not provided for these isolates. Those isolates were confirmed as CP-producers harbouring the *bla*<sub>NDM-5</sub> gene, responsible for the carbapenemase phenotype, by the EUROSAR during the confirmatory testing exercise. In addition, within the 2020 ESBL-/AmpC- producers monitoring, Austria detected one isolate with a CP phenotype from broilers. This isolate harboured the metallo-β-lactamase resistance gene *bla*<sub>VIM-1</sub>, as well as the β-lactamase genes *bla*<sub>TEM-1C</sub> and *bla*<sub>TEM-1B</sub> (EFSA and ECDC, 2022).
5.5.2. Specific CP-producers monitoring

In 2020 (EFSA and ECDC, 2022) and 2021, specific monitoring of CP-producing microorganisms using selective media for CP-producers, in accordance with a protocol developed by the EURL on AMR, was performed by a number of countries (Annex D4; see Appendix F, Materials and methods). In the 2 years combined, 23 countries (20 MSs and 3 non-MSs) investigated 5,089 samples from fattening pigs; 2,214 samples from bovines under 1 year of age; 6,088 samples from broilers; 2,250 samples from fattening turkeys, 4,843 samples of meat from pigs, 4,688 samples of meat from bovines and 4,456 samples of meat from broilers.

For 2020, the Netherlands also reported data on additional specific monitoring of CP-producing E. coli in broilers, fattening pigs, bovines under 1 year, laying hens and dairy cows using a different isolation protocol. All these samples (n = 1,408) were negative (EFSA and ECDC, 2022).

In 2021, suspected CP-producing E. coli isolates were detected in two samples from fattening pigs (Spain), three samples from bovine meat (Hungary) and one sample of meat from pigs (Hungary) (Annex D4) in the specific monitoring of CP-producing E. coli (some of the isolates seems to proceed from the same samples positive in the specific E. coli ESBL/AmpC/CP-producers monitoring, see Section 5.5.1 above). The isolates from fattening pigs reported by Spain carried the blaOXA-48 gene. For the isolates reported by Hungary, the presence of CP-encoding genes is pending of confirmation.

Only two out of the four MSs, which reported and selected WGS results for the analysis, detected CP resistance genes in 29 E. coli isolates from fattening pigs and bovine animals under 1 year of age (Czechia and Italy) (Figure 50; Appendix H, Table H.3). Among them, the CP gene blaOXA-181 was identified in 20 E. coli isolates from fattening pigs and four isolates from bovines under 1 year of age from Italy; and blaOXA-48 was identified in an isolate from a fattening pig in Italy; blaNDM-5 was identified in three E. coli isolates from fattening pigs in Czechia and in an E. coli isolate from a bovine under 1 year of age in Italy.

![Percentage of E. coli isolates with carbapenemase encoding genes by animal population and meat category](image)

N = Total number of isolates harbouring a CP-encoding gene. These figures incorporate data from countries that provided WGS results to be used for analysis instead of MIC values. This excludes countries that provided MIC results as well as WGS results voluntarily.

**Figure 50**: E. coli isolates with carbapenemase encoding genes in fattening pigs and bovines animals under > 1 year of age, isolated within the specific CP-monitoring in 2021

5.5.3. Discussion

Among all samples and isolates investigated within the harmonised monitoring in 2020 and 2021, by phenotypic methods, 14 *E. coli* with elevated MIC to meropenem were detected. Of these, four (one from broilers, one from pig meat, two from meat from bovines) where detected within the specific monitoring of ESBL/AmpC-producing *E. coli* on selective media and 10 (three from broilers, one from fattening turkey, two from fattening pigs and one from pig meat, and three from bovine meat) within the specific monitoring of CP-producing microorganisms using selective media for CP-producers. Countries using WGS detected CP genes in 29 *E. coli* isolates (24 from fattening pigs, five from bovine animals under 1 year) within the specific CP-producing *E. coli* monitoring.

Although the total number of suspected CP-producing *E. coli* isolated within the monitoring is still low, there has been an increase in numbers compared with the previous years (EFSA and ECDC, 2022), probably also facilitated by the use of WGS.

The occurrence of CP-producing *E. coli* among farm animals and meat derived thereof in several countries is of concern. Due to the public health importance of CP-producing *E. coli* and/or *Salmonella*, both as pathogens and as vectors for resistance mechanisms, there is a need to follow up possible further developments in this area for farm animals and food derived thereof. WGS seems to have detected more CP-producing *E. coli* isolates than phenotypic methods, even though only four MSs reported molecular data. WGS being authorised as an alternative method to phenotypic testing will hopefully strengthen the detection rates.

In 2021, a high variety of CP genes were detected in different countries: *bla*\(_{OXA-48}\) in Spain (confirmed by the MSs) and Italy, in both countries isolates from fattening pigs. *bla*\(_{OXA-181}\) in Italy, in isolates from fattening pigs and bovines (Carfora et al., 2022). *bla*\(_{NDM-5}\) in Czechia, in isolates from fattening pigs, in Italy from a bovine isolate and Hungary (confirmed by the EURL-AR) from pig and bovine meat isolates collected at retail. In 2020, *bla*\(_{VIM-1}\) was detected in Austria from poultry. The CP-encoding genes *bla*\(_{OXA-181}\) and *bla*\(_{NDM-5}\) were the most frequently reported in 2021. The gene *bla*\(_{OXA-181}\) belongs to class D carbapenemases, and the first report of its isolation from porcine *E. coli* was in Italy (Pulss et al., 2017). Prior to which it was mainly identified in human isolates and rarely in animals. The gene *bla*\(_{NDM-5}\) belongs to the New Delhi metallo-beta-lactamases (NDMs), which are a class of carbapenemase genes that have previously been identified in *E. coli*. This gene was previously isolated in *E. coli* isolates from dairy cows in Algeria, as well as in dogs and humans (Yaici et al., 2016). Based on nucleotide similarity of the plasmids containing CP genes and others identified in human animal sources, it has been suggested that specific antimicrobial resistance plasmids have been circulating among *E. coli* strains across vertebrate species barriers, which could increase the risk of dissemination of carbapenem resistance in animal reservoirs.

Apart from isolates detected within the harmonised monitoring in the EU (shown in this report, as well as in EFSA and ECDC, 2022; Diaconu et al., 2020; Garcia-Graells et al., 2020; Bortolaia et al., 2021; Carfora et al., 2022), CP-producing Enterobacteriales has also been reported, not only in companion animals (Rincon-Real et al., 2022), farm animals and food derived thereof but also from vegetables from many parts of the world including Europe (Zurlock et al., 2015; Touati et al., 2017; Brouwer et al., 2018; Köck et al., 2018; Liu et al., 2018; Irrgang et al., 2019, 2020). In addition, a number of closely related but non identical plasmids carrying the carbapenem resistance gene *bla*\(_{VIM-1}\) has been found in isolates from livestock in Germany (Pauly et al., 2021). Consequently, the concern of animals becoming a reservoir for CP-producing Enterobacteriales has been raised (Taggar et al., 2020). Carbapenems are not authorised for use in animals in the EU, and the spill-over of resistant genes and/or bacteria from humans has been suggested as potential source of CP Enterobacteraceae in the food production (Irrgang et al., 2020). However, the spread of the same or related CP-encoding genes in isolates from different farms in certain regions could point to horizontal/vertical transmission of these isolates within the food chain (Carfora et al., 2022). Furthermore, as CP-producing Enterobacteriales are probably still emerging among the investigated animal species in Europe, potential actions to preserve this situation can hopefully still be effective, ensuring that farm animals do not become an important source of such bacteria for humans.
6. Antimicrobial resistance in methicillin-resistant *Staphylococcus aureus* (MRSA)

6.1. Key findings

- The monitoring of MRSA in 2020 and 2021 provided useful information on the occurrence of MRSA in livestock and food. The situation continues to develop and evolve and there is a clear requirement for the continued monitoring and appropriate molecular characterisation of MRSA isolates recovered from livestock and food.

- Molecular characterisation is necessary to fully evaluate the significance of MRSA isolates. There are limitations to the analyses which can be performed when spa-typing is used as the only technique to characterise isolates. Isolates from the same spa-type may have very divergent sources and characteristics. For the assessment of the risk for humans, determination of the production of the PVL toxin seems relevant as well as the presence of the immune evasion cluster.

- Where typing data were available, most MRSA isolates were associated with spa-types that are assigned to livestock associated (LA-)MRSA in both reporting years. However, spa-types associated with community acquired (CA-) and hospital acquired (HA-)MRSA were also reported, as well as mecC-MRSA. The occasional detection of lineages of CA- and HA-MRSA primarily associated with humans is not surprising, since the sporadic interchange of strains between humans and animals may be expected.

- All spa-types of clonal complex 398 and other clonal complexes reported in 2020/2021 in animals and food are provided in Tables 14 and 15 of the present chapter. Changes in the reported occurrence of different MRSA lineages may be assessed against this list in the future.

- Isolates that could not be assigned to the clonal complex 398 were more frequent in isolates from food than in isolates from animals. This may point to contamination at slaughter or during processing with strains of non-animal origin. Many of the observed types have however repeatedly been reported in animals making it difficult to assign them unequivocally to human sources.

- An important observation from the 2021 monitoring was the detection of rifampicin resistance in dairy cows and bovine meat.

- A relevant observation from the 2020 monitoring was the occurrence of a vancomycin-resistant t011 isolate in meat from sheep. The isolate lacks the typical vancomycin resistance genes and it is likely, that the increased MIC of 4 mg/L was due to multiple point mutations as described in the literature.

6.2. Data on MRSA addressed

Periodic monitoring of methicillin-resistant *Staphylococcus aureus* (MRSA) in food-producing animals and food allows for the identification of trends in the diffusion and evolution of potentially zoonotic MRSA in food-producing and other animals. In conjunction with systematic surveillance of MRSA in humans, the transmission of MRSA from food-producing animals to the human population may be analysed (EFSA, 2009a,b, 2012). To this end, in addition to determining the occurrence of MRSA in the different food chains, representative isolates should optimally be characterised with respect to their molecular subtype and AMR. The monitoring of MRSA in animals and food in Europe is voluntary and only a limited number of countries reported MRSA occurrence data in 2020 and 2021. Some countries additionally reported data on spa- and/or sequence types and/or antimicrobial susceptibility.

MRSA is commonly found on the skin and mucosa of humans and animals and can cause serious infections in both groups. Strains of MRSA can be divided into three broad categories: community-associated (CA-), healthcare-associated (HA-) and livestock-associated (LA-) MRSA. These categories differ in their epidemiology, although the separation between the types is not strict. HA-MRSA and CA-MRSA comprise strains that predominantly affect humans, and these strains are much less frequently reported from food-producing animals. LA-MRSA has been detected in most farm animal species including those covered by the antimicrobial resistance monitoring according to Decision 2020/1729/EU (2021 data) and Decision 2013/652/EU (2020 data).

Among humans, LA-MRSA are predominantly carried by people with repeated occupational contact with colonised livestock. The proportion of MRSA carried by humans in the European Union that
belong to livestock associated strains has been estimated to be small (3.9%); however, higher proportions were observed in five countries (Belgium, Denmark, the Netherlands, Slovenia and Spain) (Kinross et al., 2017). Although frequently detected in food, MRSA is generally not considered to be transmitted by food-borne routes to humans, and detection often involves selective culture techniques, which may detect very low levels of contamination (Pauly et al., 2019).

Isolates of LA-MRSA in Europe predominantly belong to clonal complex (CC) 398, although other livestock-associated clonal lineages have been reported. Although the severity of LA-MRSA infection in humans is usually less than those caused by other MRSA strains, there is still potential for the infections to become life threatening. Risk of transmission of LA-MRSA in the hospital environment is considered less likely than with HA-MRSA strains although public health surveillance in the Netherlands (2003–2014) and Denmark (1999–2011) detected distinct LA-MRSA strains disseminating into the community, sometimes in the absence of livestock contact (Kinross et al., 2017).

A variant of the methicillin resistance gene mecA, termed mecC, was first identified in 2011 in MRSA from humans and cattle in Europe (Garcia-Álvarez et al., 2011; Shore et al., 2011). It has subsequently been detected in ruminants, pigs and companion animals, with reports also from wild animals (Paterson et al., 2014; Bengtsson et al., 2017). In hindsight, mecC MRSA isolates have been found in isolates dating back to the pre-antibiotic era (Larsen et al., 2022). The mecC gene shares 70% identity with mecA at the DNA level (Garcia-Álvarez et al., 2011). Risk factors for mecC MRSA carriage in humans include contact to animals and the presence of an underlying disease (Lozano et al., 2020). mecC-MRSA strains have been negative for Panton–Valentine leukocidin (PVL) toxin – a virulence factor typically associated with CA-MRSA. However, some isolates have carried genes belonging to the immune evasion cluster (IEC) (Lozano et al., 2020). Carriage of these IEC genes is considered an adaptation to enable S. aureus colonisation and infection of humans and is not usually a feature of animal S. aureus strains (Cuny et al., 2015).

Antimicrobial susceptibility in European invasive Staphylococcus aureus isolates from humans is reported by 29 MSs to the European Antimicrobial Resistance Surveillance Network (EARS-Net) hosted by ECDC. MRSA typing data are not reported and, therefore, when there may be possible links to the animal reservoir of LA-MRSA, these cannot easily be detected with current monitoring procedures, at least at the European level. The EU/EEA (excluding the United Kingdom) population-weighted mean proportion of MRSA among invasive S. aureus infections reported to EARS-Net decreased significantly from 18.4% in 2017 to 15.8% in 2021, with significantly decreasing trends reported by 11 of the reporting EU/EEA countries (excluding the United Kingdom). Nevertheless, MRSA continues to be an important human pathogen in the EU/EEA, as levels of MRSA remain high in several countries and combined resistance to another antimicrobial group was common (WHO/ECDC, 2022).

### Technical specifications for a baseline survey on the prevalence of MRSA in pigs (EFSA, 2022)

The technical specifications for a baseline survey on the prevalence of MRSA in pigs were recently published by EFSA following a request received from the European Commission to provide scientific and technical assistance in the preparation of a EU wide baseline survey protocol for a EU coordinated monitoring programme on the prevalence of MRSA in pigs (EFSA, 2022). The baseline survey aims to estimate the prevalence of MRSA in batches of fattening pigs at slaughter at the European and national level, with a 95% level of confidence and a level of precision of 10% considering an expected prevalence of 50%. An additional objective of the baseline survey is to assess the genetic diversity and antimicrobial resistance of MRSA in pigs. This will include detailed characterisation of MRSA strains and lineages, virulence and host-adaptation factors, and other genetic markers associated with animal hosts, such as phages. This will facilitate the comparison of AMR in humans and animals.

The technical specifications published by EFSA (EFSA, 2022) define the target populations, the sample size for the baseline survey (20 pigs per batch), the sample collection requirements, the analytical methods (for isolation, identification, phenotypic susceptibility testing and further genotypic testing of MRSA isolates), the data reporting requirements and the plan of analysis. As indicated in the technical specifications, the samples are to be analysed according to the laboratory protocols available on the European Union Reference Laboratory (EURL-AR) website. Generalised linear models will be used to estimate proportion (with 95% confidence intervals) of batches of slaughter pigs tested positive to MRSA. The necessary data to be reported by the
6.3. Food and animals: MRSA

This section summarises the occurrence of MRSA and its susceptibility to antimicrobials in various food categories, in food-producing animals excluding clinical investigations, and during clinical investigations in food-producing and other animals in 2020/2021. Additional tables on MRSA in food and food-producing animals have been included in Annex E that is available as supporting documentation in zenodo (https://doi.org/10.5281/zenodo.7544221).

In 2021, five MSs (Austria, Belgium, Finland, Germany and the Netherlands) and two non-MSs (Norway and Switzerland) provided data on the occurrence of MRSA in food and animals. In addition, Belgium, Germany and Switzerland also reported isolate-based data on antimicrobial susceptibility of MRSA. In 2020, data on the occurrence of MRSA were reported by six MSs (Austria, Belgium, Finland, Germany, the Netherlands and Slovakia) and one non-MS (Norway). Out of the six MSs reporting occurrence data in 2020, Austria, Belgium and Germany also reported isolate-based data on the susceptibility of MRSA. It is important to note that monitoring of MRSA in food and animals is not harmonised in the EU. Therefore, findings and related comparison between reporting countries should be interpreted with caution, as differences exist in the sensitivity of the methods used for the isolation of MRSA from food and animals, as well as in the sampling strategies and types of samples collected. The sampling stage can influence MRSA prevalence rates and should be taken into consideration when interpreting the results discussed below.

6.3.1. Food: monitoring of MRSA

In both 2021 and 2020, a low number of countries reported data on the occurrence of MRSA in food (N = 4 and N = 4, respectively). In 2021, Austria, Germany, the Netherlands and Finland provided data (see Annex E, Table 1a). MRSA was investigated in meat from bovine animals (Austria, Germany and the Netherlands) and meat from pigs (Austria, Germany and Finland). The Netherlands also provided data on MRSA found in meat from broilers, turkeys, sheep, ducks and deer. In 2020, MRSA was investigated in meat from broilers (Austria and the Netherlands), and meat from pigs (Slovakia and the Netherlands). Moreover, data on meat from bovines and from turkeys was reported by the Netherlands, and data on meat from sheep by Germany. The Netherlands reported few negative samples from unspecified meat and meat from deer. Germany reported investigations on soft cheese with no positive MRSA findings (see Annex E, Table 1b). Monitoring results on the occurrence of MRSA in food reported in 2021 and 2020 are presented in Figure 51.

The highest occurrence of MRSA was observed in meat from turkeys (35.7% in 2020; 21.4% in 2021), though it should be noted that only 14 samples were tested in each year by only one MS (Netherlands). In meat from pigs and broilers, occurrence differed between countries with occurrence in pig meat ranging from 3.5% in the Netherlands (2020) to 20.6% and 21.3% in Slovakia (2020) and Austria (2021), respectively. In broiler meat, the proportion of positive samples ranged from 2.6% in Austria (2020) to 15.4% in the Netherlands (2020). Occurrence of MRSA in broiler meat reported by the Netherlands decreases in 2021 (8.1%) compared with 2020 (15.4%). Occurrence of MRSA was overall lower in bovine meat ranging from 3.8% (Netherlands, 2020) to 6.9% in the Netherlands (2021). Meat from sheep was found to be MRSA positive in 2.8% of samples from Germany (2020) and 12.4% in the Netherlands (2021).
6.3.2. Animals: monitoring of MRSA

6.3.2.1. Monitoring of MRSA in healthy animals

MRSA occurrence data from animals were reported by five MS (Belgium, Germany, Finland, the Netherlands and Slovakia) and Norway in 2020 (see Annex E, Table 2b) and by five countries, 3 MS (Belgium, Finland and the Netherlands) and two non-MS (Norway, Switzerland) in 2021 (see Annex E, Table 2a). The data originated from different frameworks, including a voluntary monitoring, surveillance, control programs and specific surveys, the latter being restricted to fur animals in Finland.

Figure 51: MRSA occurrence in food, 2020/2021 (only food origins where positive isolates were obtained are presented)

6.3.2. Animals: monitoring of MRSA

6.3.2.1. Monitoring of MRSA in healthy animals

Bovine meat (DE, 2021): spa-types: t1346 (1 isolate), t002 (2), t008 (2), t311 (2), t2112 (1), t174 ST41110 (1), t011 (4), t034 (4), t359 (1), t559 (1), t843 mecC positive (1), t899 (1), t1430 (1), t1451 (1).
Pig meat (FI, 2021): spa-types: t728 ST45 (1 isolate), t034 ST398 (14), t899 ST398 (1), t2741 ST398 (9), t677 ST398 (1).
Pig meat (DE, 2021) spa-types: t1430 (1 isolate).
Pig meat (DE, 2020) spa-type: t011 (1 isolate), t034 (2), t451 (1), t2576 (1), t19979 ST398 (1), t223 (2), t267 (1), t1154 ST5 (1) t15010 ST97 (1).

N: Total number of sample units tested; AT: Austria; DE: Germany; FI: Finland; NL: the Netherlands; SK: Slovakia; CH: Switzerland.

www.efsa.europa.eu/efsajournal 143 EFSA Journal 2023;21(3):7867
The voluntary monitoring performed over 2020/2021 examined turkeys, laying hens, broilers, calves (under 1 year), dairy cows, meat production cattle, fattening pigs, wild boars and wild freshwater fish. Fur animals surveyed included foxes, mink and raccoon dogs.

In 2020 and 2021, MRSA were most frequently detected in pigs (Figure 52). Among the different populations studied at farm level were herds of fattening pigs in the Netherlands (79.0% in 2020) and Switzerland (53.6% in 2021). At slaughter 18.0% of pigs were positive in Slovakia in 2020. In contrast, MRSA was not detected at all in 643 samples (2020) or 763 samples (2021) in the framework of the national control and eradication programme in pigs in Norway (see Annex E, Table 2a,b). High detection rates for MRSA in pigs except for Norway confirm the results of previous years.

MRSA were detected in turkeys (11.1%) and broilers (3.3%) in Belgium in 2020, but not in laying hens in Belgium in 2020. Low detection rates in broiler flocks and laying hen flocks have been observed frequently. In broilers, this contrasts with higher detection rates in broiler meat indicating that cross contamination at slaughter my play a relevant role here. Turkeys were more frequently positive on farm than broilers, in 2020 as well as in previous years.

Very few MRSA were found in wild boars and wild freshwater fish in Germany (0.8% and 1.0%) (Figure 52) see also Annex E, Table 2b. In Finland, no MRSA were detected in samples from farmed fur animals: racoon dogs (1 sample in 2020 and 10 samples in 2021), mink (15 samples in 2020 and 47 samples in 2021) and foxes (11 samples in 2020 and 2 samples in 2021). Absence of MRSA in farmed mink in Finland contrasts with a considerable proportion of positive samples in Denmark in 2018 (EFSA and ECDC, 2020)

In 2020, no cattle were tested for MRSA. However, in 2021, 4.7% of meat production cattle, 11.7% of dairy herds and 54.5% of veal calf herds in Belgium, were found positive for MRSA. A higher occurrence of MRSA in calves than in dairy cows has been reported previously (Graveland et al., 2010; Tenhagen et al., 2014; Schnitt et al., 2020).
Typically, clinical investigations differ from monitoring studies in food-producing animals: selective culture methods are typically not used, and the sampling is biased. These data therefore do not allow occurrence to be inferred and cannot be extrapolated at the population level. However, it is still considered relevant to report the range of animal species/populations which were affected, and the

N: Total number of sample units tested; BE: Belgium; CH: Switzerland; DE: Germany; NL: the Netherlands; NO: Norway; SK: Slovakia.
- Fattening pigs, SK 2020: data were reported as suspect sampling.
- Veal calf herds, BE 2021: spa-types: t386 ST1 (1), t011 (65), t034 (6), t1451 (1), t1456 (1), t2346 (1), t2370 (1), t3423 (1), t5210 (1), t6228 (1).
- Dairy cow herds, BE 2021: spa-types: t037 ST239 (3 isolates), t011 (10), t034 (2).
- Production cattle herds, BE 2021: spa-types: t037 ST239 (2 isolates), t011 (2).

Figure 52: MRSA occurrence in food-producing animals, 2020/2021 (only origins where positive isolates were obtained are presented)

6.3.2.2. Monitoring of MRSA in animals following clinical investigations

Typically, clinical investigations differ from monitoring studies in food-producing animals: selective culture methods are typically not used, and the sampling is biased. These data therefore do not allow occurrence to be inferred and cannot be extrapolated at the population level. However, it is still considered relevant to report the range of animal species/populations which were affected, and the
lineages of MRSA detected. Slovakia and the Netherlands reported on clinical animal data on MRSA in 2020 and 2021 (see Annex E, Tables 3 and 4a,b).

In 2020, Slovakia reported data following clinical investigations for MRSA in 46 animals of various species with no positive finding (see Annex E, Tables 3 and 4a). These included dogs (23 samples), cats (9), dairy cows (5), goats (2), horses (2), rabbits (2), guinea pigs, squirrels and falcons (1). The Netherlands reported data, predominantly on cats, dogs and horses in 2020. The highest rate of MRSA findings was in horses (5.4%) followed by cats (0.8%) and dogs (0.4%). One individual finding of MRSA in a caged bird was reported by the Netherlands. The bird species was not reported. No molecular data was provided by the two countries. In 2021, the Netherlands reported data on clinical isolates from cats (0.8%), dogs (0.1%) and horses sampled in farms (1.9%, see Annex E, Table 4b).

6.3.3. Animals and food: results of molecular typing of isolates

In 2021, molecular characterisation was reported for 124 of 1329 MRSA isolates recovered from food. Among those, 74 originated from Austria, 24 originated from Germany and 26 from Finland. Molecular characterisation was also reported by one MS (Belgium) for 98 of 358 MRSA isolates recovered from food-producing animals (see Annex E, Table 9a). In 2020, typing data were only reported for 19 isolates from food and for four isolates from food-producing animals, all of which originated from MSs (Austria, Belgium and Germany) (see Annex E, Table 9b). Over both years, most MRSA isolates from food and animals were assignable to the clonal complex 398 (food: 99 of 143, 69.2%; animals: 96/102, 94%). Results of molecular typing of isolates from animals and food are presented in Figure 53; Tables 14 and 15.

Among the CC398 isolates, most isolates with spa-typing data in both years were from spa-types t011 and t034. In 2021, t011 and t034 accounted for 92.4% (85/92) of CC398 isolates from animals and for 74.1% (63/85) of CC398 isolates from food. In 2020, t011 and t034 accounted for 11 of 14 CC398 isolates from food (78.6%) and for all four CC398 isolates from animals. All isolates from animals reported in 2020 were from t011.

In 2021, spa-types that were assignable to CC398 but were not t011 and t034 included two isolates from pig and bovine meat that were spa-type t899. Spa-type t899 can be associated with different clonal lineages, including CC398 and CC9. LA-MRSA CC9/CC398 displaying spa-type t899 is a mosaic strain, consisting of a CC398 chromosomal backbone having acquired the CC9 region containing the staphylococcal protein A gene (Guardabassi et al., 2007; Larsen et al., 2016; Tegegne et al., 2021a; Ceballos et al., 2022) Other CC398 associated spa-types in food in 2021 included one isolate of t1451 from bovine meat, one isolate of t2741 from pig meat and one t4677 from pig meat.

In 2020, three isolates from sheep meat reported by Germany were from less frequently observed spa-types (t1451, t2576 and t19979) of CC398. Spa-type t1451 had also been observed in one isolate from a veal calf in 2021. Spa-type t19979 is a comparatively new variant but was confirmed as an ST398 by Germany.

In 2021 and 2020, most spa-types of isolates from animals and food that were assignable to CC398 have already been observed in the EU-baseline in breeding pigs in 2008 (EFSA, 2009a) demonstrating a remarkable persistence in the food-producing animal population. This applies to t011, t034, t899, t1451, t1456, t2346 and t2370. Most other spa-types assigned to this clonal complex have likewise been observed previously as exemplified below:

- t3423 was previously identified in MRSA isolated from a pig and a veal calf on Belgium farms, as well as in a surgical site infection in a horse from the United Kingdom (Verhegghe et al., 2013; Nemeghaire et al., 2014; Bortolami et al., 2017).
- t5210 was previously identified in multiple farm workers and a rabbit on a rabbit farm in Italy (Agnoletti et al., 2014).
- t6228 was previously identified in dairy farms in Belgium (Nemeghaire et al., 2014).
- t7241 has been described as a dominant spa-type in Finnish fattening pigs (Heikinheimo et al., 2016).
- t2576 was previously described in a bovine clinical isolate from a dairy farm in Germany and a pork meat sample in a supermarket from the Czech Republic (Feitler et al., 2010; Tegegne et al., 2021a).
- t1793 was identified in pig meat from Austria. This spa-type has previously been identified in a slaughter pig from Denmark (Guardabassi et al., 2007).
- t9013 was identified in pig meat from Austria. It has been identified in human MRSA isolates that were suspected to be livestock associated in Germany (Köck et al., 2013)
t571 was identified in pig meat from Austria. This spa-type belonging to CC398 has been isolated from pigs and a veal calf in Germany (Cuny et al., 2013).

While this list does not claim full coverage, it clearly indicates that these spa-types persist in animal production (including at slaughter and meat).

Spa-type t19979 is a recent strain as indicated by the high spa-type number and has not been reported in animals, food or farmers before 2020. In 2021, Austria reported spa-types for 74 isolates from pig and bovine meat, Germany reported spa-types for 24 isolates recovered from imported pig and bovine meat from border control posts, and Finland reported for 26 isolates recovered from pig meat. Switzerland provided information on clonal complex for three MRSA isolates from pig and bovine meat. In 2020, molecular typing data were reported for eight isolates from broiler meat from Austria and 11 isolates from sheep meat from Germany.

Isolates that were not assigned to the CC398 included a range of spa-types that could be or were assigned to a number of different CC (see Annex E, Table 9a,b). The highest proportion of such isolates was observed in meat from sheep in 2020 (5 of 11, 45.5%), bovine meat in 2021 (20 of 38, 52.6%) and pig meat in 2021 (15 isolates). In 2021, the following isolates were from spa-types not assignable to CC398 (see also Table 15).

- Spa-type t002 was reported in imported bovine meat from border control posts by Germany in 2021. This spa-type has repeatedly been observed in turkey meat and in turkeys (Richter et al., 2012; Vossenkuhl et al., 2014; Tegegne et al., 2021b).
- Germany reported spa-type t008 from imported bovine meat from border control posts. This spa-type has been identified as one of the most prevalent in European human populations (Asadollahi et al., 2018). It belongs to CC8 which has been suggested to have made a jump from humans to bovines (Resch et al., 2013).
- mecC-MRSA spa-type t843 was reported by Germany from cattle meat. The isolate was confirmed to carry the mecC gene. The association of this spa-type with CC130 has previously been observed in cattle (Mališová et al., 2020; Cui et al., 2021; Silva et al., 2021).
- t037 was described in dairy cows and cattle from Belgium. This spa-type has been previously described in chickens from Belgium (Jungwhan Chon, 2017). This isolate was confirmed to belong to ST239. MRSA isolates with ST239 and t037 were previously identified in human infections from patients in Iran (Ghasemzadeh-Moghaddam et al., 2022).
- t174 was reported in cattle meat from Germany. This spa-type has previously been isolated from pigs in Italy (Normanno et al., 2015). This isolate was confirmed to belong to ST41110.
- t311 was described in isolates from cattle meat in Germany. This isolate has previously been described in an isolate from a cow with mastitis in Germany (Wu et al., 2020).
- t386 was isolated from veal calves in Belgium. This isolate was confirmed to belong to ST1 and CC1. T386 has been identified in methicillin susceptible S. aureus isolated from chicken samples in Gabon and in MRSA isolated from a hedgehog in Spain (Lozano et al., 2016; Silva et al., 2020).
- t359 was isolated from cattle meat in Germany. This isolate has previously been described in MRSA isolates from clinical human samples in Kuwait (Boswihi et al., 2018).
- t588 was described in bovine and pig meat samples from Austria. This isolate has been identified in a Spanish pig farmer who was suggested to have been infected by MRSA transmitted from his pigs (Lozano et al., 2011).
- t728 was isolated from pig meat in Finland. This isolate was isolated from bovine and cattle meat in Austria. Both spa-types were confirmed to belong to ST45 and CC45. CC45 is widely spread in human populations and an isolate harbouring t359-ST45 was previously identified in an Irish maternity hospital (Cuny et al., 2015; Broderick et al., 2021).
- t898 was described in bovine meat from Austria. This spa-type has previously been identified in an environmental sample on a pig farm (Golob et al., 2022).
- t1430 was described in isolates from pig and cattle meat in Germany. This spa-type was previously identified in broiler farms from Germany (Kittler et al., 2019).

In 2020 five isolates, all from sheep meat reported by Germany, were from spa-types not assignable to CC398.

- Two isolates were spa-type t223. This spa-type is frequently assigned to the MLST-type ST22 in clinical isolates from humans in Iran and was also identified in Kuwait and Palestine.
This spa-type has also been identified in community and healthcare environments in Norway and Sweden (Di Ruscio et al., 2018).

- One isolate (t15010) was identified as MLST-type ST97. This MLST-type is frequently observed among S. aureus from cattle and has also been observed in pigs, e.g. in Italy. Despite not being related to the CC398 it is considered as a livestock associated strain by some authors (Feltrin et al., 2016; Boswihi et al., 2019).

- A second spa-type that frequently occurs in ST97 is t267. This spa-type has been found in bovine milk as well as a PVL positive strain in humans (Käppeli et al., 2019; McManus et al., 2021) underlining that it could be both, of animal and human origin.

- One other isolate (t1154) was identified as MLST-type ST5. ST5 isolates are frequently observed in humans but have also been reported in turkeys (Richter et al., 2012; Vossenkuhl et al., 2014), although with different spa-types. Spa-type 1154 belonging to ST5 have been identified in clinical samples from humans (Viana et al., 2021).

**Figure 53**: MRSA types reported from food and animals in 2020 and 2021, inferred from molecular typing data.
### Table 14: spa-types of CC398 and their detection in animals and food 2020/2021

<table>
<thead>
<tr>
<th>Spa-type</th>
<th>Year</th>
<th>Animals (number of isolates)</th>
<th>Tot</th>
<th>Food (number of isolates)</th>
<th>Tot</th>
</tr>
</thead>
<tbody>
<tr>
<td>t011</td>
<td>2021</td>
<td>calves (65), dairy (10), cattle (2)</td>
<td>77</td>
<td>bovine meat (8), pig meat (24)</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>2020</td>
<td>broilers (2), turkeys (2)</td>
<td>4</td>
<td>broiler meat (4), meat from sheep (1)</td>
<td>5</td>
</tr>
<tr>
<td>t034</td>
<td>2021</td>
<td>calves (6), dairy cows (2)</td>
<td>8</td>
<td>Pig meat (26), bovine meat (5)</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>2020</td>
<td>0</td>
<td>0</td>
<td>broiler meat (4), meat from sheep (2)</td>
<td>6</td>
</tr>
<tr>
<td>t1451</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>Bovine meat (1)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2020</td>
<td>0</td>
<td>0</td>
<td>Sheep meat (1)</td>
<td>1</td>
</tr>
<tr>
<td>t1456</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t2346</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t2370</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t3423</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t5210</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t6228</td>
<td>2021</td>
<td>Calves (1)</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>t899*</td>
<td>2021</td>
<td>0</td>
<td>Bovine meat (1), pig meat (6)</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>t2741</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (9)</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>t4677</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>t2576</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2020</td>
<td>0</td>
<td>Sheep meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>t19979</td>
<td>2020</td>
<td>0</td>
<td>Sheep meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>t1793</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>t9013</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (1)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>t571</td>
<td>2021</td>
<td>0</td>
<td>Pig meat (1)</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Calves are bovine animals below 1 year of age.

*: t899 is sometimes also attributed to CC9 as it is a hybrid strain.

### Table 15: spa-types of other clonal complexes and their occurrence in animals and food in 2020/2021

<table>
<thead>
<tr>
<th>Spa-type</th>
<th>Clonal complex (sequence type)</th>
<th>Year</th>
<th>Animals Population (number of isolates)</th>
<th>Tot</th>
<th>Food Matrix (number of isolates)</th>
<th>Tot</th>
</tr>
</thead>
<tbody>
<tr>
<td>t002</td>
<td>5*</td>
<td>2021</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t008</td>
<td>8*</td>
<td>2021</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t037</td>
<td>8</td>
<td>2021</td>
<td>Dairy cows (3), cattle (2)</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t095</td>
<td>45</td>
<td>2021</td>
<td>0</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t174</td>
<td>1</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t223</td>
<td>22*</td>
<td>2020</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t311</td>
<td>5*</td>
<td>2021</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t386</td>
<td>1</td>
<td>2021</td>
<td>Calves (1)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t359</td>
<td>97*</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t559</td>
<td>1*</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t728</td>
<td>45</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t843</td>
<td>130*</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t1154</td>
<td>5</td>
<td>2020</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t1346</td>
<td>8</td>
<td>2021</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t1430</td>
<td>9*</td>
<td>2021</td>
<td>0</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t2112</td>
<td>97*</td>
<td>2020</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t15010</td>
<td>97</td>
<td>2020</td>
<td>0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*: The CC associated with the spa-type is based on information from the literature and not from data reported by countries.
6.4. Temporal trends of MRSA occurrence

Isolation of MRSA from food-producing animals and the farm environment

In 2018, the European Union Reference Laboratory-Antimicrobial Resistance (EURL-AR) published revised recommendations for the isolation of MRSA from food-producing animals and the farm environment (known as 1-step (1-S) method) (EURL (European Union Reference Laboratory for Antimicrobial Resistance), 2018). The revised recommendations were based on a study of Danish and Norwegian pig herds which confirmed that the 1-S method resulted in a lower proportion of false-negative results than the 2-step (2-S) method (comprising of a pre-enrichment step and a selective enrichment step) used prior to 2017 (Larsen et al., 2017). For broiler meat, it has been shown that the 1-S method may improve sensitivity but decrease the specificity (Pauly et al., 2019). Direct comparison of the data obtained using the different protocols should be performed with caution.

In 2021, occurrence data was obtained using the 1-S method by 2/3 reporting countries in food-producing animals (Belgium, Norway, Switzerland) and 3/4 reporting countries in food (Austria, Finland, the Netherlands). Belgium used the 2-S method in animals and Germany described their method as 'other' in food. In 2020, the 2-S method was used by Belgium (animals) and Germany (animals and food), while Austria, the Netherlands and Norway used the 1-S method.

Considering the monitoring performed in 2019/2020 and 2021 and for previous years, comparable longitudinal data were available for the animal species and food items, as presented in the following sections.

Based on the limited number of available data no statistical trend analyses were carried out. Therefore, changes in occurrence are reported here only descriptively.

6.4.1. Temporal trends of MRSA occurrence in various types of meat

Four countries reported comparable data over time on MRSA from broiler meat (Figure 54; Annex E, Table 5). Over the last 4 years, the Netherlands consistently provided data on broiler meat. The proportion of positive samples decreased slightly over time from 20.2% in 2018 (no data before that date) to 8.1% in 2021. Austria provided similar data in 2018 (1.0%) and 2020 (2.6%). Both countries used the 1-S method. Germany and Switzerland used the 2-S method. Germany last provided data in 2018 (16.4%), which was a higher proportion than seen in 2016 (13.0%) but lower than 2013 and before, when detection rates were between 22% and 26%. Samples of broiler meat in Switzerland rarely contained MRSA in 2016 (3.0%) and 2018 (1.3%).

The Netherlands provided MRSA data from turkey meat in 2018–2021. However, the number of collected samples was very low (45 over the 3 years) not allowing a meaningful analysis of trends. Germany last reported on MRSA in turkey meat in 2018 with 42.7% positive samples. This was in the range of results reported between 2009 and 2017 for fresh turkey meat from Germany (39.9%–44.5%). While the Netherlands used the 1-S method throughout, Germany used the 2-S method.

The Netherlands reported data on pig meat in 2018–2020, with results ranging from 3.5% (2020) to 8.4% (2019) and 2018 in between (5.9%), i.e. without a clear trend. Slovakia reported on different kinds of pig meat over the years precluding straightforward comparison of data. Switzerland reported data in 2017 and 2019, with very low detection rates (0.7% and 0.3%). While the Netherlands used the 1-S method throughout, Switzerland changed from 2-S to 1-S in 2019. Austria used the 1-S method and reported an increase from 15.7% (2019) to 21.3% (2021), although much fewer samples were collected in 2021.

The Netherlands reported on bovine meat in 2018–2021. The number of positive samples have slowly increased from 2.1% (2018), to 3.8% (2019/2020), to 6.9% (2021). Austria also reported a small increase in MRSA positive bovine meat from 2.6% (2019) to 4.6% (2021). In Switzerland, reporting in 2017 and 2019, MRSA were only detected in two samples of fresh bovine meat in 2019 (0.6%). As in pig meat, the Netherlands and Austria used the 1-S method throughout, while Switzerland changed from 2-S to 1-S in 2019.
AT: Austria; CH: Switzerland; DE: Germany; NL: the Netherlands.
The 2-S method of isolation was used by CH and DE from 2011 to 2018; while the 1-S method was used by the NL from 2018 to 2021, as well as CH in 2019.

**Bovine meat (CH):** In 2019, spa-types were not reported; however, both isolates were confirmed to belong to CC398 using the sau1-hsdS1 CC398 PCR reaction (Stegger et al., 2011).

**Pig meat (CH):** In 2017, spa-type: t011 (1 isolate), t002 (1). PVL status of the t002 isolate was not reported. In 2019, spa-type was not reported; however, the isolate was confirmed to belong to CC398 using the sau1-hsdS1 CC398 PCR reaction (Stegger et al., 2011).

**Broiler meat (AT):** In 2018, spa-types: t011 (2 isolates), t034 (1 isolate). In 2020, spa-types: t011 (4 isolates), t034 (4 isolates).

**Broiler meat (CH):** In 2016, spa-types: t034 (3 isolates), t153 (1), t1430 (3), t2123 (2). PVL status of the t153 isolate was not reported. In 2018, spa-types: t034 CC398 (1 isolate), t1430 (1), t571 CC398 (1), t13177 (1).

*spa-types were not provided for Bovine meat (NL), Pig meat (NL), Broiler meat (DE), Turkey meat (DE and NL).

**Figure 54:** Temporal trends of MRSA occurrence in various types of meat, 2011–2021
6.4.2. Temporal trends of MRSA occurrence in various animals

As monitoring of MRSA is not mandatory and methodology is not harmonised, comparable data over time are only available for some populations in a few reporting countries. These are presented in Figures 55 and 56 (as well as in Annex E, Figure 1 and Table 6).

Belgium provided data on MRSA in broiler flocks using the 2-S method in 2014, 2017 and 2020 (Figure 55). While sampling details changed between the years, the proportion of positive holdings or flocks was very low in all 3 years with only two herds positive in 2014 (2.5%), 2017 (2.5%) and 2020 (3.3%). Spa-type was t011 of CC398 in five positive samples and t1985 (likewise CC398) in one isolate in 2014.

Flocks/holdings of laying hens investigated in the same years in Belgium using the 2-S method were also rarely positive for MRSA (see Annex E, Figure 1). Six herds (2.4%) were positive in 2014, three (1.3%) in 2017 and none in 2020. Among the 9 isolates collected in 2014 and 2017, 3 were t011 CC398 and 6 were spa-type t037 (ST239).

Investigations in turkey flocks were repeatedly reported from Germany (2012, 2014 and 2018). In contrast to chicken flocks, these were more frequently positive with 12.8, 21.9 and 17.2% positive over the years (see Annex E, Figure 1). Investigations were carried out using the 2-S method.

Switzerland reported on bovines < 1 year of age at slaughter in 2015, 2017, 2019 and 2021 with results ranging between 6.1% (2021) and 8.1% (2017) without a clear trend (Figure 55). In contrast to 2015 and 2017, Switzerland used the 1-S method in 2019. In Belgium, MRSA in herds of calves under 1 year of age was investigated in 2012, 2015, 2018 and 2021 using the 2-S method. Results varied widely with 78.9% in 2015 and 47.1% in 2012. The last investigations in 2018 and 2021 resulted in an occurrence in between the two (54.5%).

Data on MRSA in dairy cows using the 2-S method were provided by Belgium in 2012, 2015, 2018 and 2021 (Figure 55) with values ranging between 9.9% (2012) and 10.2% (2021). Denmark reported on dairy cows in 2018 and 2019 using the 1-S method, with occurrence seemingly lower in 2019 (1.5%) than in 2018 (6.1%).

Meat production cattle herds were reported by Belgium in 2012, 2015, 2018 and 2021 using the 2-S isolation method with values ranging between 15.4% (2015) and 4.7% (2021) (Figure 55).

Considering the monitoring of pigs (Figure 56), MRSA occurrence data for Swiss fattening pigs at slaughter were reported from 2010 to 2015, as well as in 2017, 2019 and 2021. Generally, occurrence has increased annually, rising from 5.9% in 2010 to 53.6% in 2021; and from 2015 to 2017, a marked increase was observed from 25.7% to 44.0%, respectively. Notably, spa-types associated with CC398 have shown a steady increase in occurrence; and where molecular typing data were available, all isolates in 2017 and 2019 were those associated with CC398, with most belonging to spa-types t011 and t034 in 2017 (associated spa-types were not provided in 2019). Molecular typing data was not available for 2021 isolates. It should be noted however, that from 2010 to 2017, the 2-S method of isolation was used in comparison to the 1-S method in 2019. It is important to note that all isolates tested by Norway (641 in 2020 and 763 in 2021) were MRSA negative as it is the only country with a control programme in place for MRSA in pigs. MRSA occurrence data from Belgian fattening pig herds using the 2-S method was reported in 2016 (63.3%) and 2019 (58.3%) with a similar number of herds tested in both years. Belgium also reported MRSA occurrence data from breeding pig herds in 2016 (59.5%) and 2019 (46.4%). In both populations the occurrence tended to be lower in 2019 than in 2016. All MRSA isolates recovered from these production types over these years were spa-types associated with CC398 (LA-MRSA), except for a single isolate of spa-type t037 reported from fattening pigs in 2016 (categorised as HA-MRSA) in Belgium. Denmark reported results from a national survey on the occurrence of MRSA in breeding pig herds in 2016, 2018 and 2019. However, the number of tested herds in 2016 (n = 6) was too low for a meaningful comparison of the results between the years and populations studied differed slightly between years with multiplier herds sampled in 2019 and a census on breeding pig herds carried out in 2018. Spa-typing data were reported in 2018 and 2019: All reported spa-types were those associated with CC398 (LA-MRSA). To note, Denmark used the 2-S method in 2016 but changed to 1-S in 2018. Norway is the only reporting country with a systematic surveillance and control programme that has been in operation since 2013. From 2014 to 2017 and again in 2019, very low levels of occurrence were reported as 0.1%, 0.5%, 0.1%, 0.4% and 0.1%, respectively. No pig herds tested positive for MRSA in 2018 and 2020 despite the large number of tested herds (641 in 2020). Since 2018, Norway has used the 1-S method of isolation, replacing the 2-S method that was in use until 2017.
MRSA occurrence data obtained from horse premises in Denmark were reported in 2018 and 2019 using the 1-S method, with similar levels seen in both years (8.1 and 10.8%). In both years, most isolates were spa-types associated with LA-MRSA, except for t843 in 2018/2019 and t3256 in 2019; all three isolates were confirmed to belong to CC130 and carry the mecC gene.

**Temporal trends of MRSA occurrence in cattle 2012-2021**

<table>
<thead>
<tr>
<th>Herd Type</th>
<th>Year</th>
<th>Spa Types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dairy cow herds (BE)</td>
<td>2018</td>
<td>t034 (6), t011 (10), t034 (2)</td>
</tr>
<tr>
<td>Dairy cow herds (DK)</td>
<td>2018</td>
<td>t034 (8 isolates), t034 (7 isolates), t267 CC97 (1)</td>
</tr>
<tr>
<td>Meat production cattle herds (BE)</td>
<td>2012</td>
<td>t011 (16 isolates), t223 (2), t223 ST22 (1)</td>
</tr>
</tbody>
</table>

*spa-types not reported.

**Veal calf herds < 1(BE):** In 2012, spa-types: t011 (40 isolates), t1451 (3), t1456 (1), t1985 (3), t3423 (1), untypable (1).
In 2015, spa-types: t011 (64 isolates), t034 (15), t037 (8), t044 (3), t1451 (3), t1580 (7), t1985 (8), t2287 (2), t3423 (5), untypable (1). The t044 isolates were PVL-negative. In 2018, spa-types: t011 CC398 (65 isolates), t034 CC398 (8), t1451 CC398 (1), t1580 CC398 (2), t3423 CC398 (1), t1985 CC398 (1), t1985 CC398 (1), t9433 CC398 (1). In 2021, spa-types: t386 (1), t011 (65), t034 (6), t1451 (1), t1456 (1), t2346 (1), t2370 (1), t3423 (1), t5210 (1), t6228 (1)

**Veal calf herds < 1(CH):** In 2015, spa-types: t011 (11 isolates), t034 (6) and t008 (2). The t008 isolates were PVL-positive.
In 2017, spa-types: t011 (14 isolates), t034 (7), t127 (1), t17359 (2). PVL status of the t127 isolate was not reported. In 2019, spa-types were not reported; however, all 11 isolates were confirmed to belong to CC398 using the sau1-hsdS1 CC398 PCR reaction (Stegger et al., 2011).

**Dairy cow herds (BE):** In 2012, spa-types: t011 (8 isolates), t037 (1), t1456 (1), t6228 (2), untypable (1). In 2015, t011 (4 isolates), t034 (1), t1580 (1), t1985 (2), t2383 (1), untypable (1). In 2018, spa-types: t011 CC398 (8 isolates), t034 CC398 (1), t223 (3), t1257 (1). The t223 isolates were PVL-negative; TSST status was not determined. The PVL status of the t1257 isolate was not reported. In 2021, spa-types: t037 (3), t011 (10), t034 (2).

**Dairy cow herds (DK):** In 2018, spa-types: t034 (7 isolates), t267 CC97 (1). In 2019, spa-types: t127 CC1 (1 isolate), t843 CC130 (1). The t127 isolate was PVL-negative, as well as negative for the human IEC gene scn. spa-type t843 was confirmed to carry the mecC gene.

**Meat production cattle herds (BE):** In 2012, spa-types: t011 (16 isolates), t221 (1), t1456 (1), t1985 (1). In 2015, spa-types: t011 (9 isolates), t034 (2), t1451 (1), t1580 (2), t2287 (1), t3423 (1). In 2018, spa-types: t011 CC398 (5 isolates), t1451 CC398 (1), t223 (2), t223 ST22 (1). All three t223 isolates were PVL-negative. One t223 isolate was confirmed to belong to ST22, harbour the tst gene and IEC genes (chp, sak and scn) from WGS data. In 2021, spa-types: t037 (2), t011 (2).

**Figure 55:** Temporal trends of MRSA occurrence in bovine animals, 2009–2021
Note: The 2-S method of isolation was used by Belgium and Germany from 2016 to 2019, as well as by Denmark in 2016, in Switzerland from 2010 to 2017 and in Norway from 2014 to 2017. The 1-S method was used by Switzerland in 2019 and 2021, by Denmark in 2018 and 2019, and by Norway in 2018–2021.

All isolates tested by Norway in 2018, 2020 and 2021 (n = 716 in 2018, n = 641 in 2020 and n = 763 in 2021) were MRSA negative; extremely low % positive MRSA isolates (range: 0.1%–0.5%) were reported in the other years. Norway is the only country with a control programme in place for MRSA in pigs.

**Fattening pigs (CH):** In 2010, spa-types: t034 ST398 (17 isolates), t011 ST398 (1), t208 ST49 (5). In 2011, spa-types: t034 ST398 (19 isolates), t011 ST398 (1), t208 ST49 (1), t2279 ST1 (1). In 2012, spa-types: t034 CC398 (61 isolates), t011 CC398 (9), t208 ST49 (2). In 2013, spa-types: t034 (63 isolates), t011 (10). In 2014, spa-types: t034 (57 isolates), t011 (19), t208 (1), t899 (1), t2741 (1). In 2015, spa-types: t034 (48 isolates), t011 (23), t032 (1), t571 (1), t899 (1), t1145 (1), t1250 (1), t4475 (1). In 2017, spa-types: t034 (63 isolates), t011 (61), t899 (2), t1451 (3), t2330 (1), t2876 (1). In 2019, spa-types were not reported; however, 159/160 isolates were confirmed to belong to CC398 using the sau1-hsdS1 CC398 PCR reaction (Stegger et al., 2011).

The remaining isolate did not survive cryo-conservation, therefore typing could not be performed.

**Fattening pigs (BE):** In 2016, spa-types: t011 CC398 (71 isolates), t1451 (1), t1456 (1), t1456 CC398 (1), t1580 (5), t1985 (6), t1985 CC398 (3), t034 (7), t034 CC398 (2), t037 (1), t898 (1), unspecified (11). In 2019, spa-types: t011 CC398 (67 isolates), t034 CC398 (11), t1451 CC398 (2), t1457 CC398 (1), t2346 CC398 (1), t2370 CC398 (2), t2383 CC398 (1), t3041 CC398 (1), t3119 CC398 (1), unspecified (18).

**Fattening pigs (DE):** No molecular typing results available.

**Fattening pigs (DK):** In 2016, spa-types not reported. In 2018, spa-types: t011 CC398 (22 isolates), t034 CC398 (85), t571 CC398 (3), t898 CC398 (1), t2383 CC398 (1), t2974 CC398 (1), t4652 CC398 (1), t9266 CC398 (1). Prevalence data for fattening pig herds (not raised under controlled housing conditions) from 2018 are not included.

**Breeding pigs (BE):** In 2016, spa-types: t011 CC398 (55 isolates), t1451 (2), t1456 (1), t1456 CC398 (3), t1580 (1), t1985 (5), t1985 CC398 (1), t034 (1), t034 CC398 (4), t4659 CC398 (1), unspecified (17). In 2019, spa-types: t011 CC398 (57 isolates), t034 CC398 (18), t108 CC398 (2), t779 CC398 (1), t2346 CC398 (1), t2582 CC398 (1), t2922 CC398 (1), t3119 CC398 (2).

**Breeding pigs (DK):** In 2016, spa-types not reported. In 2018, spa-types: t011 CC398 (6 isolates), t034 CC398 (24), t1250 CC398 (2), t1793 CC398 (1), t1771 CC398 (1). In 2019, spa-types t011 CC398 (10), t034 CC398 (57), t1928 CC398 (1), t4652 CC398 (1) were identified in isolates from multiplier pig herds.

**Pig herds (NO):** In 2014, spa-type: t011 CC398 (1). In 2015, spa-type: t034 CC398 (2), t177 CC1 (2). In 2016, spa-type: t034 CC398 (1). In 2017, spa-types: t091 CC7 (1 isolate), t843 CC130 (1), t6292 CC425 (1). The t091 isolate was PVL-negative, spa-types t843 and t6292 were confirmed to carry the mecC gene. In 2019, spa-type: t034 CC398 (1).

Figure 56: Temporal trends of MRSA occurrence in pigs, 2010–2020
6.5. Summary data on the occurrence and susceptibility of MRSA

Determination of the susceptibility of MRSA isolates to antimicrobials, including those of medical importance, such as linezolid and vancomycin, provides valuable information on the MRSA situation in animals and food. The importance of monitoring AMR patterns among different lineages is underlined by the potential for multiple resistance genes harboured by less virulent strains to spread to other *S. aureus* strains (Sahibzada et al., 2017).

In 2021, data on the antimicrobial susceptibility of MRSA isolates were reported by Belgium, Germany and Switzerland. In 2020, such data were provided by Austria, Belgium and Germany (see Annex E, Table 7a,b). All countries used a broth dilution method and applied EUCAST epidemiological cut-offs (ECOFFs) to determine the susceptibility of isolates, and as expected, all MRSA isolates were resistant to penicillin and ceftaroline.

6.5.1. Susceptibility data of MRSA isolates from meat and food-producing animals (excluding clinical investigations)

Figures 57 and 58 (see also Annex E, Table 7a,b) present the overall resistance to selected antimicrobials within food-producing animal and the meat origins in 2020 and 2021.

In 2020 and 2021, extremely high levels of tetracycline resistance were reported in isolates from most reported animal populations (see Figure 57; see also Annex E, Table 7a,b). This is in line with a very high proportion of isolates from animals that can be assigned to the CC398, which are typically resistant to tetracycline (Crombé et al., 2012). All isolates from food-producing animals were reported to be resistant to tetracycline, except for three isolates out of 155 from pigs reported by Switzerland in 2021. In 2020, only Belgium provided susceptibility data for only a few animal isolates (two isolates from broiler flocks and two from fattening turkeys) and all were resistant to tetracycline.

Resistance to other antimicrobials was more heterogeneous among the animal populations. High heterogeneity was observed in the 155 isolates from fattening pigs from Switzerland in 2021. Moderate to high resistance levels were reported for aminoglycosides (gentamicin 10.3%, kanamycin 10.3%, streptomycin 25.2%) and chloramphenicol (12.3%), clindamycin (43.2%), quinupristin/dalfopristin (42.6%), tiamulin (43.2%) and trimethoprim (47.7%).

Susceptibility data was reported for calves under 1 year of age in Switzerland (18 isolates), and Belgium (79 isolates). Isolates from Swiss calves displayed very high resistance to streptomycin, ciprofloxacin, erythromycin and clindamycin (50%, 55.6%, 55.6% and 61.1%, respectively). Extremely high levels of resistance were detected for erythromycin (93.7%) and clindamycin (93.7%) in isolates from Belgian calves. Moreover, isolates from Belgium calves also displayed very high resistance to gentamicin (67.1%), kanamycin (70.9%) and trimethoprim (96.2%).

Belgium also reported susceptibility data for MRSA isolated from dairy cows (15 isolates) and bovine meat production animals (4 isolates). Isolates from meat production animals displayed very high resistance to streptomycin (60%), erythromycin (60%), trimethoprim (66.7%) in dairy cows, and to gentamicin (50%), kanamycin (100%), streptomycin (50%), rifampicin (50%), erythromycin (50%), sulfamethoxazole (50%) and trimethoprim (50%). However, cautious interpretation of these results is advised due to the small sample size.

In 2021, two MRSA isolates from meat production animals and three isolates from dairy cows were resistant to rifampicin, an important antimicrobial for human use. No isolates were resistant to other antimicrobials of specific importance to the control of MRSA in humans, including vancomycin and mupirocin. Two isolates were resistant to rifampicin, and another three to mupirocin (Figure 57; Annex E, Table 7a).

Germany reported susceptibility data for 23 isolates from bovine meat and a single isolate from pig meat in 2021, several which were from imported meat at border control posts. Germany also reported susceptibility data for 11 isolates from sheep meat in 2020. Austria reported on 8 isolates from broiler meat in 2020 (Figure 58; see also Annex E, Table 7a,b). Isolates from bovine meat showed a lower frequency of resistance to gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, quinupristin/dalfopristin, trimethoprim and tetracycline than those from bovine animals.

Resistance data on eight isolates from boiler meat were reported by Austria in 2020 (Annex E, Table 7b). Five of those isolates were also resistant to erythromycin and clindamycin. However, cautious interpretation of these results is advised due to the small sample size of eight isolates.

Only six of the 11 isolates from sheep meat in 2020 and 10 of the 23 isolates from bovine meat in 2021 from Germany were resistant to tetracycline (Figure 58; see also Annex E, Table 7a,b). This is in
line with the high proportion of non-CC398 strains (n = 5) among these isolates. All non-CC398 strains were susceptible to tetracycline. Resistance in more than one of the isolates was only observed for three antimicrobials: erythromycin (5 isolates), clindamycin (2) and trimethoprim (3). However, interpretation of the results needs caution on account of the limited number of isolates. Interestingly, one of the isolates from sheep meat was resistant to vancomycin, an antimicrobial of utmost importance for the treatment of MRSA infections in the medical field. Whole genome sequencing revealed that the isolate did not carry a specific vancomycin-resistance gene. This is in accordance with the limited MIC value of 4 mg/l, i.e. one dilution step above the cut off.
BE: Belgium; CH: Switzerland. N: number of tested isolates. All isolates were resistant to Penicillin and Cefoxitin.

Figure 57: Antimicrobial resistance in MRSA from animals, in 2021
6.5.2. Meat and food-producing animals: multidrug resistance in MRSA isolates (excluding clinical investigations)

MRSA are typically resistant to penicillins and cephalosporins. Moreover, most isolates also show resistance to three or more substances and can be considered multi-drug resistant (MDR). Overall, MDR patterns displayed substantial variability (Annex E, Table 8a). In 2021, 98% (289/295) of MRSA isolates reported in bovine animals, pigs and meat thereof from Switzerland, Germany and Belgium displayed MDR patterns. All MDR isolates were resistant to penicillin and cefoxitin.

All isolates from pigs (155/155) and calves (18/18) reported by Switzerland were MDR. The most common MDR pattern in pig isolates (27) displayed resistance to erythromycin, clindamycin, quinupristin/dalfopristin, tiamulin, trimethoprim and tetracycline. In contrast, the most common MDR pattern observed in calf isolates (4) included streptomycin, erythromycin, clindamycin and tetracycline. One-hundred percent (79/79) of isolates from calves, dairy cows (15/15) and meat production bovine animals (4/4) from Belgium were MDR. Twenty-eight of the MDR calf isolates were resistant to gentamicin, kanamycin, erythromycin, clindamycin, trimethoprim and tetracycline. Three isolates from dairy cows and two from meat production animals displayed resistance to kanamycin, streptomycin, chloramphenicol, rifampicin, erythromycin, sulfamethoxazole and tetracycline. Germany reported that 73.9% (17/23) of isolates from bovine meat were MDR. The most commonly reported MDR pattern included penicillin, cefoxitin and ciprofloxacin. This was the only MDR pattern identified without tetracycline resistance.

The most commonly described MDR pattern in isolates from 2020 included penicillin, cefoxitin and tetracycline (18/23 isolates). These were isolated from turkeys, broilers, broiler meat and sheep meat reported by Belgium, Austria and Germany (Annex E, Table 8b). Only five sheep meat isolates from Germany did not display resistance to tetracycline.
6.6. Discussion

The monitoring of MRSA in animals and food was voluntary in 2020 and 2021 and only a limited number of countries reported data on the occurrence of MRSA. Moreover, sampling and laboratory techniques are not fully harmonised across countries. Therefore, comparisons across countries should be done with prudence.

Recently, EFSA has published the technical specifications for a baseline survey to assess the prevalence of MRSA and the associated antimicrobial resistance in fattening pigs at the EU level (EFSA, 2022). The survey will also investigate the genetic diversity of the MRSA isolates, including lineages/strains and virulence factors. The timing of these surveys is planned to be harmonised between MSs to optimise the comparability of results. This will allow scientists to gain an overview of the current situation of MRSA in European pig populations.

Food: occurrence of MRSA

The monitoring of MRSA in various food products performed by MSs in 2020/2021 indicates that MRSA can be detected in different types of food. Imported meat may also play a role. However, occurrence varies between types of food and countries. While the numbers of investigated samples differed, MRSA were detected in all reported meat categories.

It should be underlined that the laboratory techniques used to detect MRSA employ selective bacterial culture and therefore, very low levels of contamination in food can be detected (Pauly et al., 2019). Although a previous report has cautiously suggested that some strains of LA-MRSA may be adapted to colonise and infect humans and reported poultry meat as a possible source of MRSA for humans (Larsen et al., 2016), food is not generally considered to be a significant source of MRSA infection or colonisation of humans (EFSA, 2009a; FSA (Food Standards Agency), 2017). Nevertheless, MRSA is still frequently detected in animal food products and are considered to be a public health concern (da Silva et al., 2020; Titouche et al., 2022).

Animals: occurrence of MRSA

In 2020 and 2021 MRSA were reported in animals in the framework of monitoring programs, surveys and as a result of clinical investigations. While monitoring results and surveys will typically allow for an estimation of the occurrence of MRSA in the investigated animal population, this is not valid for clinical investigations due to the sampling bias associated with the clinical conditions. The comparison of the occurrence of MRSA in the animal populations is always hampered by the lack of precision and harmonisation of the definition of the animal populations. As AMR tends to differ between different animal populations of the same animal species, these differences need to be considered, when comparing the results from different reporting countries (Mesa Varona et al., 2020).

Another potential confounder could include the sampling strategy. Norway has been investigating pig herds in the framework of the control programme for several years, which could increase the likelihood of detecting positive herds even if they are rare.

The location of sampling could also influence the detection of MRSA, as Broens et al., 2011 found that batches of pigs at slaughter were more frequently positive than pigs at farm, potentially due to contamination of pigs during transport. Therefore, prevalence estimates should not be directly compared for the two sampling locations.

An additional aspect to be considered are differences in the types and numbers of samples collected. Sampling of nasal swabs is a frequent approach, but the numbers of samples tested may differ between countries with a likely effect on the prevalence estimate. Frequently, for the convenience of sample collection, dust from the housing environment is sampled despite concerns over the sensitivity of testing these samples (EFSA, 2012).

The occurrence of MRSA appears stable in veal calves and dairy cows from Belgium between 2012 and 2021, with a higher rate of detection in calves. Stable levels of MRSA have also been observed in calves from Switzerland between 2015 and 2021. In contrast, the occurrence of MRSA isolates detected in meat production animals in Belgium has slowly been reducing.

No MRSA was isolated in pigs from Norway in 2020 and 2021. This is in line with the low levels of MRSA identified in the previous years. These findings might be explained by the annual comprehensive surveillance programme of MRSA that Norway has implemented in their pig populations. In contrast, the occurrence of MRSA in pigs from Switzerland has slowly been increasing since 2010, with the
occurrence in 2021 (53.6%) being only slightly higher than 2019 (52.8%). Kittler et al., 2019 suggested that the increase observed in Swiss pigs could be due to clonal complex 398 with the spa-type t011, however, molecular data was not available for the isolates submitted and so this cannot be confirmed.

Occurrence of MRSA in flocks of broilers and laying hens in Belgium was very low in 2020, as it had been in previous years. The reason for this rare occurrence is not known yet as it contrasts with the regular detection of MRSA in broiler meat. MRSA were more often observed in turkey flocks from Germany, which was also previously reported for turkey carcasses elsewhere (Vossenkuhl et al., 2014; El-Adawy et al., 2016).

Typing findings of MRSA in animals and food

Some countries additionally reported data on spa-type/clonal complex and antimicrobial susceptibility of the MRSA isolates from animals and food. The number of reported isolates was higher in 2021 than in 2020.

Among the isolates from animals with available typing results in 2020 and 2021, only six isolates reported in 2021 could not be assigned to CC398. This underlines the fact that CC398 widely dominates the MRSA from animals in the reporting countries. These six isolates originated from bovine animals. Remarkably, all isolates were from Belgium and five of the six isolates were assigned to CC8, a major clonal complex worldwide, including both hospital and community associated strains (Aires-de-Sousa, 2017; Turner et al., 2019). The identification of this CC in bovine animals could be due to the emergence of the bovine adapted strain belonging to CC8 which has been suggested to have made a jump from humans to bovines (Resch et al., 2013). The other non-CC398 isolate was an ST1/CC1 of spa-type t386, that has been identified in methicillin susceptible S. aureus isolated from chicken samples in Gabon and in MRSA isolated from a hedgehog in Spain (Lozano et al., 2016; Silva et al., 2020). The origin of such isolates is debatable. This spa-type does not seem to be established in the food-producing animal populations, the clonal complex has been described as being livestock associated. This particular isolate might have originated from people handling the animals as exchange of bacterial strains between animals and humans is likely for strains that can colonise several species. In 2020, typing information on isolates from animals was only provided for four isolates (two isolates from broiler flocks, and two from turkey flocks). These were all from the predominant spa-type t011.

The livestock associated lineage of CC398 was also the most prevalent MRSA type detected in food with 68.5% of 124 typed isolates assignable to that CC in 2021 and 73.7% of 19 isolates in 2020. Remarkably, the proportion of non-CC398 isolates in food is higher than in animals, which may indicate contamination at slaughterhouses or processing plants. This is in line with the literature and requires further targeted investigations (Tenhagen et al., 2014; Vossenkuhl et al., 2014). Isolates from broiler meat in Austria in 2020 were, however, all attributed to the CC398.

Isolates of other CCs (CC1, CC5, CC8, CC45, CC97, CC130) and of spa-types assignable to other CCs were observed in aveal calf, dairy cows, cattle, meat from bovines and pigs in 2021. Interestingly, isolates from meat at border inspection posts were all non CC398. CC1 is commonly isolated in humans and is considered to be community-associated, but has also been widely reported in livestock as well as wildlife in Europe (Silva et al., 2020). MRSA isolates belonging to CC5 have previously been observed in turkeys; however, this clonal complex is also a major HA-MRSA lineage worldwide. CC45 was identified in a single MRSA isolate from pig meat. This CC is another widely disseminated clonal complex that is primarily associated with isolates from humans, suggesting potential contamination of the meat (Cuny et al., 2015). CC97 isolates have previously been associated with bovines (Kappeli et al., 2019) and pigs in Italy (Feltrin et al., 2016), but they have also been observed in human cases unrelated to animal production (Monecke et al., 2011; Boswihi et al., 2020). Therefore, their origin in food is doubtful. Isolates of CC130 harbouring the mecC gene have been observed in horses, cattle and sheep before (Paterson et al., 2014; Haenni et al., 2015; Giacinti et al., 2017; Islam et al., 2017). However, they are also a medical concern (Lozano et al., 2020).

Further typing data would in many cases provide useful additional information to aid classification and help assess the origin and significance of the MRSA isolates. For example, possession of the IEC genes (chp, sak and scn) is considered an adaptation facilitating colonisation and infection of humans and is not usually a feature seen in animal strains (Cuny et al., 2015; Larsen et al., 2016). Similarly, the presence of the PVL toxin is a virulence feature typically associated with most CA-MRSA strains; other genetic factors can be associated with particular strains or may suggest a particular host preference (e.g. lukM has been associated with certain animal strains, particularly those affecting...
ruminants). Some genomic factors that seem to be associated with MRSA strains that shifted from human hosts to animals included the *vwfb* gene, an animal specific virulence factor that is associated with clotting of animal plasma, and a novel staphylococcal cassette chromosome mec island (Resch et al., 2013; Yu et al., 2021).

**Antimicrobial resistance in MRSA from animals and food**

Antimicrobial resistance of MRSA differed substantially between the different origins of the bacteria. In line with the literature, MRSA of CC398 were mostly resistant to tetracycline and lower resistance rates to tetracycline were only observed if MRSA of other CCs were involved, e.g. in meat from a pig in Germany in 2021 and meat from sheep in Germany 2020. Here, all five non-CC398 isolates were susceptible to tetracycline. Resistance to important medical drugs for the treatment and control of MRSA was overall extremely low. However, resistance to vancomycin was observed in an isolate from sheep meat in Germany in 2020, and resistance to rifampicin was detected in isolates from dairy cows and bovine meat from Belgium in 2021.

The occurrence of these types of resistance is worrisome as vancomycin is one of the preferred drugs of choice to treat MRSA infections, and rifampicin is often used in combination with vancomycin to treat implant associated *S. aureus* infections (Guo et al., 2021; Maraolo et al., 2021). Interestingly the rifampicin resistant isolates all belonged to ST239, which has been associated with high rates of rifampicin resistance previously (Guo et al., 2021). The vancomycin resistant isolate did not harbour one of the typical vancomycin resistance genes, which is in line with the limited increase in the MIC (4 mg/L). These moderate increases are typically caused by multiple point mutations rather than by specific vancomycin resistance genes like *vanA* or *vanB* (McGuinness et al., 2017). Fortunately, resistance to other medically important drugs for the control of MRSA such as mupirocin was not observed in 2020/2021. Mupirocin is an important component of the decolonisation therapy used prior to surgery in MRSA positive patients.

**Temporal trends of MRSA occurrence in various types of meat and food-producing animals**

In 2018, the recommended method for the isolation of MRSA was revised by the EURL-AR from the 2-S method (which comprised a pre-enrichment step and a selective enrichment step) to the 1-S method (whereby the selective enrichment step is omitted). Therefore, and because of the limited number of reported samples, direct comparisons of longitudinal data obtained using different protocols should be performed with caution. In line with these limitations, we did not perform statistical trend analyses but only presented changes over time descriptively.

The Netherlands reported an incremental annual increase in the occurrence of MRSA isolated from meat from bovines under 1 year old between 2018 and 2021. This might be due to contamination of the meat by workers and the environment of the slaughterhouses, or perhaps the bovine population has been exposed to MRSA via farmers. A recent review suggested that MRSA isolation in dairy cows from the Netherlands might be due to exposure to pigs or pig farmers (Lam et al., 2020). Pig populations and pig farmers in the Netherlands have been shown to have a high prevalence of MRSA (Dierikx et al., 2016). We do not have 2021 data on MRSA occurrence in fattening pigs from Netherlands and the isolation of MRSA seemed to decrease from 2019 to 2020; however, this could be linked to a small sample size in 2020. Low rates of MRSA isolation in the pig population could also be due to the 69.6% reduction in antimicrobial usage by Dutch farmers (those raising broilers, pigs and veal calves) between 2009 and 2019 (Mallioris et al., 2022). However, a recent review noted that despite a decrease in antimicrobial usage in European animal production in recent years, the occurrence of MRSA in farm animals has not decreased. It was suggested that this is most likely due to other reservoirs of MRSA such as farm workers and veterinarians (Crespo-Piazuelo and Lawlor, 2021).

Similarly, Austria has also reported an increase in MRSA detected in samples from pig and bovine meat in 2021 compared to 2019. Without data on MRSA isolation in live pigs and bovines it is difficult to say whether this might be due to an increase of MRSA colonisation in farm animals or whether this could be due to contamination at the slaughterhouses. The occurrence of MRSA isolated from fattening pigs reported by Switzerland also increased annually from 2010 to 2021, with a marked increase noted from 2015 to 2017. This increase most likely represents the dissemination of particular livestock-associated spa-types in Swiss fattening pig populations; and where molecular typing data
were available, all isolates in 2017 and 2019 were those associated with CC398, with most belonging to spa-types t011 and t034 in 2017. A longitudinal study carried out by Kraemer et al. (2017) also supports these trends, in which MRSA occurrence of pig farms in Western Switzerland were reported to increase from 7.3% in 2008 to 31% in 2015.

The complete epidemiological data should however be considered when evaluating trends apparent in this chapter, because the summary data reported to EFSA may not include full details of any changes to methodology or monitoring procedures. A detailed longitudinal study illustrated that pigs are intermittently and repeatedly colonised, and that colonisation may also occur during transportation and while being in the lairage (Bangerter et al., 2016). The detection of intermittent, repeated colonisation suggests that the number of animals sampled as part of a batch, including whether individual animals are sampled to represent a herd or batch, is likely to influence the batch or herd occurrence obtained. These factors should therefore be taken into consideration when comparing trends, as the Swiss annual MRSA monitoring examines a single pig from a herd at slaughter.

References


EURL (European Union Reference Laboratory for Antimicrobial Resistance), 2018. Laboratory Protocol, Isolation of methicillin-resistant Staphylococcus aureus (MRSA) from food-producing animals and farm environment. Technical University of Denmark.
FSA (Food Standards Agency), 2017. Risk Assessment on Meticillin-Resistant Staphylococcus aureus (MRSA), with a focus on Livestock-associated MRSA in the UK Food Chain. Available online: https://www.food.gov.uk/sites/default/files/media/document/mrsa_risk_assessment_feb17_0.pdf


García AB and Steele WB, Reid SW and Taylor DJ, 2010a. Risk of carcase contamination with Campylobacter in sheep sent for slaughter into an abattoir in Scotland. Preventive Veterinary Medicine, 95(1–2), 99–107.


Garcia AB, Steele WB, Reid SW and Taylor DJ, 2010a. Risk of carcase contamination with Campylobacter in sheep sent for slaughter into an abattoir in Scotland. Preventive Veterinary Medicine, 95(1–2), 99–107.


**Abbreviations**

% Percentage  
% f Percentage frequency of isolates tested  
% Res Percentage of resistant isolates  
AMC Antimicrobial consumption  
AMR Antimicrobial resistance  
AMS Antimicrobial stewardship  
AST Antimicrobial susceptibility test  
CA-MRSA Community associated MRSA  
CASFM Comité de l’Antibiogramme de la Société Française de Microbiologie  
CBP Clinical breakpoints  
CC Clonal complex  
CI Confidence interval  
CIA Critically important antimicrobial  
CLSI Clinical and Laboratory Standards Institute  
CS Complete susceptibility  
CP Carbapenemase producer  
DD Disc diffusion method  
DL Dilution/dilution method  
DLG Dilution with gradient step  
EARS-Net European Antimicrobial Resistance Surveillance Network  
ECDC European Centre for Disease Prevention and Control  
ECOFF Epidemiological cut-off value
Antimicrobial substances

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMC</td>
<td>Amoxicillin/clavulanate</td>
</tr>
<tr>
<td>AMK</td>
<td>Amikacin</td>
</tr>
<tr>
<td>AMP</td>
<td>Ampicillin</td>
</tr>
<tr>
<td>AZM</td>
<td>Azithromycin</td>
</tr>
<tr>
<td>CLA</td>
<td>Clavulanate</td>
</tr>
<tr>
<td>CTZ/CAZ</td>
<td>Ceftazidime</td>
</tr>
<tr>
<td>CHL</td>
<td>Chloramphenicol</td>
</tr>
<tr>
<td>CIP</td>
<td>Ciprofloxacin</td>
</tr>
<tr>
<td>CLI</td>
<td>Clindamycin</td>
</tr>
<tr>
<td>COL</td>
<td>Colistin</td>
</tr>
</tbody>
</table>

WHO

World Health Organization
CTX Cefotaxime
ERT/ETP Ertapenem
ERY Erythromycin
CFT Cefoxitin
FUS Fusidic acid
GEN Gentamicin
KAN Kanamycin
LZD Linezolid
MEM Meropenem
MUP Mupirocin
NAL Nalidixic acid
PEN Penicillin
PEF Pefloxacin
QD Quinupristin/Dalfopristin
RIF Rifampicin
SMX Sulfonamides
STR Streptomycin
SUL Sulfonamides
SXT Trimethoprim-sulfamethoxazole
TET/TCY Tetracycline
TIA Tiamulin
TIG Tigecycline
TMP Trimethoprim

**MSs of the EU and other reporting countries**

AT Austria
BE Belgium
BG Bulgaria
HR Croatia
CY Cyprus
CZ Czechia
DK Denmark
EE Estonia
FI Finland
GR France
DE Germany
EL Greece
HU Hungary
IE Ireland
IT Italy
LV Latvia
LT Lithuania
LU Luxembourg
MT Malta
NL Netherlands
PL Poland
PT Portugal
RO Romania
SK Slovakia
SI Slovenia
ES Spain
SE Sweden

**Non-MSs reporting**

AL Albania
IS Iceland
MK Republic of North Macedonia
Definitions

'Antimicrobial-resistant isolate'  In the case of quantitative data, an isolate was defined as 'resistant' to a selected antimicrobial when its minimum inhibitory concentration (MIC) value (in mg/L) was above the cut-off value or the disc diffusion diameter (in mm) was below the cut-off value. The cut-off values, used to interpret MIC distributions (mg/L) for bacteria from animals and food, are shown in Appendix F 'Material and methods', Tables F.5–F.7.

In the case of qualitative data, an isolate was regarded as resistant when the country reported it as resistant using its own cut-off value or break point.

'Level of antimicrobial resistance'  The percentage of resistant isolates among the tested isolates.

'Reporting MS group'  Member States (MSs) that provided data and were included in the relevant table for antimicrobial resistance data for the bacteria–food/animal category–antimicrobial combination.

Terms used to describe the levels of antimicrobial resistance

Rare: < 0.1%
Very low: 0.1%–1.0%
Low: > 1.0–10.0%
Moderate: > 10.0% to 20.0%
High: > 20.0% to 50.0%
Very high: > 50.0% to 70.0%
Extremely high: > 70.0%
Appendix A – High-level resistance to ciprofloxacin among certain Salmonella serovars recovered from poultry origins as well as a single isolate from a fattening pig

High-level resistance to ciprofloxacin in S. Kentucky

Considering individual serovars, in 2020, S. Kentucky accounted for most of the Salmonella isolates recovered from the poultry origins which exhibited MICs to ciprofloxacin of ≥ 4 mg/L. Within each of the poultry origins, the highest number of Salmonella isolates exhibiting high-level resistance to this antimicrobial were attributed to S. Kentucky; this serovar accounted for 86.4%, 91.7%, 76.5%, 100% and 93.1% of the total number of isolates displaying MICs of ≥ 4 mg/L from broiler carcasses, turkey carcasses, broilers, laying hens and turkeys, respectively. Additionally, in 2021, only a single isolate recovered from a fattening pig also displayed high-level ciprofloxacin resistance and was serotyped as S. Kentucky. No Salmonella spp. isolates from calves displayed high-level resistance to ciprofloxacin.

S. Kentucky isolates exhibiting high-level ciprofloxacin resistance are likely to belong to the multilocus sequence type (ST) 198 clone, which has shown epidemic spread, first in Africa, then the Middle East, Asia and finally Europe (Le Hello et al., 2011, 2013; Hawkey et al., 2019). Notably in 2018, the occurrence of this serovar exhibiting high-level resistance was observed by many MSs from most parts of Europe, suggesting further clonal expansion (S. Kentucky ST198-X1) within poultry populations. In view of reported MIC values, most of the S. Kentucky isolates exhibiting high-level ciprofloxacin resistance in 2020/2021 displayed MICs of ≥ 8 mg/L. Additionally, a very high proportion of the poultry S. Kentucky isolates displaying ciprofloxacin MICs of ≥ 4 mg/L were also multiresistant, primarily showing resistance to ampicillin, gentamicin, nalidixic acid, sulfamethoxazole and tetracycline (AMP-CIP-GEN-NAL-SMX-TET). The single isolate from the fattening pig showing high resistance to ciprofloxacin, was also resistant to nalidixic acid (with an MIC > 64 mg/L for nalidixic acid), sulfamethoxazole, tetracycline and trimethoprim.

Figure A.1 presents the overall AMR levels among MDR S. Kentucky isolates from poultry which exhibited high-level ciprofloxacin resistance.

Figure A.1: Resistance levels among MDR Salmonella Kentucky isolates exhibiting high-level ciprofloxacin resistance from poultry, reported by MSs in 2020

In 2021, S. Kentucky was the 21st most commonly reported serovar in humans, with 145 cases reported in EU/EEA countries. From the monitoring of human cases in 2021, high to extremely high levels of resistance were noted to gentamicin (27.9%), sulfonamides (51.6%), ampicillin (62.9%), tetracyclines (58.1%), ciprofloxacin (78.1%) and nalidixic acid (79.7%); consistent with the
multiresistance patterns observed in isolates from the monitoring of poultry in 2020, and the possible dissemination of the S. Kentucky ST198 strain within Europe. Furthermore, of 6,162 Salmonella isolates from humans where ciprofloxacin MIC data was available, 76 of these (1.2%) exhibited MICs of $\geq$ 4 mg/L, of which S. Kentucky accounted for 56 (73.7%).

Hawkey et al. (2019) recently documented that MDR S. Kentucky ST198 is a globally disseminated clone, capable of rapid spread and accumulation of resistance determinants to last-line antimicrobials. Acquisition of Salmonella genomic island 1 (SGI1) and plasmids, as well as mutations in the Quinolone Resistance-determining regions (QRDR), were the only genetic features found during this study to explain the global epidemiological success of the MDR S. Kentucky ST198 lineage which is highly resistant to ciprofloxacin. Coipan et al. (2020) describe how a clone of this lineage, with an ESBL-gene (blaCTX-M-14b) incorporated on the chromosome, has emerged in Europe. In contrast to plasmid-mediated resistance, chromosomal-mediated resistance is most likely to be maintained also without antibiotic pressure, especially if it incurs no fitness cost for the bacteria.

**High-level resistance to ciprofloxacin among other Salmonella serovars**

In 2020, while S. Kentucky generally accounted for an important number of the Salmonella isolates exhibiting high-level resistance to ciprofloxacin, there was also a significant contribution from S. Infantis in broilers and broiler carcasses, many other serovars exhibiting resistance by this definition were noted among the poultry origins (namely S. Newport, S. Derby and S. Bredeney). Figure A.2 shows the number of isolates exhibiting high-level resistance to ciprofloxacin by serovar within each of the poultry origins. Considering ciprofloxacin MICs among the serovars presented in Figure A.2 (excluding S. Kentucky), MICs of 4 mg/L were reported in S. Derby (from turkeys), S. Infantis and S. Newport (from broiler carcases), S. Bredeney (from turkey carcases), S. Infantis and S. Newport (from broilers).

![Number of isolates displaying high-level ciprofloxacin resistance by serovar in fattening poultry, 2020](image)

**n:** Total number of Salmonella isolates exhibiting high-level ciprofloxacin resistance; **ns:** number of isolates by serovar exhibiting high-level ciprofloxacin resistance; In addition, a single S. Kentucky isolate displaying high-level ciprofloxacin resistance was also recovered from a fattening pig in 2021.

**Figure A.2:** Number of Salmonella isolates displaying high-level ciprofloxacin resistance by serovar, reported from the different poultry origins by MSs in 2020
Appendix B – Cefotaxime, ceftazidime and ciprofloxacin resistance in *Salmonella* spp. recovered from each of the animal/carcase origins and humans considering all reporting MSs in 2020/2021

Table B.1: Occurrence of resistance to third-generation cephalosporins and fluoroquinolones in non-typhoidal *Salmonella* spp. from food-producing animals, animal carcases and humans, reported by MSs in 2020/2021

<table>
<thead>
<tr>
<th>Human/animal category</th>
<th>No. of MSs</th>
<th>N</th>
<th>Cefotaxime</th>
<th>Ceftazidime</th>
<th>Ciprofloxacin/pefloxacin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Humans – 2020*</td>
<td>See footnote below</td>
<td>–</td>
<td>0.8(a)</td>
<td>–</td>
<td>0.8%(c)</td>
</tr>
<tr>
<td>Humans – 2021*</td>
<td>–</td>
<td>–</td>
<td>1.1%(d)</td>
<td>–</td>
<td>1.1%(e)</td>
</tr>
<tr>
<td>Broiler carcases – 2020</td>
<td>18 MSs</td>
<td>905</td>
<td>3</td>
<td>0.1%</td>
<td>1</td>
</tr>
<tr>
<td>Turkey carcases – 2020</td>
<td>8 MSs</td>
<td>320</td>
<td>0</td>
<td>0%</td>
<td>0</td>
</tr>
<tr>
<td>Broilers – 2020</td>
<td>22 MSs</td>
<td>1,953</td>
<td>39</td>
<td>2.0%</td>
<td>40</td>
</tr>
<tr>
<td>Laying hens – 2020</td>
<td>24 MSs</td>
<td>1,030</td>
<td>4</td>
<td>0.4%</td>
<td>4</td>
</tr>
<tr>
<td>Fattening turkeys – 2020</td>
<td>16 MSs</td>
<td>674</td>
<td>3</td>
<td>0.5%</td>
<td>3</td>
</tr>
<tr>
<td>Fattening pigs – 2021</td>
<td>26 MSs + XI</td>
<td>1,258</td>
<td>11</td>
<td>0.9%</td>
<td>11</td>
</tr>
<tr>
<td>Calves (&lt; 1 year) – 2021</td>
<td>10 MSs</td>
<td>79</td>
<td>2</td>
<td>2.5%</td>
<td>1</td>
</tr>
</tbody>
</table>

N: Total number of isolates tested/reported by MSs; n: Total number of isolates resistant; MSs: Member states.

*: In most countries using disk diffusion methods, ciprofloxacin has been replaced by pefloxacin for screening for fluoroquinolone resistance, as recommended by EUCAST.

(a): N = 7,101, 19 MSs.
(b): N = 6,000, 16 MSs.
(c): N = 6,906, 20 MSs.
(d): N = 11,572, 22 MSs.
(e): N = 10,385, 21 MSs.
(f): N = 11,725, 23 MSs.
Appendix C – Occurrence of antimicrobial resistance at the *Salmonella* serovar level

**In carcasses of food-producing animals**

**Breakdown of the most prevalent serovars**

The detailed reporting of results at the serovar level clearly demonstrated the major contribution of a few serovars to the observed occurrence of resistance in *Salmonella* spp. Figure C.1 illustrates the relative contribution of some of the most dominant serovars recovered from each of the carcass origins considering all reporting countries (including non-MSs). In broiler carcasses, six serovars (Infantis, Enteritidis, Agona, Montevideo, Indiana and Chester) accounted for 76.3\% of *Salmonella* isolates; while in turkey carcasses, Bredeney, Hadar, Indiana, monophasic Typhimurium and Kentucky accounted for 57.5\% of *Salmonella* spp. isolated from this origin. Other serovars represented about 30\% of the *Salmonella* isolates reported in both broiler and turkey carcasses.

![Commonly reported serovars from carcasses of food-producing animals, 2020](image)

*Monophasic *S*. Typhimurium includes antigenic formulas; serovars in the legend are listed according to their predominance within all the carcass origins.*

**Figure C.1:** Commonly reported *Salmonella* serovars from carcasses of broilers and fattening turkeys, for all reporting countries (including two non-MSs in broiler carcasses) in 2020

**Complete susceptibility and multidrug resistance**

Patterns of resistance associated with these different serovars have a marked influence on the overall resistance levels in *Salmonella* spp., and Figure C.2 summarises the proportion of completely susceptible and MDR isolates among particular serovars recovered from each of these carcass origins considering all reporting countries (including non-MSs). Large contributions of a few resistant serovars to the overall level of MDR among *Salmonella* spp. were evident within some of the carcass origins; notably *S*. Infantis (79.2\%, 400/505) in broiler carcasses (see Figure C.6).
N: Total number of *Salmonella* spp. or total number of particular serovars recovered from the carcass monitoring.

*Monophasic S. Typhimurium includes antigenic formulas. The ECOFF used to determine resistance to tigecycline was MIC $> 1$ mg/L.

**Figure C.2:** Proportions of isolates completely susceptible (green), resistant to 1 or 2 antimicrobial classes (gold) and multidrug-resistant (red) in *Salmonella* spp. and particular *Salmonella* serovars.
In food-producing animal populations

Breakdown of the most prevalent serovars

Considering all reporting countries (including non-MSs), the relative contribution of some of the most dominant serovars recovered from each of the food-producing animal populations is illustrated in Figure C.3. In pigs, six serovars (Derby, monophasic Typhimurium, Typhimurium, Rissen, Infantis and Brandenburg) accounted for 82.2% of *Salmonella* spp., while in calves, serovars monophasic Typhimurium, Typhimurium, Dublin, Bredeney, Stanleyville and Enteritidis accounted for 62.0% of the total *Salmonella* spp. recovered from this origin. Additionally, in broilers, six serovars (Infantis, Enteritidis, Kedougou, Montevideo, Mbandaka and Newport) accounted for 59.8% of *Salmonella* isolates, while in laying hens five serovars (Enteritidis, Kentucky, Infantis, Typhimurium and Mbandaka) accounted for 55.4% of isolates; and in turkeys, serovars Derby, Anatum, Infantis, Bredeney, Kedougou and Senftenberg accounted for 56.5% of *Salmonella* isolates.

Complete susceptibility and multidrug resistance

In 2021, the ECOFF used to determine microbiological resistance of *Salmonella* isolates to tigecycline was changed from >1 to >0.5 mg/L (EFSA, 2021). Therefore, in this report, complete susceptibility (CS) and multidrug resistance (MDR) to tigecycline for 2021 data (i.e. pigs and calves) is determined using the new ECOFF (MIC >0.5 mg/L). While for 2020 data from poultry populations and derived meat, tigecycline resistance is analysed using the previous ECOFF (i.e. MIC >1 mg/L).

The patterns of resistance associated with these different serovars influenced the overall resistance levels in *Salmonella* isolates, and Figures C.4 and C.5 summarise the proportion of completely susceptible and MDR isolates among particular serovars recovered from each of these food-producing animal populations considering all reporting countries (including non-MSs).

High proportions of MDR isolates were reported in the different food-producing animal populations. For instance, 55.2% of the *S*. Typhimurium isolated in pigs were MDR. Similarly, the *S*. Infantis isolates...
from broilers were largely MDR (83.9%) (see Figures C.4 and C.5). Like in broilers, S. Infantis were the lead serovar contributing with MDR in laying hens (24.5%); while in turkeys, MDR isolates were mainly S. Infantis (88.8%), Bredeney (88.9%) and Kentucky (79.3%).

On the human side, 22.6% of 6,867 isolates were MDR, while 60.0% were susceptible to all tested antimicrobials (Annex A, Table 16). Furthermore, the most common MDR pattern in human Salmonella isolates was AMP-SXT-TET found in 209 isolates. This is also confirmed in Annex A, Table 1 where the human isolates showed the most resistant to ampicillin (25.3%, N = 11,832), sulfamethoxazole (26.8%, N = 6,872) and tetracycline (26.2%, N = 10,949). Only a few isolates (0.8%, N = 11,532) showed microbiological and clinical resistance to ciprofloxacin and cefotaxime (Annex A, Table 8).
N: Total number of isolates recovered; *monophasic S. Typhimurium includes antigenic formulas. The MDR analysis of animal isolates included the following antimicrobials: ampicillin, ceftaxime/ceftazidime, chloramphenicol, ciprofloxacin/nalidixic acid, gentamicin/amikacin, meropenem, sulfamethoxazole, tetracycline/tigecycline and trimethoprim. In 2021, amikacin was also included in the analysis of pigs and calves, for the MDR analysis it was considered together with gentamicin for the aminoglycosides antimicrobial class. The ECOFF used to determine resistance to tigecycline for pig and calf data was MIC > 0.5 mg/L, while for poultry data was MIC > 1 mg/L.

**Figure C.4:** Proportions of isolates completely susceptible (green), resistant to 1 or 2 antimicrobial classes (gold), and MDR (red) in *Salmonella* spp. and certain serovars recovered from (a) fattening pigs, (b) calves, for all reporting countries, 2021
N: Total number of isolates recovered; *monophasic S. Typhimurium includes antigenic formulas. The MDR analysis of animal isolates included the following antimicrobials: ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/nalidixic acid, gentamicin, meropenem, sulfamethoxazole, tetracycline, tigecycline and trimethoprim. The ECOFF used to determine resistance to tigecycline for poultry data was MIC > 1 mg/L while for pig and calf data MIC > 0.5 mg/L.

Figure C.5: Proportions of isolates completely susceptible (green), resistant to 1 or 2 antimicrobial classes (gold) and MDR (red) in Salmonella spp. and certain serovars recovered from (a) broilers, (b) laying hens and (c) fattening turkeys, for all reporting countries, 2020/2021.
Resistance exhibited by particular serovars

**S. Derby** was the most common serovar detected in fattening pigs (2021) and turkeys (2020), accounting for 29.4% and 14% of *Salmonella* isolates recovered from these animal origins, respectively (see Figure C.3). While multidrug resistance was not frequently observed among S. Derby isolates from pigs (10.2%, see Figure C.6), it was detected at high levels in the 2020 isolates from turkeys (35.4%, Figure C.5). Among S. Derby isolates recovered from these animal/carcass origins, different core resistance patterns predominated. In pigs, the most common resistance pattern in MDR S. Derby was AMP-SXT-TET, and was seen in isolates reported by Denmark, Estonia, Germany, Poland and Slovenia. Five of the MDR isolates from pigs were resistant to up to five classes of antimicrobials.

One of the two S. Derby isolated in calves was multidrug resistant. This isolate was reported by Spain with the pattern GEN-CHL-AMP-CTX-NAL-CIP-SMX-TMP-TET, including a third-generation cephalosporin (see Figure C.4). The most frequently reported resistance pattern among MDR S. Derby isolates from turkeys was AMP-NAL-CIP-SMX-TMP-TET (32/93, 34.4%).

In human isolates, 10.1% (N = 148) of S. Derby were MDR (Annex A, Table 22), with the predominant MDR pattern being AMP-SXT-TET. This is confirmed in Table 7 where human isolates showed mainly resistance to ampicillin (10.3%, N = 261), sulfamethoxazole (32.4%, N = 148) and tetracycline (19.3%, N = 259).

Under the new legislation (2020/1729/EU), the ECOFF used to determine microbiological resistance of *Salmonella* isolates to nalidixic acid changed from > 16 to > 8 mg/L, while the clinical breakpoint for ciprofloxacin changed from > 1 to 0.06 mg/L. In this report, the occurrence of resistance to nalidixic acid for 2021 data (i.e. pigs and calves) is determined using the new ECOFF (MIC > 8 mg/L), and for 2020 poultry and meat derived data, nalidixic acid resistance is analysed using the previous ECOFFs (MIC > 16 mg/L). Quinolone resistance (ciprofloxacin/nalidixic acid) was reported in the single MDR S. Derby isolate from a calf and in seven MDR isolates from pigs, while tigecycline resistance was observed in six isolates originating from pigs. Resistance to third-generation cephalosporin was detected in the single MDR S. Derby isolated from a calf in Spain and in two isolates from pigs reported by Hungary and Romania. Moreover, the pig isolate from Hungary and the isolate from a calf exhibited an ESBL phenotype. Only a single isolate from a turkey (Poland) was determined to be resistant to third-generation cephalosporins. This S. Derby isolate exhibited an ESBL phenotype. Where third-generation cephalosporin resistance was reported in this turkey isolate, it did not display resistance to ciprofloxacin (MIC > 0.064 mg/L).

Recent studies on S. Derby originating from the pork and poultry sectors in France identified four major host-specific lineages, corresponding to multilocus sequence typing (MLST) profiles ST39, ST40, ST71 and ST682 (Sévellec et al., 2018, 2020). The lineages ST39, ST40 and ST682 were associated with pork, and ST71 with poultry. While ST71 and ST682 isolates were generally devoid of resistance genes, ST40 isolates commonly harboured several resistance genes, with Clade 2 of this lineage characterised by SG11 and the pattern of resistance to streptomycin, sulfonamides and tetracycline. Additionally, the presence of a resistance gene for fosfomycin was detected in all genomes from ST39 (Sévellec et al., 2020).

**Monophasic S. Typhimurium** was the main serovar recovered in calves and the second most frequently reported in pigs, accounting for 16.5% and 26.1% of *Salmonella* isolates recovered from these origins, respectively (see Figure C.3). The proportion of all *Salmonella* isolates showing MDR in calves and pigs was largely influenced by the occurrence of multidrug resistance monophasic S. Typhimurium, which accounted for 41.7% (10/24) and 53.1% (262/493), of the MDR *Salmonella* isolates recovered from these animal origins, respectively (Figure C.4). Similarly, this serovar contributed with the highest level of overall MDR among *Salmonella* isolates recovered from turkey carcasses (24.6%, see Figure C.3).

Monophasic S. Typhimurium isolates were MDR in the majority of the carcasses/animal origins with resistance to ampicillin, sulfamethoxazole and tetracycline (AMP-SMX-TET) seen as the most frequent pattern in calves and pigs. This pattern with the addition of chloramphenicol was the second leading pattern in isolates from calves (AMP-CHL-SMX-TET); however, in pig isolates the second leading pattern was an addition of ciprofloxacin and nalidixic acid to the core resistance pattern (AMP-NAL-CIP-SMX-TET).

Monophasic S. Typhimurium has spread widely among European pig populations. There are particular MDR patterns associated with monophasic S. Typhimurium and because this serovar is prevalent in many countries, these patterns greatly influenced the overall resistance figures. This is
exemplified by the resistance pattern to ampicillin, sulamethoxazole and tetracycline (AMP-SMX-TET) which occurred as the main MDR pattern in 159/493 (32.2%) monophasic S. Typhimurium isolates from pigs. This resistance pattern (together with resistance to streptomycin) is typical of the European clone of monophasic S. Typhimurium (Hopkins et al., 2010). The genes conferring resistance to these antimicrobials are commonly found in association together with IS26 mobile genetic elements, responsible for their integration at different chromosomal locations, in recently described European strains of monophasic S. Typhimurium (Sun et al., 2020). It is noteworthy that multidrug resistance in the European clone of monophasic S. Typhimurium appears to have originated from integration of MDR plasmids into the chromosome, facilitated by the presence of these IS26 mobile genetic elements (Sun et al., 2020).

Resistance to five or more classes of antimicrobials was observed among 31 monophasic S. Typhimurium isolates from pigs, with nine of them exhibiting resistance to six antimicrobial classes. No isolates from other animals/carcasse origins showed such multi-drug resistance. In human isolates, 78.4% (N = 1,235) of monophasic S. Typhimurium were MDR (Annex A, Table 19), with the predominant MDR pattern being AMP-SXT-TET (found in 187 isolates). This is confirmed in Table 4 where human isolates showed mainly resistance to ampicillin (88.2%, N = 1,958), sulamethoxazole (85.2%, N = 1,236) and tetracycline (84.5%, N = 1,913). A few of these isolates (1.2%, N = 1,957) showed microbiological and clinical resistance to ciprofloxacin and cefotaxime (Annex A, Table 11). Notably, isolates from food-producing animals, resistance to quinolones (ciprofloxacin/nalidixic acid) was only reported in pig isolates, accounting for 13.7% (36/262) of all MDR monophasic S. Typhimurium isolated from this origin. Similarly, tigecycline resistance was only reported in isolates from pigs (21/262). Resistance to third-generation cephalosporins was rare in this serovar with a single isolate from a pig reported by Italy exhibiting resistance to cefotaxime/ceftazidime, its phenotype was confirmed by the presence of the \textit{bla}_{SXT-12} gene.

From the monitoring of human monophasic S. Typhimurium cases reported to ECDC in 2021, out of 1,867 isolates for which data were available, 23 had an ESBL phenotype and six had an AmpC phenotype, with genes encoding different types of CTX-M enzymes as well as CMY-2 enzymes detected.

\textbf{S. Typhimurium} was the second most frequently reported serovar from calves (2021), the third most commonly reported serovar from pigs (2021) and fourth in laying hens (2020); accounting for 12.7%, 12.9% and 7.7% of \textit{Salmonella} isolates recovered from these origins, respectively (Figure C.3). Among \textit{S. Typhimurium} isolates recovered from calves and pigs, MDR was also frequently observed: 40.0% and 55.2%, respectively (Figure C.4). MDR \textit{S. Typhimurium} represented 44.0% of \textit{Salmonella} spp. isolated from turkeys. Notably, the proportion of all \textit{Salmonella} isolates showing MDR in calves and pigs was greatly influenced by the occurrence of multiresistant \textit{S. Typhimurium}, which come second after monophasic Typhimurium in all the MDR \textit{Salmonella} isolates recovered from these animal origins (see Figure C.6). The most frequent MDR pattern among \textit{S. Typhimurium} isolates from pigs was AMP-SXT-TET with an addition of CHL to this pattern as the second most commonly encountered. Moreover, of the five MDR \textit{S. Typhimurium} isolates recovered from calves, four different resistance patterns were noted, with the pattern TGC-SMX-TET observed in two isolates.

Mobile genetic elements which could account for this resistance pattern in \textit{S. Typhimurium} isolates have previously been described. \textit{Salmonella} genomic island 1 (SGI1), known to contain a multidrug resistance region located on a complex class 1 integron designated 1n104, confers pentavalent resistance (the ampicillin, chloramphenicol, streptomycin, sulamethoxazole, tetracycline resistance phenotype – AMP-CHL-STR-SMX-TET) and has widely been documented in a range of \textit{Salmonella} serovars.

In pigs, (fluoro)quinolone resistance (ciprofloxacin/nalidixic acid) was encountered in 23.1% of the 91 MDR \textit{S. Typhimurium} isolates. However, only a single isolate from a calf showed this resistance. Tigecycline resistance among multiresistant \textit{S. Typhimurium} isolates was reported in three isolates from calves and in 13.2% of the 91 pig isolates. While a single isolate from a calf was resistant to at least five classes of antimicrobials, 23.1% (21/91) MDR \textit{S. Typhimurium} from pigs showed resistance to five or more antimicrobial classes. No MDR \textit{S. Typhimurium} isolates recovered from any of the animal/carcasse origins displayed resistance to third-generation cephalosporins.

In human isolates, 23% (N = 871) of the serovar \textit{S. Typhimurium} were MDR (Annex A, Table 18), with the predominant MDR pattern being AMP-SXT-TCY (found in 18 isolates and the addition of CHL to this pattern in 14 isolates). The human isolates showed mainly resistance to ampicillin (35.5%, N = 1,382), sulamethoxazole (28.8%, N = 872) and tetracycline (28%, N = 1,330) (Annex A, Table 3). A few of the isolates (0.9%, N = 1,353) showed microbiological and clinical resistance to ciprofloxacin and cefotaxime and/or carbapenems (Annex A, Table 5) that is consistent with the presence of the \textit{bla}_{SXT-12} gene.
(Annex A, Table 10). Additionally, of 1,246 human S. Typhimurium isolates for which data were available to ECDC in 2021, 11 isolates exhibited an ESBL phenotype and 1 isolates exhibited an AmpC phenotype; genes encoding different types of CTX-M enzymes, as well as CMY-2 enzymes, were detected.

Multiresistant **S. Rissen** isolates were recovered from pigs, broilers and laying hens, as well as carcases of broilers (see Figures C.2 and C.5). In 2021, S. Rissen isolates were detected mainly in pigs, representing 8.1% of the total *Salmonella* isolates from pigs (see Figure C.3), while only a single S. Rissen isolate was detected in calves. The majority of the S. Rissen isolated from pigs were MDR (93%, 44/47). A wide range of MDR patterns were observed in S. Rissen isolates from pigs with the leading pattern of resistance to ampicillin, chloramphenicol, sulfoxamethoxazole, tetracycline and trimethoprim (AMP-CHL-SMX-TET-TMP) being detected in five isolates. García-Fierro et al. (2016) previously identified a dominant S. Rissen clone in pork, pigs and humans in Spain, which was shown to carry genes conferring resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides, tetracycline and trimethoprim (AMP-CHL-STR-SMX-TET-TMP) at varying frequencies, mostly on integrons. S. Rissen is also a common serovar in pigs, chicken, pork and man in some parts of Asia. (Pornsukarom et al., 2015) demonstrated that S. Rissen isolates originating from Thai pig farms were frequently multidrug resistant to most of the antimicrobials listed above.

A single S. Rissen isolate recovered from a broiler carcase also exhibited resistance to ampicillin, chloramphenicol, sulfoxamethoxazole, trimethoprim and tetracycline (AMP-CHL-SMX-TMP-TET). In broilers, where 2/7 (28.6%) S. Rissen isolates exhibited MDR, four different combinations were noted (the most common being the pattern: AMP-CTX-CHL-CIP-GEN-SXT-TMP-TET). Resistance to six antimicrobial classes was also observed among isolates from broilers; however, 22 isolates from pigs showed resistance to at least five classes of antimicrobials with one isolate reported by Romania exhibiting resistance to seven antimicrobial classes. The core pattern of resistance AMP-SXT-TET-TMP was noted in the only two MDR S. Rissen isolates recovered from laying hens (N = 12). Tigecycline resistance was not a feature of any of the MDR S. Rissen isolates recovered from these animal/carcase origins. Resistance to quinolones (ciprofloxacin/ nalidixic acid) was reported in 51.1% (24/47) of isolates from pigs, while 16 of such isolates showed resistance to tigecycline. Four isolates reported by Romania displayed resistance to third-generation cephalosporins (CTX-CAZ), and all exhibited an ESBL phenotype; one of which has in addition an AmpC phenotype.

Considering **S. Infantis**, this serovar was most frequently recovered from broilers and their derived carcasses, accounting for 36.4% and 50.3% of *Salmonella* isolates recovered from these origins, respectively (see Figures C.1 and C.3). Additionally, this serovar was the second most frequently reported in turkeys (9.5%), and the third most frequently reported in laying hens (8.8%). While MDR was common among S. Infantis isolates from broilers and turkeys as well as their derived carcasses, (84.0%, 88.8%, 79.8% and 75.0%, respectively), isolates recovered from laying hens (N = 98) were less frequently MDR (24.5%). Notably, the proportion of all *Salmonella* isolates showing MDR in broilers and their derived carcasses was greatly influenced by the occurrence of multiresistant S. Infantis, which accounted for 84% (653/777) and 79.8% (399/500) of the MDR *Salmonella* isolates from these origins, respectively (see Figures C.2 and C.5). Similarly, this serovar contributed the highest levels of multiresistance to overall MDR among *Salmonella* isolates recovered from laying hens, turkeys and turkey carcasses (as did monophasic S. Typhimurium in turkey carcasses).

Although a wide range of different MDR patterns were reported among S. Infantis isolates from poultry, the most frequent core MDR pattern was AMP-CIP-NAL-SXT-TET. This resistance pattern is typical of a major European clone of S. Infantis which is prevalent among broilers (Nógrády et al., 2012). Where MDR was detected, this resistance profile (resistance to only ampicillin, ciprofloxacin, nalidixic acid, sulfoxamethoxazole and tetracycline) accounted for 26.8%, 95.6%, 95.5%, 83.7%, 81.9% of MDR patterns, respectively. Previous scientific publications in Europe highlight the involvement of plasmids, which appear to be responsible for resistance in many European MDR S. Infantis isolates (Nógrády et al., 2012; Franco et al., 2015). In Australia, a S. Infantis strain harbouring a SGII homologue with an integron related to In104 and conferring resistance to streptomycin, sulfoxamethoxazole and trimethoprim was identified (Levings et al., 2005). Resistance to five antimicrobial classes was noted among isolates from all poultry origins, with the exception of turkey carcasses where all isolates displayed the core resistance pattern as described above (CIP-NAL-SMX-TET). Resistance to six antimicrobial classes was noted among isolates from broilers and turkeys, as well as a single isolate from laying hens; while four isolates from broilers also displayed resistance to seven antimicrobial classes. Additionally, tigecycline resistance was observed among some MDR isolates from poultry, with the exception once more of turkey carcasses. Multiresistant S. Infantis was
also reported from pig carcases; of only five MDR isolates, four different combinations were noted, of which resistance to sulfamethoxazole and tetracycline was a feature of all five isolates.

Resistance to third-generation cephalosporins was detected in 34 S. Infantis isolates recovered from broilers, 30 originating from Italy (all displaying an ESBL phenotype, with 6/30 also exhibiting an AmpC phenotype) and 4 from Hungary (2 exhibiting an ESBL phenotype and 2 exhibiting an AmpC phenotype). Additionally, Italy reported resistance to this antimicrobial class in 7/12 S. Infantis isolates from turkeys and in 1/11 isolates from laying hens. An ESBL phenotype was identified in the isolate from laying hens and seven isolates from turkeys, as well as an AmpC phenotype in two of the seven isolates from turkeys. For information on ESBL-carrying S. Infantis, please see the specific text box within the discussion. Where third-generation cephalosporin resistance was reported, 32/34 isolates from broilers and all seven isolates from turkeys, as well as the single isolate from laying hens, displayed resistance to ciprofloxacin.

While high-level resistance to ciprofloxacin (MIC ≥ 4 mg/L) was mostly observed among S. Kentucky isolates from poultry, 19.8% (50/252) of isolates displaying resistance by this definition were attributed to S. Infantis. Particular MDR patterns are associated with S. Infantis and because this serovar was prevalent in many countries, these patterns greatly influenced the overall resistance figures. Moreover, resistance to third-generation cephalosporins, as well as high-level resistance to ciprofloxacin, further underline the significance of this multiresistant serovar.

In 2021, the serovar S. Infantis represented only 3.6% of Salmonella isolated from pigs. Seven isolates from pigs showed seven different MDR patterns. Three out of the seven isolates from pigs showed resistance to quinolones. Only one MDR isolate from a pig was resistant to tigecycline. Resistance to third-generation cephalosporins was detected in 1/7 MDR isolates from pigs. Only one S. Infantis isolate from a calf was MDR with the pattern CIP-NAL-SMX-TET-TGC, showing quinolone and tigecycline resistance.

In human isolates, 38.1% (N = 336) of the serovar S. Infantis were MDR (Table 20), with the predominant MDR patterns being CIP-NAL-SXT-TET (found in eight isolates) and CIP-NAL-TET-SMX (found in six isolates). The human isolates showed resistance to nalidixic acid (33.3%, N = 438), ciprofloxacin (33.9%, N = 528), sulfamethoxazole (40.5%, N = 36), co-trimoxazole (30.3%, N = 188) and tetracycline (34.1%, N = 499) (Annex A, Table 5). Combined microbiological resistance to ciprofloxacin and cefotaxime was reported in 5.0% while clinical resistance to these two antimicrobials was 4.8% (N = 525) (Table 12).

**MDR and ESBL-producing S. Infantis**

In 2020, the proportion of all Salmonella isolates showing MDR in broilers and their derived carcases was greatly influenced by the occurrence of multiresistant S. Infantis, which accounted for 73% and 79.4% of the MDR Salmonella isolates from these origins, respectively. Additionally, this serovar accounted for 22% and 5% of the MDR isolates in turkeys and their derived carcases, respectively. In human cases from 2020 and 2021, 45.3% and 38.1% of S. Infantis were MDR, with four and five countries reporting S. Infantis with an ESBL phenotype, respectively, and most frequently reported by Italy. All ESBL-carrying S. Infantis in 2021 except one were also ciprofloxacin-resistant.

Over the last decade, multiresistant S. Infantis has increasingly been reported from food-producing animals and humans in Italy. Subsequently, an S. Infantis clone harbouring a pESI-like megaplasmid and carrying the ESBL gene blaCTX-M-1 (mediating cefotaxime resistance), as well as the resistance genes tet(A), sul1, dfrA1 and dfrA14 (confering resistance to tetracycline, sulfamethoxazole and trimethoprim, respectively), was identified from food-producing animals and humans in Italy (Franco et al., 2015). This MDR clone was mainly detected among the Italian broiler chicken industry, where it is thought to have disseminated through the food chain to humans (Franco et al., 2015). A proportion of the Italian isolates of MDR S. Infantis also possessed the streptomycycin resistance gene aadA1.

The pESI megaplasmid (pESI = ‘plasmid for emerging S. Infantis,’ Tate et al., 2017) was first reported among S. Infantis isolates from Israel; and while these isolates were susceptible to extended-spectrum cephalosporins, this megaplasmid also conferred resistance to tetracycline, sulfamethoxazole and trimethoprim (Aviv et al., 2014). Additionally, a S. Infantis clone harbouring the pESI-like megaplasmid, but carrying the ESBL gene blaCTX-M-65, has been reported in the United States (Tate et al., 2017), as well as Switzerland (Hindermann et al., 2017). In the US, this genotype
has been associated with travel to South America (Tate et al., 2017; Brown et al., 2018). In 2019, three countries (Denmark, Germany and Spain) together reported 11 domestically acquired cases of S. Infantis with blaCTX-M-65 (the majority of cases in Germany), and in 2020, two countries (Spain and the Netherlands) reported one case each. The majority of the blaCTX-M-65 isolates were resistant to ciprofloxacin, nalidixic acid, chloramphenicol, gentamicin, sulfamethoxazole, tetracycline and trimethoprim, in addition of being ESBL-producing. In 2021, only Germany reported S. Infantis with blaCTX-M-65 (5 isolates).

In contrast, S. Enteritidis isolates exhibited much lower multiresistance. This serovar was the most frequently reported in laying hens and the second most commonly reported in broilers and broiler carcases, accounting for 25.5%, 10.6% and 10.7% of Salmonella spp. recovered from these poultry origins, respectively (see Figures C.1 and C.3). While complete susceptibility was observed at 46.9% in S. Enteritidis isolates from broiler carcases; in isolates recovered from broilers and laying hens, the majority of isolates exhibited complete susceptibility (53.1% and 92%, respectively). Notably, a greater number of countries reported S. Enteritidis data from broilers and laying hens in comparison to those reporting data from broiler carcases, which may reflect the overall reported levels of complete susceptibility. S. Enteritidis belongs to D Salmonella (serogroup O9) which tend to show elevated colistin MICs, a phenomenon considered to reflect slightly decreased intrinsic susceptibility of wild-type isolates belonging to Group D (Agersø et al., 2012). This is exemplified by the proportion of colistin-resistant isolates attributed to S. Enteritidis (from laying hens, broilers and broiler carcases) in comparison to other serovars belonging to different serogroups. In 2021, S. Enteritidis were recovered in 6.3% of Salmonella isolates originating from calves (see Figure C.3). No S. Enteritidis was reported in pigs in 2021. In human isolates, only 1.9% (N = 1,722) of the serovar S. Enteritidis were MDR (Annex A, Table 17), with the predominant MDR patterns being AMP-CIP-TET (found in four isolates). However, the highest proportions of resistance in these isolates were reported to nalidixic acid (24.8%, N = 1,793), ciprofloxacin (22.6%, N = 3,103) and colistin (17.6%, N = 574) (Annex A, Table 2).

S. Kentucky was the second most commonly reported serovar in laying hens and the tenth in turkeys, as well as the eighth most frequently reported in broilers, accounting for 8.9%, 3.5% and 2.8% of Salmonella spp. recovered from these poultry origins, respectively (see Figure C.3). MDR was observed at an extremely high level in S. Kentucky isolates from turkeys (79.3%) while the proportion of isolates with MDR recovered from broilers was high (30.5%) but low for and laying hens (4% MDR). MDR was also frequent among S. Kentucky isolates recovered from carcases of turkeys and broilers (60% and 61.9%, respectively), although the total number of isolates available for analysis from these carcase origins was relatively low (N = 15 and N = 21, respectively).

A wide range of different MDR patterns were reported among S. Kentucky isolates from broilers, laying hens and turkeys. Among all poultry origins (including carcases of broilers and turkeys), the most frequent core pattern of resistance was AMP-CIP-NAL-GEN-SXT-TET. Where MDR was detected, this resistance pattern accounted for 64.9%, 75.6%, 80% and 83.3% of the multiresistant S. Kentucky isolates recovered from broilers, turkeys, broiler carcases and turkey carcases, respectively. In 2021, eight isolates of S. Kentucky were recovered from pigs (0.6%). One isolate of them showed the resistance pattern TGC-NAL-CIP-SMX-TMP-TET demonstrating resistance to tigecycline and to quinolones. No S. Kentucky was reported in calves in 2021.

In human isolates, 54.8% (N = 62) of the serovar S. Kentucky were MDR (Annex A, Table 21), with the predominant MDR pattern being AMP-CIP-NAL-GEN-SXT-TET (found in 5 isolates). The human isolates showed most resistant to gentamicin (27.9%, N = 104), ampicillin (62.9%, N = 105), nalidixic acid (79.7%, N = 74), ciprofloxacin (78.1%, N = 105), sulfamethoxazole (51.6%, N = 62) and tetracycline (58.1%, N = 86) (Annex A, Table 6). Microbiological resistance to CIP and CTX was reported in 5.7%, while clinical resistance to CIP and CTX was reported in 4.8% (N = 105) of the isolates (Annex A, Table 13).

Considering isolates exhibiting high-level resistance to ciprofloxacin (MIC ≥ 4 mg/L), S. Kentucky accounted for most of the Salmonella isolates recovered from poultry in 2020 and from humans in 2021 which exhibited resistance by this definition (180/252 and 56/76, respectively). Additionally, a single S. Kentucky isolate recovered from a pig carcase displayed high-level resistance to ciprofloxacin. Resistance to third-generation cephalosporins was detected in five S. Kentucky isolates recovered from broilers by Malta (4 isolates) and the Netherlands (1 isolate), as well as an isolate recovered from laying hens by Hungary. An ESBL phenotype was reported in the five isolates from broilers, while an AmpC phenotype was reported in the single isolate from laying hens. Where third-generation
cephalosporin resistance was reported in these S. Kentucky isolates, resistance to ciprofloxacin was also observed. The detection of third-generation cephalosporin resistance and high-level resistance to ciprofloxacin, underline the significance of this serovar.

Coipan et al. (2020) recently described the introduction and spread of a highly ciprofloxacin-resistant S. Kentucky with the ESBL-gene \( \text{bla}_{\text{CTX-M-14b}} \) among humans in Europe. Cases were identified in eight countries in the period 2013–2018. While the clone seems to have originated in Egypt, the study pointed to a potential establishment of the clone in Malta. Germany and the Netherlands reported human cases of S. Kentucky \( \text{bla}_{\text{CTX-M-14b}} \) to tESSy in 2019 and the Netherlands also in 2020. Additionally, in 2019 and 2020, Malta reported three S. Kentucky isolates, one with an ESBL phenotype and two with a combined ESBL + AmpC phenotype; genotyping was not performed. In 2021, France (1), the Netherlands (2) and Sweden (1) reported human cases of ESBL S. Kentucky. Genotyping was confirmed to be \( \text{bla}_{\text{CTX-M-14b}} \) in two of the isolates, \( \text{bla}_{\text{CTX-M}} \) not further specified in one and the fourth lacking genotype information. Medialdea Carrera et al. (2020) were able to confirm a link between Maltese isolates of ESBL-producing S. Kentucky from poultry and at least one human case in 2019.

**S. Newport** isolates recovered from turkeys in 2020 displayed very high levels of MDR, where 58.8% (30/51) of isolates were multiresistant. Notably, the level of MDR among turkeys was greatly influenced by one MS, with Hungary (\( N = 39 \)) reporting 30 multiresistant isolates. While a relatively low number of S. Newport isolates were available for analysis from broiler and turkey carcasses (\( N = 26 \) and \( N = 27 \), respectively), a greater proportion of isolates from broiler carcasses were multiresistant in comparison to those from turkey carcasses (84.6% and 18.5%, respectively). The level of MDR among broiler carcasses was again strongly influenced by the results of one MS, with Poland (\( N = 22 \)) reporting 22 multiresistant isolates. In 2021, S. Newport isolates were recovered in a single calf. No isolates from pigs were reported as S. Newport. In 2020, out of 165 S. Newport isolates from humans, one had a presumptive AmpC phenotype. Similarly in 2021, one isolate from a human case had a presumptive AmpC phenotype.

Among MDR S. Newport isolates recovered from turkeys and their derived carcasses, the most frequent pattern of resistance was AMP-CIP-NAL-TET; followed by the same pattern but without nalidixic acid resistance. In broiler carcasses, the combination AMP-CIP-NAL-SXT-TET predominated. This pattern was also the second most frequently reported in broilers, although the combination CHL-CIP-NAL-SXT-TET was most frequently noted.

**S. Bredeney** represents about 25% of *Salmonella* isolates recovered from turkey carcasses in 2020, being the most frequently recovered serovar from this origin (see Figure C.1). In 2021, this serovar was the fourth most reported (7.6%) in calves (see Figure C.3). Multidrug resistance was extremely high in this serovar in 2020, especially among isolates recovered from turkeys (88.9%), while only 20.6% of Bredeney isolates from turkey carcasses were MDR (see Figure C.2). One isolate from a calf reported by Italy showed quinolone resistance (NAL-CIP-SMX-TET), while tigecycline resistance was reported by Poland in one isolate from a pig (AMP-TGC-SMX-TMP-TET). Interestingly, multidrug resistance was observed at an extremely high level among S. Bredeney isolates from turkeys in 2020 (82%); while a low level was noted among S. Bredeney isolates from turkey carcasses (4.7%). Notably, among isolates reported from turkeys (\( N = 50 \)), the level of MDR was greatly influenced by one MS, with Hungary (\( N = 31 \)) reporting 31 multiresistant isolates. In 2020, out of 29 S. Bredeney isolates from humans, two AmpC-producers were identified, both by Spain and carrying \( \text{bla}_{\text{CMY-2}} \).

Among MDR S. Bredeney isolates recovered from turkeys, the most frequent pattern of resistance was to AMP-CIP-NAL-TET-TGC (34.1%); followed by the same pattern but with the addition of trimethoprim (24.4%). This second core pattern was also the most commonly noted among turkey carcasses (40%). While a wide range of different resistance patterns were noted among S. Bredeney isolates from turkeys, tigecycline resistance among MDR isolates from this animal origin was observed at 68.3% (all MDR isolates displaying tigecycline-resistance originated from Hungary).

**Multiresistant serovars**

Considering all reporting countries (including non-MSs), the contributions of particular multiresistant serovars to overall MDR levels in *Salmonella* spp. from each of the animal/carcase categories are illustrated in Figure C.6. Overall, the figure shows that monophasic S. Typhimurium and S. Infantis were the lead serovars contributing with multidrug resistance among all *Salmonella* spp. isolated from carcass/animal origins in 2020/2021.
Contributions of selected multiresistant serovars to overall MDR levels in *Salmonella* spp., 2020/2021

Figure C.6: Proportions of certain serovars exhibiting multiresistance to overall MDR levels in *Salmonella* spp. recovered from each of the food-producing animal populations and derived carcases, for all reporting countries in 2020/2021.
Appendix D – Comparison of human *Salmonella* data by serovar to that in food-producing animals

In 2020/2021 the quantitative human data were interpreted using EUCAST ECOFF values (categorised into wild-type and non-wild type), when available, in the same way as for the animal and food data. For 2021 data, this resulted in one dilution difference (e.g. defining a higher number of samples to be of the non-wild type) compared to Commission Implementing Decision (EU) 2020/1729 regarding ampicillin (Figure D.1). Also, for 2021 data, the clinical breakpoint for ciprofloxacin for animal data was changed from > 1 to > 0.064 mg/L with the new Implementing Decision and now aligns with the EUCAST ECOFF (> 0.064 mg/L). For tigecycline, the applied ECOFF was changed from > 1 to > 0.5 mg/L, and the clinical breakpoint changed from > 2 mg/L to NA. Where ECOFFs do not exist, EUCAST or Clinical and Laboratory Standards Institute (CLSI) CBPs were applied. Notably, for sulfamethoxazole/sulfonamides, there is no EUCAST interpretative criterion for *Salmonella* and therefore a threshold of > 256 mg/L was applied to both the human and animal data. For qualitative data interpreted with clinical breakpoints (*S* = susceptible, *I* = susceptible with increased exposure* and *R* = resistant), I+R results were combined into one category, except for tetracycline where only R was used. When aligning susceptible isolates with wild-type isolates and I+R isolates with non-wild-type isolates, there is generally close concordance across categories (Figure D.1). An exception is meropenem where the EUCAST CBP is substantially higher (+4 dilutions) than the ECOFF.

*EUCAST has changed the definitions of SIR from 2019 (EUCAST, 2019 – http://www.eucast.org/newslandr/). For Intermediate (I), the new definition ‘susceptible, increased exposure’ is used when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection. †EFSA Manual for reporting 2021 antimicrobial resistance data within the framework of Directive 2003/99/EC and Decision 2020/1729/EU. ‡Only R category included.

**Figure D.1:** Comparison of CBPs and ECOFFs used to interpret MIC data reported for *Salmonella* spp. from humans, animals or food

It is of note that the countries reporting data on particular *Salmonella* serovars from human cases are not always the same as those reporting corresponding serovar data within the animal categories. Additionally, the number of isolates reported from human cases and from the animal origins varied, both at the MS and MS-group level. Further, *Salmonella* isolates have been derived from different scenarios, for human data is from clinical cases while animal data comes from healthy animals at slaughter. All of these factors mentioned above may introduce a source of variation to results when comparing overall percentage resistance to particular antimicrobials and MDR levels among human and animal isolates. The panel of nine antimicrobial classes comprising the MDR analysis of human isolates includes ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/pefloxacin/nalidixic acid, gentamicin, meropenem, sulfonamides/sulfamethoxazole, tetracyclines and trimethoprim/trimethoprim-sulfamethoxazole (co-trimoxazole) and does not include tigecycline. Not all MSs use the full panel when resistance testing clinical *Salmonella* isolates; most use a selected number of antimicrobials that reflect local or national prescribing habits and or treatment guidelines. For animal isolates, the MDR analysis included the same nine antimicrobial classes, as well as tigecycline (glycylcycline class). Tigecycline was not included in the MDR analysis of human isolates, and has been addressed together.
with Tetracycline from the MDR analysis of animal isolates as tigecycline has very limited effect on MDR outputs and therefore, negligible effect on human and animal comparisons.

**Comparison of 2021 human data to that in poultry and their derived carcases from 2020**

*S. Infantis* was the fourth most common serovar identified in human cases in 2021, with 1,076 cases reported in the EU/EEA. For most countries, the number of *S. Infantis* isolates tested were low and testing results were therefore excluded from the analysis. All countries reported AST results for ampicillin, gentamicin, chloramphenicol, cefotaxime/ceftazidime and meropenem. Resistance to ampicillin in *S. Infantis* from humans was, on average, 15.7%, and ranged from 0 to 65.6%. The highest levels of resistance were noted to sulfonamides (40.5%), tetracyclines (34.1%), ciprofloxacin/pefloxacin (33.9%) and co-trimoxazole (30.3%), reported by altogether nine MSs (Austria, Belgium, France, Germany, Italy, Malta, Netherlands, Slovakia and Spain). Resistance levels varied markedly between these countries. At the reporting MS-group level for *S. Infantis* from poultry in 2020, generally very high or extremely high resistance to ciprofloxacin, nalidixic acid, sulfamethoxazole and tetracycline was reported, with the exception of laying hens where much lower resistance levels to these antimicrobials were noted. Figure D.2 presents the resistance levels to these four antimicrobials considering all reporting MSs.

![Figure D.2: Occurrence of resistance to selected antimicrobials in *S. Infantis* from humans (2021) and poultry and poultry carcases (2020), reported by MSs](image)

With the exception of laying hens, MDR among *S. Infantis* was reported at higher levels in isolates from poultry compared to those from humans considering all reporting countries. In human isolates, overall MDR was observed at 38.1% (14 MSs); while 79.8%, 88.8%, 84% and 75% of isolates from broiler carcases (13 MSs and 1 non-MS), turkeys (6 MSs), broilers (16 MSs) and turkey carcases (1 MS) were MDR, respectively. At the reporting MS-group level for *S. Infantis* isolates recovered from laying hens, MDR was noted at a much lower level of 24.5% (16 MSs). Notably, only four *S. Infantis* isolates were reported by one MS in turkey carcases and only 80 isolates were reported by six MSs in turkeys; comparative assessment of AMR data to that in humans at the country level was therefore not considered for these categories. Comparative data for nalidixic acid resistance among isolates from both broilers and humans was available for six MSs. Considering only the 4 MSs reporting a similar number of *S. Infantis* isolates from both broilers and humans and where more than ten isolates were reported, a higher occurrence of nalidixic acid resistance as well as ciprofloxacin/pefloxacin resistance was noted in isolates from broilers in comparison to those from humans by Austria, Belgium, Italy and Spain. Also concerning sulfamethoxazole resistance and tetracycline resistance, Austria, Belgium, Italy and Spain registered a higher occurrence of resistance in isolates from broilers compared to isolates from humans.
When applying the same considerations to AMR data for S. Infantis from both broiler carcases and humans (i.e. where a similar number and ten or more isolates were reported), apparent differences in the levels of nalidixic acid resistance were noted by Austria, Belgium and Spain; with a higher occurrence of resistance in isolates from broiler carcases compared to those from humans. This was also the case for resistance to ciprofloxacin/penlocacin, sulfamethoxazole and tetracycline. Although comparable AMR data for S. Infantis from both laying hens and humans was available, a much lower number of isolates were reported from laying hens, with only 3 MSs (Italy, Poland and Spain) reporting data on ten or more isolates from this poultry origin. Italy and Spain reported a lower occurrence of resistance to nalidixic acid, ciprofloxacin, sulfamethoxazole and tetracyclines among isolates from laying hens in comparison to isolates from humans.

**S. Enteritidis** was the most common *Salmonella* serovar identified in human cases in 2021, with 28,453 cases reported in the EU/EEA. While MDR was uncommon among S. Enteritidis isolates (from both humans and poultry), the highest levels of resistance in S. Enteritidis from humans were noted to ciprofloxacin/penlocacin (22.6%), nalidixic acid (24.8%) and colistin (17.6%). Colistin resistance among S. Enteritidis is not uncommon, since this serovar belongs to group D salmonellas (serogroup O9) which tend to show decreased intrinsic susceptibility to colistin (Agersø et al., 2012; Ricci et al., 2020). Figure D.3 presents the resistance levels to these antimicrobials considering all reporting MSs.

![Figure D.3: Occurrence of resistance to selected antimicrobials in S. Enteritidis from humans (2021) and poultry and broiler carcases (2020), reported by MSs](image)

N: Total number of isolates reported by MSs.

NB. S. Enteritidis was not reported from turkey carcases.

**Figure D.3:** Occurrence of resistance to selected antimicrobials in S. Enteritidis from humans (2021) and poultry and broiler carcases (2020), reported by MSs

Only 22 S. Enteritidis isolates were reported by six MSs in turkeys; a comparative assessment of AMR data to that in humans at the country level was therefore not considered for this category. Considering data available for broiler carcases, Poland and Slovakia were the only countries to report on ten or more S. Enteritidis isolates from this poultry origin. A much higher occurrence of nalidixic acid and ciprofloxacin/penlocacin resistance was reported among isolates from broiler carcases in Slovakia in comparison to those from humans; however, for ciprofloxacin/penlocacin, a considerably lower number of isolates were available from broiler carcases than from humans (N = 42 and N = 527, respectively). Similarly, France, Poland and Slovakia were the only countries to report on 10 or more S. Enteritidis isolates from broilers in 2020, while also reporting data from humans in 2021. While nalidixic acid and ciprofloxacin/penlocacin resistance was not detected among broiler isolates from France, and low resistance levels to these antimicrobials were 9.7% among human isolates, a much lower number of isolates were available from broilers in comparison to humans (N = 18 and N = 155, respectively). In Poland, extremely high occurrence of nalidixic acid and ciprofloxacin/penlocacin resistance was reported among broiler isolates in 2020 (75.8% and 76.9%, respectively) and even higher levels in isolates collected from humans in 2021 (95.5%).
In isolates from human cases from all reporting MSs, resistance to ciprofloxacin/pefloxacin was reported at 22.6% (N = 3,143) and to nalidixic acid at 24.8% (N = 1,793); while in laying hens (N = 258), ciprofloxacin and nalidixic acid resistance were reported at levels of 17.1% and 17.1%, respectively. Considering data available in laying hens, Belgium, Cyprus, France, Hungary, Italy, Poland and Spain reported on ten or more S. Enteritidis isolates from both poultry in 2020 and humans in 2021. In four of those Member States (Belgium, Cyprus, France and Hungary), the ciprofloxacin/ pefloxacin resistance among laying hen isolates, which ranged from none detected to low or moderate, was lower than that observed in isolates from humans which ranged from 6.5 to 26.4%. This was also the case for Poland, although resistance levels here were considerably higher, 31.3% from laying hens and from humans, 95.5%. In Spain, the resistance levels were similarly lower in isolates from laying hens, (16.0%), than from humans (32.2%). Conversely, in Italy (60.5%), ciprofloxacin/pefloxacin resistance in laying hen isolates was greater than that reported in human isolates (41.7% vs. 14.7%).

Considering S. Kentucky, the 21st most commonly reported serovar from human cases in 2021, with 145 cases reported in the EU/EEA, very high levels of resistance were noted to ampicillin (62.9%), ciprofloxacin/pefloxacin (78.1%), nalidixic acid (79.7%), gentamicin (27.9%), sulfonamides (51.6%) and tetracyclines (58.1%). Figure D.4 presents the resistance levels to these antimicrobials in human and poultry isolates considering all reporting MSs. Resistances to the most commonly used antimicrobials for treatment of human Salmonellosis, cefotaxime, ceftazidime and azithromycin, were notably lower (5.7%, 6.2% and 3.9%), respectively.

The number of S. Kentucky isolates recovered from broilers and turkeys and their derived carcases was relatively low (N = 59, N = 21, N = 29 and N = 15, respectively). While for laying hens, a higher number of isolates were recovered (N = 99). Overall, high and very high level of MDR was noted among isolates from broiler flocks (30.5%) and turkey flocks (79.3%), an overall low level was reported among isolates from laying hen flocks (4.0%). Because only 21 S. Kentucky isolates were reported by five MSs in broiler carcases and only 15 isolates were reported by four MSs in turkey carcases; comparative assessment of AMR data to that in humans at the country level was therefore not considered for these categories. Although comparable AMR data for S. Kentucky from both laying hens and humans were available, only Malta reported data for altogether 86 isolates from laying hens and 23 isolates from broilers in 2020 and 18 isolates from humans in 2021. Due to these low numbers of reported isolates comparison of data was not performed on MS level.
Comparison of 2021 human data to that in pigs and calves, and their derived carcases

*S. Typhimurium* was the second most common *Salmonella* serovar identified in human cases in 2021, with 5,861 cases reported in the EU/EEA. Considering all reporting MSs, the highest levels of resistance in *S. Typhimurium* from humans were observed for ampicillin (35.5%), sulfonamides (28.8%), tetracyclines (28.0%) and co-trimoxazole (30.7%); as was the case for *S. Typhimurium* isolates from pigs (n = 163). In calves, just 10 *S. Typhimurium* isolates from four MSs were reported. Figure D.5 presents the resistance levels to these compounds considering all reporting MSs.

![Figure D.5: Occurrence of resistance to selected antimicrobials in *S. Typhimurium* from humans, pig and calves, reported by MSs in 2021](image)

N: Total number of isolates reported by MSs.

**Figure D.5**: Occurrence of resistance to selected antimicrobials in *S. Typhimurium* from humans, pig and calves, reported by MSs in 2021

Considering all reporting countries, MDR levels in *S. Typhimurium* were reported at 23.0%, 55.8% and 50% in isolates from humans (14 MSs), pigs (24 MSs) and calves (4 MSs), respectively. While 871 isolates were included in the MDR analysis from humans, a much lower number of isolates were available from pigs (n = 163) and calves (n = 10). Assessment of human and animal *S. Typhimurium* AMR data at the country level was not performed, as where comparable data were available, a much lower number of isolates were reported from animals in comparison to humans by given MSs; such small sample sizes are subject to high statistical variation.

**Monophasic *S. Typhimurium*** was the third most common serovar reported from human cases in 2021, with 4,826 registered cases in the EU/EEA. Considering all reporting MSs, the highest levels of resistance in monophasic *S. Typhimurium* from humans were observed for ampicillin (88.2%), sulfonamides (85.2%) and tetracyclines (84.5%); as was also the case for isolates from pigs and calves. Notably, this resistance pattern (together with resistance to streptomycin) is typical of monophasic *S. Typhimurium* (Hopkins et al., 2010). Figure D.6 presents resistance levels to these compounds considering all reporting MSs.

Considering all reporting countries, MDR levels in monophasic *S. Typhimurium* were reported at 78.4%, 79.6% and 76.9% in isolates from humans (13 MSs), pigs (24 MSs) and calves (6 MSs), respectively. In total, 1,235 isolates were included in the MDR analysis from humans, while a much lower number of isolates were available from pigs (n = 329) and calves (n = 13). Assessment of human and animal monophasic *S. Typhimurium* AMR data at the country level was not performed, as where comparable data were available, a much lower number of isolates were reported from animals.
**Figure D.6:** Occurrence of resistance to selected antimicrobials in monophasic *S. Typhimurium* from humans, fattening pigs and calves, reported by MSs in 2021

*S. Derby* was the fifth most common serovar reported from human cases in 2021, with 490 cases registered by EU/EEA countries. While MDR was not as frequently observed among human/animal *S. Derby* isolates in comparison to *S. Typhimurium* and its monophasic variant, resistance to sulfonamides and tetracycline was relatively common in *S. Derby* isolates from human cases (32.4% and 19.3%, respectively). This was also observed among *S. Derby* isolates from the animal origins. Figure D.7 presents resistance levels to these compounds considering all reporting MSs. Assessment of human and animal *S. Derby* AMR data at the country level was not performed due to the low number of isolates reported by MSs from human cases and within the animal categories.

**Figure D.7:** Occurrence of resistance to selected antimicrobials in *S. Derby* from humans, fattening pigs and calves, reported by MSs in 2021

N: Total number of isolates reported by MSs.

N: Total of isolates reported by MSs.
Within a given MS, attempts to relate the occurrence of AMR in human *Salmonella* isolates to that in isolates from food/food-producing animals is complicated, as much of the food consumed in a MS may have originated from other MSs or non-member countries. *Salmonella* infections can also be associated with foreign travel, other types of animal contact (such as pet reptiles) or the environment. Additionally, some human infections may result from human-to-human transmission and, although known travel-associated isolates from human cases were excluded from the analysis, a large proportion of cases lacked information on travel status. Such circumstances may influence the human AMR data at the reporting MS level. Furthermore, the local medical and diagnostic practices and policies for referral to clinical laboratories may vary between countries, which may result in reporting of various clinical or regional subsets of isolates from humans.
Appendix E – Trends in colistin resistance in indicator *E. coli* from fattening pigs, calves under 1 year of age and broilers

The statistical significance (p < 0.05) of trends in colistin resistance in indicator *E. coli* from fattening (pigs), bovines under 1 year of age (calves), broilers and fattening turkeys was analysed by logistic regression for countries reporting data for 3 years or more in the period 2014–2020 for broilers and turkeys and 2014–2021 for pigs and calves (see Appendix F – for details on methodology). The temporal trend analyses are presented in Figures E.1–E.4 below.

At the MS-group level, statistically significant decreasing trends were observed in isolates from broilers and calves and no change in trends for pigs and turkeys. In calves, decreasing trend in colistin resistance was observed in one MS (Italy) and no others reported an increase (Figure E.1). In pigs, decreasing trends were reported in two MSs (Germany and Spain) and one non-MS (The Republic of North Macedonia), while no countries reported an increasing trend (Figure E.2). In 2020, the trends for colistin resistance in broilers decreased in three MSs (Italy, Portugal, Romania) and increased in two MSs (Bulgaria and Cyprus) (Figure E.3). In isolates from turkeys, there were no reported statistically significant increasing or decreasing trends in colistin resistance (Figure E.4).

**Figure E.1:** Temporal trends in resistance to colistin in indicator *E. coli* from calves < 1 year of age, 11 EU MSs and 2 non-MSs, 2015–2021

Statistically significant increase (↑) or decrease (↓) indicated (p < 0.05).
Statistically significant increase (↑) or decrease (↓) indicated (p < 0.05).

**Figure E.2:** Temporal trends in resistance to colistin in indicator *E. coli* from fattening pigs, 28 EU MSs and 3 non-MSs, 2015–2021
Statistically significant increase (↑) or decrease (↓) indicated (p < 0.05).

**Figure E.3:** Temporal trends in resistance to colistin in indicator *E. coli* from broilers, 25 EU MSs and 4 non-MSs, 2014–2020
Statistically significant increase (↑) or decrease (↓) indicated ($p < 0.05$).

**Figure E.4:** Temporal trends in resistance to colistin in indicator *E. coli* from fattening turkeys (turkeys), 10 EU MSs and 2 non-MS, 2014–2020
Appendix F – Materials and methods

Antimicrobial susceptibility data from humans available in 2021

Data reported to The European Surveillance System (TESSy)

EU MSs report results from antimicrobial susceptibility testing of Salmonella spp. and Campylobacter spp. isolated from clinical cases to ECDC on an annual basis. Data can be submitted to ECDC and The European Surveillance System (TESSy) either as results interpreted with clinical breakpoints via the case-based reporting of Salmonella and Campylobacter infections or as measured values (inhibition zone diameters or minimum inhibitory concentrations (MIC)) through the isolate-based reporting in TESSy. From 2019 MSs can also submit data as phenotypes predicted from sequencing of the bacterial genome sequencing via the isolate-based reporting. The reporting of quantitative data via the isolate-based reporting is the preferred route, as stipulated in the EU protocol for harmonised monitoring of AMR in human Salmonella and Campylobacter isolates (ECDC, 2016, 2021).

Salmonella spp.: For 2021, 24 MSs, plus Iceland and Norway provided data on antimicrobial resistance (AMR) in human Salmonella isolates. Twenty-one countries reported measured values and four reported results interpreted as susceptible standard dosing regimen, susceptible increased exposure or resistant (SIR) according to the clinical breakpoints (CBPs) applied. One country reported results categorised as predicted wild type or predicted non-wild type based on analysis of bacterial genomes (Table F.1).

Campylobacter spp.: For 2021, 22 MSs, plus Iceland and Norway provided AMR data from human isolates. Fifteen countries reported measured values, seven reported results interpreted as susceptible standard dosing regimen, susceptible increased exposure or resistant (SIR) according to the clinical breakpoints (CBPs) applied and two countries (Ireland and Sweden) reported result categorised as predicted wild type or predicted non-wild type based on analysis of bacterial genomes (Table F.2).

Harmonised testing

Most laboratories follow the ‘EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and Campylobacter isolates’ on the antimicrobial panel to be tested (ECDC, 2016, 2021). The antimicrobials tested, the method used (dilution, disk diffusion, gradient strip, WGS), the type of data provided, and the interpretive criteria applied are presented in Table F.1 for Salmonella and in Table F.2 for Campylobacter. For Salmonella, eight MSs, plus Iceland and Norway used only disk diffusion methods (DDs) for their antimicrobial susceptibility tests (AST), seven MSs used dilution methods (DLS) and another eight MSs used various combinations of DD/DL or dilution with gradient strip (DLG) methods. One country used sequencing and bioinformatics tools to predict phenotypic resistance from the genome (Table F.1). For Campylobacter, ten MSs used only disk diffusion methods (DDs) for their AST, six MSs and Norway used dilution methods (DLS or DLG), two MSs used a combination of the two. Two countries (Ireland and Sweden) used sequencing and bioinformatics tools to predict phenotypic resistance from the genome. Three MSs did not provide the methodology (Table F.2). All data on measured MIC or zone mm values were results of AST performed at the national public health reference laboratories, with the exception of Italy for Salmonella where two regional laboratories also contributed, and Finland for Campylobacter where the quantitative data had been collected from regional laboratories. Data interpreted with clinical breakpoints were normally from local or regional laboratories and reported together with the information on the clinical case. In these cases, AST had primarily been performed with the purpose of treatment of the case rather than AMR monitoring. For this reason, the number of tests per antimicrobial varied.

Salmonella test panel

The national public health laboratories within the Food- and Waterborne Diseases and Zoonoses (FWD) network has agreed on a panel of priority antimicrobials and optional antimicrobials to test for and report to ECDC (ECDC, 2016, 2021). Compared with earlier recommendations, a second beta-lactam (ceftazidime) and a carbapenem (meropenem) were added. For 2021, all MS reported results on meropenem and all but four for ceftazidime. Three last-line antimicrobials – azithromycin, colistin and tigecycline – are also included in the priority list. For colistin, however, the methodology is complicated due to chemical properties of the substance and a joint EUCAST and Clinical and Laboratory Standards Institute (CLSI) subcommittee confirmed that broth microdilution is so far the
against the three main antimicrobials ciprofloxacin, tetracycline and colistin for 2021.

Due to the problems in detecting low-level fluoroquinolone resistance in *Salmonella* spp. using disk diffusion, nalidixic acid was, for a long time, used as a marker for fluoroquinolone resistance. After the discovery that plasmid-mediated fluoroquinolone resistance is often not detected using nalidixic acid, EUCAST studied alternative disks and concluded that pefloxacin was an excellent surrogate marker (except for isolates having the aac(6’)-Ib-cr gene as the only resistance determinant) (Skov and Monnet, 2016). Since 2014, EUCAST has recommended this agent for screening of low-level fluoroquinolone resistance in *Salmonella* with disk diffusion (EUCAST, 2014) and, since June 2016, this is also reflected in the EU protocol. In 2021, all countries reporting measured values for disk diffusion tested with pefloxacin instead of ciprofloxacin, except for Latvia where this information is unknown. Eleven countries reported the combination drug co-trimoxazole (trimethoprim–sulfamethoxazole) in addition to, or instead of, testing the substances separately, partly because this combination is used for clinical treatment and partly because no EUCAST interpretive criterion exists for sulfamethoxazole for *Salmonella*.

**Campylobacter test panel**

The antimicrobials included in the 2021 report followed the panel of antimicrobials from the EU protocol for harmonised monitoring of AMR in human *Salmonella* and *Campylobacter* isolates (ECDC, 2016, 2021). The priority panel for *Campylobacter* includes ciprofloxacin, erythromycin, tetracyclines and, since June 2016, gentamicin. Gentamicin is recommended for screening of invasive isolates and was added to the priority panel after a EUCAST ECOFF became available for disk diffusion for *C. jejuni*. Co-amoxiclav (combination drug with amoxicillin and clavulanic acid) was included from the list of optional antimicrobials. In 2021, all reporting countries except Iceland tested the isolates against the three main antimicrobials ciprofloxacin, erythromycin and tetracycline (although some countries tested less than 10 isolates). In relation to *C. jejuni* isolates, sixteen reporting countries also tested for gentamicin and thirteen tested for co-amoxiclav. With regards to *C. coli* isolates, thirteen reporting countries also tested these isolates for gentamicin and six tested for co-amoxiclav (Annex B, Tables 1 and 2).

**Analyses of antimicrobial resistance testing**

**Harmonised interpretation of data with animal and food data**

Data reported as measured values were interpreted by ECDC based on the EUCAST ECOFF values, when available. For MIC data, the same criteria as used by EFSA were applied (Tables F.5 and F.6) except for when EUCAST had changed the ECOFF after the regulation for animal and food AMR monitoring had been implemented, e.g. as for ampicillin in 2021 for *Salmonella* enterica (MIC lowered with 1 dilution). Where EUCAST had removed the ECOFF (colistin, tigecycline and trimethoprim–sulfamethoxazole for *Salmonella*), the same criteria were applied as recommended by EFSA (EFSA, 2021). For zone diameter data, corresponding EUCAST disk diffusion ECOFF values were applied with a few exceptions (Tables F.1 and F.2). Regarding data reported as SIR values, the categories of ‘susceptible, increased exposure’ (I) and ‘clinically’ resistant (R) were combined into one group, except for tetracycline and *Salmonella*. Alignment of the susceptible category with the ‘wild type’ category based on epidemiological cut-off values (ECOFFs) and of the I+R category with the ECOFF-based ‘non-wild type’ category provides better comparability and more straightforward interpretation of the data for most antimicrobial agents included (Figure 27 in Section 3.5 and Figure D.1 in Appendix D of the 2020/2021 EUSR-AMR). For *Salmonella*, this procedure results in good concordance (+1 dilution) across categories with the exception of meropenem where the MIC for non-susceptible category is substantially higher (+4 dilutions) than the ECOFF. For *Campylobacter*, there was full concordance across interpretive categories with this procedure, except for the EUCAST CBP for *C. jejuni* for tetracyclines, which is one dilution step higher than the EUCAST ECOFF.
Separation by species or serovar

As resistance levels differ substantially between *Salmonella* serovars, results are presented separately for selected serovars of importance in humans. The serovars presented in the report are *S.* Enteritidis, *S.* Typhimurium, monophasic *S.* Typhimurium, *S.* Infantis, *S.* Kentucky and *S.* Derby. AMR data on the 10 most common serovars in human cases in the last years are also available in the ECDC Surveillance Atlas for Infectious Diseases (https://atlas.ecdc.europa.eu/public/index.aspx). For *Campylobacter*, resistance levels differ quite substantially between the two most important *Campylobacter* species, *C.* jejuni and *C.* coli, and data are therefore presented by species. The proportion of resistant isolates is only shown when at least 10 isolates were reported from a MS.

Exclusion of travel-associated cases

To better assess the impact from food consumed within each reporting country on the AMR levels found in human isolates, cases known to have travelled outside of the country during the incubation period were excluded from the analysis. However, as several countries had not provided any information on travel status of their cases, cases with unknown travel status were also included in addition to domestically acquired cases. The exception to this is Denmark and Finland, where it has been agreed that cases of unknown travel status have been excluded from analyses for *Salmonella* spp. and for Denmark also for *Campylobacter* spp. The proportions of travel-associated, domestic and cases with unknown travel status among the tested isolates are presented in Tables F.3 and F.4.

Temporal trends in resistance

Temporal trends in the proportion of resistant human isolates to selected antimicrobials over the period 2013–2021 were analysed by country and for the EU MSs group. The statistical significance was assessed with logistic regression in R 4.2.1 and a p-value of < 0.05 was considered to be significant. Only countries testing at least ten isolates per year and for at least 3 years in the 6-year period were included. As the number of isolates reported by country was markedly lower in almost all countries in 2020 compared to previous years as an effect of the pandemic, it may have affected on the power of the statistical test. For *Salmonella*, the antimicrobials analysed were ciprofloxacin/pefloxacin/nalidixic acid, cefotaxime, ampicillin and tetracycline. For *Campylobacter*, the corresponding antimicrobials were ciprofloxacin, erythromycin and tetracycline (Annex B, Tables 1 and 2).

Within the framework of the temporal trend analyses covering data from 2013 to 2021, all EU/EEA countries reporting data during the period have been included. From 1 February 2020, the United Kingdom withdrew and became a ‘third- country’ in relation to the EU, with final withdrawal effective after a transition period ending on 31 December 2020. The withdrawal of the UK from the EU has an impact on the AMR data reported at the EU level as no data from 2020 onwards has been reported by the United Kingdom. In this report, data at the EU level are reported in accordance with the membership of the EU, whether before 2020 (EU including the UK) or in 2020–2021 (EU without the UK). In relation to trend analysis at country level for the 2021 report, UK data are referred to as from a non-EU MS and the UK was excluded for the trend analysis for the EU MSs group.

Maps for critically important antimicrobials resistance

For *Salmonella*, the proportions of human isolates resistant to both of the critically important antimicrobials for treatment of severe *Salmonella* infections (WHO, 2019), fluoroquinolones (ciprofloxacin/pefloxacin) and third-generation cephalosporins (ceftaxime), were presented in blue shaded maps to provide an overview of the geographical distribution of resistance in the EU/EEA. Combined ‘microbiological resistance’ was presented for *Salmonella* spp. and selected serovars (tables with combined resistance are also available in Annex A). For *Campylobacter*, the proportions of human isolates resistant to both critically important antimicrobials for treatment of severe *Campylobacter* infections (WHO, 2019), fluoroquinolones (ciprofloxacin) and macrolides (erythromycin), were presented in maps to provide an overview of the geographical distribution of this combined resistance in the EU/EEA. Combined ‘microbiological’ resistance (using EUCAST ECOFFs and EUCAST CBPs) were presented for *C.* jejuni and *C.* coli.
Analysis of multidrug resistance

Multidrug resistance (MDR) of human *Salmonella* spp. to nine antimicrobial classes was analysed, these classes being harmonised between ECDC and EFSA for better comparison between the two sectors. Multidrug resistance of an isolate was defined as resistance or non-susceptibility to at least three different antimicrobial classes (Magiorakos et al., 2012). The antimicrobials included were ampicillin, cefotaxime/ceftazidime, chloramphenicol, ciprofloxacin/pefl oxacin/nalidixic acid, gentamicin, meropenem, sulfonamides/sulfamethoxazole, tetracyclines and trimethoprim/trimethoprim-sulfamethoxazole (co-trimoxazole). Resistance to nalidixic acid, ciprofloxacin and pefl oxacin were addressed together, as they belong to the same class of antimicrobials: quinolones. Isolates that were non-wild type or I+R to any of these antimicrobials were classified as microbiologically resistant to the class of quinolones. The same method was applied to the two third-generation cephalosporins cefotaxime and ceftazidime. Trimethoprim and co-trimoxazole were also addressed together, as a few countries had only tested for susceptibility to the combination. This approach was considered appropriate because among the countries that provided data on both trimethoprim alone and the combination co-trimoxazole, the proportion of resistant or non-susceptibles corresponded closely between the two. Multidrug resistance of a *C. jejuni* or *C. coli* isolate was defined as resistance or non-susceptibility to at least three different antimicrobial classes (Magiorakos et al., 2012). The antimicrobials in the MDR analysis were harmonised between EFSA and ECDC and included ciprofloxacin, erythromycin, gentamicin and tetracycline.

Analysis of ESBL, AmpC and carbapenemase-production in *Salmonella*

All countries reported results from AST of third-generation cephalosporins in 2021. Those which reported findings of ESBL and/or AmpC or non-wild type results to third-generation cephalosporins and ampicillin, were contacted by mail to provide further details on phenotypic and/or genotypic results. Of the 16 MSs and one non-MS reporting such isolates, all except two could provide further information.
Table F.1: Antimicrobials reported, methods used, type of data reported and interpretive criteria applied by MSs for human *Salmonella* AST data in 2021

<table>
<thead>
<tr>
<th>Country</th>
<th>Gentamicin</th>
<th>Chloramphenicol</th>
<th>Ampicillin</th>
<th>Cefotaxime</th>
<th>Cefazidime</th>
<th>Meropenem</th>
<th>Tigecycline</th>
<th>Nalidixic acid/ Ciprofloxacin/ pefloxacin</th>
<th>Azithromycin</th>
<th>Colistin</th>
<th>Sulfonamides</th>
<th>Trimethoprim</th>
<th>Trimethoprim-sulfa</th>
<th>Tetracyclines</th>
<th>Method used</th>
<th>Quantitative (Q) or Categorical (SIR or PWT/PNWT)</th>
<th>Interpretive criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DD Q</td>
<td>Interpreted by ECDC. EUCAST ECOFFs for all except CLSI CBP for SUL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL Q</td>
<td>Interpreted by ECDC, as for Austria except for MEM where EUCAST CBP were used.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyprus</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL/DLG Q</td>
<td>Interpreted by ECDC, as for Austria, except for CTX, MEM and SXT where EUCAST CBP were used.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL Q</td>
<td>Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DD Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ●</td>
<td>DL Q</td>
<td>Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Gentamicin</td>
<td>Chloramphenicol</td>
<td>Ampicillin</td>
<td>Cefotaxime</td>
<td>Cefazidine</td>
<td>Meropenem</td>
<td>Tigecycline</td>
<td>Nalidixic acid</td>
<td>Ciprofloxacin/cefoxacin</td>
<td>Azithromycin</td>
<td>Colistin</td>
<td>Sulfonamides</td>
<td>Trimethoprim</td>
<td>Trimethoprim-sulfa</td>
<td>Tetracyclines</td>
<td>Method used</td>
<td>Quantitative (Q) or categorical (SIR or PWT/PNWT)</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>-----------------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>----------------</td>
<td>----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Germany</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Greece</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● (a) ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Hungary</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>SIR</td>
<td>EUCAST CBP except CLSI CBP for NAL, SUL and TET</td>
</tr>
<tr>
<td>Iceland</td>
<td>● ● ● (a)</td>
<td>●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Latvia</td>
<td>● ● ● ● ●</td>
<td>●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>SIR</td>
<td>No recent information on guidelines used.</td>
</tr>
<tr>
<td>Lithuania</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>SIR</td>
<td>EUCAST CBP</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● (a) ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Malta</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● (a) ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria, except for CTX and MEM where EUCAST CBP were used.</td>
</tr>
<tr>
<td>Netherlands</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria, MIC ECOFF for TGC according to EFSA reporting manual 2021.</td>
</tr>
<tr>
<td>Norway</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● (a) ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Country</td>
<td>Gentamicin</td>
<td>Chloramphenicol</td>
<td>Ampicillin</td>
<td>Cefotaxime</td>
<td>Ceftazidime</td>
<td>Meropenem</td>
<td>Tigecycline</td>
<td>Nalidixic acid</td>
<td>Ciprofloxacin/pefloxacin</td>
<td>Azithromycin</td>
<td>Colistin</td>
<td>Sulfonamides</td>
<td>Trimethoprim</td>
<td>Trimethoprim-sulfa</td>
<td>Tetracyclines</td>
<td>Method used</td>
<td>Quantitative (Q) or categorical (SIR or PWT/PNWT)</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>-----------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------</td>
<td>-----------</td>
<td>-------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>---------------</td>
<td>----------</td>
<td>-------------</td>
<td>--------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Poland</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD/DLG/DL</td>
<td>Q</td>
<td>DD/DLG/DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria. MIC ECOFF for TGC according to EFSA reporting manual 2021.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD</td>
<td>Q</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD</td>
<td>Q</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD/DL</td>
<td>SIR</td>
<td>EUCAST CBP except CLSI CBP for NAL, SUL and TET.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD/DLG</td>
<td>Q</td>
<td>DD/DLG</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>DD</td>
<td>Q</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>● ● ● ● ●</td>
<td>● ● ● ● ● ● ●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ●● ● ● ● ●●● ● ●●●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>● ● ● ● ● ● ● ● ● ● ● ● ● ●</td>
<td>WGS</td>
<td>PWT/PNWT</td>
<td>Sequencing results interpreted by the laboratory with NCBI AMRFinder and CGE ResFinder and PointFinder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AST: antimicrobial susceptibility testing; CBP: clinical breakpoint; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; WGS: whole genome sequencing; Q: quantitative data; SIR: susceptible standard dosing regimen, susceptible increased exposure, resistant (categorical data); PWT/PNWT: predicted wild type/predicted non-wild type (categorical); ECDC: European Centre for Disease Prevention and Control; ECOFF: epidemiological cut-off; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; NCBI: National Center for Biotechnology Information, US; CGE: Center for Genomic Epidemiology, Denmark; MIC: minimum inhibitory concentration; AZM: azithromycin; CTX: cefotaxime; GEN: gentamicin; MEM: meropenem; NAL: nalidixic acid; SUL: sulfonamides; TET: tetracycline. (a): Pefloxacin used in disk diffusion.
Table F.2: Antimicrobials reported, method used, type of data reported and interpretive criteria applied by MSs for human *Campylobacter* data in 2021

<table>
<thead>
<tr>
<th>Country</th>
<th>Gentamicin</th>
<th>Co-amoxiclav</th>
<th>Ciprofloxacin</th>
<th>Erythromycin</th>
<th>Tetracyclines</th>
<th>Method used</th>
<th>Quantitative (Q) or categorical (SIR)</th>
<th>Interpretive criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DL</td>
<td>Q</td>
<td>Interpreted by ECDC, EUCAST ECOFF (CIP, ERY, GEN, TET), CA-SFM CBP 2021 (AMC)</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>SIR</td>
<td>No information available.</td>
</tr>
<tr>
<td>Cyprus</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Denmark</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Estonia</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Finland</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD/DLG</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>France</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>SIR</td>
<td>EUCAST CBP (CIP, ERY, TET), CA-SFM CBP (AMC, GEN)</td>
</tr>
<tr>
<td>Germany</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Hungary</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>No information available.</td>
</tr>
<tr>
<td>Ireland</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>WGS</td>
<td>PWT/PNWT</td>
<td>No information available.</td>
</tr>
<tr>
<td>Iceland</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD/DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Italy</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Lithuania</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>SIR</td>
<td>EUCAST CBP</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Malta</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DLG/DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Netherlands</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD/DL</td>
<td>SIR</td>
<td>EUCAST CBP</td>
</tr>
<tr>
<td>Norway</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DLG</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Country</td>
<td>Gentamicin</td>
<td>Co-amoxiclav</td>
<td>Ciprofloxacin</td>
<td>Erythromycin</td>
<td>Tetracyclines</td>
<td>Method used</td>
<td>Quantitative (Q) or Categorical (SIR)</td>
<td>Interpretive criteria</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>---------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Poland</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>No information</td>
<td>SIR</td>
<td>No information available.</td>
</tr>
<tr>
<td>Portugal</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Romania</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Slovakia</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>No information</td>
<td>SIR</td>
<td>No information available.</td>
</tr>
<tr>
<td>Slovenia</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DD</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Spain</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>DL</td>
<td>Q</td>
<td>Interpreted by ECDC, as for Austria.</td>
</tr>
<tr>
<td>Sweden</td>
<td>●</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>WGS</td>
<td>PWT/PNWT</td>
<td>Sequencing results interpreted by the laboratory with NCBI AMRFinder and CGE ResFinder and PointFinder</td>
</tr>
</tbody>
</table>

MSs: Member States; AST: antimicrobial susceptibility testing; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; WGS: whole genome sequencing; Q: quantitative data; SIR: susceptible standard dosing regimen, susceptible increased exposure, resistant (categorical data); PWT/PNWT: predicted wild type/predicted non-wild type (categorical); ECDC: European Centre for Disease Prevention and Control; EUCAST: European Committee on Antimicrobial Susceptibility Testing; CA-SFM: French Society for Microbiology; NCBI: National Center for Biotechnology Information, US; CGE: Center for Genomic Epidemiology, Denmark; ECOFF: epidemiological cut-off; CBP: clinical breakpoint; CIP: ciprofloxacin; ERY: erythromycin; GEN: gentamicin; TET: tetracycline; AMC: amoxicillin/clavulanate.
Table F.3: Proportion of tested *Salmonella* spp. isolates from human cases associated with travel, domestic cases and cases with unknown travel information by country, 2021

<table>
<thead>
<tr>
<th>Country</th>
<th>Total <em>Salmonella</em> tested</th>
<th>Travel- associated</th>
<th>Domestic</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Austria</td>
<td>1,052</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Belgium</td>
<td>781</td>
<td>4.4</td>
<td>19</td>
<td>76.7</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Cyprus</td>
<td>75</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Denmark</td>
<td>383</td>
<td>10.4</td>
<td>89.6</td>
<td>0</td>
</tr>
<tr>
<td>Estonia</td>
<td>136</td>
<td>4.4</td>
<td>64</td>
<td>31.6</td>
</tr>
<tr>
<td>Finland</td>
<td>170</td>
<td>1.8</td>
<td>98.2</td>
<td>0</td>
</tr>
<tr>
<td>France</td>
<td>883</td>
<td>5.7</td>
<td>14.3</td>
<td>80.1</td>
</tr>
<tr>
<td>Germany</td>
<td>2,996</td>
<td>0.3</td>
<td>99.7</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>249</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Hungary</td>
<td>534</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Italy</td>
<td>693</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Latvia</td>
<td>8</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Lithuania</td>
<td>224</td>
<td>2.2</td>
<td>97.8</td>
<td>0</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>116</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Malta</td>
<td>205</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Netherlands</td>
<td>645</td>
<td>5.1</td>
<td>94.9</td>
<td>0</td>
</tr>
<tr>
<td>Poland</td>
<td>75</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Portugal</td>
<td>278</td>
<td>0</td>
<td>1.8</td>
<td>98.2</td>
</tr>
<tr>
<td>Romania</td>
<td>25</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Slovakia</td>
<td>780</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Slovenia</td>
<td>185</td>
<td>4.9</td>
<td>21.1</td>
<td>74.1</td>
</tr>
<tr>
<td>Spain</td>
<td>1,003</td>
<td>0.1</td>
<td>75.9</td>
<td>24</td>
</tr>
<tr>
<td>Sweden</td>
<td>659</td>
<td>6.1</td>
<td>90.7</td>
<td>3.2</td>
</tr>
<tr>
<td><strong>Total (25 MSs)</strong></td>
<td><strong>12,157</strong></td>
<td><strong>1.9</strong></td>
<td><strong>55.9</strong></td>
<td><strong>42.2</strong></td>
</tr>
<tr>
<td>Iceland</td>
<td>55</td>
<td>12.7</td>
<td>54.5</td>
<td>32.7</td>
</tr>
<tr>
<td>Norway</td>
<td>222</td>
<td>9.9</td>
<td>65.3</td>
<td>24.8</td>
</tr>
</tbody>
</table>

MSs: Member States; N: number of isolates tested.

Table F.4: Proportion of tested *Campylobacter jejuni* and *Campylobacter coli* isolates from human cases associated with travel, domestic cases and cases with unknown travel information by country in 2021

<table>
<thead>
<tr>
<th>Country</th>
<th>Total <em>C. jejuni</em> and <em>C. coli</em> tested</th>
<th>Travel- associated</th>
<th>Domestic</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Austria</td>
<td>473</td>
<td>1.1</td>
<td>92.6</td>
<td>6.3</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>22</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Cyprus</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Denmark</td>
<td>331</td>
<td>9.7</td>
<td>90.3</td>
<td>0</td>
</tr>
<tr>
<td>Estonia</td>
<td>214</td>
<td>1.4</td>
<td>36.4</td>
<td>62.1</td>
</tr>
<tr>
<td>Finland</td>
<td>1,042</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>France</td>
<td>7,931</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Germany</td>
<td>1,547</td>
<td>0.1</td>
<td>99.9</td>
<td>0</td>
</tr>
<tr>
<td>Hungary</td>
<td>586</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Ireland</td>
<td>202</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Italy</td>
<td>139</td>
<td>0</td>
<td>23.7</td>
<td>76.3</td>
</tr>
<tr>
<td>Lithuania</td>
<td>230</td>
<td>0</td>
<td>99.6</td>
<td>0.4</td>
</tr>
</tbody>
</table>
Antimicrobial susceptibility data from animals and food in 2020–2021


EU MSs reported mandatory data collected following AMR monitoring programs during 2020 and 2021. ‘Directive 2003/99/EC requires Member States to ensure that monitoring provides comparable data on the occurrence of antimicrobial resistance (‘AMR’) in zoonotic agents and, in so far as they present a threat to public health, other agents.’ ‘Directive 2003/99/EC also requires Member States to assess the trends and sources of AMR in their territory and to transmit a report every year covering data collected in accordance with that Directive to the Commission.’ Furthermore, some non-EU countries reported AMR data and both, some EU and non-EU reporting countries (RCs) also reported voluntary data from samples that were not included in the mandatory programs per reporting year.

The Commission Implementing Decision 2013/652/EU\(^{30}\) lays down detailed rules for the harmonised monitoring and reporting of AMR in zoonotic and commensal bacteria applicable until 31 December 2020. The Commission Implementing Decision (EU) 2020/1729\(^{31}\) of 17 November 2020 lays down new rules for antimicrobial resistance monitoring performed in 2021 onwards. This Decision specifies harmonised rules for the period 2021–2027 for the monitoring and reporting of AMR to be carried out by Member States in accordance with EU Regulations.

The Commission Implementing Decision (EU) 2020/1729 determines specific technical requirements for AMR testing and reporting in relation to sampling in food-producing animals and derived meat (at retail and at border control posts). The Commission Implementing Decision (EU) 2020/1729 indicates that the monitoring and reporting of AMR shall cover the following bacteria: (a) Salmonella spp.; (b) Campylobacter coli (C. coli); (c) Campylobacter jejuni (C. jejuni); (d) Indicator commensal Escherichia coli (E. coli); (e) Salmonella spp. and E. coli producing the following enzymes: (i) Extended Spectrum \(\beta\)-Lactamases (ESBL); (ii) AmpC \(\beta\)-Lactamases (AmpC); (iii) Carbapenemases (CP). Therefore, during 2021, AMR data were collected from the bacteria listed above. It seems relevant to notice that the collection of AMR data from Campylobacter coli isolates was not compulsory in 2020. Despite this, some countries reported AMR data related to Campylobacter coli.

Countries can also report AMR data from other agents of public health importance such as methicillin-resistant Staphylococcus aureus (MRSA). According to Commission Implementing Decision

<table>
<thead>
<tr>
<th>Country</th>
<th>Total C. jejuni and C. coli tested</th>
<th>Travel- associated</th>
<th>Domestic</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>208</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Malta</td>
<td>244</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Netherlands</td>
<td>1,408</td>
<td>0</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Poland</td>
<td>78</td>
<td>0</td>
<td>79.5</td>
<td>20.5</td>
</tr>
<tr>
<td>Portugal</td>
<td>325</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Romania</td>
<td>2</td>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Slovakia</td>
<td>1,287</td>
<td>0.1</td>
<td>99.9</td>
<td>0</td>
</tr>
<tr>
<td>Slovenia</td>
<td>855</td>
<td>0.1</td>
<td>4.8</td>
<td>95.1</td>
</tr>
<tr>
<td>Spain</td>
<td>571</td>
<td>0</td>
<td>60.2</td>
<td>39.8</td>
</tr>
<tr>
<td>Sweden</td>
<td>281</td>
<td>11</td>
<td>83.6</td>
<td>5.3</td>
</tr>
<tr>
<td>Total (23 MSs)</td>
<td>18,008</td>
<td>0.4</td>
<td>30.6</td>
<td>69</td>
</tr>
<tr>
<td>Iceland</td>
<td>54</td>
<td>31.5</td>
<td>48.1</td>
<td>20.4</td>
</tr>
<tr>
<td>Norway</td>
<td>296</td>
<td>9.1</td>
<td>56.8</td>
<td>34.1</td>
</tr>
</tbody>
</table>

MSs: Member States; N: number of isolates tested.

(EU) 2020/1729 the monitoring and reporting of AMR may also cover indicator commensal Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium).

A scientific report published by EFSA in 2012 included technical specifications on the harmonised monitoring and reporting of antimicrobial resistance in methicillin-resistant Staphylococcus aureus (MRSA) in food-producing animals and food (EFSA, 2012). Detailed rules were specified for harmonised monitoring and reporting on the prevalence of resistant microorganisms in food-producing animals and food, in particular as regards the microorganisms to be included, the origin of the isolates of the microorganisms, the number of isolates to be tested, the antimicrobial susceptibility tests to be used, the specific monitoring of MRSA and ESBL- or AmpC-producing bacteria and the collection and reporting of the data. Comparison between human data and data from food-producing animals and food sector was ensured by involvement of ECDC.

The Commission Implementing Decision (EU) 2020/1729 specifies that the monitoring and reporting of AMR shall cover the following food-producing animal populations and food: (a) broilers; (b) laying hens; (c) fattening turkeys; (d) bovine animals under 1 year of age; (e) fattening pigs; (f) fresh meat from broilers; (g) fresh meat from turkeys; (h) fresh meat from pigs; (i) fresh meat from bovine animals. This European Commission Decision indicates the sampling frequency for MSs to carry out the AMR monitoring and reporting in accordance with the following rotational system: (a) In the years 2021, 2023, 2025 and 2027: in fattening pigs, bovine animals under 1 year of age, pig meat and bovine meat. (b) In the years 2022, 2024 and 2026: in laying hens, broilers, fattening turkeys and fresh meat derived from broilers and turkeys.

Therefore, following relevant EU legislation AMR data presented in this Report were collected from poultry populations and derived meat thereof in 2020 and from pigs and from bovines under 1 year of age in 2021.

The Commission Implementing Decision (EU) 2013/652 and the Commission Implementing Decision (EU) 2020/1729 lay down detailed rules for sampling design and sample size as well as for antimicrobial susceptibility testing for the different bacteria. These European Commission Decisions indicate the analytical methods for detection and antimicrobial susceptibility testing that shall be performed by the laboratories referred to in Article 3(2). AMR testing shall be performed by using the broth microdilution method according to the reference method ISO 20776-1:2019.

For AMR testing, isolates were obtained through harmonised national programs. The broth microdilution testing method was widely used for susceptibility testing following EU legislation.

On November 17, 2020, the European Commission laid down the new technical specifications in Commission Implementing Decision (EU) 2020/1729 and repealed Commission Implementing Decision (EU) 2013/652. The new legislation came into effect on 1 January 2021, and updates technical specifications for harmonised AMR monitoring and reporting to include the monitoring of AMR in derived meat sampled at border control posts, the testing of new substances. The new legislation also authorises WGS as an alternate method to phenotypic testing for AMR monitoring. The new rules apply until December 2027.

Resulting quantitative isolate-based data were reported to EFSA and considered for this report. Resistance was interpreted using EUCAST ECOFF values (see text box below for further information). The antimicrobials incorporated in this report were selected based on their public health relevance and as representatives of different antimicrobial classes. Data on methicillin resistant Staphylococcus aureus (MRSA) and other microorganisms apart from those required by legislation were reported on a voluntary basis.

**Harmonised representative sampling and monitoring**

Representative sampling and AMR monitoring should be performed following the current legislation and the technical specifications published by EFSA (EFSA, 2012, 2014, 2019, 2020). Regulation (EC) No 2073/2005 Article 4 indicates that: ‘Food business operators shall perform testing as appropriate against the microbiological criteria set out in Annex I, when they are validating or verifying the correct functioning of their procedures based on HACCP principles and good hygiene practice.’
**Salmonella spp.**

The Commission Implementing Decision (EU) 2020/1729 lays down new rules for antimicrobial resistance monitoring performed in 2021 onwards. The Commission Implementing Decision (EU) 2020/1729 determines specific technical requirements for AMR testing and reporting in relation to sampling in food-producing animals and derived meat (at retail and at border control posts). In 2021, MSs collected representative *Salmonella* spp. isolates for AMR monitoring from samples of caecal content taken at slaughter from bovines under 1 year of age where the production of meat of those bovines in the MSs was more than 10,000 tonnes per year sampled for testing and verification of compliance, in accordance with point 2.1.3 of chapter 2 of Annex I of Regulation (EC) No 2073/2005. Also in 2021, representative *Salmonella* isolates for AMR monitoring were obtained by MSs from samples of caecal content fattening pigs sampled for testing and verification of compliance, in accordance with point 2.1.4 of chapter 2 of Annex I of Regulation (EC) No 2073/2005. In compliance with EU legislation and EFSA guidelines, MSs sampled the caecal contents of fattening pigs and of bovines under 1 year of age at the slaughterhouse. MSs employed a two-stage stratified sampling design (with slaughterhouses as primary sampling units and carcases as secondary units) based on proportional allocation of the number of samples to the annual throughput of the slaughterhouse. Moreover, samples of fresh meat from pigs and calves were collected at retail and at the border control posts.

In 2020, representative *Salmonella* isolates for monitoring AMR were collected by MSs from the populations of broilers, laying hens and fattening turkeys sampled following the *Salmonella* National Control Programmes (NCPs), set up in accordance with Article 5(1) of Regulation (EC) No 2160/2003. Moreover, carcasses of broilers and fattening turkeys were sampled for testing and verification of compliance, in accordance with paragraph 2.1.5 of chapter 2 of Annex I of Regulation (EC) No 2073/2005. For the purposes of sampling design and representativeness, no more than one isolate per *Salmonella* serovar from the same epidemiological unit (herd/holding/flock of birds) per year should be included in the AMR monitoring program. Moreover, samples of fresh meat from broilers and fattening turkeys were collected at retail. In most MSs, the isolates tested for AMR formed a representative subsample of the total *Salmonella* isolates available at the National Reference Laboratory (NRL) and/or other laboratories involved. The sampling was performed in such way as to ensure geographical representativeness and even distribution over the year. However, when sampling from low prevalence areas, all the *Salmonella* isolates available should be tested for susceptibility.

**Campylobacter spp.**

The Commission Implementing Decision (EU) 2020/1729 lays down new rules for antimicrobial resistance monitoring performed in 2021 onwards. The Commission Implementing Decision (EU) 2020/1729 determines specific technical requirements for AMR testing and reporting in relation to sampling in food-producing animals and derived meat (at retail and at border control posts).

In 2021, MSs collected at least 170 isolates of the nationally most prevalent species of *Campylobacter* (*C. coli* and *C. jejuni*) from samples obtained from pigs and bovines under 1 year of age following regulations and technical requirements for AMR testing. The sample collection was approximately evenly distributed over the year 2021. One representative caecal sample (single or pooled) per epidemiological unit (e.g. batch of animals sent to the slaughterhouse), was gathered to account for clustering. Isolates were recovered from caecal samples (single or pooled), in accordance with EFSA’s recommendations (EFSA, 2014, 2019, 2021). Moreover, samples of meat from pigs and bovines under 1 year of age were collected at retail and at the border control posts.

Regarding AMR testing of *C. coli* and *C. jejuni* isolated from different animal species (depending on the year), the Commission Implementing Decision (EU) 2020/1729 specifies where the isolates shall be obtained from (referred to in point 1(b)(i) to (iv)) or, for Member States making use of the derogation referred to in the second paragraph of point 3(1)(b), all isolates obtained from these samples. MSs shall test at least 170 isolates of the nationally most prevalent species of *Campylobacter* (among *C. coli* and *C. jejuni*) obtained from samples referred to in point 1(b)(i) to (iii) or, for Member States making use of the derogation referred to in the second paragraph of point 3(1)(b), all isolates obtained from these samples. By way of derogation, where Member States have a national annual production of less than 100 000 tonnes of broiler meat, they may decide to test a minimum of 85 isolates for monitoring AMR were collected by MSs from the populations of broilers, laying hens and fattening turkeys sampled following the *Salmonella* National Control Programmes (NCPs), set up in accordance with Article 5(1) of Regulation (EC) No 2160/2003. Moreover, carcasses of broilers and fattening turkeys were sampled for testing and verification of compliance, in accordance with paragraph 2.1.5 of chapter 2 of Annex I of Regulation (EC) No 2073/2005. For the purposes of sampling design and representativeness, no more than one isolate per *Salmonella* serovar from the same epidemiological unit (herd/holding/flock of birds) per year should be included in the AMR monitoring program. Moreover, samples of fresh meat from broilers and fattening turkeys were collected at retail. In most MSs, the isolates tested for AMR formed a representative subsample of the total *Salmonella* isolates available at the National Reference Laboratory (NRL) and/or other laboratories involved. The sampling was performed in such way as to ensure geographical representativeness and even distribution over the year. However, when sampling from low prevalence areas, all the *Salmonella* isolates available should be tested for susceptibility.

**Campylobacter spp.**

The Commission Implementing Decision (EU) 2020/1729 lays down new rules for antimicrobial resistance monitoring performed in 2021 onwards. The Commission Implementing Decision (EU) 2020/1729 determines specific technical requirements for AMR testing and reporting in relation to sampling in food-producing animals and derived meat (at retail and at border control posts).

In 2021, MSs collected at least 170 isolates of the nationally most prevalent species of *Campylobacter* (*C. coli* and *C. jejuni*) from samples obtained from pigs and bovines under 1 year of age following regulations and technical requirements for AMR testing. The sample collection was approximately evenly distributed over the year 2021. One representative caecal sample (single or pooled) per epidemiological unit (e.g. batch of animals sent to the slaughterhouse), was gathered to account for clustering. Isolates were recovered from caecal samples (single or pooled), in accordance with EFSA’s recommendations (EFSA, 2014, 2019, 2021). Moreover, samples of meat from pigs and bovines under 1 year of age were collected at retail and at the border control posts.

Regarding AMR testing of *C. coli* and *C. jejuni* isolated from different animal species (depending on the year), the Commission Implementing Decision (EU) 2020/1729 specifies where the isolates shall be obtained from (referred to in point 1(b)(i) to (iv)) or, for Member States making use of the derogation referred to in the second paragraph of point 3(1)(b), all isolates obtained from these samples. MSs shall test at least 170 isolates of the nationally most prevalent species of *Campylobacter* (among *C. coli* and *C. jejuni*) obtained from samples referred to in point 1(b)(i) to (iii) or, for Member States making use of the derogation referred to in the second paragraph of point 3(1)(b), all isolates obtained from these samples. By way of derogation, where Member States have a national annual production of less than 100 000 tonnes of broiler meat, they may decide to test a minimum of 85

---

isolates instead of 170 isolates. Similarly, by way of derogation, where Member States have a national annual production of less than 100,000 tonnes of pig meat, they may decide to test a minimum of 85 isolates instead of 170 isolates.

In 2020, MSs collected *C. jejuni* isolates as part of their national monitoring programme of AMR according to the provisions of Commission Implementing Decision (EU) 2013/652, based on representative random sampling of broilers/fattening turkeys at the slaughterhouse. A two-stage stratified sampling design was applied considering slaughterhouses as primary sampling units and carcasses as secondary units, with proportional allocation of the number of samples to the annual throughput of the slaughterhouse. In 2021, MSs collected *C. jejuni* isolates as part of their national monitoring programme of AMR according to the provisions of Commission Implementing Decision (EU) 2013/652, based on representative random sampling of fattening pigs and bovines under 1 year of age. Moreover, reporting countries can collect AMR data from other animal species than the required each year on voluntary basis.

*Campylobacter coli* caecal samples gathered at slaughter from fattening pigs and bovines under 1 year of age were collected in compliance with new legislation in 2021 and on voluntary basis in 2020. One representative caecal sample (single or pooled) per epidemiological unit (batch of carcasses deriving from the same herd), was gathered to account for clustering. Isolates were recovered from caecal contents samples (single or pooled), in accordance with EFSA’s recommendations (EFSA, 2012, 2014, 2019, 2020). The sample collection was approximately evenly distributed over the year 2021.

**Indicator commensal *E. coli***

**Routine monitoring of indicator *E. coli***

Indicator *E. coli* isolates were collected by MSs as part of their national monitoring programme of AMR according to the provisions of the Commission Implementing Decision (EU) 2020/1729. In 2021, MSs collected indicator *E. coli* isolates based on random sampling of caecal samples gathered at slaughter from fattening pigs and calves under one year of age where the production of bovine meat in the MSs is more than 10,000 tonnes slaughtered per year as specified in Annex Part A paragraph 1(c) (iv). One representative caecal sample (single or pooled) per epidemiological unit (herds), was gathered to account for clustering. Isolates were recovered from caecal samples (single or pooled), in accordance with regulations and EFSA’s recommendations (EFSA, 2012, 2014, 2019, 2020).

As per Regulations, from 2021 MSs shall test at least 170 isolates obtained from samples referred to in points 1(c)(v). By way of derogation, where MSs have a national annual production of less than 100,000 tonnes of pig meat, less than 100,000 tonnes of broiler meat or less than 100,000 tonnes of turkey meat, they may test a minimum of 85 isolates instead of 170 isolates for each specific animal population (depending on the mandatory testing every year).

In 2020, MSs collected indicator commensal *E. coli* isolates as part of their national monitoring programme of AMR according to the provisions of Commission Implementing Decision (EU) 2013/652, based on representative random sampling of broilers and fattening turkeys at the slaughterhouse. A two-stage stratified sampling design was applied in the reporting countries, with slaughterhouses as primary sampling units and carcasses as secondary units, accounting for proportional allocation of the number of samples to the annual throughput of the slaughterhouse. Only one representative caecal sample (single or pooled) per epidemiological unit (batch of carcasses deriving from the same flock), was gathered to account for clustering. Isolates were recovered from caecal contents samples (single or pooled), in accordance with EFSA’s recommendations (EFSA, 2014, 2019). The sample collection was approximately evenly distributed over the year 2020.

In 2021, MSs collected indicator commensal *E. coli* isolates as part of their national monitoring programme of AMR according to the provisions of Commission Implementing Decision (EU) 2020/1729, based on representative random sampling of fattening pigs and bovines under 1 year of age. Samples and isolates were obtained as previously indicated in accordance with EU legislation and EFSA’s recommendations (EFSA, 2014, 2019, 2020). The sample collection was approximately evenly distributed over the year 2021.

**Specific monitoring of *E. coli* ESBL/AmpC/carbapenemase producers**

In 2021, MSs collected caecal samples from fattening pigs and bovines under 1 year of age at slaughter, where the production of meat of those bovines in the MSs was more than 10,000 tonnes slaughtered per year and samples of fresh pig meat and bovine meat gathered at retail and at the
border control posts. In 2020, MSs obtained caecal samples from broilers and from fattening turkeys at slaughter, in those MSs where the production of turkey meat in the MS was more than 10,000 tonnes slaughtered per year. Moreover, samples of fresh meat from broilers and fattening turkeys were collected at retail and at the border control posts. Only one representative caecal sample (single or pooled) per epidemiological unit (batch of carcasses deriving from the same herd/flock), was collected to account for clustering. Isolates were recovered from caecal contents samples (single or pooled), in accordance with relevant Regulations and EFSA’s recommendations (EFSA, 2014, 2019, 2020). The sample collection as described above was approximately evenly distributed over the years 2020 and 2021. The same sampling design was used to collect indicator *E. coli* isolates, whether dedicated to the routine monitoring of AMR or the specific monitoring of ESBL-/AmpC-/carbapenemase-producing *E. coli*. EUSR on AMR in zoonotic and indicator bacteria from humans, animals and food in 2020–2021.

### Epidemiological cut-off values (ECOFFs) and clinical breakpoints (CBPs)

*Epidemiological cut-off values (ECOFFs) and clinical breakpoints (CBPs)*

A microorganism is defined as ‘clinically’ resistant when the degree of resistance shown is associated with a high likelihood of therapeutic failure. The microorganism is categorised as resistant by applying the appropriate CBP in a defined phenotypic test system, and this breakpoint may alter with legitimate changes in circumstances (for example alterations in dosing regimen, drug formulation, patient factors). A microorganism is defined as wild type for a bacterial species when no acquired or mutational resistance mechanisms are present to the antimicrobial in question. A microorganism is categorised as wild type for a given bacterial species presenting a lower MIC to the antimicrobial in question than the appropriate ECOFF in a defined phenotypic test system. This cut-off value will not be altered by changing circumstances (such as alterations in frequency of antimicrobial administration). Wild-type microorganisms may or may not respond clinically to antimicrobial treatment. A microorganism is defined as non-wild type for a given bacterial species by the presence of an acquired or mutational resistance mechanism to the antimicrobial in question. A microorganism is categorised as non-wild type for a given bacterial species by applying the appropriate ECOFF value in a defined phenotypic test system; non-wild-type organisms are considered to show ‘microbiological’ resistance (as opposed to ‘clinical’ resistance). CBPs and ECOFFs may be the same, although it is often the case that the ECOFF is lower than the CBP. EUCAST has defined CBPs and ECOFFs.

*Clinical breakpoints (clinical resistance)*

The clinician, or veterinarian, choosing an antimicrobial agent to treat humans or animals with a bacterial infection requires information that the antimicrobial selected is effective against the bacterial pathogen. Such information will be used, together with clinical details such as the site of infection, ability of the antimicrobial to reach the site of infection, formulations available and dosage regimes, when determining an appropriate therapeutic course of action. The *in vitro* susceptibility of the bacterial pathogen can be determined and CBPs used to ascertain whether the organism is likely to respond to treatment. CBPs will take into account the distribution of the drug in the tissues of the body following administration and assume that a clinical response will be obtained if the drug is given as recommended and there are no other adverse factors which affect the outcome. Conversely, if the CBP indicates resistance, then it is likely that treatment will be unsuccessful. Frequency of dosing is one factor that can affect the antimicrobial concentration achieved at the site of infection. Therefore, different dosing regimens can lead to the development of different CBPs, as occurs in some countries for certain antimicrobials where different therapeutic regimes are in place. Although the rationale for the selection of different CBPs may be clear, their use makes the interpretation of results from different countries in reports of this type problematic, as the results are not directly comparable between those different countries.

*Epidemiological cut-off values (microbiological resistance)*

For a given bacterial species, the pattern of the MIC distribution (i.e. the frequency of occurrence of each given MIC plotted against the MIC value) can enable the separation of the wild-type population of microorganisms from those populations that show a degree of acquired resistance.
The wild-type susceptible population is assumed to have no acquired or mutational resistance and commonly shows a normal distribution. When bacteria acquire resistance by a clearly defined and efficacious mechanism, such as the acquisition of a plasmid bearing a gene which produces an enzyme capable of destroying the antimicrobial, then the MIC commonly shows two major subpopulations, one a fully susceptible normal distribution of isolates and the other a fully resistant population which has acquired the resistance mechanism. Resistance may be achieved by a series of small steps, such as changes in the permeability of the bacterial cell wall to the antimicrobial or other mechanisms which confer a degree of resistance. In this case, there may be populations of organisms which occur lying between the fully susceptible population and more resistant populations. The ECOFF value indicates the MIC or zone diameter above which the pathogen has some detectable reduction in susceptibility. ECOFFs are derived by testing an adequate number of isolates to ensure that the wild-type population can be confidently identified for a given antimicrobial. The clinical breakpoint, which is set to determine the therapeutic effectiveness of the antimicrobial, may fail to detect emergent resistance. Conversely, the ECOFF detects any deviation in susceptibility from the wild-type population, although it may not be appropriate for determining the likelihood of success or failure for clinical treatment.

MRSA
MRSA Isolates may have been collected by reporting countries using different monitoring approaches, either by active surveillance and monitoring of animals and foods or, in some cases, by passive monitoring (for example based on diagnostic submission of samples from clinical cases of disease in animals, or from foods sampled as part of investigatory work).

Harmonised antimicrobial susceptibility testing

Routine monitoring antimicrobial susceptibility

MSs followed Commission Implementing Decision (EU) 2020/1729 and recommendations from EFSA regarding the use of epidemiologic cut-off values for AMR monitoring. MSs tested antimicrobials and interpreted the results using the ECOFFs and concentration ranges shown in Tables F.5 and F.6 to determine the susceptibility of the following microorganisms: Salmonella spp., C. coli, C. jejuni and indicator commensal E. coli. Under the new legislation (Commission Implementing (EU) 2020/1729), changes were made to the ECOFFs and clinical breakpoints for several antimicrobial substances included in the harmonised panel for testing of Salmonella spp., and E. coli. The substances with changes to ECOFFs and or clinical breakpoints included tigecycline, nalidixic acid and ciprofloxacin (Table F.5). For 2021 data from pigs, calves and meat from BCPS, the occurrence of resistance to tigecycline, nalidixic acid and ciprofloxacin is determined using the new ECOFFs and clinical breakpoints, and for 2020 data from poultry, tigecycline, nalidixic acid and ciprofloxacin resistance are analysed using the ECOFFs and clinical breakpoints from the previous legislation (Decision 2013/652/EU). Also, in 2021, a new substance, amikacin, was added to the harmonised panel for both Salmonella spp. and E. coli. While for Campylobacter spp., no changes were made to ECOFFs and clinical breakpoints for the substances included in the harmonised panel. However, two new substances were added (chloramphenicol and ertapenem) and two substances were removed (nalidixic acid and streptomycin).

Presumptive ESBL- AmpC- or carbapenemase-producing E. coli isolates identified through selective plating, as well as randomly selected isolates of Salmonella spp. and E. coli that, after testing with the first panel of antimicrobials in accordance with Commission Implementing Decision (EU) 2020/1729 were found to be resistant to cefotaxime, ceftazidime or meropenem, should be further tested with a second panel of antimicrobial substances (Table F.7) or further investigated using WGS. The second panel includes cefoxitin, ceftazime and clavulanic acid in combination with cefotaxime and ceftazidime for the detection of presumptive ESBL- and AmpC- producing isolates. Moreover, the second panel contains imipenem, meropenem and ertapenem to phenotypically verify presumptive carbapenemase-producers.
Specific monitoring of ESBL-/AmpC-/carbapenemase-producing \textit{E. coli}  

For the specific monitoring of ESBL-/AmpC-/carbapenemase-producing \textit{E. coli}, the isolation method used an initial non-selective pre-enrichment step, followed by inoculation on MacConkey agar containing a third-generation cephalosporin in a selective concentration (cefotaxime 1 mg/L), in accordance with the most recent version of the detailed protocol for standardisation of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR).\textsuperscript{35} Following this protocol, also presumptive carbapenemase-producing isolates can be recovered. If available, one presumptive ESBL/AmpC/carbapenemase-producing \textit{E. coli} isolate obtained from each positive caecal sample and meat sample was tested for its antimicrobial susceptibility to the first panel of antimicrobials (Table F.5). This step was performed to confirm the microbiological resistance to cefotaxime (expected as the antimicrobial is present in the isolation medium at a concentration higher than the ECOFF), as well as to identify possible resistance to cefotaxime and/or ceftazidime and/or meropenem. In a second step, the isolate should be tested using the second panel of antimicrobials (Table F.7) to infer the presumptive ESBL/AmpC/carbapenemase-producing phenotypes according to the \textit{β}-lactams resistance phenotypes obtained (Figure F.1).

Specific monitoring of carbapenemase-producing microorganisms  

This monitoring programme has been implemented and reported on a voluntary basis. For the specific monitoring of carbapenemase-producing microorganisms, isolation required the use of non-selective pre-enrichment and subsequent selective plating on carbapenem-containing media, in accordance with the most recent version of the detailed protocol of the EURL-AR. The microbial species was identified using appropriate methods. If available, one presumptive carbapenemase-producing isolate (primarily \textit{E. coli}, but also \textit{Salmonella}) obtained from each positive caecal sample and meat sample should be tested for its antimicrobial susceptibility to the first panel of antimicrobials (Table F.5) to confirm the microbiological resistance to meropenem and to identify possible resistance to other antimicrobials such as cefotaxime and/or ceftazidime. In a second step, the isolate should be tested against the second panel of antimicrobials (Table F.7) to infer the presumptive carbapenemase-producer phenotype according to the \textit{β}-lactam resistance phenotypes obtained (Figure F.1). The EUCAST epidemiological cut-off values applied for the antimicrobial susceptibility testing (Tables F.5–F.7) are based on Commission Implementing Decision (EU) 2020/1729. For some antimicrobials, these values have been changed compared to the previous legislation. For example, the panel of antimicrobials included in AMR monitoring for \textit{Salmonella} spp. and indicator commensal \textit{E. coli} indicates that for these microorganisms the EUCAST ECOFF has changed in relation to nalidixic acid from > 16 to > 8 and in relation to tigecycline from > 1 to > 0.5 based on the new legislation (Table F.5).

Table F.5: Panel of antimicrobial substances included in AMR monitoring, thresholds for interpreting resistance and concentration ranges tested in \textit{Salmonella} spp. and indicator commensal \textit{E. coli} (first panel) based on Commission Implementing Decision (EU) 2020/1729 and EFSA Technical Report 2021

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th>\textit{Salmonella} EU surveillance 2021 EUCAST ECOFF*</th>
<th>\textit{E. coli} EU surveillance 2021 EUCAST ECOFF*</th>
<th>Concentration range, mg/L (no. of wells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin\textsuperscript{(a)}</td>
<td>&gt; 4</td>
<td>&gt; 8</td>
<td>4–128 (6)</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>1–32 (6)</td>
</tr>
<tr>
<td>Azithromycin\textsuperscript{(b)}</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>2–64 (6)</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>&gt; 0.5</td>
<td>&gt; 0.25</td>
<td>0.25–4 (5)\textsuperscript{(c)} 0.25–64 (9)\textsuperscript{(d)}</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>&gt; 2</td>
<td>&gt; 0.5</td>
<td>0.25–8 (6)\textsuperscript{(c)} 0.25–128 (10)\textsuperscript{(d)}</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>8–64 (4)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>&gt; 0.06</td>
<td>&gt; 0.06</td>
<td>0.015–8 (10)</td>
</tr>
</tbody>
</table>

\textsuperscript{35} Available online: www.eurl-ar.eu.
Table F.6: Panel of antimicrobial substances included in AMR monitoring, thresholds for interpreting resistance and concentration ranges tested in *C. jejuni* and *C. coli* based on Commission Implementing Decision (EU) 2020/1729 and EFSA Technical Report 2021

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th><em>C. jejuni</em> EU surveillance 2021 EUCAST ECOFF*</th>
<th><em>C. coli</em> EU surveillance 2021 EUCAST ECOFF*</th>
<th>Concentration range, mg/L (no. of wells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colistin</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
<td>1–16 (5)</td>
</tr>
<tr>
<td>Gentamicin(a)</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
<td>0.5–16 (6)</td>
</tr>
<tr>
<td>Meropenem</td>
<td>&gt; 0.125</td>
<td>&gt; 0.125</td>
<td>0.03–16 (10)</td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>4–64 (5)</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>&gt; 256</td>
<td>&gt; 64</td>
<td>8–512 (7)</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>2–32 (5)</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>&gt; 0.5</td>
<td>&gt; 0.5</td>
<td>0.25–8 (6)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
<td>0.25–16 (7)</td>
</tr>
</tbody>
</table>

AMR: antimicrobial resistance; ECOFFs: epidemiological cut-off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing.

*: EUCAST epidemiological cut-off values. ‘>’ than the ECOFF, criteria used to determine microbiological resistance.

(a): EUCAST epidemiological cut-off (ECOFF) value for *Salmonella* is tentative.

(c): Range to be used when the substance is tested in panel 1.

(d): Range to be used when the substance is tested in panel 2.

Table F.7: Panel of antimicrobial substances, EUCAST ECOFFs and concentration ranges used for testing *Salmonella* spp. and indicator commensal *E. coli* isolates resistant to cefotaxime, ceftazidime or meropenem (second panel)

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th><em>Salmonella</em> EU surveillance 2021 EUCAST ECOFF*</th>
<th><em>E. coli</em> EU surveillance 2021 EUCAST ECOFF*</th>
<th>Concentration range, mg/L (no. of wells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime(a)</td>
<td>&gt; 0.125</td>
<td>&gt; 0.125</td>
<td>0.06–32 (10)</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>&gt; 0.5</td>
<td>&gt; 0.25</td>
<td>0.25–4 (5)(b)</td>
</tr>
<tr>
<td>Cefotaxime + clavulanic acid</td>
<td>&gt; 0.5</td>
<td>&gt; 0.25</td>
<td>0.25–64 (9)(c)</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>0.5–64 (8)</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>&gt; 2</td>
<td>&gt; 0.5</td>
<td>0.25–8 (6)(b)</td>
</tr>
<tr>
<td>Ceftazidime + clavulanic acid</td>
<td>&gt; 2</td>
<td>&gt; 0.5</td>
<td>0.25–128 (10)(c)</td>
</tr>
<tr>
<td>Ertapenem(d)</td>
<td>&gt; 0.06</td>
<td>&gt; 0.06</td>
<td>0.015–2 (8)</td>
</tr>
</tbody>
</table>

AMR: antimicrobial resistance; ECOFFs: epidemiological cut-off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing.

As these values are based on Commission Implementing Decision 2020/1729, no values for STR and NAL are presented.

*: EUCAST epidemiological cut-off values. ‘>’ than the ECOFF, criteria used to determine microbiological resistance.

(a): The updated EUCAST epidemiological cut-off (ECOFF) value for *Salmonella* is 1 mg/L.
Data validation

Validation against business rules

The reported data were first checked for usability against a series of ‘business rules’, which were automatically applied in the EFSA data collection system once a file was sent. This automatic data validation process refers to the first validation of incoming data. Quality checks are related to a specific business only.

Scientific data validation

The scientific validation of the data collected by the MSs/non-MSs and submitted to EFSA consisted of the reviewing the data and making comparisons between data reported for the same antimicrobials when tested by different panels. Special attention was given to carbapenems, colistin, azithromycin, tigecycline and to possible discrepancies between results for antimicrobials present in both panels (i.e. cefotaxime, ceftazidime, meropenem). MSs were contacted by EFSA asking for clarifications. If necessary, MSs were asked to confirm the MIC results and the species identification of the reported isolates.

Reference testing

To ensure the quality of data submitted, a reference testing exercise was run by the EUR-L-AR in close collaboration with the MSs. The exercise consisted in retesting the AST of the isolates received using both Panel 1 and Panel 2 of antimicrobials, as well as whole genome sequencing (WGS) analyses of the isolates (WGS analyses on-going by the time of drafting the present report). Based on the data submitted to EFSA, a selection of approximately 277 isolates was made. The selection of these isolates was based on different criteria:

- Isolates representing the categorisations presumptive ESBLs-, AmpC and ESBL + AmpC producers.
- *Salmonella* spp. and *E. coli* isolates showing high resistance to Amikacin (MIC > 128 mg/L).
- Isolates having genes reported at low frequency identified in their genome.
- Isolates having multiple genes identified as belonging to the same family.

MSs sent the selected isolates to the EUR-L-AR, where they were retested. EFSA, EUR-L-AR and MSs liaised together to address possible discrepancies found.

Analyses of antimicrobial resistance data

Data are reported in separate sections dedicated to each microorganism. Clinical investigation data were not accounted for in this report.

Overview tables of the resistance data reported

Data generated from the antimicrobial susceptibility testing and reported as quantitative at the isolate level by MSs have been described in the overview tables included in the Annexes A–E published on the EFSA Knowledge Junction community on Zenodo (https://doi.org/10.5281/zenodo.7544221). The tables

<table>
<thead>
<tr>
<th>Antimicrobial</th>
<th><em>Salmonella</em> EU surveillance 2021</th>
<th><em>E. coli</em> EU surveillance 2021</th>
<th>Concentration range, mg/L (no. of wells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem</td>
<td>&gt; 1</td>
<td>&gt; 0.5</td>
<td>0.12–16 (8)</td>
</tr>
<tr>
<td>Meropenem</td>
<td>&gt; 0.125</td>
<td>&gt; 0.125</td>
<td>0.03–16 (10)</td>
</tr>
<tr>
<td>Temocillin</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>0.5–128 (9)</td>
</tr>
</tbody>
</table>

AMR: antimicrobial resistance; ECOFFs: epidemiological cut-off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing.

*: EUCAST epidemiological cut-off values. ‘>’ than the ECOFF, criteria used to determine microbiological resistance.
(a): EUCAST epidemiological cut-off (ECOFF) value for *E. coli* is 0.25 mg/L.
(b): Range to be used when the substance is tested in panel 1.
(c): Range to be used when the substance is tested in panel 2.
(d): EUCAST epidemiological cut-off (ECOFF) value for *E. coli* is tentative 0.03 mg/L.
also display complete susceptibility, multidrug resistance and co-resistance. These analyses are described in Section 2.4.

Minimum inhibitory concentration distributions

For each combination of microorganism, antimicrobial and food category/animal population were tested, MIC distributions were tabulated in frequency tables, giving the number of isolates tested that have a given MIC at each test dilution (mg/L) of the antimicrobial. Isolate-based dilution results allowed MIC distributions reported:

- for *Salmonella* for amikacin, ampicillin, azithromycin, cefepime, cefotaxime, cefotaxime and clavulanic acid, ceftazidime, ceftazidime and clavulanic acid, cefoxitin, chloramphenicol, ciprofloxacin, colistin, ertapenem, gentamicin, imipenem, meropenem, nalidixic acid, sulfamethoxazole, tetracycline, tigecycline and trimethoprim;
- for *Campylobacter* for chloramphenicol, ciprofloxacin, ertapenem, erythromycin, gentamicin, nalidixic acid and tetracycline;
- for indicator *E. coli* for amikacin, ampicillin, azithromycin, cefepime, cefotaxime, cefotaxime and clavulanic acid, ceftazidime, ceftazidime and clavulanic acid, cefoxitin, chloramphenicol, ciprofloxacin, colistin, ertapenem, gentamicin, imipenem, meropenem, nalidixic acid, sulfamethoxazole, tetracyclin, tigecycline and trimethoprim;
- for MRSA for cefoxitin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusidic acid, gentamicin, kanamycin, linezolid, mupirocin, penicillin, quinupristin/dalfopristin, rifampicin, streptomycin, sulfamethoxazole, tetracycline, tiamulin, trimethoprim and vancomycin.

Epidemiological cut-off values and the occurrence of resistance

ECOFFs, as listed in Commission Implementing Decision (EU) 2020/1729, have been used in this report to interpret the isolate based reported MIC data and determine non-wild-type organisms also termed 'microbiologically' resistant organisms (i.e. displaying a decreased susceptibility), and to ensure that results from different MSs are comparable. From this point onwards in this report, 'microbiologically' antimicrobial resistant organisms are referred to as ‘resistant’ for brevity. This report also incorporates re-evaluation of the historical data accounting for the revised EU legislation, which included the revised ECOFFs. Under the new legislation, the ECOFF used to determine microbiological resistance of *Salmonella* isolates to tigecycline changed from > 1 to > 0.5 mg/L. Therefore, in this report, the occurrence of resistance to tigecycline for 2021 data (i.e. pigs and calves) is determined using the new ECOFF (MIC > 0.5 mg/L), and for 2020 poultry and carcase data, tigecycline resistance is analysed using the old ECOFF (i.e. MIC > 1 mg/L). To note for tigecycline testing is the instability of the substance in aged (> 12 hours old) Mueller-Hinton broth medium used in MIC-testing, which may result in elevated MIC values for some isolates (Bradford et al., 2005). The reported instability of tigecycline during testing, coupled with the lower ECOFF, may result in elevated reporting of resistance to tigecycline in *Salmonella* and *E. coli* isolates with MICs within one dilution range of the ECOFF.

Starting in 2021, new legislative requirements listed in Commission Implementing Decision (EU) 2020/1729, require MSs to test target bacterial isolates for new substances. For *Salmonella* spp., and *E. coli*, the new substance to be tested is amikacin. For *Campylobacter* spp., the new substances are chloramphenicol and ertapenem. Nalidixic acid and streptomycin were removed from the harmonised panel for *Campylobacter* spp.

The occurrence of resistance to a number of antimicrobials was determined for *Salmonella*, *Campylobacter* and indicator commensal *E. coli* isolates and are tabulated at the production-type level in this report. The occurrence of resistance (i.e. resistance levels) in reporting MS groups was calculated as totals (the total number of resistant isolates out of the total number of tested isolates across reporting MSs) and in the *E. coli* chapter, also as weighted means to account for the animal population sizes. Data description throughout the report, level or occurrence of AMR means the percentage of resistant isolates as a proportion of the isolates tested of that microorganism. MSs reporting group means the MSs that provided data and were included in the relevant table of antimicrobial resistance for that bacterium–food or animal category–antimicrobial combination. Terms used to describe the levels or occurrence of antimicrobial resistance are 'rare': < 0.1%, 'very low': 0.1%–1.0%, 'low': > 1%–10.0%, 'moderate': > 10.0%–20.0%, 'high': > 20.0%–50.0%, 'very high': > 50.0%–70.0%, 'extremely high': > 70.0%. Although these terms are applied to all antimicrobials,
the significance of a given level of resistance depends on the particular antimicrobial and its importance in human and veterinary medicine.

**Temporal trends in resistance**

Trend graphs were generated for data meeting the minimum criteria for inclusion, e.g., ten or more isolates reported and with three or more time points. Additional criteria, where applicable, are indicated in the specific chapters. Temporal trends show the resistance to different antimicrobials overtime, by plotting the level of resistance for each year of sampling and for diverse species such as humans and different food-producing animals. Graphs were created for those countries for which resistance data were available for three or more years in the 2009–2020 period. When historical data was available the trends could cover the full period, otherwise, the time period could be different. To assess the statistical significance of temporal trends, the proportions of resistance were modelled using logistic regression. Logistic regression models used resistance as the outcome variable (with resistant (1)/non-resistant (0)) and year as a covariate. This analysis was carried out using the PROC LOGISTIC of SAS 9.2. for each country reporting at least 10 total tested isolates, where there were 3 years or more of available data to use in the model. The PROC LOGISTIC function uses a logit transformation to model the proportions against year and provides estimates for both intercepts and slope. Models where the likelihood ratio test suggested it to be meaningful and resulting in a p-value associated with slope of $< 0.05$ were significant (linear model fit). It is important to note that between-year fluctuations in the occurrence resistance (%) may not be captured in the evaluation of the linear trend over the entire time period (2009–2021) and that very recent decreasing or increasing trends may therefore be masked by the overall trend. Also, when interpreting the results, it is important to note that trend analyses may be driven by particularly high or low levels of resistance reported in one or few data points leading to unexpected findings (e.g., detection of significant increasing or decreasing trends where the observed data do not show any clear trend over the entire period). The withdrawal of the UK from the EU has an impact on the AMR data reported at the EU level in 2020. In this report, data at the EU level are reported in accordance with the membership of the EU, whether before 2020 (EU including the UK) or after 2020 (EU without the UK).

**Spatial analysis of resistance through maps**

MS-specific AMR levels for selected bacterium–food category/animal population combinations were plotted in blue shaded maps for 2020 and 2021, using ArcGIS 9.3. In the maps, resistance levels are presented with colours reflecting the continuous scale of resistance to the antimicrobial of interest among reporting MSs; so, there might be some apparent discrepancies between the colours and resistance levels between maps.

**Resistance in Salmonella serovars of public health importance**

In this report, AMR in tested Salmonella isolates were aggregated to give a value for Salmonella spp. for each country and food/animal category. In addition, the most prevalent Salmonella serovars were also reported separately for particular food/animal category. Additional tables have been included in this report to describe the occurrence of AMR among selected Salmonella serovars of public health importance or of high prevalence in animals. To present a complete overview of the animal populations and food categories in which specific Salmonella serovars of public health importance have been recovered, all the data reported (derived even from fewer than four reporting countries and less than 10 isolates tested) have been included.

**Analysis of multidrug resistance, complete susceptibility and co-resistance data**

The analysis of MDR and co-resistance data is important considering the emergence of multiresistant bacteria. The intention is to focus mainly on multi/co-resistance patterns involving critically important antimicrobials (WHO, 2019), such as cephalosporins, fluoroquinolones and macrolides, and to summarise important information in the EU Summary Report. The occurrence of the isolates of a serotype/resistance pattern of interest is studied both at the MS level and at the EU level (by grouping data for all MSs and where also relevant for MSs and other reporting countries), as the overall picture for all MSs might show a more definite pattern of emergence and spread.
Analysis of MDR and complete susceptibility

For the analysis of MDR and complete susceptibility, a multiresistant isolate is one defined as resistant to at least three of the antimicrobial substances. In contrast, a completely susceptible isolate is one defined as non-resistant (MIC < ECOFF) to these antimicrobial substances. For indicator E. coli and Salmonella spp., all substances from the harmonised test panel laid out in Commission Implementing Decision (EU) 2020/1729 will be included in the assessment of MDR, which is consistent with the approach taken in the 2019–2020 EUSR on AMR. The substances included will be amikacin/gentamicin (assessed together as aminoglycoside antimicrobial class for 2021 data), ampicillin, azithromycin (macrolide antimicrobial class), cefotaxime/ceftazidime (assessed together as third-generation cephalosporin), chloramphenicol, ciprofloxacin/nalidixic acid (assessed together as quinolone antimicrobial class), meropenem, sulfamethoxazole, tetracycline/tigecycline (assessed together as glycylcycline antimicrobial class) and trimethoprim. For C. coli and C. jejuni, the substances included will be ciprofloxacin, erythromycin (macrolide antimicrobial class), gentamicin and tetracycline.

Key Outcome Indicators

To support EU countries in their progress to reduce use of antimicrobials and AMR a list of key outcome indicators has been jointly published by ECDC, EFSA and EMA (ECDC, EFSA, and EMA, 2017). Two of these key outcome indicators (KOI) are included in the report: (1) The key outcome indicator of complete susceptibility (KOICS) in indicator E. coli; and (2) the key outcome indicator of the prevalence of ESBL- and/or AmpC-producing E. coli (KOIESC). KOICS is the proportion of fully susceptible indicator E. coli isolates, weighted by the size of the populations of the most important production animals (broilers, fattening turkeys, fattening pigs, calves) and is used as an indicator (KOICS) for the overall AMR situation in food-producing animals. KOIESC is the weighted mean of the prevalence of ESBL- and/or AmpC-producing E. coli in each of the four animal populations monitored. The KOICS and KOIESC account for differences in the relative size of food animal populations in a country and are therefore relevant in evaluation of risks related to resistance in food animals. These KOIs are displayed in bar charts showing changes in KOI over the years. The statistical significance of the trends was analysed using a simple linear regression over time. The F-test was used to assess the overall significance of the models (p-value < 0.05).

Combined resistance patterns of interest

The term combined resistance is used in this report to indicate phenotypic resistance to two or more different classes of antimicrobials, exhibited by the same bacterial isolate. In Salmonella and E. coli isolates, co-resistance to cefotaxime (CTX) and ciprofloxacin (CIP) was estimated, as these two antimicrobials are of particular interest in human medicine. In 2021, co-resistance was addressed using both ECOFFs (CTX > 0.25 mg/L and CIP > 0.064 mg/L) and CBPs (CTX > 2 mg/L and CIP > 0.064 mg/L) for E. coli. In C. jejuni and C. coli isolates, co-resistance to ciprofloxacin and erythromycin (ERY) was estimated, as these two antimicrobials are of particular interest in human medicine in the treatment of severe campylobacteriosis. The interpretive ECOFFs used to address co-resistance to ciprofloxacin and erythromycin were, for C. jejuni, CIP > 0.5 mg/L and ERY > 4 mg/L and, for C. coli, CIP > 0.5 mg/L and ERY > 8 mg/L. These values may be considered as very similar to CBPs.

Identification of presumptive ESBL, AmpC and/or carbapenemase producers

Definition of ESBL, AmpC, ESBL + AmpC, CP-phenotypes

The categorisation of isolates resistant to third-generation cephalosporins and/or carbapenems in presumptive ESBL, AmpC or carbapenemase producers was carried out based on the EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance (EUCAST, 2017).
For the occurrence and prevalence tables, as well as the violet shaded maps and graphics shown in Section 'ESBL/AmpC/CP producers monitoring', presumptive ESBL producers were considered as those exhibiting an ESBL and/or ESBL + AmpC phenotype and presumptive AmpC producers, those with an AmpC and ESBL + AmpC phenotype (see below).

For the present report, the terms:

'Presumptive ESBL/AmpC producers' refers to those isolates who present an ESBL and/or and AmpC and/or an ESBL + AmpC phenotype (presumptive ESBL producers and/or presumptive AmpC producers).

'Presumptive ESBL producers' refers to those isolates with MICs $> 1$ mg/L for cefotaxime and/or ceftazidime and a synergy test positive for any of these antimicrobials and susceptibility to meropenem (MEM $\leq 0.125$ mg/L, see CP phenotype). These isolates may also harbour other resistance mechanisms (e.g. AmpC-encoding genes).

'Presumptive ESBL-cefotaximase producers' refers to those presumptive ESBL producers with MICs $> 1$ mg/L for cefotaxime and a synergy test positive for cefotaxime only. These isolates may also harbour other resistance mechanisms.

'Presumptive ESBL-ceftazidimase producers' refers to those presumptive ESBL producers with MICs $> 1$ mg/L for ceftazidime and synergy test positive for ceftazidime only. These isolates may also harbour other resistance mechanisms.

'Presumptive AmpC producers' refers to isolates with MICs $> 1$ mg/L for cefotaxime and/or ceftazidime and cefoxitin MIC $> 8$ mg/L together with susceptibility to meropenem (MEM $\leq 0.125$ mg/L, see CP phenotype). No distinction between acquired AmpC and natural AmpC was made. These isolates may also harbour other resistance mechanisms (e.g. ESBL-encoding genes).

'Presumptive ESBL + AmpC producers' refers to isolates with the ESBL + AmpC phenotype described above. 'Presumptive carbapenemase-producers (CP-producers)' refers to those isolates with the CP phenotype described above.

**Data on ESBL/AmpC/CP genes**

From 2021, MSs and non-MSs can choose to report whole genome sequencing (WGS) data for characterisation of presumptive ESBL-, AmpC-, CP-producing *E. coli* and *Salmonella* spp. isolates from the routine monitoring (when further testing to the second panel of antimicrobials was performed, if resistant isolates to cefotaxime, ceftazidime and meropenem were detected in the first panel) or from the specific ESBL-, AmpC-, CP-producing *E. coli* monitoring. Definitions for genotypic interpretation of AMR data for 2021 are listed below:

- Positive isolate is an isolate where at least one ESBL- or AmpC- or CP- gene was detected using WGS.
Negative isolate is an isolate where no ESBL- or AmpC- or CP- genes are detected using WGS.

It is important to highlight that genotypic complete susceptibility is not the same as phenotypic complete susceptibility because not all genes that are detected are phenotypically expressed.

For the analysis, in relation to genotypic data the following definitions are applied:

- **genotypic prevalence** will be defined using the following formula:

  \[
  \text{Prevalence} = \frac{\text{Number of positive samples}}{\text{Number of samples tested}} \times \frac{\text{Number of positive isolates}}{\text{Number of isolates tested}} \times 100
  \]

- **genotypic occurrence** will be defined as the proportion (%) of ESBL- or AmpC- or CP- producing *E. coli* or *Salmonella* positive isolates (associated with at least one ESBL-, AmpC- or CP- gene) divided by the total number of ESBL- or AmpC- or CP- isolates tested.

Bar charts were also used to present the WGS data.

The list of ESBL-, AmpC- and CP- encoding genes used for the analysis of the ESBL-, AmpC- and CP- producing isolates can be consulted in the catalogue browser [https://github.com/openefsa/catalogue-browser/wiki](https://github.com/openefsa/catalogue-browser/wiki).

**Data on methicillin-resistant *Staphylococcus aureus* (MRSA)**

The occurrence of MRSA and its susceptibility to antimicrobials in various food categories (including meat samples from various species) and food-producing animals was reported by few MSs. MRSA occurrence data reported from clinical investigations of food-producing and companion animals in 2020–2021 were also reported. Details of the antimicrobials selected are provided in the section on MRSA. For further information on reported MIC distributions and the number of resistant isolates, refer to the submitted and validated MS data published on the EFSA website. The methods for collecting and testing samples for MRSA are not harmonised between MSs and, as a result, MSs may use differing procedures. Due to the variety of methods employed by MSs, these are explained in detail within the section on MRSA to enable readers to better follow the procedures carried out by individual countries.
Appendix G – Additional information and supporting data

List of Annexes

The annexes are available on the EFSA Knowledge Junction community on Zenodo at: https://doi.org/10.5281/zenodo.7544221

The annexes contain the following information:

Annex A. Data reported on antimicrobial resistance in *Salmonella* spp.

The annex contains tables on antimicrobial resistance data:
- Antimicrobial resistance in *Salmonella* spp. from humans, 2020–2021;
- Occurrence of resistance to selected antimicrobials in *Salmonella* spp. from animal carcases, 2020–2021;
- Occurrence of resistance to selected antimicrobials in *Salmonella* spp. from animals, 2020–2021;
- Occurrence of resistance (%) to selected antimicrobials in specific *Salmonella* serovars.

Annex B. Data reported on antimicrobial resistance in *Campylobacter* spp.

The annex contains tables and figures showing antimicrobial resistance data:
- Antimicrobial resistance in *Campylobacter* spp. from humans, 2021 and trends for 2016–2021 period;
- Data reported on antimicrobial resistance and occurrence of resistance to selected antimicrobials in *C. jejuni* and *C. coli* from food-producing animals and derived meat, for 2020/2021 and trends of resistance in broilers (2009–2020) and in fattening turkeys (2014–2020).

Annex C. Data reported on AMR in indicator *Escherichia coli* from food-producing animals and derived meat

The annex contains tables on data reported on AMR in indicator *Escherichia coli* from food-producing animals and derived meat (data from poultry from 2020 and data from calves and pigs from 2021).

Annex D. Data on presumptive ESBL-, AmpC- and/or carbapenemase-producing microorganisms and their resistance occurrence (routine and specific monitorings)

The annex contains tables with the data reported on presumptive ESBL-, AmpC- and/or carbapenemase-producing microorganisms for poultry (2020), pigs and cattle (2021) and meat thereof, and their resistance occurrence (routine and specific monitorings):
- ESBL-, AmpC-producers prevalence and occurrence tables – pigs and cattle and meat thereof, 2021;
- ESBL-, AmpC, carbapenemase-producers prevalence and occurrence tables – poultry 2020;
- Specific carbapenemase-producing *E. coli* monitoring 2020–2021;
- Occurrence of antimicrobial resistance in poultry isolates collected in 2020;

Annex E. Data reported on antimicrobial resistance in MRSA from food-producing animals and derived meat

The annex contains tables 2020 and 2021 data reported on the prevalence, genetic diversity and antimicrobial resistance of MRSA from food-producing animals and derived meat.

Annex F. WGS data reported complementary to MIC values

The annex contains tables with WGS data additionally to the MICs reported for the routine monitoring, when further testing to the second panel of antimicrobials was performed (when resistant isolates to cefotaxime, ceftazidime and meropenem were detected in the first panel) as well as for the specific ESBL-/AmpC-/CP-producing *E. coli* monitoring.
Supporting data


The aggregated dataset submitted on the negative results for extended-spectrum \( \beta \)-lactamases (ESBL) and carbapenemase-producers is also available on the Knowledge Junction at: https://doi.org/10.5281/zenodo.7660134

The 2021 prevalence of MRSA aggregated dataset is also available on the Knowledge Junction at: https://doi.org/10.5281/zenodo.7636225

Country datasets

All country datasets containing the tables on the occurrence of antimicrobial resistance per each country are available on the EFSA Knowledge Junction community on Zenodo – please see below the list and corresponding link to the datasets.

The countries that submitted datasets on the 2020/2021 monitoring years are: the 27 EU Member States, the four non-EU Member States, and Albania and Republic of North Macedonia as pre-accession countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Link to the dataset</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EU member states</strong></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td><a href="https://doi.org/10.5281/zenodo.7554059">https://doi.org/10.5281/zenodo.7554059</a></td>
</tr>
<tr>
<td>Belgium</td>
<td><a href="https://doi.org/10.5281/zenodo.7554383">https://doi.org/10.5281/zenodo.7554383</a></td>
</tr>
<tr>
<td>Bulgaria</td>
<td><a href="https://doi.org/10.5281/zenodo.7553699">https://doi.org/10.5281/zenodo.7553699</a></td>
</tr>
<tr>
<td>Croatia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554422">https://doi.org/10.5281/zenodo.7554422</a></td>
</tr>
<tr>
<td>Cyprus</td>
<td><a href="https://doi.org/10.5281/zenodo.7553683">https://doi.org/10.5281/zenodo.7553683</a></td>
</tr>
<tr>
<td>Czechia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554049">https://doi.org/10.5281/zenodo.7554049</a></td>
</tr>
<tr>
<td>Denmark</td>
<td><a href="https://doi.org/10.5281/zenodo.7554405">https://doi.org/10.5281/zenodo.7554405</a></td>
</tr>
<tr>
<td>Estonia</td>
<td><a href="https://doi.org/10.5281/zenodo.7553636">https://doi.org/10.5281/zenodo.7553636</a></td>
</tr>
<tr>
<td>Finland</td>
<td><a href="https://doi.org/10.5281/zenodo.7553650">https://doi.org/10.5281/zenodo.7553650</a></td>
</tr>
<tr>
<td>France</td>
<td><a href="https://doi.org/10.5281/zenodo.7554039">https://doi.org/10.5281/zenodo.7554039</a></td>
</tr>
<tr>
<td>Germany</td>
<td><a href="https://doi.org/10.5281/zenodo.7553833">https://doi.org/10.5281/zenodo.7553833</a></td>
</tr>
<tr>
<td>Greece</td>
<td><a href="https://doi.org/10.5281/zenodo.7553707">https://doi.org/10.5281/zenodo.7553707</a></td>
</tr>
<tr>
<td>Hungary</td>
<td><a href="https://doi.org/10.5281/zenodo.7554431">https://doi.org/10.5281/zenodo.7554431</a></td>
</tr>
<tr>
<td>Ireland</td>
<td><a href="https://doi.org/10.5281/zenodo.7554447">https://doi.org/10.5281/zenodo.7554447</a></td>
</tr>
<tr>
<td>Italy</td>
<td><a href="https://doi.org/10.5281/zenodo.7554439">https://doi.org/10.5281/zenodo.7554439</a></td>
</tr>
<tr>
<td>Latvia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554615">https://doi.org/10.5281/zenodo.7554615</a></td>
</tr>
<tr>
<td>Lithuania</td>
<td><a href="https://doi.org/10.5281/zenodo.7554369">https://doi.org/10.5281/zenodo.7554369</a></td>
</tr>
<tr>
<td>Luxembourg</td>
<td><a href="https://doi.org/10.5281/zenodo.7554076">https://doi.org/10.5281/zenodo.7554076</a></td>
</tr>
<tr>
<td>Malta</td>
<td><a href="https://doi.org/10.5281/zenodo.7554081">https://doi.org/10.5281/zenodo.7554081</a></td>
</tr>
<tr>
<td>Netherlands</td>
<td><a href="https://doi.org/10.5281/zenodo.7554604">https://doi.org/10.5281/zenodo.7554604</a></td>
</tr>
<tr>
<td>Poland</td>
<td><a href="https://doi.org/10.5281/zenodo.7554600">https://doi.org/10.5281/zenodo.7554600</a></td>
</tr>
<tr>
<td>Portugal</td>
<td><a href="https://doi.org/10.5281/zenodo.7554508">https://doi.org/10.5281/zenodo.7554508</a></td>
</tr>
<tr>
<td>Romania</td>
<td><a href="https://doi.org/10.5281/zenodo.7554068">https://doi.org/10.5281/zenodo.7554068</a></td>
</tr>
<tr>
<td>Slovenia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554495">https://doi.org/10.5281/zenodo.7554495</a></td>
</tr>
<tr>
<td>Slovakia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554489">https://doi.org/10.5281/zenodo.7554489</a></td>
</tr>
<tr>
<td>Spain</td>
<td><a href="https://doi.org/10.5281/zenodo.7553721">https://doi.org/10.5281/zenodo.7553721</a></td>
</tr>
<tr>
<td>Sweden</td>
<td><a href="https://doi.org/10.5281/zenodo.7554502">https://doi.org/10.5281/zenodo.7554502</a></td>
</tr>
<tr>
<td>United Kingdom (Northern Ireland)</td>
<td><a href="https://doi.org/10.5281/zenodo.7554483">https://doi.org/10.5281/zenodo.7554483</a></td>
</tr>
<tr>
<td><strong>Non-EU countries</strong></td>
<td></td>
</tr>
<tr>
<td>Iceland</td>
<td><a href="https://doi.org/10.5281/zenodo.7554468">https://doi.org/10.5281/zenodo.7554468</a></td>
</tr>
<tr>
<td>Norway</td>
<td><a href="https://doi.org/10.5281/zenodo.7554451">https://doi.org/10.5281/zenodo.7554451</a></td>
</tr>
<tr>
<td>Republic of North Macedonia</td>
<td><a href="https://doi.org/10.5281/zenodo.7554455">https://doi.org/10.5281/zenodo.7554455</a></td>
</tr>
<tr>
<td>Switzerland</td>
<td><a href="https://doi.org/10.5281/zenodo.7554472">https://doi.org/10.5281/zenodo.7554472</a></td>
</tr>
</tbody>
</table>
Appendix H – ESBL-, AmpC- and CP- encoding genes identified during the specific monitoring of ESBL-/AmpC-/CP- producing E. coli isolates using whole genome sequencing (WGS)

In total four MSs, Italy, Germany, Czechia and Finland, provided genotypic data on ESBL-, AmpC- and CP- producing E. coli isolates detected in the specific monitoring of ESBL-/AmpC-/CP- isolates (Tables H.1–H.3).

A variety of ESBL genes were identified in all the 4 MSs providing WGS data (Table H.1). The most frequently ESBL gene reported in the majority of animal populations and meat categories was \textit{bla}_{CTX-M-1}. This gene was detected in pigs in 64 isolates from Czechia (21.2%, N = 302), 92 isolates from Italy (31%, N = 301) and 94 isolates from Germany (25%, N = 381). It was also detected in calves in 99 isolates from Italy (32.0%, N = 310) and 103 isolates from Germany (34.4%, N = 299). The detection of \textit{bla}_{CTX-M-1} in meat samples was much lower being identified in 12 isolates from bovine meat (4%, N = 298) and 12 isolates of pig meat (4.1%, N = 294) in Czechia, 16 isolates (3.4%, N = 466) of pig meat and 4 bovine meat isolates (1%, N = 418) from Germany and in 5 isolates of bovine meat (1.7%, N = 301) and 5 isolates from pig meat (1.6%, N = 305) from Italy.

The second most frequently ESBL gene identified was \textit{bla}_{CTXM-15}, being detected in bovines in 133 isolates from Italy (42.9%, N = 310) and 60 isolates from Germany (20.1%, N = 299), in pigs in 36 isolates from Italy (12.0%, N = 301), 25 isolates from Germany (8.5%, N = 382), 18 isolates from Czechia (6.0%, N = 302) and two isolates from Finland (0.7%, N = 307). As well as in bovine meat: five isolates from Italy (1.7%, N = 301), two isolates from Czechia (0.7%, N = 298) and two isolates from Germany (0.5%, N = 418); and in pig meat in two isolates in each country Germany (0.4%, N = 466), Italy (0.7%, N = 305) and Czechia (0.7%, N = 294). In general ESBL-encoding genes were more commonly detected in food-producing animals than in their derived food products, although the number of samples tested was higher in the derived meat than in animals.

Three AmpC genes were also identified in \textit{E. coli} isolates in all MSs reporting WGS data, Czechia, Germany, Italy and Finland, including \textit{bla}_{CMY-2}, \textit{bla}_{CMY-113} and \textit{bla}_{DHA-1} (Table H.2). Among these, the \textit{bla}_{CMY-2} gene was the only one identified in all four countries. This included 7 isolates from calves (2.3%, N = 310), 1 isolate from bovine meat (0.33%, N = 301), 4 isolates from pig meat (1.31%, N = 305) and 24 isolates from fattening pigs (8.0%, N = 301) in Italy. This gene was also detected in 2 isolates from bovine meat (0.67%, N = 298), 2 isolates from pig meat (0.68%, N = 294), 3 isolates from bovine meat (1.0%, N = 298) and 9 isolates from fattening pigs (3.0%, N = 302) from Czechia. In Germany, two isolates from pigs (0.5% N = 382) and one isolate from bovine animals (0.2%, N = 418) presented this gene, while only 1 isolate from a fattening pig (0.33%, N = 307) in Finland was identified to carry this gene. However, most of the AmpC-producing \textit{E. coli} isolates detected presented a point mutation in the AmpC promotor.

Four CP-encoding genes were identified in the specific CP-producing \textit{E. coli} monitoring, including \textit{bla}_{OXA-181}, \textit{bla}_{OXA-48}, \textit{bla}_{NMD-4} and \textit{bla}_{NMD-5}, in bovines under 1 year old and fattening pigs from Italy and Czechia (Table H.3). The most frequently identified gene was \textit{bla}_{OXA-181} detected in 20 pig isolates (6.6%, N = 301) and 1.3% of calf isolates from Italy, followed by \textit{bla}_{NMD-5} detected in three pig isolates from Czechia (1.0%, N = 302) and a bovine isolate from Italy. \textit{bla}_{OXA-48} was identified in a pig isolate from Italy.

Several MSs also reported data on WGS additionally to the MICs reported for the routine monitoring, when further testing to the second panel of antimicrobials (if resistant isolates to cefotaxime, ceftazidime and meropenem were detected in the first panel) as well as for the specific \textit{E. coli} ESBL/AmpC/CP-producers monitoring. These data can be consulted in the Annex E.
**Table H.1:** ESBL genes detected in *E. coli* isolates from the specific monitoring of ESBL-/AmpC-/CP-producers in food-producing animals and meat derived thereof, by country, in 2021

<table>
<thead>
<tr>
<th>ESBL encoding genes</th>
<th>Bovines under 1 year old</th>
<th>Bovine meat</th>
<th>Fattening pigs</th>
<th>Pig meat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E. coli</strong> N n N n N n N n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Italy</strong>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-1&lt;/sub&gt;</td>
<td>310 99</td>
<td>301 5</td>
<td>301 92</td>
<td>305 5</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-2&lt;/sub&gt;</td>
<td>310 1</td>
<td>301 0</td>
<td>301 0</td>
<td>305 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-3&lt;/sub&gt;</td>
<td>310 0</td>
<td>301 0</td>
<td>301 1</td>
<td>305 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-8&lt;/sub&gt;</td>
<td>310 0</td>
<td>301 0</td>
<td>301 4</td>
<td>305 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-14&lt;/sub&gt;</td>
<td>310 4</td>
<td>301 0</td>
<td>301 9</td>
<td>305 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-15&lt;/sub&gt;</td>
<td>310 133</td>
<td>301 5</td>
<td>301 36</td>
<td>305 2</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-27&lt;/sub&gt;</td>
<td>310 1</td>
<td>301 0</td>
<td>301 3</td>
<td>305 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-32&lt;/sub&gt;</td>
<td>310 1</td>
<td>301 0</td>
<td>301 3</td>
<td>305 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-55&lt;/sub&gt;</td>
<td>310 11</td>
<td>301 0</td>
<td>301 13</td>
<td>305 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-65&lt;/sub&gt;</td>
<td>310 1</td>
<td>301 0</td>
<td>301 3</td>
<td>305 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;SHV-12&lt;/sub&gt;</td>
<td>310 11</td>
<td>301 1</td>
<td>301 20</td>
<td>305 4</td>
</tr>
<tr>
<td><strong>Germany</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-1&lt;/sub&gt;</td>
<td>299 103</td>
<td>418 4</td>
<td>382 94</td>
<td>466 16</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-2&lt;/sub&gt;</td>
<td>299 1</td>
<td>418 0</td>
<td>382 0</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-3&lt;/sub&gt;</td>
<td>299 2</td>
<td>418 1</td>
<td>382 2</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-8&lt;/sub&gt;</td>
<td>299 0</td>
<td>418 0</td>
<td>382 3</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-9&lt;/sub&gt;</td>
<td>299 0</td>
<td>418 0</td>
<td>382 1</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-14&lt;/sub&gt;</td>
<td>299 2</td>
<td>418 2</td>
<td>382 4</td>
<td>466 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-15&lt;/sub&gt;</td>
<td>299 60</td>
<td>418 2</td>
<td>382 25</td>
<td>466 2</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-27&lt;/sub&gt;</td>
<td>299 0</td>
<td>418 0</td>
<td>382 1</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-32&lt;/sub&gt;</td>
<td>299 6</td>
<td>418 0</td>
<td>382 2</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-55&lt;/sub&gt;</td>
<td>299 4</td>
<td>418 0</td>
<td>382 1</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-65&lt;/sub&gt;</td>
<td>299 5</td>
<td>418 0</td>
<td>382 2</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;SHV-12&lt;/sub&gt;</td>
<td>299 1</td>
<td>418 0</td>
<td>382 2</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;TEM-52&lt;/sub&gt;</td>
<td>299 1</td>
<td>418 0</td>
<td>382 2</td>
<td>466 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;TEM-207&lt;/sub&gt;</td>
<td>299 1</td>
<td>418 0</td>
<td>382 0</td>
<td>466 0</td>
</tr>
<tr>
<td><strong>Czechia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-1&lt;/sub&gt;</td>
<td>– 298</td>
<td>12</td>
<td>302 64</td>
<td>294 12</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-3&lt;/sub&gt;</td>
<td>– 298</td>
<td>1</td>
<td>302 1</td>
<td>294 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-8&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 3</td>
<td>294 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-14&lt;/sub&gt;</td>
<td>– 298</td>
<td>1</td>
<td>302 1</td>
<td>294 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-15&lt;/sub&gt;</td>
<td>– 298</td>
<td>1</td>
<td>302 18</td>
<td>294 2</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-27&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 5</td>
<td>294 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-32&lt;/sub&gt;</td>
<td>– 298</td>
<td>1</td>
<td>302 0</td>
<td>294 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-55&lt;/sub&gt;</td>
<td>– 298</td>
<td>1</td>
<td>302 3</td>
<td>294 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-125&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 1</td>
<td>294 0</td>
</tr>
<tr>
<td>bla&lt;sub&gt;SHV-12&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 1</td>
<td>294 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;TEM-52&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 0</td>
<td>294 1</td>
</tr>
<tr>
<td>bla&lt;sub&gt;TEM-126&lt;/sub&gt;</td>
<td>– 298</td>
<td>0</td>
<td>302 1</td>
<td>294 0</td>
</tr>
<tr>
<td><strong>Finland</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;CTX-M-15&lt;/sub&gt;</td>
<td>– 309</td>
<td>0</td>
<td>307 2</td>
<td>313 0</td>
</tr>
</tbody>
</table>

N = number of samples tested by each country; n = the number of isolates carrying the gene.

*: Please note that Italy reported additional information only at family level (CTX-M) for 7 isolates from bovines under 1 year of age and 4 isolates from fattening pigs. These isolates have not been included in the table.
**Table H.2:** AmpC genes detected in *E. coli* isolates from the specific monitoring of ESBL-/AmpC-/CP- producers in food-producing animals and meat derived thereof, by country, in 2021

<table>
<thead>
<tr>
<th>AmpC encoding genes</th>
<th>Bovines under 1 year old</th>
<th>Bovine meat</th>
<th>Fattening pigs</th>
<th>Pig meat</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td>N</td>
<td>n</td>
<td>N</td>
<td>n</td>
</tr>
<tr>
<td>Italy*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;CMY-2&lt;/sub&gt;</td>
<td>310</td>
<td>7</td>
<td>301</td>
<td>1</td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;CMY-113&lt;/sub&gt;</td>
<td>310</td>
<td>0</td>
<td>301</td>
<td>0</td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;DHA-1&lt;/sub&gt;</td>
<td>310</td>
<td>1</td>
<td>301</td>
<td>0</td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;CMY-2&lt;/sub&gt;</td>
<td>299</td>
<td>1</td>
<td>418</td>
<td>0</td>
</tr>
<tr>
<td>Czechia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;CMY-2&lt;/sub&gt;</td>
<td>–</td>
<td>–</td>
<td>298</td>
<td>2</td>
</tr>
<tr>
<td>Finland</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;CMY-2&lt;/sub&gt;</td>
<td>–</td>
<td>–</td>
<td>309</td>
<td>0</td>
</tr>
</tbody>
</table>

N = the number of samples tested by each country; n = the number of isolates carrying the gene.

*·: No data reported for this animal category or derived meat, by the MS.

*: Please, note that Italy reported the presence of an AmpC phenotype/genotype for 28 isolates from fattening pigs, three isolates from bovines under 1 year of age, one isolate from pig meat and one isolate from bovine meat. These isolates have not been included in the table.

**Table H.3:** CP-encoding genes detected in *E. coli* isolates from the specific monitoring of CP- producers in food-producing animals and meat derived thereof, by country, in 2021

<table>
<thead>
<tr>
<th>CP encoding genes</th>
<th>Bovines under 1 year of age</th>
<th>Fattening pigs</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td>N</td>
<td>n</td>
</tr>
<tr>
<td>Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;NDM-5&lt;/sub&gt;</td>
<td>310</td>
<td>1</td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;OXA-181&lt;/sub&gt;</td>
<td>310</td>
<td>4</td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;OXA-48&lt;/sub&gt;</td>
<td>310</td>
<td>0</td>
</tr>
<tr>
<td>Czechia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>bla</em>&lt;sub&gt;NDM-5&lt;/sub&gt;</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

N = the number of samples tested by each country; n = the number of isolates carrying the gene.

*: No data reported for this animal category, by the MS.